[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fb1vm6V43l2bFhpNWpSsXJSfL6liy28DKmmAsp_S9p-U":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":38,"phaseBuckets":86,"rows":93},"Vanderbilt University",[6,4],"Vanderbilt University Medical Center",1333,false,262,47,5990087,108,890,[15,18,21,24,27,30,33,36],{"name":16,"count":17},"Obesity",56,{"name":19,"count":20},"Hypertension",34,{"name":22,"count":23},"Depression",26,{"name":25,"count":26},"Delirium",22,{"name":28,"count":29},"Autism Spectrum Disorder",20,{"name":31,"count":32},"Critical Illness",18,{"name":34,"count":35},"Type 2 Diabetes",17,{"name":37,"count":35},"Postural Tachycardia Syndrome",[39,44,49,54,58,63,68,73,78,82],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04417595","Omega-3 Fatty Acids for Smoking Cessation in Pregnancy","2024-11-30","Fish Oil",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05297786","Hemodialysis.-Induced Hypotension Therapy for End Stage Kidney Disease","2024-12-30","Lanadelumab Injection [Takhzyro]",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT04050410","Autonomic Determinants of POTS - Pilot1","2025-12-31","Moxonidine",{"nctId":55,"briefTitle":56,"date":52,"intervention":57},"NCT04140721","Autonomic Determinants of POTS - Pilot 2","Moxonidine Pill",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT07123350","Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease","2026-03-31","Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT04801589","Goal-Directed Sedation in Mechanically Ventilated Infants and Children","2026-04-17","Dexmedetomidine",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT07116421","Effect of Rose Odor Exposure on Ictal Apnea","2026-05-08","2-phenylethanol rose scent",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06057675","Tranexamic Acid in Nasal Mohs Reconstruction","2026-06","Treatment",{"nctId":79,"briefTitle":80,"date":76,"intervention":81},"NCT05357612","Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases","Pimavanserin",{"nctId":83,"briefTitle":84,"date":76,"intervention":85},"NCT03654066","Botox or Botox With Esophageal Dilation in Patients With Achalasia","Botulinum toxin type A",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,141,176,194,212,230,248,266,284,308,336,366,394,418,436,459,530,593,671,743,770,788,813,838,864,890,1028,1071,1118,1161,1199,1230,1267,1289,1355,1392,1421,1468,1507,1540,1562,1586,1611,1629,1653,1671,1689,1707,1733,1758,1783,1805,1828,1846,1873,1891,1909,1938,1956,1974,2001,2023,2041,2064,2088,2120,2148,2237,2287,2309,2344,2362,2387,2410,2433,2456,2474,2492,2530,2578,2627,2660,2694,2712,2730,2748,2766,2784,2813,2836,2856,2881,2900,2943,3002,3087,3109,3131,3160,3189,3215,3239,3265,3292,3310,3328,3350,3372,3399,3461,3505,3562,3594,3625,3653,3686,3712,3734,3769,3817,3835,3853,3871,3894,3912,3937,3955,3979,3997,4021,4039,4066,4084,4111,4129,4154,4178,4204,4222,4240,4258,4276,4300,4326,4344,4365,4390,4408,4434,4460,4478,4502,4520,4538,4556,4582,4605,4623,4647,4673,4691,4709,4727,4751,4777,4801,4819,4842,4860,4885,4903,4921,4944,4962,4986,5012,5040,5065,5092,5110,5134,5152,5170,5188,5212,5230,5256,5274,5299,5317,5339,5362,5389,5407,5431,5455,5479,5497,5520,5544,5562,5588,5611,5635,5661,5679,5703,5727,5751,5769,5792,5810,5835,5853,5871,5907,5937,5960,5983,6001,6023,6050,6068,6090,6113,6131,6154,6172,6200,6218,6236,6254,6272,6297,6325,6349,6367,6385,6410,6432,6458,6476,6499,6528,6546,6569,6594,6616,6639,6664,6698,6733,6767,6789,6823,6856,6893,6919,6937,6961,6985,7006,7031,7049,7073,7091,7109,7127,7151,7169,7195,7213,7242,7266,7288,7312,7333,7355,7378,7401,7426,7447,7465,7483,7501,7519,7537,7555,7578,7600,7623,7648,7666,7690,7716,7740,7764,7793,7818,7844,7868,7886,7911,7929,7947,7971,7996,8018,8042,8067,8085,8108,8131,8154,8176,8209,8241,8263,8285,8312,8339,8361,8396,8418,8451,8469,8493,8517,8535,8558,8582,8607,8625,8643,8661,8679,8697,8715,8733,8751,8769,8787,8805,8823,8841,8859,8877,8902,8924,8942,8960,8978,8996,9014,9032,9050,9068,9086,9104,9122,9140,9158,9176,9194,9212,9235,9258,9276,9298,9316,9337,9359,9380,9404,9425,9450,9468,9493,9517,9535,9558,9576,9601,9625,9649,9667,9685,9703,9721,9744,9762,9785,9810,9828,9852,9874,9897,9915,9938,9962,9980,10004,10022,10046,10064,10088,10112,10136,10160,10183,10206,10228,10252,10270,10292,10310,10332,10394,10453,10493,10546,10594,10648,10681,10720,10765,10804,10842,10868,10899,10925,10961,10987,11013,11042,11071,11100,11122,11152,11174,11196,11218,11240,11265,11290,11312,11334,11360,11389,11411,11433,11458,11488,11518,11540,11565,11593,11615,11637,11659,11681,11703,11725,11748,11766,11784,11802,11829,11851,11869,11894,11912,11934,11952,11970,11988,12006,12024,12042,12060,12078,12101,12119,12137,12155,12173,12191,12209,12227,12245,12263,12281,12299,12317,12335,12353,12371,12389,12407,12425,12443,12465,12483,12507,12533,12551,12573,12597,12619,12637,12655,12677,12699,12720,12738,12756,12777,12799,12817,12835,12857,12879,12897,12915,12936,12959,12980,12998,13016,13034,13058,13076,13099,13122,13146,13171,13193,13215,13238,13256,13281,13299,13323,13345,13366,13389,13411,13435,13453,13476,13494,13512,13534,13552,13570,13588,13610,13628,13651,13669,13691,13716,13734,13752,13770,13788,13806,13824,13842,13860,13878,13896,13914,13932,13950,13968,13986,14004,14029,14047,14065,14088,14112,14130,14156,14174,14192],{"intervention":95,"totalTrials":96,"cells":97},"Botulinum Toxin Type A",3,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":116,"PHASE4":118,"NA":139},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"completion":110,"start":111,"enrollment":29,"conditions":112,"interventions":115},"NCT00178945","Botulinum Toxin Type A (Botox) for the Treatment of Cervical Dystonia and Upper Thoracic Muscular Pain","COMPLETED",[88,89],"2006-03","2004-03",[113,114],"Refractory Cervicothoracic Myofascial Pain Syndrome (CMPS)","Cervical Dystonia",[95],{"trials":117,"activeCount":100},[],{"trials":119,"activeCount":138,"soonestReadout":76},[120,128],{"nctId":83,"briefTitle":84,"status":121,"phases":122,"primaryCompletion":76,"completion":76,"start":123,"enrollment":124,"conditions":125,"interventions":127},"ENROLLING_BY_INVITATION",[91],"2019-05-13",50,[126],"Achalasia",[85],{"nctId":129,"briefTitle":130,"status":108,"phases":131,"completion":132,"start":133,"enrollment":29,"conditions":134,"interventions":136},"NCT00179114","Vanderbilt University Spasticity Management Program Evaluation Plan",[91],"2006-02","2002-08",[135],"Spasticity",[95,137],"Intrathecal baclofen administered by the Medtronic SyncroMed",1,{"trials":140,"activeCount":100},[],{"intervention":142,"totalTrials":138,"cells":143},"Buccal Buprenorphine 300 mcg",{"EARLY_PHASE1":144,"PHASE1":146,"PHASE2":148,"PHASE3":150,"PHASE4":152,"NA":174},{"trials":145,"activeCount":100},[],{"trials":147,"activeCount":100},[],{"trials":149,"activeCount":100},[],{"trials":151,"activeCount":100},[],{"trials":153,"activeCount":138,"soonestReadout":159},[154],{"nctId":155,"briefTitle":156,"status":157,"phases":158,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":167},"NCT05988710","Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia","RECRUITING",[91],"2028-01","2028-02","2023-10-19",120,[164,165,166],"Analgesia","Abuse Opioids","Pain",[142,168,169,170,171,172,173],"Buccal Buprenorphine 600 mcg","Buccal Buprenorphine 900 mcg","Buccal Placebo","Oral Placebo","Oral immediate-release oxycodone 10mg","Buccal Buprenorphine 450mcg",{"trials":175,"activeCount":100},[],{"intervention":168,"totalTrials":138,"cells":177},{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":184,"PHASE4":186,"NA":192},{"trials":179,"activeCount":100},[],{"trials":181,"activeCount":100},[],{"trials":183,"activeCount":100},[],{"trials":185,"activeCount":100},[],{"trials":187,"activeCount":138,"soonestReadout":159},[188],{"nctId":155,"briefTitle":156,"status":157,"phases":189,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":190,"interventions":191},[91],[164,165,166],[142,168,169,170,171,172,173],{"trials":193,"activeCount":100},[],{"intervention":169,"totalTrials":138,"cells":195},{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":202,"PHASE4":204,"NA":210},{"trials":197,"activeCount":100},[],{"trials":199,"activeCount":100},[],{"trials":201,"activeCount":100},[],{"trials":203,"activeCount":100},[],{"trials":205,"activeCount":138,"soonestReadout":159},[206],{"nctId":155,"briefTitle":156,"status":157,"phases":207,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":208,"interventions":209},[91],[164,165,166],[142,168,169,170,171,172,173],{"trials":211,"activeCount":100},[],{"intervention":170,"totalTrials":138,"cells":213},{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":222,"NA":228},{"trials":215,"activeCount":100},[],{"trials":217,"activeCount":100},[],{"trials":219,"activeCount":100},[],{"trials":221,"activeCount":100},[],{"trials":223,"activeCount":138,"soonestReadout":159},[224],{"nctId":155,"briefTitle":156,"status":157,"phases":225,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":226,"interventions":227},[91],[164,165,166],[142,168,169,170,171,172,173],{"trials":229,"activeCount":100},[],{"intervention":171,"totalTrials":138,"cells":231},{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":238,"PHASE4":240,"NA":246},{"trials":233,"activeCount":100},[],{"trials":235,"activeCount":100},[],{"trials":237,"activeCount":100},[],{"trials":239,"activeCount":100},[],{"trials":241,"activeCount":138,"soonestReadout":159},[242],{"nctId":155,"briefTitle":156,"status":157,"phases":243,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":244,"interventions":245},[91],[164,165,166],[142,168,169,170,171,172,173],{"trials":247,"activeCount":100},[],{"intervention":172,"totalTrials":138,"cells":249},{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":256,"PHASE4":258,"NA":264},{"trials":251,"activeCount":100},[],{"trials":253,"activeCount":100},[],{"trials":255,"activeCount":100},[],{"trials":257,"activeCount":100},[],{"trials":259,"activeCount":138,"soonestReadout":159},[260],{"nctId":155,"briefTitle":156,"status":157,"phases":261,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":262,"interventions":263},[91],[164,165,166],[142,168,169,170,171,172,173],{"trials":265,"activeCount":100},[],{"intervention":173,"totalTrials":138,"cells":267},{"EARLY_PHASE1":268,"PHASE1":270,"PHASE2":272,"PHASE3":274,"PHASE4":276,"NA":282},{"trials":269,"activeCount":100},[],{"trials":271,"activeCount":100},[],{"trials":273,"activeCount":100},[],{"trials":275,"activeCount":100},[],{"trials":277,"activeCount":138,"soonestReadout":159},[278],{"nctId":155,"briefTitle":156,"status":157,"phases":279,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":280,"interventions":281},[91],[164,165,166],[142,168,169,170,171,172,173],{"trials":283,"activeCount":100},[],{"intervention":81,"totalTrials":138,"cells":285},{"EARLY_PHASE1":286,"PHASE1":288,"PHASE2":290,"PHASE3":292,"PHASE4":294,"NA":306},{"trials":287,"activeCount":100},[],{"trials":289,"activeCount":100},[],{"trials":291,"activeCount":100},[],{"trials":293,"activeCount":100},[],{"trials":295,"activeCount":138,"soonestReadout":76},[296],{"nctId":79,"briefTitle":80,"status":157,"phases":297,"primaryCompletion":76,"completion":298,"start":299,"enrollment":300,"conditions":301,"interventions":305},[91],"2026-08","2023-01-23",75,[302,303,304],"Neurodegenerative Diseases","Parkinson Disease","Parkinson Disease Psychosis",[81],{"trials":307,"activeCount":100},[],{"intervention":309,"totalTrials":138,"cells":310},"GlyNAC",{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":319,"NA":334},{"trials":312,"activeCount":100},[],{"trials":314,"activeCount":100},[],{"trials":316,"activeCount":100},[],{"trials":318,"activeCount":100},[],{"trials":320,"activeCount":138,"soonestReadout":325},[321],{"nctId":322,"briefTitle":323,"status":157,"phases":324,"primaryCompletion":325,"completion":326,"start":327,"enrollment":328,"conditions":329,"interventions":333},"NCT06083480","Reducing Perioperative Oxidative Stress to Prevent Postoperative Chronic Pain Following Total Knee Arthroplasty",[91],"2028-09","2029-03","2024-12-06",148,[330,331,332],"Osteoarthritis, Knee","Total Knee Arthroplasty","Chronic Postsurgical Pain",[309],{"trials":335,"activeCount":100},[],{"intervention":337,"totalTrials":138,"cells":338},"Vericiguat",{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":345,"PHASE4":347,"NA":364},{"trials":340,"activeCount":100},[],{"trials":342,"activeCount":100},[],{"trials":344,"activeCount":100},[],{"trials":346,"activeCount":100},[],{"trials":348,"activeCount":138,"soonestReadout":353},[349],{"nctId":350,"briefTitle":351,"status":157,"phases":352,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":357,"interventions":363},"NCT05812755","SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery",[91],"2026-12","2027-11","2023-05-19",170,[358,359,360,361,362],"Endothelial Dysfunction","Vascular Diseases","Kidney Injury","Brain Disease","Vascular Inflammation",[337],{"trials":365,"activeCount":100},[],{"intervention":367,"totalTrials":138,"cells":368},"Lidocaine HCl 0.8% in D5W",{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":373,"PHASE3":375,"PHASE4":377,"NA":392},{"trials":370,"activeCount":100},[],{"trials":372,"activeCount":100},[],{"trials":374,"activeCount":100},[],{"trials":376,"activeCount":100},[],{"trials":378,"activeCount":138,"soonestReadout":384},[379],{"nctId":380,"briefTitle":381,"status":382,"phases":383,"primaryCompletion":384,"completion":384,"start":385,"enrollment":386,"conditions":387,"interventions":390},"NCT07224711","The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery","NOT_YET_RECRUITING",[91],"2028-05-30","2026-07-01",2290,[166,388,389],"Post Operative Analgesia","Opioid Consumption, Postoperative",[367,391],"Sodium Chloride 0.9%",{"trials":393,"activeCount":100},[],{"intervention":395,"totalTrials":138,"cells":396},"ValACYclovir 1000 MG",{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":403,"PHASE4":405,"NA":416},{"trials":398,"activeCount":100},[],{"trials":400,"activeCount":100},[],{"trials":402,"activeCount":100},[],{"trials":404,"activeCount":100},[],{"trials":406,"activeCount":138,"soonestReadout":298},[407],{"nctId":408,"briefTitle":409,"status":157,"phases":410,"primaryCompletion":298,"completion":298,"start":411,"enrollment":412,"conditions":413,"interventions":414},"NCT05550194","VZV in the Enteric Nervous System: Pathogenesis and Consequences",[91],"2023-03-27",40,[126],[395,415],"Shingrix",{"trials":417,"activeCount":100},[],{"intervention":415,"totalTrials":138,"cells":419},{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":426,"PHASE4":428,"NA":434},{"trials":421,"activeCount":100},[],{"trials":423,"activeCount":100},[],{"trials":425,"activeCount":100},[],{"trials":427,"activeCount":100},[],{"trials":429,"activeCount":138,"soonestReadout":298},[430],{"nctId":408,"briefTitle":409,"status":157,"phases":431,"primaryCompletion":298,"completion":298,"start":411,"enrollment":412,"conditions":432,"interventions":433},[91],[126],[395,415],{"trials":435,"activeCount":100},[],{"intervention":437,"totalTrials":138,"cells":438},"Botulinum Toxin Type A Injection [Botox]",{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":443,"PHASE3":445,"PHASE4":447,"NA":457},{"trials":440,"activeCount":100},[],{"trials":442,"activeCount":100},[],{"trials":444,"activeCount":100},[],{"trials":446,"activeCount":100},[],{"trials":448,"activeCount":138,"soonestReadout":453},[449],{"nctId":450,"briefTitle":451,"status":382,"phases":452,"primaryCompletion":453,"completion":453,"start":385,"enrollment":124,"conditions":454,"interventions":456},"NCT07295288","Botox Injections in Non-Cranial Nerve VII Innervated Muscles for Facial Synkinesis",[91],"2027-06-30",[455],"Synkinesis",[437],{"trials":458,"activeCount":100},[],{"intervention":460,"totalTrials":461,"cells":462},"Hydroxyurea",5,{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":494,"PHASE4":507,"NA":519},{"trials":464,"activeCount":100},[],{"trials":466,"activeCount":100},[],{"trials":468,"activeCount":100},[469,482],{"nctId":470,"briefTitle":471,"status":108,"phases":472,"primaryCompletion":473,"completion":474,"start":475,"enrollment":476,"conditions":477,"interventions":480},"NCT03634488","Management of Severe Acute Malnutrition in SCD, in Northern Nigeria",[89],"2022-10-05","2022-11-09","2021-08-18",132,[478,479],"Sickle Cell Anemia","Severe Acute Malnutrition",[481],"hydroxyurea",{"nctId":483,"briefTitle":484,"status":108,"phases":485,"primaryCompletion":486,"completion":487,"start":488,"enrollment":489,"conditions":490,"interventions":492},"NCT05142254","A Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study",[89],"2023-07-10","2023-11-09","2022-04-01",64,[491],"Priapism Due to Sickle Cell Disease",[493,460],"Tadalafil",{"trials":495,"activeCount":100},[496],{"nctId":497,"briefTitle":498,"status":108,"phases":499,"primaryCompletion":500,"completion":500,"start":501,"enrollment":502,"conditions":503,"interventions":506},"NCT02560935","Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II",[90],"2020-03-03","2016-07-19",440,[504,505],"Sickle Cell Disease","Stroke",[460,460],{"trials":508,"activeCount":138,"soonestReadout":513},[509],{"nctId":510,"briefTitle":511,"status":157,"phases":512,"primaryCompletion":513,"completion":514,"start":515,"enrollment":516,"conditions":517,"interventions":518},"NCT06526117","Stroke Prevention in Nigeria 2 Trial",[91],"2029-12-31","2030-06-30","2024-08-05",220,[504,505],[460],{"trials":520,"activeCount":100},[521],{"nctId":522,"briefTitle":523,"status":108,"phases":524,"primaryCompletion":525,"completion":525,"start":526,"enrollment":527,"conditions":528,"interventions":529},"NCT01801423","Sickle Cell Disease - Stroke Prevention in Nigeria Trial",[92],"2019-01-31","2013-04-24",29,[478,504,505],[460],{"intervention":391,"totalTrials":531,"cells":532},2,{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":539,"PHASE4":541,"NA":547},{"trials":534,"activeCount":100},[],{"trials":536,"activeCount":100},[],{"trials":538,"activeCount":100},[],{"trials":540,"activeCount":100},[],{"trials":542,"activeCount":138,"soonestReadout":384},[543],{"nctId":380,"briefTitle":381,"status":382,"phases":544,"primaryCompletion":384,"completion":384,"start":385,"enrollment":386,"conditions":545,"interventions":546},[91],[166,388,389],[367,391],{"trials":548,"activeCount":100},[549],{"nctId":550,"briefTitle":551,"status":108,"phases":552,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":557,"interventions":559},"NCT02726620","Decision Support for Intraoperative Low Blood Pressure",[92],"2017-12-31","2018-12-29","2017-01-05",22435,[558],"Hypotension",[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],"Propofol","Sevoflurane","Desflurane","Isoflurane","Ephedrine","Phenylephrine","Norepinephrine","Epinephrine","Dobutamine","Dopamine","Isoproterenol","Milrinone","Atropine","Glycopyrrolate","Vasopressin","Terlipressin","Ringer's lactate","Hydroxyethyl starch solutions","Fresh Frozen Plasma","Packed Red Blood Cells","Albumin solutions","Plasma-Lyte","Lidocaine","Bupivacaine","Levobupivacaine","Ropivacaine","Mepivacaine","Tetracaine","Prilocaine","Procaine","Chloroprocaine","Benzocaine","Articaine",{"intervention":594,"totalTrials":461,"cells":595},"Icatibant",{"EARLY_PHASE1":596,"PHASE1":598,"PHASE2":600,"PHASE3":629,"PHASE4":640,"NA":669},{"trials":597,"activeCount":100},[],{"trials":599,"activeCount":100},[],{"trials":601,"activeCount":100},[602,617],{"nctId":603,"briefTitle":604,"status":605,"phases":606,"primaryCompletion":607,"completion":607,"start":608,"enrollment":100,"conditions":609,"interventions":613},"NCT03005184","Mechanism(s) Underlying Cardiovascular Effects of ARB\u002FNEP Inhibition - Aim 2","WITHDRAWN",[89],"2020-01","2017-09",[610,611,612],"Heart Failure NYHA Class I","Heart Failure NYHA Class II","Heart Failure NYHA Class III",[614,615,616,594],"Valsartan 80 mg bid","Enalapril 10 mg bid","Sacubitril-Valsartan 200 mg bid",{"nctId":618,"briefTitle":619,"status":108,"phases":620,"primaryCompletion":621,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":628},"NCT03177798","Mitochondria and Chronic Kidney Disease",[89],"2018-06-30","2018-12-31","2017-08-01",11,[626,627],"Hemodialysis-Induced Symptom","Mitochondrial Diseases",[594],{"trials":630,"activeCount":138,"soonestReadout":385},[631],{"nctId":632,"briefTitle":633,"status":157,"phases":634,"primaryCompletion":385,"completion":635,"start":636,"enrollment":23,"conditions":637,"interventions":639},"NCT05834777","Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor",[90],"2026-11-01","2023-12-11",[638],"Intradialytic Hypotension",[594],{"trials":641,"activeCount":100},[642,656],{"nctId":643,"briefTitle":644,"status":108,"phases":645,"primaryCompletion":646,"completion":647,"start":648,"enrollment":649,"conditions":650,"interventions":652},"NCT04113109","Mechanisms Underlying Hypotensive Response to ARB\u002FNEP Inhibition - Aim 2",[91],"2025-04-01","2025-07-30","2019-11-01",46,[651],"Heart Failure",[653,594,654,655],"LCZ 696","Para-aminohippurate","Iohexol",{"nctId":657,"briefTitle":658,"status":659,"phases":660,"primaryCompletion":661,"completion":662,"start":663,"enrollment":664,"conditions":665,"interventions":667},"NCT01574248","Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema","TERMINATED",[91],"2015-09","2016-02","2011-08",33,[666],"ACE Inhibitor-associated Angioedema",[668],"icatibant",{"trials":670,"activeCount":100},[],{"intervention":67,"totalTrials":461,"cells":672},{"EARLY_PHASE1":673,"PHASE1":675,"PHASE2":688,"PHASE3":701,"PHASE4":725,"NA":741},{"trials":674,"activeCount":100},[],{"trials":676,"activeCount":100},[677],{"nctId":678,"briefTitle":679,"status":659,"phases":680,"primaryCompletion":681,"completion":681,"start":682,"enrollment":683,"conditions":684,"interventions":686},"NCT00826553","How Your Patients' Non-REM Sleep Changes On Sedatives in the Intensive Care Units",[88],"2013-12","2009-01",6,[25,685],"Respiratory Failure",[67,687],"GABA agonist",{"trials":689,"activeCount":100},[690],{"nctId":691,"briefTitle":692,"status":108,"phases":693,"primaryCompletion":694,"completion":695,"start":696,"enrollment":697,"conditions":698,"interventions":699},"NCT00095251","MENDS Study: Trial in Ventilated ICU Patients Comparing an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)-Agonist to Determine Delirium Rates, Efficacy of Sedation, Analgesia and Discharge Cognitive Status",[89],"2007-08","2016-12","2004-08",100,[25],[67,700],"Lorazepam",{"trials":702,"activeCount":138,"soonestReadout":66},[703,714],{"nctId":64,"briefTitle":65,"status":157,"phases":704,"primaryCompletion":66,"completion":705,"start":706,"enrollment":707,"conditions":708,"interventions":712},[90],"2026-09-16","2021-05-10",372,[25,31,709,710,711],"Sedation Complication","Executive Dysfunction","Post Traumatic Stress Disorder",[67,713],"Midazolam",{"nctId":715,"briefTitle":716,"status":108,"phases":717,"primaryCompletion":718,"completion":718,"start":719,"enrollment":720,"conditions":721,"interventions":724},"NCT01739933","The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure",[90],"2019-07","2013-05-15",438,[722,25,723],"Sepsis","Impaired Cognition",[67,560],{"trials":726,"activeCount":100},[727],{"nctId":728,"briefTitle":729,"status":108,"phases":730,"primaryCompletion":731,"completion":731,"start":732,"enrollment":733,"conditions":734,"interventions":739},"NCT00808665","Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion",[91],"2012-12","2009-06",68,[735,736,737,738],"Spinal Fusion Acquired","Spinal Stenosis","Lesions of Lumbosacral Intervertebral Disc","Spinal Diseases",[67,740],"0.9% Saline",{"trials":742,"activeCount":100},[],{"intervention":744,"totalTrials":138,"cells":745},"Deutetrabenazine",{"EARLY_PHASE1":746,"PHASE1":748,"PHASE2":750,"PHASE3":752,"PHASE4":766,"NA":768},{"trials":747,"activeCount":100},[],{"trials":749,"activeCount":100},[],{"trials":751,"activeCount":100},[],{"trials":753,"activeCount":138,"soonestReadout":759},[754],{"nctId":755,"briefTitle":756,"status":757,"phases":758,"primaryCompletion":759,"completion":760,"start":761,"enrollment":762,"conditions":763,"interventions":765},"NCT04713982","Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease","ACTIVE_NOT_RECRUITING",[89,90],"2026-06-30","2026-10-01","2021-11-19",30,[764],"Huntington Disease",[744],{"trials":767,"activeCount":100},[],{"trials":769,"activeCount":100},[],{"intervention":713,"totalTrials":138,"cells":771},{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":778,"PHASE4":784,"NA":786},{"trials":773,"activeCount":100},[],{"trials":775,"activeCount":100},[],{"trials":777,"activeCount":100},[],{"trials":779,"activeCount":138,"soonestReadout":66},[780],{"nctId":64,"briefTitle":65,"status":157,"phases":781,"primaryCompletion":66,"completion":705,"start":706,"enrollment":707,"conditions":782,"interventions":783},[90],[25,31,709,710,711],[67,713],{"trials":785,"activeCount":100},[],{"trials":787,"activeCount":100},[],{"intervention":789,"totalTrials":138,"cells":790},"Artificial Tears Methylcellulose",{"EARLY_PHASE1":791,"PHASE1":793,"PHASE2":795,"PHASE3":797,"PHASE4":809,"NA":811},{"trials":792,"activeCount":100},[],{"trials":794,"activeCount":100},[],{"trials":796,"activeCount":100},[],{"trials":798,"activeCount":138,"soonestReadout":803},[799],{"nctId":800,"briefTitle":801,"status":157,"phases":802,"primaryCompletion":803,"completion":803,"start":804,"enrollment":697,"conditions":805,"interventions":808},"NCT05999630","Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer",[90],"2027-12-31","2023-08-21",[806,807],"Nasolacrimal Duct Obstruction","Thyroid Cancer",[789],{"trials":810,"activeCount":100},[],{"trials":812,"activeCount":100},[],{"intervention":814,"totalTrials":138,"cells":815},"Polyethylene Glycol 3350",{"EARLY_PHASE1":816,"PHASE1":818,"PHASE2":820,"PHASE3":822,"PHASE4":834,"NA":836},{"trials":817,"activeCount":100},[],{"trials":819,"activeCount":100},[],{"trials":821,"activeCount":100},[],{"trials":823,"activeCount":138,"soonestReadout":828},[824],{"nctId":825,"briefTitle":826,"status":121,"phases":827,"primaryCompletion":828,"completion":829,"start":830,"enrollment":762,"conditions":831,"interventions":833},"NCT05897086","Polyethylene-glycol Assisted Nerve Repair in Phalloplasty",[89,90],"2028-12-30","2029-12-01","2023-08-01",[832],"Gender Dysphoria",[814],{"trials":835,"activeCount":100},[],{"trials":837,"activeCount":100},[],{"intervention":839,"totalTrials":138,"cells":840},"Nitric Oxide",{"EARLY_PHASE1":841,"PHASE1":843,"PHASE2":845,"PHASE3":847,"PHASE4":860,"NA":862},{"trials":842,"activeCount":100},[],{"trials":844,"activeCount":100},[],{"trials":846,"activeCount":100},[],{"trials":848,"activeCount":138,"soonestReadout":853},[849],{"nctId":850,"briefTitle":851,"status":121,"phases":852,"primaryCompletion":853,"completion":853,"start":854,"enrollment":124,"conditions":855,"interventions":859},"NCT05101746","Nitric Oxide Effect on Brain and Kidney in Pediatric Patients Undergoing Cardiopulmonary Bypass",[89,90],"2026-09","2022-04-25",[856,857,858],"Congenital Heart Disease","Congenital Heart Defect","Congenital Heart Malformations",[839],{"trials":861,"activeCount":100},[],{"trials":863,"activeCount":100},[],{"intervention":865,"totalTrials":138,"cells":866},"Tirzepatide",{"EARLY_PHASE1":867,"PHASE1":869,"PHASE2":871,"PHASE3":873,"PHASE4":886,"NA":888},{"trials":868,"activeCount":100},[],{"trials":870,"activeCount":100},[],{"trials":872,"activeCount":100},[],{"trials":874,"activeCount":138,"soonestReadout":879},[875],{"nctId":876,"briefTitle":877,"status":121,"phases":878,"primaryCompletion":879,"completion":880,"start":881,"enrollment":762,"conditions":882,"interventions":885},"NCT06162715","GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial",[89,90],"2027-01-01","2027-12-01","2024-10-30",[883,16,884],"Severe Obesity","BMI Greater Than 30",[865],{"trials":887,"activeCount":100},[],{"trials":889,"activeCount":100},[],{"intervention":891,"totalTrials":624,"cells":892},"Saline",{"EARLY_PHASE1":893,"PHASE1":908,"PHASE2":941,"PHASE3":977,"PHASE4":995,"NA":1007},{"trials":894,"activeCount":100},[895],{"nctId":896,"briefTitle":897,"status":659,"phases":898,"primaryCompletion":899,"completion":899,"start":662,"enrollment":900,"conditions":901,"interventions":906},"NCT02591173","Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure",[87],"2020-07",7,[902,903,904,905],"Autonomic Nervous System Disorders","Pure Autonomic Failure","Shy-Drager Syndrome","Orthostatic Hypotension, Dysautonomic",[907,891],"Angiotensin-",{"trials":909,"activeCount":138,"soonestReadout":914},[910,919,930],{"nctId":911,"briefTitle":912,"status":157,"phases":913,"primaryCompletion":914,"completion":914,"start":662,"enrollment":23,"conditions":915,"interventions":918},"NCT02646475","Metabolic Effects of Angiotensin-(1-7)",[88],"2029-12",[16,916,19,917],"Insulin Resistance","Metabolic Cardiovascular Syndrome",[907,891],{"nctId":920,"briefTitle":921,"status":605,"phases":922,"primaryCompletion":923,"completion":923,"start":924,"enrollment":100,"conditions":925,"interventions":927},"NCT01119417","The Role of Endothelin in the Supine Hypertension of Autonomic Failure",[88],"2021-05","2010-05",[19,903,926],"Multiple System Atrophy",[928,928,929,928,891],"BQ123","Bq123",{"nctId":931,"briefTitle":932,"status":108,"phases":933,"primaryCompletion":934,"completion":935,"start":936,"enrollment":937,"conditions":938,"interventions":939},"NCT02953587","Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery",[88],"2019-08-21","2023-01-30","2016-09",70,[16],[940,891],"Human Ghrelin",{"trials":942,"activeCount":138,"soonestReadout":76},[943,957,968],{"nctId":944,"briefTitle":945,"status":108,"phases":946,"primaryCompletion":947,"completion":948,"start":949,"enrollment":950,"conditions":951,"interventions":955},"NCT00310401","The Effect of Nebulized Albuterol on Donor Oxygenation",[89],"2011-05","2011-06","2007-04",506,[952,953,954],"Brain Death","Organ Donor","Pulmonary Edema",[956,891],"Albuterol",{"nctId":958,"briefTitle":959,"status":659,"phases":960,"primaryCompletion":961,"completion":962,"start":963,"enrollment":96,"conditions":964,"interventions":966},"NCT03935594","Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars",[89],"2021-05-24","2022-10-19","2020-09-18",[965],"Hypertrophic Scar",[967,891],"PRP",{"nctId":969,"briefTitle":970,"status":157,"phases":971,"primaryCompletion":76,"completion":76,"start":646,"enrollment":412,"conditions":972,"interventions":975},"NCT06634030","Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction",[89],[973,974],"Wound Healing","Surgical Wound",[976,891],"RhPDGF-BB",{"trials":978,"activeCount":100},[979],{"nctId":980,"briefTitle":981,"status":108,"phases":982,"primaryCompletion":983,"completion":984,"start":985,"enrollment":986,"conditions":987,"interventions":992},"NCT02809131","Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.",[90],"2021-03-31","2021-09-30","2016-04-01",1010,[988,989,990,991],"Sick Sinus Syndrome","Complete Heart Block","Syncope","Chronic Systolic Heart Failure",[993,994,891],"polymixin\u002Fbacitracin","cephalexin, or levofloxacin, or clindamycin",{"trials":996,"activeCount":100},[997],{"nctId":998,"briefTitle":999,"status":659,"phases":1000,"primaryCompletion":1001,"completion":1001,"start":1002,"enrollment":96,"conditions":1003,"interventions":1005},"NCT04738318","Steroid Administration for Articular Fractures of the Elbow (SAFE Trial)",[91],"2023-03-10","2022-06-16",[1004],"Elbow Fracture",[1006,891],"Glucocorticoids",{"trials":1008,"activeCount":138,"soonestReadout":1013},[1009,1017],{"nctId":1010,"briefTitle":1011,"status":757,"phases":1012,"primaryCompletion":1013,"completion":1013,"start":1014,"enrollment":412,"conditions":1015,"interventions":1016},"NCT01000350","Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS)",[92],"2028-06","2009-10",[37],[891],{"nctId":1018,"briefTitle":1019,"status":108,"phases":1020,"primaryCompletion":1021,"completion":1022,"start":696,"enrollment":300,"conditions":1023,"interventions":1025},"NCT00179127","Use of Insulin Glargine to Treat Diabetic Ketoacidosis",[92],"2009-07","2012-09",[1024],"Diabetic Ketoacidosis",[1026,1027],"glargine","saline",{"intervention":1029,"totalTrials":96,"cells":1030},"Theophylline",{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1035,"PHASE3":1065,"PHASE4":1067,"NA":1069},{"trials":1032,"activeCount":100},[],{"trials":1034,"activeCount":100},[],{"trials":1036,"activeCount":531,"soonestReadout":1052},[1037,1048,1057],{"nctId":1038,"briefTitle":1039,"status":757,"phases":1040,"primaryCompletion":1041,"completion":1041,"start":1042,"enrollment":20,"conditions":1043,"interventions":1047},"NCT04551170","Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old",[89],"2026-12-31","2020-07-13",[1044,1045,1046],"Pseudohypoparathyroidism","Albright Hereditary Osteodystrophy","Pseudohypoparathyroidism Type 1a",[1029],{"nctId":1049,"briefTitle":1050,"status":757,"phases":1051,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":527,"conditions":1054,"interventions":1055},"NCT03029429","Theophylline Treatment for Pseudohypoparathyroidism",[89],"2026-12-01","2018-09-01",[1044,1045],[1029,1056],"Placebos",{"nctId":1058,"briefTitle":1059,"status":108,"phases":1060,"primaryCompletion":1061,"completion":1061,"start":1062,"enrollment":683,"conditions":1063,"interventions":1064},"NCT02463409","Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)",[89],"2016-10","2015-06",[1046,1045],[1029],{"trials":1066,"activeCount":100},[],{"trials":1068,"activeCount":100},[],{"trials":1070,"activeCount":100},[],{"intervention":1072,"totalTrials":96,"cells":1073},"2-Hydroxybenzylamine",{"EARLY_PHASE1":1074,"PHASE1":1076,"PHASE2":1078,"PHASE3":1112,"PHASE4":1114,"NA":1116},{"trials":1075,"activeCount":100},[],{"trials":1077,"activeCount":100},[],{"trials":1079,"activeCount":531,"soonestReadout":759},[1080,1090,1099],{"nctId":1081,"briefTitle":1082,"status":108,"phases":1083,"primaryCompletion":1084,"completion":935,"start":1085,"enrollment":1086,"conditions":1087,"interventions":1089},"NCT04433091","2-Hydroxybenzylamine (2-HOBA) to Prevent Early Recurrence of Atrial Fibrillation After Catheter-based Ablation",[89],"2022-01-30","2020-05-15",95,[1088],"Atrial Fibrillation",[1072],{"nctId":1091,"briefTitle":1092,"status":157,"phases":1093,"primaryCompletion":759,"completion":1041,"start":1094,"enrollment":1095,"conditions":1096,"interventions":1098},"NCT04941599","2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)",[89],"2024-02-14",72,[1097],"Familial Hypercholesterolemia",[1072],{"nctId":1100,"briefTitle":1101,"status":382,"phases":1102,"primaryCompletion":1103,"completion":1103,"start":1104,"enrollment":29,"conditions":1105,"interventions":1110},"NCT07602166","Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans",[89],"2031-07","2026-07",[1106,1107,1108,1109],"Salt Sensitivity of Blood Pressure","High Blood Pressure","Inflammation","Renin-Angiotensin-Aldosterone System",[1111],"2-hydroxybenzylamine",{"trials":1113,"activeCount":100},[],{"trials":1115,"activeCount":100},[],{"trials":1117,"activeCount":100},[],{"intervention":1119,"totalTrials":96,"cells":1120},"Transdermal Nicotine patch",{"EARLY_PHASE1":1121,"PHASE1":1123,"PHASE2":1125,"PHASE3":1155,"PHASE4":1157,"NA":1159},{"trials":1122,"activeCount":100},[],{"trials":1124,"activeCount":100},[],{"trials":1126,"activeCount":531,"soonestReadout":1141},[1127,1137,1147],{"nctId":1128,"briefTitle":1129,"status":757,"phases":1130,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":1133,"conditions":1134,"interventions":1136},"NCT05746546","Depressed Mood Improvement Through Nicotine Dosing-3 (Depressed MIND3) Extension",[89],"2026-10-31","2023-04-15",60,[1135],"Depressive Disorder",[1119],{"nctId":1138,"briefTitle":1139,"status":157,"phases":1140,"primaryCompletion":1141,"completion":1142,"start":1132,"enrollment":1133,"conditions":1143,"interventions":1144},"NCT05746273","Depressed Mood Improvement Through Nicotine Dosing 3",[89],"2026-07-31","2026-09-30",[1135],[1145,1146],"Transdermal Nicotine Patch","Transdermal Placebo Patch",{"nctId":1148,"briefTitle":1149,"status":108,"phases":1150,"primaryCompletion":1151,"completion":1151,"start":1152,"enrollment":527,"conditions":1153,"interventions":1154},"NCT04433767","Depressed Mood Improvement Through Nicotine Dosing 2",[89],"2022-10-07","2020-12-15",[1135],[1119],{"trials":1156,"activeCount":100},[],{"trials":1158,"activeCount":100},[],{"trials":1160,"activeCount":100},[],{"intervention":1162,"totalTrials":531,"cells":1163},"Semaglutide",{"EARLY_PHASE1":1164,"PHASE1":1176,"PHASE2":1178,"PHASE3":1193,"PHASE4":1195,"NA":1197},{"trials":1165,"activeCount":138,"soonestReadout":1170},[1166],{"nctId":1167,"briefTitle":1168,"status":157,"phases":1169,"primaryCompletion":1170,"completion":1170,"start":1171,"enrollment":1172,"conditions":1173,"interventions":1175},"NCT06338553","GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab",[87],"2027-03","2024-06-12",24,[1174],"Type 1 Diabetes",[1162],{"trials":1177,"activeCount":100},[],{"trials":1179,"activeCount":138,"soonestReadout":1184},[1180],{"nctId":1181,"briefTitle":1182,"status":157,"phases":1183,"primaryCompletion":1184,"completion":1185,"start":66,"enrollment":1186,"conditions":1187,"interventions":1192},"NCT07221214","GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV",[89],"2029-10-31","2030-01-31",200,[1188,1189,1190,1191],"HIV","Alcohol","Smoking Cigarette","Cardiovascular Disease Prevention",[1162],{"trials":1194,"activeCount":100},[],{"trials":1196,"activeCount":100},[],{"trials":1198,"activeCount":100},[],{"intervention":53,"totalTrials":531,"cells":1200},{"EARLY_PHASE1":1201,"PHASE1":1209,"PHASE2":1211,"PHASE3":1224,"PHASE4":1226,"NA":1228},{"trials":1202,"activeCount":138,"soonestReadout":52},[1203],{"nctId":50,"briefTitle":51,"status":757,"phases":1204,"primaryCompletion":52,"completion":1041,"start":1205,"enrollment":1206,"conditions":1207,"interventions":1208},[87],"2019-08-27",48,[37],[53],{"trials":1210,"activeCount":100},[],{"trials":1212,"activeCount":138,"soonestReadout":1217},[1213],{"nctId":1214,"briefTitle":1215,"status":157,"phases":1216,"primaryCompletion":1217,"completion":1218,"start":1219,"enrollment":1220,"conditions":1221,"interventions":1222},"NCT05312892","Sympathetic Mechanisms in Obesity-Crossover Design",[88,89],"2028-12-31","2030-12-31","2022-05-20",12,[16,19],[1223,53],"Amlodipine",{"trials":1225,"activeCount":100},[],{"trials":1227,"activeCount":100},[],{"trials":1229,"activeCount":100},[],{"intervention":1231,"totalTrials":531,"cells":1232},"High Dose Quadrivalent Inactivated Influenza Vaccine",{"EARLY_PHASE1":1233,"PHASE1":1235,"PHASE2":1237,"PHASE3":1261,"PHASE4":1263,"NA":1265},{"trials":1234,"activeCount":100},[],{"trials":1236,"activeCount":100},[],{"trials":1238,"activeCount":531,"soonestReadout":385},[1239,1252],{"nctId":1240,"briefTitle":1241,"status":757,"phases":1242,"primaryCompletion":385,"completion":1041,"start":1243,"enrollment":1244,"conditions":1245,"interventions":1250},"NCT04613206","High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients",[89],"2021-01-11",396,[1246,1247,1248,1249],"Immunization; Infection","Transplantation Infection","Influenza","Solid Organ Transplant",[1231,1251],"Standard Dose Quadrivalent Inactivated Influenza Vaccine",{"nctId":1253,"briefTitle":1254,"status":157,"phases":1255,"primaryCompletion":1256,"completion":803,"start":1257,"enrollment":1258,"conditions":1259,"interventions":1260},"NCT05215327","High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients",[89],"2027-07-31","2022-11-08",270,[1246,1247,1248],[1231,1251],{"trials":1262,"activeCount":100},[],{"trials":1264,"activeCount":100},[],{"trials":1266,"activeCount":100},[],{"intervention":1251,"totalTrials":531,"cells":1268},{"EARLY_PHASE1":1269,"PHASE1":1271,"PHASE2":1273,"PHASE3":1283,"PHASE4":1285,"NA":1287},{"trials":1270,"activeCount":100},[],{"trials":1272,"activeCount":100},[],{"trials":1274,"activeCount":531,"soonestReadout":385},[1275,1279],{"nctId":1240,"briefTitle":1241,"status":757,"phases":1276,"primaryCompletion":385,"completion":1041,"start":1243,"enrollment":1244,"conditions":1277,"interventions":1278},[89],[1246,1247,1248,1249],[1231,1251],{"nctId":1253,"briefTitle":1254,"status":157,"phases":1280,"primaryCompletion":1256,"completion":803,"start":1257,"enrollment":1258,"conditions":1281,"interventions":1282},[89],[1246,1247,1248],[1231,1251],{"trials":1284,"activeCount":100},[],{"trials":1286,"activeCount":100},[],{"trials":1288,"activeCount":100},[],{"intervention":1056,"totalTrials":461,"cells":1290},{"EARLY_PHASE1":1291,"PHASE1":1293,"PHASE2":1306,"PHASE3":1326,"PHASE4":1328,"NA":1353},{"trials":1292,"activeCount":100},[],{"trials":1294,"activeCount":100},[1295],{"nctId":1296,"briefTitle":1297,"status":659,"phases":1298,"primaryCompletion":1299,"completion":1299,"start":1300,"enrollment":531,"conditions":1301,"interventions":1304},"NCT03201952","Examination of the Metabolic Effects of Direct Bile Salt Delivery to the Ileum in Humans",[88],"2020-05-01","2018-02-01",[1302,1303],"Glucose Intolerance","Gastric Bypass Surgery",[1305,1056],"Ursodeoxycholic Acid",{"trials":1307,"activeCount":138,"soonestReadout":1052},[1308,1322],{"nctId":1309,"briefTitle":1310,"status":108,"phases":1311,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":1316,"interventions":1320},"NCT03077724","Fish Oil to Reduce Tobacco Use iN Expectant Mothers Study",[89],"2018-01-23","2018-09-05","2017-03-02",28,[1317,1318,1319],"Tobacco Use in Childbirth","Smoking Cessation","Pregnancy Related",[1321,1056],"Fish oil",{"nctId":1049,"briefTitle":1050,"status":757,"phases":1323,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":527,"conditions":1324,"interventions":1325},[89],[1044,1045],[1029,1056],{"trials":1327,"activeCount":100},[],{"trials":1329,"activeCount":100},[1330,1343],{"nctId":1331,"briefTitle":1332,"status":108,"phases":1333,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":1336,"conditions":1337,"interventions":1339},"NCT03101930","Cardiovascular Effects of GLP-1 Receptor Activation",[91],"2021-06-24","2017-05-01",329,[16,1338],"PreDiabetes",[1340,1341,1056,1342],"Liraglutide","Sitagliptin","Exendin",{"nctId":1344,"briefTitle":1345,"status":605,"phases":1346,"primaryCompletion":1347,"completion":1347,"start":1348,"enrollment":100,"conditions":1349,"interventions":1351},"NCT02975583","Vorapaxar and Lower Extremity Bypass Grafts",[91],"2018-01-10","2017-10-01",[1350],"Peripheral Artery Disease",[1352,1056],"Vorapaxar",{"trials":1354,"activeCount":100},[],{"intervention":1321,"totalTrials":96,"cells":1356},{"EARLY_PHASE1":1357,"PHASE1":1359,"PHASE2":1361,"PHASE3":1377,"PHASE4":1379,"NA":1390},{"trials":1358,"activeCount":100},[],{"trials":1360,"activeCount":100},[],{"trials":1362,"activeCount":138,"soonestReadout":42},[1363,1367],{"nctId":1309,"briefTitle":1310,"status":108,"phases":1364,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":1365,"interventions":1366},[89],[1317,1318,1319],[1321,1056],{"nctId":40,"briefTitle":41,"status":757,"phases":1368,"primaryCompletion":42,"completion":1369,"start":1370,"enrollment":1371,"conditions":1372,"interventions":1375},[89],"2026-01-08","2020-11-10",400,[1373,1374],"Preterm Labor","Tobacco Use Disorder",[43,1376],"Olive Oil",{"trials":1378,"activeCount":100},[],{"trials":1380,"activeCount":100},[1381],{"nctId":1382,"briefTitle":1383,"status":108,"phases":1384,"primaryCompletion":1385,"completion":1385,"start":1386,"enrollment":1387,"conditions":1388,"interventions":1389},"NCT00552084","Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation",[91],"2014-04","2007-11",190,[1088],[1321],{"trials":1391,"activeCount":100},[],{"intervention":1223,"totalTrials":531,"cells":1393},{"EARLY_PHASE1":1394,"PHASE1":1396,"PHASE2":1398,"PHASE3":1404,"PHASE4":1406,"NA":1419},{"trials":1395,"activeCount":100},[],{"trials":1397,"activeCount":100},[],{"trials":1399,"activeCount":138,"soonestReadout":1217},[1400],{"nctId":1214,"briefTitle":1215,"status":157,"phases":1401,"primaryCompletion":1217,"completion":1218,"start":1219,"enrollment":1220,"conditions":1402,"interventions":1403},[88,89],[16,19],[1223,53],{"trials":1405,"activeCount":100},[],{"trials":1407,"activeCount":100},[1408],{"nctId":1409,"briefTitle":1410,"status":108,"phases":1411,"primaryCompletion":1412,"completion":1412,"start":1413,"enrollment":1414,"conditions":1415,"interventions":1417},"NCT02034435","Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism",[91],"2019-12","2013-10",44,[1416],"Metabolic Syndrome",[1418,1223],"Epleronone",{"trials":1420,"activeCount":100},[],{"intervention":1422,"totalTrials":96,"cells":1423},"Galantamine",{"EARLY_PHASE1":1424,"PHASE1":1426,"PHASE2":1439,"PHASE3":1462,"PHASE4":1464,"NA":1466},{"trials":1425,"activeCount":100},[],{"trials":1427,"activeCount":100},[1428],{"nctId":1429,"briefTitle":1430,"status":605,"phases":1431,"primaryCompletion":1432,"completion":1433,"start":1434,"enrollment":100,"conditions":1435,"interventions":1438},"NCT03014323","Racial Differences in Vagal Control of Glucose Homeostasis, Chronic Study",[88],"2018-11","2018-12","2017-01",[1436,1437],"Insulin Sensitivity","Oxidative Stress",[1422],{"trials":1440,"activeCount":138,"soonestReadout":1456},[1441,1452],{"nctId":1442,"briefTitle":1443,"status":108,"phases":1444,"primaryCompletion":1445,"completion":1445,"start":1446,"enrollment":1447,"conditions":1448,"interventions":1449},"NCT02365285","Racial Differences in Vagal Control of Glucose Homeostasis",[88,89],"2017-10-05","2015-03",23,[16],[1422,1450,1451],"Intralipid","Heparin",{"nctId":1453,"briefTitle":1454,"status":157,"phases":1455,"primaryCompletion":1456,"completion":1457,"start":1458,"enrollment":1459,"conditions":1460,"interventions":1461},"NCT04769206","Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans",[88,89],"2027-05-31","2028-06-01","2021-12-20",160,[358],[1422],{"trials":1463,"activeCount":100},[],{"trials":1465,"activeCount":100},[],{"trials":1467,"activeCount":100},[],{"intervention":1469,"totalTrials":531,"cells":1470},"Montelukast Oral Granules",{"EARLY_PHASE1":1471,"PHASE1":1473,"PHASE2":1475,"PHASE3":1501,"PHASE4":1503,"NA":1505},{"trials":1472,"activeCount":100},[],{"trials":1474,"activeCount":100},[],{"trials":1476,"activeCount":138,"soonestReadout":759},[1477,1491],{"nctId":1478,"briefTitle":1479,"status":605,"phases":1480,"primaryCompletion":1481,"completion":1482,"start":1483,"enrollment":100,"conditions":1484,"interventions":1490},"NCT03277170","Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations",[89],"2028-08-31","2029-09-05","2025-09-01",[1485,1486,1487,1488,1489],"Asthma; Status","Asthma in Children","Asthma Acute","Asthma Attack","Acute Asthma Exacerbation",[1469],{"nctId":1492,"briefTitle":1493,"status":157,"phases":1494,"primaryCompletion":759,"completion":759,"start":1495,"enrollment":1496,"conditions":1497,"interventions":1499},"NCT05819541","Treating Exacerbations of Asthma With Oral Montelukast in Children",[89],"2023-10-20",90,[1498],"Status Asthmaticus",[1469,956,1500],"Corticosteroid",{"trials":1502,"activeCount":100},[],{"trials":1504,"activeCount":100},[],{"trials":1506,"activeCount":100},[],{"intervention":1508,"totalTrials":531,"cells":1509},"Empagliflozin 25 MG",{"EARLY_PHASE1":1510,"PHASE1":1512,"PHASE2":1514,"PHASE3":1534,"PHASE4":1536,"NA":1538},{"trials":1511,"activeCount":100},[],{"trials":1513,"activeCount":100},[],{"trials":1515,"activeCount":138,"soonestReadout":1142},[1516,1525],{"nctId":1517,"briefTitle":1518,"status":108,"phases":1519,"primaryCompletion":1520,"completion":1520,"start":1521,"enrollment":527,"conditions":1522,"interventions":1524},"NCT04907214","SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot",[88,89],"2023-12-08","2021-07-29",[16,1523],"Pre-diabetes",[1508],{"nctId":1526,"briefTitle":1527,"status":157,"phases":1528,"primaryCompletion":1142,"completion":1529,"start":1530,"enrollment":1531,"conditions":1532,"interventions":1533},"NCT05972564","The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function",[88,89],"2026-12-30","2023-09-06",74,[16,1416],[1508],{"trials":1535,"activeCount":100},[],{"trials":1537,"activeCount":100},[],{"trials":1539,"activeCount":100},[],{"intervention":77,"totalTrials":138,"cells":1541},{"EARLY_PHASE1":1542,"PHASE1":1544,"PHASE2":1546,"PHASE3":1556,"PHASE4":1558,"NA":1560},{"trials":1543,"activeCount":100},[],{"trials":1545,"activeCount":100},[],{"trials":1547,"activeCount":138,"soonestReadout":76},[1548],{"nctId":74,"briefTitle":75,"status":157,"phases":1549,"primaryCompletion":76,"completion":76,"start":1550,"enrollment":697,"conditions":1551,"interventions":1554},[89],"2024-03-19",[1552,1553],"Postoperative Bleeding","Skin Cancer Face",[77,1555],"Control",{"trials":1557,"activeCount":100},[],{"trials":1559,"activeCount":100},[],{"trials":1561,"activeCount":100},[],{"intervention":1563,"totalTrials":138,"cells":1564},"Intravenous iron",{"EARLY_PHASE1":1565,"PHASE1":1567,"PHASE2":1569,"PHASE3":1580,"PHASE4":1582,"NA":1584},{"trials":1566,"activeCount":100},[],{"trials":1568,"activeCount":100},[],{"trials":1570,"activeCount":138,"soonestReadout":1575},[1571],{"nctId":1572,"briefTitle":1573,"status":157,"phases":1574,"primaryCompletion":1575,"completion":353,"start":1576,"enrollment":1220,"conditions":1577,"interventions":1579},"NCT07197905","Restoring Iron Deficiency in POTS",[89],"2026-10","2025-11-24",[1578],"POTS - Postural Orthostatic Tachycardia Syndrome",[1563],{"trials":1581,"activeCount":100},[],{"trials":1583,"activeCount":100},[],{"trials":1585,"activeCount":100},[],{"intervention":1587,"totalTrials":138,"cells":1588},"Fluzone High Dose Inactivated Influenza Vaccine",{"EARLY_PHASE1":1589,"PHASE1":1591,"PHASE2":1593,"PHASE3":1605,"PHASE4":1607,"NA":1609},{"trials":1590,"activeCount":100},[],{"trials":1592,"activeCount":100},[],{"trials":1594,"activeCount":138,"soonestReadout":1599},[1595],{"nctId":1596,"briefTitle":1597,"status":157,"phases":1598,"primaryCompletion":1599,"completion":914,"start":1600,"enrollment":1133,"conditions":1601,"interventions":1603},"NCT07192458","High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)",[89],"2028-12","2025-09-17",[1602,1248],"Immunization; Infection|Transplantation Infection|Influenza",[1587,1604],"Fluzone Standard Dose Inactivated Influenza Vaccine",{"trials":1606,"activeCount":100},[],{"trials":1608,"activeCount":100},[],{"trials":1610,"activeCount":100},[],{"intervention":1604,"totalTrials":138,"cells":1612},{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1617,"PHASE3":1623,"PHASE4":1625,"NA":1627},{"trials":1614,"activeCount":100},[],{"trials":1616,"activeCount":100},[],{"trials":1618,"activeCount":138,"soonestReadout":1599},[1619],{"nctId":1596,"briefTitle":1597,"status":157,"phases":1620,"primaryCompletion":1599,"completion":914,"start":1600,"enrollment":1133,"conditions":1621,"interventions":1622},[89],[1602,1248],[1587,1604],{"trials":1624,"activeCount":100},[],{"trials":1626,"activeCount":100},[],{"trials":1628,"activeCount":100},[],{"intervention":1630,"totalTrials":138,"cells":1631},"Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2",{"EARLY_PHASE1":1632,"PHASE1":1634,"PHASE2":1636,"PHASE3":1647,"PHASE4":1649,"NA":1651},{"trials":1633,"activeCount":100},[],{"trials":1635,"activeCount":100},[],{"trials":1637,"activeCount":138,"soonestReadout":1456},[1638],{"nctId":1639,"briefTitle":1640,"status":157,"phases":1641,"primaryCompletion":1456,"completion":1457,"start":1642,"enrollment":124,"conditions":1643,"interventions":1645},"NCT05375968","Splanchnic Venous Capacitance in Postural Tachycardia Syndrome",[89],"2023-02-25",[1644],"Postural Tachycardia Syndrome (POTS)",[1630,1646],"Compare change is SVC and SMA flow due to saline",{"trials":1648,"activeCount":100},[],{"trials":1650,"activeCount":100},[],{"trials":1652,"activeCount":100},[],{"intervention":1646,"totalTrials":138,"cells":1654},{"EARLY_PHASE1":1655,"PHASE1":1657,"PHASE2":1659,"PHASE3":1665,"PHASE4":1667,"NA":1669},{"trials":1656,"activeCount":100},[],{"trials":1658,"activeCount":100},[],{"trials":1660,"activeCount":138,"soonestReadout":1456},[1661],{"nctId":1639,"briefTitle":1640,"status":157,"phases":1662,"primaryCompletion":1456,"completion":1457,"start":1642,"enrollment":124,"conditions":1663,"interventions":1664},[89],[1644],[1630,1646],{"trials":1666,"activeCount":100},[],{"trials":1668,"activeCount":100},[],{"trials":1670,"activeCount":100},[],{"intervention":1146,"totalTrials":138,"cells":1672},{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1683,"PHASE4":1685,"NA":1687},{"trials":1674,"activeCount":100},[],{"trials":1676,"activeCount":100},[],{"trials":1678,"activeCount":138,"soonestReadout":1141},[1679],{"nctId":1138,"briefTitle":1139,"status":157,"phases":1680,"primaryCompletion":1141,"completion":1142,"start":1132,"enrollment":1133,"conditions":1681,"interventions":1682},[89],[1135],[1145,1146],{"trials":1684,"activeCount":100},[],{"trials":1686,"activeCount":100},[],{"trials":1688,"activeCount":100},[],{"intervention":1500,"totalTrials":138,"cells":1690},{"EARLY_PHASE1":1691,"PHASE1":1693,"PHASE2":1695,"PHASE3":1701,"PHASE4":1703,"NA":1705},{"trials":1692,"activeCount":100},[],{"trials":1694,"activeCount":100},[],{"trials":1696,"activeCount":138,"soonestReadout":759},[1697],{"nctId":1492,"briefTitle":1493,"status":157,"phases":1698,"primaryCompletion":759,"completion":759,"start":1495,"enrollment":1496,"conditions":1699,"interventions":1700},[89],[1498],[1469,956,1500],{"trials":1702,"activeCount":100},[],{"trials":1704,"activeCount":100},[],{"trials":1706,"activeCount":100},[],{"intervention":1708,"totalTrials":138,"cells":1709},"[18F]-FEOBV Radiotracer",{"EARLY_PHASE1":1710,"PHASE1":1712,"PHASE2":1714,"PHASE3":1727,"PHASE4":1729,"NA":1731},{"trials":1711,"activeCount":100},[],{"trials":1713,"activeCount":100},[],{"trials":1715,"activeCount":138,"soonestReadout":1720},[1716],{"nctId":1717,"briefTitle":1718,"status":157,"phases":1719,"primaryCompletion":1720,"completion":1720,"start":1721,"enrollment":762,"conditions":1722,"interventions":1726},"NCT05231798","Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition",[89],"2027-04-30","2021-08-19",[1723,1724,1725],"Down Syndrome","Down Syndrome, Partial Trisomy 21","Alzheimer Disease",[1708],{"trials":1728,"activeCount":100},[],{"trials":1730,"activeCount":100},[],{"trials":1732,"activeCount":100},[],{"intervention":1734,"totalTrials":138,"cells":1735},"Furosemide 40 mg",{"EARLY_PHASE1":1736,"PHASE1":1738,"PHASE2":1740,"PHASE3":1752,"PHASE4":1754,"NA":1756},{"trials":1737,"activeCount":100},[],{"trials":1739,"activeCount":100},[],{"trials":1741,"activeCount":138,"soonestReadout":1746},[1742],{"nctId":1743,"briefTitle":1744,"status":757,"phases":1745,"primaryCompletion":1746,"completion":1747,"start":1748,"enrollment":29,"conditions":1749,"interventions":1751},"NCT03753204","Salt-Sensitivity and Immunity Cell Activation",[88,89],"2026-09-01","2026-09-15","2021-09-01",[1107,1750,1108],"Salt; Excess",[1734],{"trials":1753,"activeCount":100},[],{"trials":1755,"activeCount":100},[],{"trials":1757,"activeCount":100},[],{"intervention":1759,"totalTrials":138,"cells":1760},"2-HOBA acetate",{"EARLY_PHASE1":1761,"PHASE1":1763,"PHASE2":1765,"PHASE3":1777,"PHASE4":1779,"NA":1781},{"trials":1762,"activeCount":100},[],{"trials":1764,"activeCount":100},[],{"trials":1766,"activeCount":138,"soonestReadout":1771},[1767],{"nctId":1768,"briefTitle":1769,"status":157,"phases":1770,"primaryCompletion":1771,"completion":1771,"start":1772,"enrollment":1773,"conditions":1774,"interventions":1776},"NCT07225543","2-HOBA in Systemic Lupus Erythematosus",[89],"2030-07-31","2026-05-15",42,[1775],"Systemic Lupus Erthematosus (SLE)",[1759],{"trials":1778,"activeCount":100},[],{"trials":1780,"activeCount":100},[],{"trials":1782,"activeCount":100},[],{"intervention":48,"totalTrials":138,"cells":1784},{"EARLY_PHASE1":1785,"PHASE1":1787,"PHASE2":1789,"PHASE3":1799,"PHASE4":1801,"NA":1803},{"trials":1786,"activeCount":100},[],{"trials":1788,"activeCount":100},[],{"trials":1790,"activeCount":138,"soonestReadout":47},[1791],{"nctId":45,"briefTitle":46,"status":757,"phases":1792,"primaryCompletion":47,"completion":1793,"start":1794,"enrollment":1315,"conditions":1795,"interventions":1798},[89],"2026-01-31","2022-07-27",[1796,1797],"Hemodialysis Complication","Hypotension of Hemodialysis",[48],{"trials":1800,"activeCount":100},[],{"trials":1802,"activeCount":100},[],{"trials":1804,"activeCount":100},[],{"intervention":1806,"totalTrials":138,"cells":1807},"Budesonide and Azithromycin",{"EARLY_PHASE1":1808,"PHASE1":1810,"PHASE2":1812,"PHASE3":1822,"PHASE4":1824,"NA":1826},{"trials":1809,"activeCount":100},[],{"trials":1811,"activeCount":100},[],{"trials":1813,"activeCount":138,"soonestReadout":1529},[1814],{"nctId":1815,"briefTitle":1816,"status":757,"phases":1817,"primaryCompletion":1529,"completion":1529,"start":1818,"enrollment":489,"conditions":1819,"interventions":1821},"NCT03250975","Incidence of Acute Laryngeal Injury Following Endotracheal Intubation",[88,89],"2017-08-19",[1820],"Intubation Complication",[1806],{"trials":1823,"activeCount":100},[],{"trials":1825,"activeCount":100},[],{"trials":1827,"activeCount":100},[],{"intervention":1376,"totalTrials":138,"cells":1829},{"EARLY_PHASE1":1830,"PHASE1":1832,"PHASE2":1834,"PHASE3":1840,"PHASE4":1842,"NA":1844},{"trials":1831,"activeCount":100},[],{"trials":1833,"activeCount":100},[],{"trials":1835,"activeCount":138,"soonestReadout":42},[1836],{"nctId":40,"briefTitle":41,"status":757,"phases":1837,"primaryCompletion":42,"completion":1369,"start":1370,"enrollment":1371,"conditions":1838,"interventions":1839},[89],[1373,1374],[43,1376],{"trials":1841,"activeCount":100},[],{"trials":1843,"activeCount":100},[],{"trials":1845,"activeCount":100},[],{"intervention":1847,"totalTrials":138,"cells":1848},"Amoxicillin-Clavulanate 875 Mg-125 Mg Oral",{"EARLY_PHASE1":1849,"PHASE1":1851,"PHASE2":1853,"PHASE3":1867,"PHASE4":1869,"NA":1871},{"trials":1850,"activeCount":100},[],{"trials":1852,"activeCount":100},[],{"trials":1854,"activeCount":138,"soonestReadout":1859},[1855],{"nctId":1856,"briefTitle":1857,"status":382,"phases":1858,"primaryCompletion":1859,"completion":1860,"start":1861,"enrollment":697,"conditions":1862,"interventions":1864},"NCT07492134","APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)",[89],"2028-04-01","2028-10-01","2026-04-01",[1863],"Acute Uncomplicated Diverticulitis",[1847,1865,1866],"Metronidazole","Cefuroxime",{"trials":1868,"activeCount":100},[],{"trials":1870,"activeCount":100},[],{"trials":1872,"activeCount":100},[],{"intervention":1865,"totalTrials":138,"cells":1874},{"EARLY_PHASE1":1875,"PHASE1":1877,"PHASE2":1879,"PHASE3":1885,"PHASE4":1887,"NA":1889},{"trials":1876,"activeCount":100},[],{"trials":1878,"activeCount":100},[],{"trials":1880,"activeCount":138,"soonestReadout":1859},[1881],{"nctId":1856,"briefTitle":1857,"status":382,"phases":1882,"primaryCompletion":1859,"completion":1860,"start":1861,"enrollment":697,"conditions":1883,"interventions":1884},[89],[1863],[1847,1865,1866],{"trials":1886,"activeCount":100},[],{"trials":1888,"activeCount":100},[],{"trials":1890,"activeCount":100},[],{"intervention":1866,"totalTrials":138,"cells":1892},{"EARLY_PHASE1":1893,"PHASE1":1895,"PHASE2":1897,"PHASE3":1903,"PHASE4":1905,"NA":1907},{"trials":1894,"activeCount":100},[],{"trials":1896,"activeCount":100},[],{"trials":1898,"activeCount":138,"soonestReadout":1859},[1899],{"nctId":1856,"briefTitle":1857,"status":382,"phases":1900,"primaryCompletion":1859,"completion":1860,"start":1861,"enrollment":697,"conditions":1901,"interventions":1902},[89],[1863],[1847,1865,1866],{"trials":1904,"activeCount":100},[],{"trials":1906,"activeCount":100},[],{"trials":1908,"activeCount":100},[],{"intervention":1910,"totalTrials":138,"cells":1911},"To Measure levels of circulating monocyte\u002F T cell doublets at Baseline",{"EARLY_PHASE1":1912,"PHASE1":1914,"PHASE2":1916,"PHASE3":1932,"PHASE4":1934,"NA":1936},{"trials":1913,"activeCount":100},[],{"trials":1915,"activeCount":100},[],{"trials":1917,"activeCount":138,"soonestReadout":1922},[1918],{"nctId":1919,"briefTitle":1920,"status":157,"phases":1921,"primaryCompletion":1922,"completion":1923,"start":1924,"enrollment":124,"conditions":1925,"interventions":1929},"NCT07189936","Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS",[89],"2028-06-30","2029-06-30","2025-12-18",[1926,1644,1927,1928],"Post-Acute COVID-19 Syndrome","SARS CoV 2 Infection","Long COVID19",[1910,1930,1931],"To measure levels of circulating monocyte\u002F T cell doublets after 28 days of 2 HOBA treatment","To measure levels of circulating monocyte\u002F T cell doublets after 28 days of Placebo treatment",{"trials":1933,"activeCount":100},[],{"trials":1935,"activeCount":100},[],{"trials":1937,"activeCount":100},[],{"intervention":1930,"totalTrials":138,"cells":1939},{"EARLY_PHASE1":1940,"PHASE1":1942,"PHASE2":1944,"PHASE3":1950,"PHASE4":1952,"NA":1954},{"trials":1941,"activeCount":100},[],{"trials":1943,"activeCount":100},[],{"trials":1945,"activeCount":138,"soonestReadout":1922},[1946],{"nctId":1919,"briefTitle":1920,"status":157,"phases":1947,"primaryCompletion":1922,"completion":1923,"start":1924,"enrollment":124,"conditions":1948,"interventions":1949},[89],[1926,1644,1927,1928],[1910,1930,1931],{"trials":1951,"activeCount":100},[],{"trials":1953,"activeCount":100},[],{"trials":1955,"activeCount":100},[],{"intervention":1931,"totalTrials":138,"cells":1957},{"EARLY_PHASE1":1958,"PHASE1":1960,"PHASE2":1962,"PHASE3":1968,"PHASE4":1970,"NA":1972},{"trials":1959,"activeCount":100},[],{"trials":1961,"activeCount":100},[],{"trials":1963,"activeCount":138,"soonestReadout":1922},[1964],{"nctId":1919,"briefTitle":1920,"status":157,"phases":1965,"primaryCompletion":1922,"completion":1923,"start":1924,"enrollment":124,"conditions":1966,"interventions":1967},[89],[1926,1644,1927,1928],[1910,1930,1931],{"trials":1969,"activeCount":100},[],{"trials":1971,"activeCount":100},[],{"trials":1973,"activeCount":100},[],{"intervention":1975,"totalTrials":138,"cells":1976},"Lovastatin",{"EARLY_PHASE1":1977,"PHASE1":1979,"PHASE2":1981,"PHASE3":1995,"PHASE4":1997,"NA":1999},{"trials":1978,"activeCount":100},[],{"trials":1980,"activeCount":100},[],{"trials":1982,"activeCount":138,"soonestReadout":1987},[1983],{"nctId":1984,"briefTitle":1985,"status":757,"phases":1986,"primaryCompletion":1987,"completion":1987,"start":1988,"enrollment":162,"conditions":1989,"interventions":1994},"NCT02964884","Interventions for Reading Disabilities in NF1",[89],"2027-01","2016-11",[1990,1991,1992,1993],"Neurofibromatosis Type 1","Learning Disability","Reading Disability","NF1",[1975],{"trials":1996,"activeCount":100},[],{"trials":1998,"activeCount":100},[],{"trials":2000,"activeCount":100},[],{"intervention":2002,"totalTrials":138,"cells":2003},"CO2 gel mask",{"EARLY_PHASE1":2004,"PHASE1":2006,"PHASE2":2008,"PHASE3":2017,"PHASE4":2019,"NA":2021},{"trials":2005,"activeCount":100},[],{"trials":2007,"activeCount":100},[],{"trials":2009,"activeCount":138,"soonestReadout":453},[2010],{"nctId":2011,"briefTitle":2012,"status":382,"phases":2013,"primaryCompletion":453,"completion":453,"start":385,"enrollment":29,"conditions":2014,"interventions":2016},"NCT07431541","Topical Carboxytherapy Paste Following Microneedling",[88,89],[2015],"Skin",[2002],{"trials":2018,"activeCount":100},[],{"trials":2020,"activeCount":100},[],{"trials":2022,"activeCount":100},[],{"intervention":976,"totalTrials":138,"cells":2024},{"EARLY_PHASE1":2025,"PHASE1":2027,"PHASE2":2029,"PHASE3":2035,"PHASE4":2037,"NA":2039},{"trials":2026,"activeCount":100},[],{"trials":2028,"activeCount":100},[],{"trials":2030,"activeCount":138,"soonestReadout":76},[2031],{"nctId":969,"briefTitle":970,"status":157,"phases":2032,"primaryCompletion":76,"completion":76,"start":646,"enrollment":412,"conditions":2033,"interventions":2034},[89],[973,974],[976,891],{"trials":2036,"activeCount":100},[],{"trials":2038,"activeCount":100},[],{"trials":2040,"activeCount":100},[],{"intervention":2042,"totalTrials":138,"cells":2043},"Semaglutide Pen Injector 2.4mg weekly",{"EARLY_PHASE1":2044,"PHASE1":2046,"PHASE2":2048,"PHASE3":2058,"PHASE4":2060,"NA":2062},{"trials":2045,"activeCount":100},[],{"trials":2047,"activeCount":100},[],{"trials":2049,"activeCount":138,"soonestReadout":853},[2050],{"nctId":2051,"briefTitle":2052,"status":157,"phases":2053,"primaryCompletion":853,"completion":353,"start":2054,"enrollment":697,"conditions":2055,"interventions":2057},"NCT05254314","Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)",[89],"2022-10-11",[2056],"Asthma",[2042],{"trials":2059,"activeCount":100},[],{"trials":2061,"activeCount":100},[],{"trials":2063,"activeCount":100},[],{"intervention":2065,"totalTrials":138,"cells":2066},"Protocolized diuretic therapy",{"EARLY_PHASE1":2067,"PHASE1":2069,"PHASE2":2071,"PHASE3":2082,"PHASE4":2084,"NA":2086},{"trials":2068,"activeCount":100},[],{"trials":2070,"activeCount":100},[],{"trials":2072,"activeCount":138,"soonestReadout":1142},[2073],{"nctId":2074,"briefTitle":2075,"status":757,"phases":2076,"primaryCompletion":1142,"completion":1041,"start":2077,"enrollment":2078,"conditions":2079,"interventions":2081},"NCT04481919","Randomized Controlled Trial of urinE chemiStry Guided aCute heArt faiLure treATmEnt (ESCALATE)",[89],"2022-05-01",474,[651,2080],"Acute Heart Failure",[2065],{"trials":2083,"activeCount":100},[],{"trials":2085,"activeCount":100},[],{"trials":2087,"activeCount":100},[],{"intervention":956,"totalTrials":96,"cells":2089},{"EARLY_PHASE1":2090,"PHASE1":2092,"PHASE2":2094,"PHASE3":2104,"PHASE4":2106,"NA":2108},{"trials":2091,"activeCount":100},[],{"trials":2093,"activeCount":100},[],{"trials":2095,"activeCount":138,"soonestReadout":759},[2096,2100],{"nctId":1492,"briefTitle":1493,"status":157,"phases":2097,"primaryCompletion":759,"completion":759,"start":1495,"enrollment":1496,"conditions":2098,"interventions":2099},[89],[1498],[1469,956,1500],{"nctId":944,"briefTitle":945,"status":108,"phases":2101,"primaryCompletion":947,"completion":948,"start":949,"enrollment":950,"conditions":2102,"interventions":2103},[89],[952,953,954],[956,891],{"trials":2105,"activeCount":100},[],{"trials":2107,"activeCount":100},[],{"trials":2109,"activeCount":100},[2110],{"nctId":2111,"briefTitle":2112,"status":108,"phases":2113,"primaryCompletion":2114,"completion":2114,"start":2115,"enrollment":2116,"conditions":2117,"interventions":2119},"NCT01196377","Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study",[92],"2010-10","2010-09",16,[2118],"Acute Asthma",[956],{"intervention":1555,"totalTrials":531,"cells":2121},{"EARLY_PHASE1":2122,"PHASE1":2124,"PHASE2":2126,"PHASE3":2132,"PHASE4":2134,"NA":2136},{"trials":2123,"activeCount":100},[],{"trials":2125,"activeCount":100},[],{"trials":2127,"activeCount":138,"soonestReadout":76},[2128],{"nctId":74,"briefTitle":75,"status":157,"phases":2129,"primaryCompletion":76,"completion":76,"start":1550,"enrollment":697,"conditions":2130,"interventions":2131},[89],[1552,1553],[77,1555],{"trials":2133,"activeCount":100},[],{"trials":2135,"activeCount":100},[],{"trials":2137,"activeCount":100},[2138],{"nctId":2139,"briefTitle":2140,"status":108,"phases":2141,"primaryCompletion":682,"completion":682,"start":2142,"enrollment":1172,"conditions":2143,"interventions":2144},"NCT00685945","Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3",[92],"2007-12",[16],[1555,2145,2146,2147],"L-NMMA + bradykinin","Isosorbide + L-NMMA + bradykinin","Sildenafil + L-NMMA + bradykinin",{"intervention":2149,"totalTrials":2150,"cells":2151},"Trimethaphan",8,{"EARLY_PHASE1":2152,"PHASE1":2154,"PHASE2":2221,"PHASE3":2223,"PHASE4":2225,"NA":2227},{"trials":2153,"activeCount":100},[],{"trials":2155,"activeCount":531,"soonestReadout":1104},[2156,2164,2172,2180,2189,2198,2208],{"nctId":2157,"briefTitle":2158,"status":757,"phases":2159,"primaryCompletion":1104,"completion":298,"start":2160,"enrollment":1220,"conditions":2161,"interventions":2162},"NCT02425566","Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension",[88],"2015-04",[19],[2149,2163],"Nitroglycerin",{"nctId":2165,"briefTitle":2166,"status":108,"phases":2167,"primaryCompletion":1434,"completion":1434,"start":2168,"enrollment":2169,"conditions":2170,"interventions":2171},"NCT01137253","Autonomic Nervous System and Nitric Oxide Interactions",[88],"2010-06",21,[358],[2149],{"nctId":2173,"briefTitle":2174,"status":108,"phases":2175,"primaryCompletion":1988,"completion":1988,"start":2176,"enrollment":20,"conditions":2177,"interventions":2178},"NCT01122407","Pathophysiology of Cardiometabolic Risk Factors in African Americans",[88],"2010-01",[16,19],[2179,2149],"L-NMMA",{"nctId":2181,"briefTitle":2182,"status":757,"phases":2183,"primaryCompletion":353,"completion":353,"start":2184,"enrollment":531,"conditions":2185,"interventions":2188},"NCT02726711","Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic",[88],"2016-04",[926,2186,2187],"Orthostatic Hypotension","Supine Hypertension",[2149],{"nctId":2190,"briefTitle":2191,"status":605,"phases":2192,"primaryCompletion":2193,"completion":2194,"start":2195,"enrollment":100,"conditions":2196,"interventions":2197},"NCT03028571","Autonomic Blockade and Endogenous Glucose Production",[88],"2022-12-31","2024-12-31","2017-04-17",[916],[2149],{"nctId":2199,"briefTitle":2200,"status":659,"phases":2201,"primaryCompletion":2202,"completion":2202,"start":2203,"enrollment":1172,"conditions":2204,"interventions":2206},"NCT02245230","Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension",[88],"2023-12","2015-01",[19,2205],"Hypertension, Essential",[2207,2149,565],"Angiotensin",{"nctId":2209,"briefTitle":2210,"status":108,"phases":2211,"primaryCompletion":1434,"completion":1434,"start":2212,"enrollment":2213,"conditions":2214,"interventions":2219},"NCT00179023","The Autonomic Nervous System and Obesity",[88],"2003-04",128,[2215,2216,2217,2218],"OBESITY","HYPERTENSION","PURE AUTONOMIC FAILURE","SHY-DRAGER SYNDROME",[2149,2149,2220],"Pseudoephedrine",{"trials":2222,"activeCount":100},[],{"trials":2224,"activeCount":100},[],{"trials":2226,"activeCount":100},[],{"trials":2228,"activeCount":100},[2229],{"nctId":2230,"briefTitle":2231,"status":108,"phases":2232,"primaryCompletion":2233,"completion":2233,"start":133,"enrollment":2234,"conditions":2235,"interventions":2236},"NCT00178919","Nitric Oxide and the Autonomic Nervous System",[92],"2008-08",112,[19,903],[2179,2149],{"intervention":2238,"totalTrials":2239,"cells":2240},"Midodrine",4,{"EARLY_PHASE1":2241,"PHASE1":2255,"PHASE2":2271,"PHASE3":2281,"PHASE4":2283,"NA":2285},{"trials":2242,"activeCount":100},[2243],{"nctId":2244,"briefTitle":2245,"status":108,"phases":2246,"primaryCompletion":2247,"completion":2248,"start":2249,"enrollment":2250,"conditions":2251,"interventions":2254},"NCT04620382","Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients",[87],"2025-07-01","2025-12-01","2020-11-09",31,[2252,2253,903,926,303],"Neurogenic Orthostatic Hypotension","Autonomic Failure",[2238],{"trials":2256,"activeCount":138,"soonestReadout":853},[2257,2264],{"nctId":2258,"briefTitle":2259,"status":108,"phases":2260,"primaryCompletion":52,"completion":52,"start":2160,"enrollment":2169,"conditions":2261,"interventions":2262},"NCT02429557","Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure",[88],[2186,903,926,2253],[2263],"midodrine",{"nctId":2265,"briefTitle":2266,"status":157,"phases":2267,"primaryCompletion":853,"completion":353,"start":936,"enrollment":20,"conditions":2268,"interventions":2269},"NCT02897063","Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure",[88],[2253,903,926,303,2186],[2270,2238],"Droxidopa",{"trials":2272,"activeCount":100},[2273],{"nctId":2274,"briefTitle":2275,"status":108,"phases":2276,"primaryCompletion":2277,"completion":2277,"start":2278,"enrollment":1315,"conditions":2279,"interventions":2280},"NCT03482297","Automated Abdominal Binder for Orthostatic Hypotension",[88,89],"2025-11-19","2018-03-01",[2186,2253,903,926],[2238],{"trials":2282,"activeCount":100},[],{"trials":2284,"activeCount":100},[],{"trials":2286,"activeCount":100},[],{"intervention":907,"totalTrials":531,"cells":2288},{"EARLY_PHASE1":2289,"PHASE1":2295,"PHASE2":2301,"PHASE3":2303,"PHASE4":2305,"NA":2307},{"trials":2290,"activeCount":100},[2291],{"nctId":896,"briefTitle":897,"status":659,"phases":2292,"primaryCompletion":899,"completion":899,"start":662,"enrollment":900,"conditions":2293,"interventions":2294},[87],[902,903,904,905],[907,891],{"trials":2296,"activeCount":138,"soonestReadout":914},[2297],{"nctId":911,"briefTitle":912,"status":157,"phases":2298,"primaryCompletion":914,"completion":914,"start":662,"enrollment":23,"conditions":2299,"interventions":2300},[88],[16,916,19,917],[907,891],{"trials":2302,"activeCount":100},[],{"trials":2304,"activeCount":100},[],{"trials":2306,"activeCount":100},[],{"trials":2308,"activeCount":100},[],{"intervention":2310,"totalTrials":531,"cells":2311},"Sodium Nitroprusside",{"EARLY_PHASE1":2312,"PHASE1":2314,"PHASE2":2336,"PHASE3":2338,"PHASE4":2340,"NA":2342},{"trials":2313,"activeCount":100},[],{"trials":2315,"activeCount":138,"soonestReadout":2328},[2316,2324],{"nctId":2317,"briefTitle":2318,"status":659,"phases":2319,"primaryCompletion":1434,"completion":1434,"start":2320,"enrollment":2150,"conditions":2321,"interventions":2322},"NCT00580905","Role of Adenosine in the Release of VEGF and Cytokines",[88],"2007-06",[1108],[2323,2310,2323],"Adenosine",{"nctId":2325,"briefTitle":2326,"status":757,"phases":2327,"primaryCompletion":2328,"completion":2329,"start":2330,"enrollment":2331,"conditions":2332,"interventions":2334},"NCT03318094","Role of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity",[88],"2026-11-30","2027-11-30","2017-10-24",36,[916,2333,16],"Healthy",[2335,2310],"Phentolamine",{"trials":2337,"activeCount":100},[],{"trials":2339,"activeCount":100},[],{"trials":2341,"activeCount":100},[],{"trials":2343,"activeCount":100},[],{"intervention":2163,"totalTrials":138,"cells":2345},{"EARLY_PHASE1":2346,"PHASE1":2348,"PHASE2":2354,"PHASE3":2356,"PHASE4":2358,"NA":2360},{"trials":2347,"activeCount":100},[],{"trials":2349,"activeCount":138,"soonestReadout":1104},[2350],{"nctId":2157,"briefTitle":2158,"status":757,"phases":2351,"primaryCompletion":1104,"completion":298,"start":2160,"enrollment":1220,"conditions":2352,"interventions":2353},[88],[19],[2149,2163],{"trials":2355,"activeCount":100},[],{"trials":2357,"activeCount":100},[],{"trials":2359,"activeCount":100},[],{"trials":2361,"activeCount":100},[],{"intervention":2363,"totalTrials":138,"cells":2364},"Tranexamic acid",{"EARLY_PHASE1":2365,"PHASE1":2367,"PHASE2":2379,"PHASE3":2381,"PHASE4":2383,"NA":2385},{"trials":2366,"activeCount":100},[],{"trials":2368,"activeCount":138,"soonestReadout":2373},[2369],{"nctId":2370,"briefTitle":2371,"status":157,"phases":2372,"primaryCompletion":2373,"completion":2373,"start":2374,"enrollment":1133,"conditions":2375,"interventions":2378},"NCT05774717","Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis",[88],"2029-04-01","2023-04-01",[2376,2377],"Surgery","Postoperative Blood Loss",[2363],{"trials":2380,"activeCount":100},[],{"trials":2382,"activeCount":100},[],{"trials":2384,"activeCount":100},[],{"trials":2386,"activeCount":100},[],{"intervention":2388,"totalTrials":138,"cells":2389},"Ketone monoester",{"EARLY_PHASE1":2390,"PHASE1":2392,"PHASE2":2402,"PHASE3":2404,"PHASE4":2406,"NA":2408},{"trials":2391,"activeCount":100},[],{"trials":2393,"activeCount":138,"soonestReadout":1041},[2394],{"nctId":2395,"briefTitle":2396,"status":382,"phases":2397,"primaryCompletion":1041,"completion":803,"start":2398,"enrollment":412,"conditions":2399,"interventions":2401},"NCT07364162","Exogenous Ketone Supplementation in ICU Delirium",[88],"2026-04-06",[2400,31],"ICU Delirium",[2388],{"trials":2403,"activeCount":100},[],{"trials":2405,"activeCount":100},[],{"trials":2407,"activeCount":100},[],{"trials":2409,"activeCount":100},[],{"intervention":2411,"totalTrials":138,"cells":2412},"Tacrolimus ointment",{"EARLY_PHASE1":2413,"PHASE1":2415,"PHASE2":2425,"PHASE3":2427,"PHASE4":2429,"NA":2431},{"trials":2414,"activeCount":100},[],{"trials":2416,"activeCount":138,"soonestReadout":880},[2417],{"nctId":2418,"briefTitle":2419,"status":157,"phases":2420,"primaryCompletion":880,"completion":1457,"start":2421,"enrollment":32,"conditions":2422,"interventions":2424},"NCT05856994","Clinical Assessment of Protopic® Ointment in Deep Partial-Thickness Burns",[88],"2024-09-19",[2423],"Burn Injury",[2411],{"trials":2426,"activeCount":100},[],{"trials":2428,"activeCount":100},[],{"trials":2430,"activeCount":100},[],{"trials":2432,"activeCount":100},[],{"intervention":2434,"totalTrials":138,"cells":2435},"Pyridostigmine Pill",{"EARLY_PHASE1":2436,"PHASE1":2438,"PHASE2":2448,"PHASE3":2450,"PHASE4":2452,"NA":2454},{"trials":2437,"activeCount":100},[],{"trials":2439,"activeCount":138,"soonestReadout":76},[2440],{"nctId":2441,"briefTitle":2442,"status":757,"phases":2443,"primaryCompletion":76,"completion":353,"start":2444,"enrollment":624,"conditions":2445,"interventions":2446},"NCT03124355","Vagal Stimulation in POTS",[88],"2017-09-30",[37],[2434,2447],"Galantamine Pill",{"trials":2449,"activeCount":100},[],{"trials":2451,"activeCount":100},[],{"trials":2453,"activeCount":100},[],{"trials":2455,"activeCount":100},[],{"intervention":2447,"totalTrials":138,"cells":2457},{"EARLY_PHASE1":2458,"PHASE1":2460,"PHASE2":2466,"PHASE3":2468,"PHASE4":2470,"NA":2472},{"trials":2459,"activeCount":100},[],{"trials":2461,"activeCount":138,"soonestReadout":76},[2462],{"nctId":2441,"briefTitle":2442,"status":757,"phases":2463,"primaryCompletion":76,"completion":353,"start":2444,"enrollment":624,"conditions":2464,"interventions":2465},[88],[37],[2434,2447],{"trials":2467,"activeCount":100},[],{"trials":2469,"activeCount":100},[],{"trials":2471,"activeCount":100},[],{"trials":2473,"activeCount":100},[],{"intervention":2335,"totalTrials":138,"cells":2475},{"EARLY_PHASE1":2476,"PHASE1":2478,"PHASE2":2484,"PHASE3":2486,"PHASE4":2488,"NA":2490},{"trials":2477,"activeCount":100},[],{"trials":2479,"activeCount":138,"soonestReadout":2328},[2480],{"nctId":2325,"briefTitle":2326,"status":757,"phases":2481,"primaryCompletion":2328,"completion":2329,"start":2330,"enrollment":2331,"conditions":2482,"interventions":2483},[88],[916,2333,16],[2335,2310],{"trials":2485,"activeCount":100},[],{"trials":2487,"activeCount":100},[],{"trials":2489,"activeCount":100},[],{"trials":2491,"activeCount":100},[],{"intervention":2270,"totalTrials":96,"cells":2493},{"EARLY_PHASE1":2494,"PHASE1":2496,"PHASE2":2502,"PHASE3":2504,"PHASE4":2506,"NA":2518},{"trials":2495,"activeCount":100},[],{"trials":2497,"activeCount":138,"soonestReadout":853},[2498],{"nctId":2265,"briefTitle":2266,"status":157,"phases":2499,"primaryCompletion":853,"completion":353,"start":936,"enrollment":20,"conditions":2500,"interventions":2501},[88],[2253,903,926,303,2186],[2270,2238],{"trials":2503,"activeCount":100},[],{"trials":2505,"activeCount":100},[],{"trials":2507,"activeCount":100},[2508],{"nctId":2509,"briefTitle":2510,"status":108,"phases":2511,"primaryCompletion":2512,"completion":2512,"start":2513,"enrollment":2514,"conditions":2515,"interventions":2516},"NCT03115827","Norepinephrine-targeted Therapy for Action Control in Parkinson Disease",[91],"2018-12-21","2017-04-18",15,[303],[2270,2517],"Carbidopa",{"trials":2519,"activeCount":100},[2520],{"nctId":2521,"briefTitle":2522,"status":2523,"phases":2524,"primaryCompletion":1062,"completion":1062,"start":2525,"conditions":2526,"interventions":2528},"NCT00889135","Long Term Treatment With L-DOPS","APPROVED_FOR_MARKETING",[],"2004-09",[2527],"Dopamine Beta Hydroxylase (DBH) Deficiency",[2529],"droxidopa",{"intervention":2531,"totalTrials":96,"cells":2532},"Prednisone",{"EARLY_PHASE1":2533,"PHASE1":2547,"PHASE2":2560,"PHASE3":2572,"PHASE4":2574,"NA":2576},{"trials":2534,"activeCount":138,"soonestReadout":453},[2535],{"nctId":2536,"briefTitle":2537,"status":157,"phases":2538,"primaryCompletion":453,"completion":803,"start":2539,"enrollment":1206,"conditions":2540,"interventions":2542},"NCT04469842","Early Use of Long-acting Tacrolimus in Lung Transplant Recipients",[87],"2023-12-01",[2541],"Lung Transplant; Complications",[2543,2544,2545,2531,2546],"Tacrolimus Extended Release Oral Tablet [Envarsus]","Tacrolimus","Mycophenolate Mofetil Hydrochloride","Azathioprine",{"trials":2548,"activeCount":100},[2549],{"nctId":2550,"briefTitle":2551,"status":108,"phases":2552,"primaryCompletion":2553,"completion":2554,"start":2555,"enrollment":2556,"conditions":2557,"interventions":2559},"NCT03023891","Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids",[88],"2019-01-10","2019-12-31","2017-02-15",25,[2558,1302],"Glucocorticoids Toxicity",[2531],{"trials":2561,"activeCount":100},[2562],{"nctId":2563,"briefTitle":2564,"status":605,"phases":2565,"primaryCompletion":2566,"completion":2566,"start":2567,"enrollment":100,"conditions":2568,"interventions":2571},"NCT04652414","Corticosteroids in Community Acquired Pneumonia",[89],"2022-07-30","2020-12-01",[2569,2570],"Community-acquired Pneumonia","Cognition Disorder",[2531],{"trials":2573,"activeCount":100},[],{"trials":2575,"activeCount":100},[],{"trials":2577,"activeCount":100},[],{"intervention":2579,"totalTrials":531,"cells":2580},"Modafinil",{"EARLY_PHASE1":2581,"PHASE1":2591,"PHASE2":2619,"PHASE3":2621,"PHASE4":2623,"NA":2625},{"trials":2582,"activeCount":138,"soonestReadout":353},[2583],{"nctId":2584,"briefTitle":2585,"status":757,"phases":2586,"primaryCompletion":353,"completion":353,"start":2587,"enrollment":29,"conditions":2588,"interventions":2589},"NCT01988883","Modafinil and Cognitive Function in POTS",[87],"2014-10",[37],[2579,2590],"Propranolol",{"trials":2592,"activeCount":100},[2593],{"nctId":2594,"briefTitle":2595,"status":108,"phases":2596,"primaryCompletion":1434,"completion":1434,"start":2597,"enrollment":2598,"conditions":2599,"interventions":2600},"NCT00223691","Treatment of Orthostatic Hypotension in Autonomic Failure",[88],"2002-03",389,[2253,2186],[2601,2602,2603,2604,2605,2579,2606,2607,2608,2609,2610,2611,2220,2612,2613,2614,2615,2616,2617,2618],"Atomoxetine","Acarbose","Pyridostigmine Bromide","Yohimbine","Midodrine HCl","Octreotide","Diphenhydramine Hydrochloride","Ranitidine HCL","Tranylcypromine","Ergotamine\u002F Caffeine","Celecoxib","Methylphenidate","Indomethacin","Ibuprofen","Oxymetazoline 0.05% nasal solution","Acetazolamide","Rivastigmine tartrate","Carbidopa\u002Flevodopa",{"trials":2620,"activeCount":100},[],{"trials":2622,"activeCount":100},[],{"trials":2624,"activeCount":100},[],{"trials":2626,"activeCount":100},[],{"intervention":2628,"totalTrials":531,"cells":2629},"Donepezil",{"EARLY_PHASE1":2630,"PHASE1":2639,"PHASE2":2652,"PHASE3":2654,"PHASE4":2656,"NA":2658},{"trials":2631,"activeCount":138,"soonestReadout":1746},[2632],{"nctId":2633,"briefTitle":2634,"status":757,"phases":2635,"primaryCompletion":1746,"completion":1746,"start":1001,"enrollment":124,"conditions":2636,"interventions":2638},"NCT05438264","Effect of Donepezil on Speech Recognition in Cochlear Implant Users",[87],[2637],"Bilateral Sensorineural Hearing Loss",[2628],{"trials":2640,"activeCount":100},[2641],{"nctId":2642,"briefTitle":2643,"status":108,"phases":2644,"primaryCompletion":2645,"completion":2645,"start":2646,"enrollment":2647,"conditions":2648,"interventions":2650},"NCT00408525","Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease",[88],"2012-08-24","2006-12",41,[2649],"Alzheimer's Disease",[2651],"donepezil",{"trials":2653,"activeCount":100},[],{"trials":2655,"activeCount":100},[],{"trials":2657,"activeCount":100},[],{"trials":2659,"activeCount":100},[],{"intervention":2661,"totalTrials":531,"cells":2662},"Mecamylamine Challenge",{"EARLY_PHASE1":2663,"PHASE1":2684,"PHASE2":2686,"PHASE3":2688,"PHASE4":2690,"NA":2692},{"trials":2664,"activeCount":138,"soonestReadout":1922},[2665,2674],{"nctId":2666,"briefTitle":2667,"status":157,"phases":2668,"primaryCompletion":1922,"completion":1922,"start":2669,"enrollment":2670,"conditions":2671,"interventions":2673},"NCT06002477","Attentional Mechanisms in SCD",[87],"2025-03-27",80,[2672],"Subjective Cognitive Decline",[2661],{"nctId":2675,"briefTitle":2676,"status":108,"phases":2677,"primaryCompletion":2678,"completion":2679,"start":2680,"enrollment":2681,"conditions":2682,"interventions":2683},"NCT04756232","Cholinergic Mechanisms of Attention in Aging",[87],"2025-04-30","2025-05-01","2022-04-21",19,[2672],[2661],{"trials":2685,"activeCount":100},[],{"trials":2687,"activeCount":100},[],{"trials":2689,"activeCount":100},[],{"trials":2691,"activeCount":100},[],{"trials":2693,"activeCount":100},[],{"intervention":2590,"totalTrials":138,"cells":2695},{"EARLY_PHASE1":2696,"PHASE1":2702,"PHASE2":2704,"PHASE3":2706,"PHASE4":2708,"NA":2710},{"trials":2697,"activeCount":138,"soonestReadout":353},[2698],{"nctId":2584,"briefTitle":2585,"status":757,"phases":2699,"primaryCompletion":353,"completion":353,"start":2587,"enrollment":29,"conditions":2700,"interventions":2701},[87],[37],[2579,2590],{"trials":2703,"activeCount":100},[],{"trials":2705,"activeCount":100},[],{"trials":2707,"activeCount":100},[],{"trials":2709,"activeCount":100},[],{"trials":2711,"activeCount":100},[],{"intervention":2543,"totalTrials":138,"cells":2713},{"EARLY_PHASE1":2714,"PHASE1":2720,"PHASE2":2722,"PHASE3":2724,"PHASE4":2726,"NA":2728},{"trials":2715,"activeCount":138,"soonestReadout":453},[2716],{"nctId":2536,"briefTitle":2537,"status":157,"phases":2717,"primaryCompletion":453,"completion":803,"start":2539,"enrollment":1206,"conditions":2718,"interventions":2719},[87],[2541],[2543,2544,2545,2531,2546],{"trials":2721,"activeCount":100},[],{"trials":2723,"activeCount":100},[],{"trials":2725,"activeCount":100},[],{"trials":2727,"activeCount":100},[],{"trials":2729,"activeCount":100},[],{"intervention":2544,"totalTrials":138,"cells":2731},{"EARLY_PHASE1":2732,"PHASE1":2738,"PHASE2":2740,"PHASE3":2742,"PHASE4":2744,"NA":2746},{"trials":2733,"activeCount":138,"soonestReadout":453},[2734],{"nctId":2536,"briefTitle":2537,"status":157,"phases":2735,"primaryCompletion":453,"completion":803,"start":2539,"enrollment":1206,"conditions":2736,"interventions":2737},[87],[2541],[2543,2544,2545,2531,2546],{"trials":2739,"activeCount":100},[],{"trials":2741,"activeCount":100},[],{"trials":2743,"activeCount":100},[],{"trials":2745,"activeCount":100},[],{"trials":2747,"activeCount":100},[],{"intervention":2545,"totalTrials":138,"cells":2749},{"EARLY_PHASE1":2750,"PHASE1":2756,"PHASE2":2758,"PHASE3":2760,"PHASE4":2762,"NA":2764},{"trials":2751,"activeCount":138,"soonestReadout":453},[2752],{"nctId":2536,"briefTitle":2537,"status":157,"phases":2753,"primaryCompletion":453,"completion":803,"start":2539,"enrollment":1206,"conditions":2754,"interventions":2755},[87],[2541],[2543,2544,2545,2531,2546],{"trials":2757,"activeCount":100},[],{"trials":2759,"activeCount":100},[],{"trials":2761,"activeCount":100},[],{"trials":2763,"activeCount":100},[],{"trials":2765,"activeCount":100},[],{"intervention":2546,"totalTrials":138,"cells":2767},{"EARLY_PHASE1":2768,"PHASE1":2774,"PHASE2":2776,"PHASE3":2778,"PHASE4":2780,"NA":2782},{"trials":2769,"activeCount":138,"soonestReadout":453},[2770],{"nctId":2536,"briefTitle":2537,"status":157,"phases":2771,"primaryCompletion":453,"completion":803,"start":2539,"enrollment":1206,"conditions":2772,"interventions":2773},[87],[2541],[2543,2544,2545,2531,2546],{"trials":2775,"activeCount":100},[],{"trials":2777,"activeCount":100},[],{"trials":2779,"activeCount":100},[],{"trials":2781,"activeCount":100},[],{"trials":2783,"activeCount":100},[],{"intervention":2785,"totalTrials":138,"cells":2786},"Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor",{"EARLY_PHASE1":2787,"PHASE1":2803,"PHASE2":2805,"PHASE3":2807,"PHASE4":2809,"NA":2811},{"trials":2788,"activeCount":138,"soonestReadout":2793},[2789],{"nctId":2790,"briefTitle":2791,"status":157,"phases":2792,"primaryCompletion":2793,"completion":2794,"start":2795,"enrollment":2796,"conditions":2797,"interventions":2802},"NCT06609356","Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes",[87],"2027-07","2027-12","2025-07-03",27,[2798,2799,2800,2801],"Type 1 Diabetes Mellitus","Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY)","MODY2 Diabetes","Healthy Volunteer",[2785],{"trials":2804,"activeCount":100},[],{"trials":2806,"activeCount":100},[],{"trials":2808,"activeCount":100},[],{"trials":2810,"activeCount":100},[],{"trials":2812,"activeCount":100},[],{"intervention":2814,"totalTrials":138,"cells":2815},"[11C]-PIB",{"EARLY_PHASE1":2816,"PHASE1":2826,"PHASE2":2828,"PHASE3":2830,"PHASE4":2832,"NA":2834},{"trials":2817,"activeCount":138,"soonestReadout":1041},[2818],{"nctId":2819,"briefTitle":2820,"status":757,"phases":2821,"primaryCompletion":1041,"completion":1041,"start":2822,"enrollment":2823,"conditions":2824,"interventions":2825},"NCT04768101","Quantitative Imaging of Brain Glymphatic Function in Humans",[87],"2020-04-15",140,[303],[2814],{"trials":2827,"activeCount":100},[],{"trials":2829,"activeCount":100},[],{"trials":2831,"activeCount":100},[],{"trials":2833,"activeCount":100},[],{"trials":2835,"activeCount":100},[],{"intervention":72,"totalTrials":138,"cells":2837},{"EARLY_PHASE1":2838,"PHASE1":2846,"PHASE2":2848,"PHASE3":2850,"PHASE4":2852,"NA":2854},{"trials":2839,"activeCount":138,"soonestReadout":71},[2840],{"nctId":69,"briefTitle":70,"status":157,"phases":2841,"primaryCompletion":71,"completion":71,"start":2247,"enrollment":412,"conditions":2842,"interventions":2845},[87],[2843,2844],"Epilepsy","Sudden Unexpected Death in Epilepsy",[72],{"trials":2847,"activeCount":100},[],{"trials":2849,"activeCount":100},[],{"trials":2851,"activeCount":100},[],{"trials":2853,"activeCount":100},[],{"trials":2855,"activeCount":100},[],{"intervention":2857,"totalTrials":138,"cells":2858},"Vaginal Seeding",{"EARLY_PHASE1":2859,"PHASE1":2871,"PHASE2":2873,"PHASE3":2875,"PHASE4":2877,"NA":2879},{"trials":2860,"activeCount":138,"soonestReadout":2865},[2861],{"nctId":2862,"briefTitle":2863,"status":157,"phases":2864,"primaryCompletion":2865,"completion":2865,"start":474,"enrollment":29,"conditions":2866,"interventions":2870},"NCT05505110","MOdification Of THe Early-Life Respiratory Microbiome Through Vaginal SEEDing",[87],"2028-08-10",[2867,2857,2868,2869],"C-section","Respiratory","Microbiome",[2857],{"trials":2872,"activeCount":100},[],{"trials":2874,"activeCount":100},[],{"trials":2876,"activeCount":100},[],{"trials":2878,"activeCount":100},[],{"trials":2880,"activeCount":100},[],{"intervention":57,"totalTrials":138,"cells":2882},{"EARLY_PHASE1":2883,"PHASE1":2890,"PHASE2":2892,"PHASE3":2894,"PHASE4":2896,"NA":2898},{"trials":2884,"activeCount":138,"soonestReadout":52},[2885],{"nctId":55,"briefTitle":56,"status":757,"phases":2886,"primaryCompletion":52,"completion":1041,"start":2887,"enrollment":1206,"conditions":2888,"interventions":2889},[87],"2021-08-31",[37],[57],{"trials":2891,"activeCount":100},[],{"trials":2893,"activeCount":100},[],{"trials":2895,"activeCount":100},[],{"trials":2897,"activeCount":100},[],{"trials":2899,"activeCount":100},[],{"intervention":2901,"totalTrials":96,"cells":2902},"aspirin",{"EARLY_PHASE1":2903,"PHASE1":2915,"PHASE2":2917,"PHASE3":2919,"PHASE4":2921,"NA":2933},{"trials":2904,"activeCount":138,"soonestReadout":1141},[2905],{"nctId":2906,"briefTitle":2907,"status":121,"phases":2908,"primaryCompletion":1141,"completion":2909,"start":2910,"enrollment":2911,"conditions":2912,"interventions":2914},"NCT04464070","Pathways of Eicosanoid Metabolism",[87],"2026-08-31","2020-08-15",10,[2913],"Metabolism of Prostaglandin D2",[2901],{"trials":2916,"activeCount":100},[],{"trials":2918,"activeCount":100},[],{"trials":2920,"activeCount":100},[],{"trials":2922,"activeCount":100},[2923],{"nctId":2924,"briefTitle":2925,"status":659,"phases":2926,"primaryCompletion":2927,"completion":2927,"start":2928,"enrollment":2929,"conditions":2930,"interventions":2932},"NCT00748371","Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration",[91],"2011-02","2004-06",51,[2931],"Platelet Aggregation",[2901,2901],{"trials":2934,"activeCount":100},[2935],{"nctId":2936,"briefTitle":2937,"status":605,"phases":2938,"primaryCompletion":2939,"completion":2939,"start":1021,"enrollment":100,"conditions":2940,"interventions":2941},"NCT00942617","Measurement of Platelet Dense Granule Release in Healthy Volunteers",[92],"2012-06",[2931],[2942],"Aspirin",{"intervention":565,"totalTrials":461,"cells":2944},{"EARLY_PHASE1":2945,"PHASE1":2947,"PHASE2":2953,"PHASE3":2955,"PHASE4":2957,"NA":2971},{"trials":2946,"activeCount":100},[],{"trials":2948,"activeCount":100},[2949],{"nctId":2199,"briefTitle":2200,"status":659,"phases":2950,"primaryCompletion":2202,"completion":2202,"start":2203,"enrollment":1172,"conditions":2951,"interventions":2952},[88],[19,2205],[2207,2149,565],{"trials":2954,"activeCount":100},[],{"trials":2956,"activeCount":100},[],{"trials":2958,"activeCount":100},[2959],{"nctId":2960,"briefTitle":2961,"status":659,"phases":2962,"primaryCompletion":2963,"completion":2963,"start":2964,"enrollment":35,"conditions":2965,"interventions":2970},"NCT02203630","Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients",[91],"2016-01","2014-08",[2966,722,2967,2968,2969],"Septic Shock","Shock","Tachycardia","Arrhythmia",[565,566],{"trials":2972,"activeCount":138,"soonestReadout":1575},[2973,2983,2987],{"nctId":2974,"briefTitle":2975,"status":108,"phases":2976,"primaryCompletion":2977,"completion":2978,"start":682,"enrollment":2979,"conditions":2980,"interventions":2982},"NCT00838695","Variability in Adrenergic Response",[92],"2010-12","2011-12",106,[2981],"Vascular Reaction to Medications",[565],{"nctId":550,"briefTitle":551,"status":108,"phases":2984,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":2985,"interventions":2986},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"nctId":2988,"briefTitle":2989,"status":121,"phases":2990,"primaryCompletion":1575,"completion":353,"start":662,"enrollment":2991,"conditions":2992,"interventions":2999},"NCT02725060","Autoimmune Basis for Postural Tachycardia Syndrome",[92],58,[2993,37,2968,2994,2995,2996,2997,2998],"Postural Orthostatic Tachycardia Syndrome","Arrhythmias, Cardiac","Autonomic Nervous System Diseases","Orthostatic Intolerance","Cardiovascular Diseases","Primary Dysautonomias",[3000,3001],"phenylephrine","isoproterenol",{"intervention":3003,"totalTrials":2239,"cells":3004},"Ketamine",{"EARLY_PHASE1":3005,"PHASE1":3007,"PHASE2":3009,"PHASE3":3011,"PHASE4":3013,"NA":3040},{"trials":3006,"activeCount":100},[],{"trials":3008,"activeCount":100},[],{"trials":3010,"activeCount":100},[],{"trials":3012,"activeCount":100},[],{"trials":3014,"activeCount":100},[3015,3029],{"nctId":3016,"briefTitle":3017,"status":108,"phases":3018,"primaryCompletion":3019,"completion":3020,"start":3021,"enrollment":3022,"conditions":3023,"interventions":3028},"NCT04625283","The Impact of Perioperative Ketamine Infusion on Surgical Recovery",[91],"2024-01-26","2024-02-01","2021-04-12",1570,[3024,3025,3026,3003,3027],"Opioid Use","Enhanced Recovery After Surgery","Anesthesia","Pain, Postoperative",[3003],{"nctId":3030,"briefTitle":3031,"status":108,"phases":3032,"primaryCompletion":3033,"completion":3033,"start":3034,"enrollment":3035,"conditions":3036,"interventions":3038},"NCT05277896","Randomized Trial of Sedative Choice for Intubation",[91],"2025-09-06","2022-04-06",2367,[3037],"Acute Respiratory Failure",[3003,3039],"Etomidate",{"trials":3041,"activeCount":138,"soonestReadout":1987},[3042,3051],{"nctId":3043,"briefTitle":3044,"status":121,"phases":3045,"primaryCompletion":1987,"completion":3046,"start":3034,"enrollment":3047,"conditions":3048,"interventions":3050},"NCT06179485","Effect of Ketamine and Etomidate During RSI on Long Term Outcomes",[],"2028-03",1756,[3049,3037],"Post-Traumatic Stress Disorder",[3003,3039],{"nctId":3052,"briefTitle":3053,"status":108,"phases":3054,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":3059,"interventions":3061},"NCT02625181","Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis",[92],"2017-11-02","2017-11-30","2016-07",27034,[3060],"Postoperative Nausea and Vomiting",[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],"Scopolamine","Droperidol","Haloperidol","Dexamethasone","Promethazine","Meclizine","Aprepitant","Metoclopramide","Fentanyl","Sufentanil","Alfentanil","Remifentanil","Morphine","Meperidine","Hydromorphone","Methadone","Oxycodone","Oxymorphone","Hydrocodone","Ondansetron","Granisetron","Dolasetron mesylate","Palonosetron","Tropisetron","Ramosetron",{"intervention":3039,"totalTrials":531,"cells":3088},{"EARLY_PHASE1":3089,"PHASE1":3091,"PHASE2":3093,"PHASE3":3095,"PHASE4":3097,"NA":3103},{"trials":3090,"activeCount":100},[],{"trials":3092,"activeCount":100},[],{"trials":3094,"activeCount":100},[],{"trials":3096,"activeCount":100},[],{"trials":3098,"activeCount":100},[3099],{"nctId":3030,"briefTitle":3031,"status":108,"phases":3100,"primaryCompletion":3033,"completion":3033,"start":3034,"enrollment":3035,"conditions":3101,"interventions":3102},[91],[3037],[3003,3039],{"trials":3104,"activeCount":138,"soonestReadout":1987},[3105],{"nctId":3043,"briefTitle":3044,"status":121,"phases":3106,"primaryCompletion":1987,"completion":3046,"start":3034,"enrollment":3047,"conditions":3107,"interventions":3108},[],[3049,3037],[3003,3039],{"intervention":570,"totalTrials":531,"cells":3110},{"EARLY_PHASE1":3111,"PHASE1":3113,"PHASE2":3115,"PHASE3":3117,"PHASE4":3119,"NA":3121},{"trials":3112,"activeCount":100},[],{"trials":3114,"activeCount":100},[],{"trials":3116,"activeCount":100},[],{"trials":3118,"activeCount":100},[],{"trials":3120,"activeCount":100},[],{"trials":3122,"activeCount":138,"soonestReadout":1575},[3123,3127],{"nctId":550,"briefTitle":551,"status":108,"phases":3124,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":3125,"interventions":3126},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"nctId":2988,"briefTitle":2989,"status":121,"phases":3128,"primaryCompletion":1575,"completion":353,"start":662,"enrollment":2991,"conditions":3129,"interventions":3130},[92],[2993,37,2968,2994,2995,2996,2997,2998],[3000,3001],{"intervention":3078,"totalTrials":531,"cells":3132},{"EARLY_PHASE1":3133,"PHASE1":3135,"PHASE2":3137,"PHASE3":3139,"PHASE4":3141,"NA":3143},{"trials":3134,"activeCount":100},[],{"trials":3136,"activeCount":100},[],{"trials":3138,"activeCount":100},[],{"trials":3140,"activeCount":100},[],{"trials":3142,"activeCount":100},[],{"trials":3144,"activeCount":138,"soonestReadout":1141},[3145,3156],{"nctId":3146,"briefTitle":3147,"status":157,"phases":3148,"primaryCompletion":1141,"completion":1141,"start":3149,"enrollment":162,"conditions":3150,"interventions":3154},"NCT05142267","Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms",[92],"2022-03-02",[3151,3152,3153],"Opioid Use Disorder","Back Pain","Stress",[3078,3155],"Naloxone",{"nctId":3052,"briefTitle":3053,"status":108,"phases":3157,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":3158,"interventions":3159},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":3155,"totalTrials":531,"cells":3161},{"EARLY_PHASE1":3162,"PHASE1":3164,"PHASE2":3166,"PHASE3":3168,"PHASE4":3170,"NA":3172},{"trials":3163,"activeCount":100},[],{"trials":3165,"activeCount":100},[],{"trials":3167,"activeCount":100},[],{"trials":3169,"activeCount":100},[],{"trials":3171,"activeCount":100},[],{"trials":3173,"activeCount":138,"soonestReadout":1141},[3174,3178],{"nctId":3146,"briefTitle":3147,"status":157,"phases":3175,"primaryCompletion":1141,"completion":1141,"start":3149,"enrollment":162,"conditions":3176,"interventions":3177},[92],[3151,3152,3153],[3078,3155],{"nctId":3179,"briefTitle":3180,"status":108,"phases":3181,"primaryCompletion":3182,"completion":3182,"start":3183,"enrollment":3184,"conditions":3185,"interventions":3187},"NCT02469077","Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function",[92],"2019-09","2015-08",117,[3186],"Chronic Pain",[3074,3188],"naloxone",{"intervention":3190,"totalTrials":138,"cells":3191},"Midodrine or atomoxetine pill",{"EARLY_PHASE1":3192,"PHASE1":3194,"PHASE2":3196,"PHASE3":3198,"PHASE4":3200,"NA":3202},{"trials":3193,"activeCount":100},[],{"trials":3195,"activeCount":100},[],{"trials":3197,"activeCount":100},[],{"trials":3199,"activeCount":100},[],{"trials":3201,"activeCount":100},[],{"trials":3203,"activeCount":138,"soonestReadout":3208},[3204],{"nctId":3205,"briefTitle":3206,"status":157,"phases":3207,"primaryCompletion":3208,"completion":3209,"start":3210,"enrollment":527,"conditions":3211,"interventions":3214},"NCT04782830","Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms",[92],"2027-06-01","2027-10-01","2021-02-05",[3212,2253,903,926,3213],"Orthostatic; Hypotension, Neurogenic","Orthostatic; Hypotension, Parkinsonism",[3190],{"intervention":3216,"totalTrials":138,"cells":3217},"Detemir",{"EARLY_PHASE1":3218,"PHASE1":3220,"PHASE2":3222,"PHASE3":3224,"PHASE4":3226,"NA":3228},{"trials":3219,"activeCount":100},[],{"trials":3221,"activeCount":100},[],{"trials":3223,"activeCount":100},[],{"trials":3225,"activeCount":100},[],{"trials":3227,"activeCount":100},[],{"trials":3229,"activeCount":138,"soonestReadout":1599},[3230],{"nctId":3231,"briefTitle":3232,"status":757,"phases":3233,"primaryCompletion":1599,"completion":1599,"start":3234,"enrollment":3235,"conditions":3236,"interventions":3238},"NCT01239550","Insulin Detemir in Obesity Management",[92],"2011-04",240,[3237,16],"Diabetes",[3216],{"intervention":3240,"totalTrials":138,"cells":3241},"13C6-Glucose",{"EARLY_PHASE1":3242,"PHASE1":3244,"PHASE2":3246,"PHASE3":3248,"PHASE4":3250,"NA":3252},{"trials":3243,"activeCount":100},[],{"trials":3245,"activeCount":100},[],{"trials":3247,"activeCount":100},[],{"trials":3249,"activeCount":100},[],{"trials":3251,"activeCount":100},[],{"trials":3253,"activeCount":138,"soonestReadout":453},[3254],{"nctId":3255,"briefTitle":3256,"status":157,"phases":3257,"primaryCompletion":453,"completion":453,"start":3258,"enrollment":1220,"conditions":3259,"interventions":3264},"NCT06930976","Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells",[92],"2025-10-01",[3260,3261,3262,3263],"Glucose","Metabolism","Isotope Labeling","Immune System and Related Disorders",[3240],{"intervention":3266,"totalTrials":138,"cells":3267},"0.9% Sodium Chloride",{"EARLY_PHASE1":3268,"PHASE1":3270,"PHASE2":3272,"PHASE3":3274,"PHASE4":3276,"NA":3278},{"trials":3269,"activeCount":100},[],{"trials":3271,"activeCount":100},[],{"trials":3273,"activeCount":100},[],{"trials":3275,"activeCount":100},[],{"trials":3277,"activeCount":100},[],{"trials":3279,"activeCount":138,"soonestReadout":513},[3280],{"nctId":3281,"briefTitle":3282,"status":757,"phases":3283,"primaryCompletion":513,"completion":513,"start":3284,"enrollment":3285,"conditions":3286,"interventions":3289},"NCT04036305","Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers",[],"2019-07-26",230,[3287,3288],"Ehlers-Danlos Syndrome","Anesthesia, Local",[3266,3290,3291],"Lidocaine Injection 2%","Bupivacaine Injection 0.5%",{"intervention":3290,"totalTrials":138,"cells":3293},{"EARLY_PHASE1":3294,"PHASE1":3296,"PHASE2":3298,"PHASE3":3300,"PHASE4":3302,"NA":3304},{"trials":3295,"activeCount":100},[],{"trials":3297,"activeCount":100},[],{"trials":3299,"activeCount":100},[],{"trials":3301,"activeCount":100},[],{"trials":3303,"activeCount":100},[],{"trials":3305,"activeCount":138,"soonestReadout":513},[3306],{"nctId":3281,"briefTitle":3282,"status":757,"phases":3307,"primaryCompletion":513,"completion":513,"start":3284,"enrollment":3285,"conditions":3308,"interventions":3309},[],[3287,3288],[3266,3290,3291],{"intervention":3291,"totalTrials":138,"cells":3311},{"EARLY_PHASE1":3312,"PHASE1":3314,"PHASE2":3316,"PHASE3":3318,"PHASE4":3320,"NA":3322},{"trials":3313,"activeCount":100},[],{"trials":3315,"activeCount":100},[],{"trials":3317,"activeCount":100},[],{"trials":3319,"activeCount":100},[],{"trials":3321,"activeCount":100},[],{"trials":3323,"activeCount":138,"soonestReadout":513},[3324],{"nctId":3281,"briefTitle":3282,"status":757,"phases":3325,"primaryCompletion":513,"completion":513,"start":3284,"enrollment":3285,"conditions":3326,"interventions":3327},[],[3287,3288],[3266,3290,3291],{"intervention":3329,"totalTrials":138,"cells":3330},"GLP-1 receptor agonist",{"EARLY_PHASE1":3331,"PHASE1":3333,"PHASE2":3335,"PHASE3":3337,"PHASE4":3339,"NA":3341},{"trials":3332,"activeCount":100},[],{"trials":3334,"activeCount":100},[],{"trials":3336,"activeCount":100},[],{"trials":3338,"activeCount":100},[],{"trials":3340,"activeCount":100},[],{"trials":3342,"activeCount":138,"soonestReadout":853},[3343],{"nctId":3344,"briefTitle":3345,"status":157,"phases":3346,"primaryCompletion":853,"completion":1987,"start":3347,"enrollment":1133,"conditions":3348,"interventions":3349},"NCT07115069","Comparison of Body Composition Changes With Weight Loss Interventions",[],"2025-08-09",[16],[3329],{"intervention":62,"totalTrials":138,"cells":3351},{"EARLY_PHASE1":3352,"PHASE1":3354,"PHASE2":3356,"PHASE3":3358,"PHASE4":3360,"NA":3362},{"trials":3353,"activeCount":100},[],{"trials":3355,"activeCount":100},[],{"trials":3357,"activeCount":100},[],{"trials":3359,"activeCount":100},[],{"trials":3361,"activeCount":100},[],{"trials":3363,"activeCount":138,"soonestReadout":61},[3364],{"nctId":59,"briefTitle":60,"status":757,"phases":3365,"primaryCompletion":61,"completion":1041,"start":3366,"enrollment":162,"conditions":3367,"interventions":3371},[],"2025-10-16",[3368,3369,3370],"Inflammatory Bowel Disease (IBD)","Crohn&Amp;#39;s Disease (CD)","Ulcerative Colitis (UC)",[62],{"intervention":3373,"totalTrials":138,"cells":3374},"Hydroxyurea therapy per standard care",{"EARLY_PHASE1":3375,"PHASE1":3377,"PHASE2":3379,"PHASE3":3381,"PHASE4":3383,"NA":3385},{"trials":3376,"activeCount":100},[],{"trials":3378,"activeCount":100},[],{"trials":3380,"activeCount":100},[],{"trials":3382,"activeCount":100},[],{"trials":3384,"activeCount":100},[],{"trials":3386,"activeCount":138,"soonestReadout":3391},[3387],{"nctId":3388,"briefTitle":3389,"status":757,"phases":3390,"primaryCompletion":3391,"completion":3391,"start":3392,"enrollment":3393,"conditions":3394,"interventions":3398},"NCT04808778","Stroke Prevention in Young Adults With Sickle Cell Anemia",[],"2029-06-01","2021-05-17",250,[504,478,3395,3396,3397,505],"Stroke, Ischemic","Silent Stroke","Silent Cerebral Infarct",[3373],{"intervention":3400,"totalTrials":2239,"cells":3401},"Spironolactone",{"EARLY_PHASE1":3402,"PHASE1":3404,"PHASE2":3424,"PHASE3":3436,"PHASE4":3449,"NA":3459},{"trials":3403,"activeCount":100},[],{"trials":3405,"activeCount":100},[3406],{"nctId":3407,"briefTitle":3408,"status":108,"phases":3409,"primaryCompletion":3410,"completion":3411,"start":3412,"enrollment":3413,"conditions":3414,"interventions":3419},"NCT01103245","Aldosterone and the Metabolic Syndrome",[88],"2012-07","2013-09","2010-03",69,[3415,3416,3417,3418],"Metabolic Diseases","Diabetes Mellitus","Endocrine System Diseases","Glucose Metabolism Disorders",[3420,3421,3400,3422,3423],"Hydrochlorothiazide","Aliskiren 150 mg","Aliskiren 300 mg","Spironolactone 50 mg",{"trials":3425,"activeCount":100},[3426],{"nctId":3427,"briefTitle":3428,"status":108,"phases":3429,"primaryCompletion":3430,"completion":3430,"start":3431,"enrollment":3432,"conditions":3433,"interventions":3434},"NCT02236520","Tissue Sodium in Pre-hypertensive Patients",[89],"2018-05-01","2014-09",71,[19],[3400,3435],"Chlorthalidone",{"trials":3437,"activeCount":100},[3438],{"nctId":3439,"briefTitle":3440,"status":108,"phases":3441,"primaryCompletion":3442,"completion":3443,"start":3444,"enrollment":3445,"conditions":3446,"interventions":3447},"NCT00141778","Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)",[89,90],"2010-07","2010-08","2005-04",455,[1088],[3448,3400],"Ramipril",{"trials":3450,"activeCount":100},[3451],{"nctId":3452,"briefTitle":3453,"status":108,"phases":3454,"primaryCompletion":3410,"completion":3410,"start":2142,"enrollment":2116,"conditions":3455,"interventions":3457},"NCT00574119","Effect of Aldosterone on Energy Starvation in Heart Failure",[91],[651,3456],"Nonischemic Dilated Cardiomyopathy",[3458],"spironolactone",{"trials":3460,"activeCount":100},[],{"intervention":3462,"totalTrials":96,"cells":3463},"Valsartan",{"EARLY_PHASE1":3464,"PHASE1":3466,"PHASE2":3468,"PHASE3":3478,"PHASE4":3489,"NA":3503},{"trials":3465,"activeCount":100},[],{"trials":3467,"activeCount":100},[],{"trials":3469,"activeCount":100},[3470],{"nctId":3471,"briefTitle":3472,"status":108,"phases":3473,"primaryCompletion":2978,"completion":2978,"start":2233,"enrollment":2681,"conditions":3474,"interventions":3477},"NCT00732069","Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis",[89],[3475,3476],"End Stage Renal Failure on Dialysis","Complication of Hemodialysis",[3448,3462],{"trials":3479,"activeCount":100},[3480],{"nctId":3481,"briefTitle":3482,"status":659,"phases":3483,"primaryCompletion":1062,"completion":1062,"start":2176,"enrollment":3484,"conditions":3485,"interventions":3486},"NCT00878969","Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3",[90],78,[1437,358],[3487,3488],"valsartan","ramipril",{"trials":3490,"activeCount":100},[3491],{"nctId":3492,"briefTitle":3493,"status":659,"phases":3494,"primaryCompletion":3495,"completion":3495,"start":3496,"enrollment":2239,"conditions":3497,"interventions":3498},"NCT03738878","Mechanism(s) Underlying Hypotensive Response to ARB\u002FNEP Inhibition - Aim 1",[91],"2024-12-01","2018-11-15",[19],[3462,3499,3500,3501,3502,1341],"LCZ696","Bradykinin","Substance P","BNP",{"trials":3504,"activeCount":100},[],{"intervention":3506,"totalTrials":96,"cells":3507},"Eplerenone",{"EARLY_PHASE1":3508,"PHASE1":3510,"PHASE2":3538,"PHASE3":3540,"PHASE4":3542,"NA":3560},{"trials":3509,"activeCount":100},[],{"trials":3511,"activeCount":100},[3512],{"nctId":3513,"briefTitle":3514,"status":108,"phases":3515,"primaryCompletion":1434,"completion":1434,"start":3516,"enrollment":3517,"conditions":3518,"interventions":3519},"NCT00223717","Treatment of Supine Hypertension in Autonomic Failure",[88],"2001-01",152,[19],[3520,3521,3522,3523,3524,3525,3526,3420,3527,3528,3506,3529,3530,3531,3532,3533,3534,3535,3536,3537],"Clonidine","Nitroglycerin transdermal","Dipyridamole\u002F Aspirin","Desmopressin","Sildenafil","Nifedipine","Hydralazine","Bosentan","Diltiazem","guanfacine","captopril","carbidopa","losartan","metoprolol tartrate","nebivolol hydrochloride","prazosin hydrochloride","tamsulosin hydrochloride","aliskiren",{"trials":3539,"activeCount":100},[],{"trials":3541,"activeCount":100},[],{"trials":3543,"activeCount":100},[3544,3553],{"nctId":3545,"briefTitle":3546,"status":659,"phases":3547,"primaryCompletion":3548,"completion":947,"start":3549,"enrollment":2239,"conditions":3550,"interventions":3552},"NCT00608465","Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity",[91],"2009-05","2006-05",[3551],"Metabolic Syndrome X",[3506,3448],{"nctId":3554,"briefTitle":3555,"status":108,"phases":3556,"primaryCompletion":3557,"completion":3557,"start":949,"enrollment":2169,"conditions":3558,"interventions":3559},"NCT00515021","Diurnal Variation of Plasminogen Activator Inhibitor-1",[91],"2010-04",[3551],[3506,3506],{"trials":3561,"activeCount":100},[],{"intervention":3524,"totalTrials":96,"cells":3563},{"EARLY_PHASE1":3564,"PHASE1":3566,"PHASE2":3572,"PHASE3":3581,"PHASE4":3583,"NA":3592},{"trials":3565,"activeCount":100},[],{"trials":3567,"activeCount":100},[3568],{"nctId":3513,"briefTitle":3514,"status":108,"phases":3569,"primaryCompletion":1434,"completion":1434,"start":3516,"enrollment":3517,"conditions":3570,"interventions":3571},[88],[19],[3520,3521,3522,3523,3524,3525,3526,3420,3527,3528,3506,3529,3530,3531,3532,3533,3534,3535,3536,3537],{"trials":3573,"activeCount":100},[3574],{"nctId":3575,"briefTitle":3576,"status":108,"phases":3577,"primaryCompletion":3578,"completion":3578,"start":3234,"enrollment":649,"conditions":3579,"interventions":3580},"NCT01334554","Study of Sildenafil Citrate on Insulin Resistance in African American",[88,89],"2013-08",[1416,16],[3524],{"trials":3582,"activeCount":100},[],{"trials":3584,"activeCount":100},[3585],{"nctId":3586,"briefTitle":3587,"status":659,"phases":3588,"primaryCompletion":1988,"completion":1988,"start":663,"enrollment":3484,"conditions":3589,"interventions":3591},"NCT01409993","Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis",[91],[3590],"Impaired Glucose Tolerance",[3524],{"trials":3593,"activeCount":100},[],{"intervention":2517,"totalTrials":96,"cells":3595},{"EARLY_PHASE1":3596,"PHASE1":3598,"PHASE2":3604,"PHASE3":3606,"PHASE4":3617,"NA":3623},{"trials":3597,"activeCount":100},[],{"trials":3599,"activeCount":100},[3600],{"nctId":3513,"briefTitle":3514,"status":108,"phases":3601,"primaryCompletion":1434,"completion":1434,"start":3516,"enrollment":3517,"conditions":3602,"interventions":3603},[88],[19],[3520,3521,3522,3523,3524,3525,3526,3420,3527,3528,3506,3529,3530,3531,3532,3533,3534,3535,3536,3537],{"trials":3605,"activeCount":100},[],{"trials":3607,"activeCount":100},[3608],{"nctId":3609,"briefTitle":3610,"status":108,"phases":3611,"primaryCompletion":899,"completion":3612,"start":3613,"enrollment":3614,"conditions":3615,"interventions":3616},"NCT00685919","Peripheral Dopamine in Postural Tachycardia Syndrome",[89,90],"2021-12","2008-05",32,[37,2996],[2517],{"trials":3618,"activeCount":100},[3619],{"nctId":2509,"briefTitle":2510,"status":108,"phases":3620,"primaryCompletion":2512,"completion":2512,"start":2513,"enrollment":2514,"conditions":3621,"interventions":3622},[91],[303],[2270,2517],{"trials":3624,"activeCount":100},[],{"intervention":3626,"totalTrials":531,"cells":3627},"diltiazem",{"EARLY_PHASE1":3628,"PHASE1":3630,"PHASE2":3636,"PHASE3":3638,"PHASE4":3640,"NA":3651},{"trials":3629,"activeCount":100},[],{"trials":3631,"activeCount":100},[3632],{"nctId":3513,"briefTitle":3514,"status":108,"phases":3633,"primaryCompletion":1434,"completion":1434,"start":3516,"enrollment":3517,"conditions":3634,"interventions":3635},[88],[19],[3520,3521,3522,3523,3524,3525,3526,3420,3527,3528,3506,3529,3530,3531,3532,3533,3534,3535,3536,3537],{"trials":3637,"activeCount":100},[],{"trials":3639,"activeCount":100},[],{"trials":3641,"activeCount":100},[3642],{"nctId":3643,"briefTitle":3644,"status":108,"phases":3645,"primaryCompletion":3646,"completion":3646,"start":3647,"enrollment":138,"conditions":3648,"interventions":3650},"NCT06534671","Diltiazem in Jervell and Lange-Nielsen Syndrome",[91],"2024-10-23","2024-10-16",[3649],"Jervell and Lange Nielsen Syndrome",[3626],{"trials":3652,"activeCount":100},[],{"intervention":3654,"totalTrials":531,"cells":3655},"levetiracetam",{"EARLY_PHASE1":3656,"PHASE1":3658,"PHASE2":3660,"PHASE3":3671,"PHASE4":3673,"NA":3684},{"trials":3657,"activeCount":100},[],{"trials":3659,"activeCount":100},[],{"trials":3661,"activeCount":100},[3662],{"nctId":3663,"briefTitle":3664,"status":108,"phases":3665,"completion":3666,"start":3667,"enrollment":762,"conditions":3668,"interventions":3670},"NCT00156689","A Study to Determine if Levetiracetam Will Assist Those Suffering From Chronic Idiopathic Axonal Polyneuropathy.",[89],"2007-05","2005-08",[3669],"Chronic Idiopathic Axonal Polyneuropathy",[3654],{"trials":3672,"activeCount":100},[],{"trials":3674,"activeCount":100},[3675],{"nctId":3676,"briefTitle":3677,"status":605,"phases":3678,"primaryCompletion":3679,"completion":3679,"start":3679,"enrollment":100,"conditions":3680,"interventions":3683},"NCT01935908","Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage - Pilot Study",[91],"2013-05",[3681,3682],"Subarachnoid Hemorrhage","Seizures",[3654],{"trials":3685,"activeCount":100},[],{"intervention":3421,"totalTrials":531,"cells":3687},{"EARLY_PHASE1":3688,"PHASE1":3690,"PHASE2":3696,"PHASE3":3698,"PHASE4":3700,"NA":3710},{"trials":3689,"activeCount":100},[],{"trials":3691,"activeCount":100},[3692],{"nctId":3407,"briefTitle":3408,"status":108,"phases":3693,"primaryCompletion":3410,"completion":3411,"start":3412,"enrollment":3413,"conditions":3694,"interventions":3695},[88],[3415,3416,3417,3418],[3420,3421,3400,3422,3423],{"trials":3697,"activeCount":100},[],{"trials":3699,"activeCount":100},[],{"trials":3701,"activeCount":100},[3702],{"nctId":3703,"briefTitle":3704,"status":108,"phases":3705,"primaryCompletion":3706,"completion":3706,"start":732,"enrollment":2250,"conditions":3707,"interventions":3708},"NCT03115853","The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function",[91],"2012-01",[1107],[3421,3709,3422],"HCTZ",{"trials":3711,"activeCount":100},[],{"intervention":3422,"totalTrials":531,"cells":3713},{"EARLY_PHASE1":3714,"PHASE1":3716,"PHASE2":3722,"PHASE3":3724,"PHASE4":3726,"NA":3732},{"trials":3715,"activeCount":100},[],{"trials":3717,"activeCount":100},[3718],{"nctId":3407,"briefTitle":3408,"status":108,"phases":3719,"primaryCompletion":3410,"completion":3411,"start":3412,"enrollment":3413,"conditions":3720,"interventions":3721},[88],[3415,3416,3417,3418],[3420,3421,3400,3422,3423],{"trials":3723,"activeCount":100},[],{"trials":3725,"activeCount":100},[],{"trials":3727,"activeCount":100},[3728],{"nctId":3703,"briefTitle":3704,"status":108,"phases":3729,"primaryCompletion":3706,"completion":3706,"start":732,"enrollment":2250,"conditions":3730,"interventions":3731},[91],[1107],[3421,3709,3422],{"trials":3733,"activeCount":100},[],{"intervention":3735,"totalTrials":531,"cells":3736},"Candesartan",{"EARLY_PHASE1":3737,"PHASE1":3739,"PHASE2":3741,"PHASE3":3743,"PHASE4":3745,"NA":3767},{"trials":3738,"activeCount":100},[],{"trials":3740,"activeCount":100},[],{"trials":3742,"activeCount":100},[],{"trials":3744,"activeCount":100},[],{"trials":3746,"activeCount":100},[3747,3760],{"nctId":3748,"briefTitle":3749,"status":108,"phases":3750,"primaryCompletion":663,"completion":2978,"start":3751,"enrollment":3752,"conditions":3753,"interventions":3759},"NCT00607672","The RAS, Fibrinolysis and Cardiopulmonary Bypass",[91],"2006-08",111,[3754,3755,3756,3757,3758,1108],"Coronary Artery Disease","Angiotensin Converting Enzyme","Angiotensin Receptor Blockers","Cardiopulmonary Bypass","Fibrinolysis",[3448,3735],{"nctId":3761,"briefTitle":3762,"status":659,"phases":3763,"primaryCompletion":1446,"completion":1446,"start":3679,"enrollment":138,"conditions":3764,"interventions":3765},"NCT01794455","Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression",[91],[22,19],[3766,3735],"Sertraline",{"trials":3768,"activeCount":100},[],{"intervention":3770,"totalTrials":531,"cells":3771},"Corticosteroid with normal saline",{"EARLY_PHASE1":3772,"PHASE1":3774,"PHASE2":3776,"PHASE3":3778,"PHASE4":3780,"NA":3815},{"trials":3773,"activeCount":100},[],{"trials":3775,"activeCount":100},[],{"trials":3777,"activeCount":100},[],{"trials":3779,"activeCount":100},[],{"trials":3781,"activeCount":100},[3782,3805],{"nctId":3783,"briefTitle":3784,"status":108,"phases":3785,"primaryCompletion":3786,"completion":3786,"start":3787,"enrollment":2250,"conditions":3788,"interventions":3803},"NCT03630198","Pain Outcomes Following Intralesional Corticosteroid Injections",[91],"2019-09-01","2018-10-01",[3789,3790,3791,965,3792,3793,3794,3795,3796,3797,3798,3799,3800,3801,3802],"Keloid","Alopecia Areata","Acne","Epidermal Inclusion Cyst","Frontal Fibrosing Alopecia","Lichen Plano-Pilaris","Keratoacanthoma","Plaque Psoriasis","Lichen Simplex Chronicus","Prurigo Nodularis","Nummular Eczema","Granuloma Annulare","Morphea","Lichen Planus",[3804,3770],"Corticosteroid with lidocaine",{"nctId":3806,"briefTitle":3807,"status":108,"phases":3808,"primaryCompletion":3809,"completion":3809,"start":1348,"enrollment":3810,"conditions":3811,"interventions":3813},"NCT04023695","Trigger Finger Corticosteroid Injection With and Without Local Anesthetic",[91],"2018-08-30",110,[3812],"Trigger Finger",[3814,3770],"Corticosteroid with lidocaine with epinephrine",{"trials":3816,"activeCount":100},[],{"intervention":653,"totalTrials":138,"cells":3818},{"EARLY_PHASE1":3819,"PHASE1":3821,"PHASE2":3823,"PHASE3":3825,"PHASE4":3827,"NA":3833},{"trials":3820,"activeCount":100},[],{"trials":3822,"activeCount":100},[],{"trials":3824,"activeCount":100},[],{"trials":3826,"activeCount":100},[],{"trials":3828,"activeCount":100},[3829],{"nctId":643,"briefTitle":644,"status":108,"phases":3830,"primaryCompletion":646,"completion":647,"start":648,"enrollment":649,"conditions":3831,"interventions":3832},[91],[651],[653,594,654,655],{"trials":3834,"activeCount":100},[],{"intervention":654,"totalTrials":138,"cells":3836},{"EARLY_PHASE1":3837,"PHASE1":3839,"PHASE2":3841,"PHASE3":3843,"PHASE4":3845,"NA":3851},{"trials":3838,"activeCount":100},[],{"trials":3840,"activeCount":100},[],{"trials":3842,"activeCount":100},[],{"trials":3844,"activeCount":100},[],{"trials":3846,"activeCount":100},[3847],{"nctId":643,"briefTitle":644,"status":108,"phases":3848,"primaryCompletion":646,"completion":647,"start":648,"enrollment":649,"conditions":3849,"interventions":3850},[91],[651],[653,594,654,655],{"trials":3852,"activeCount":100},[],{"intervention":655,"totalTrials":138,"cells":3854},{"EARLY_PHASE1":3855,"PHASE1":3857,"PHASE2":3859,"PHASE3":3861,"PHASE4":3863,"NA":3869},{"trials":3856,"activeCount":100},[],{"trials":3858,"activeCount":100},[],{"trials":3860,"activeCount":100},[],{"trials":3862,"activeCount":100},[],{"trials":3864,"activeCount":100},[3865],{"nctId":643,"briefTitle":644,"status":108,"phases":3866,"primaryCompletion":646,"completion":647,"start":648,"enrollment":649,"conditions":3867,"interventions":3868},[91],[651],[653,594,654,655],{"trials":3870,"activeCount":100},[],{"intervention":3872,"totalTrials":138,"cells":3873},"dabigatran etexilate mesylate",{"EARLY_PHASE1":3874,"PHASE1":3876,"PHASE2":3878,"PHASE3":3880,"PHASE4":3882,"NA":3892},{"trials":3875,"activeCount":100},[],{"trials":3877,"activeCount":100},[],{"trials":3879,"activeCount":100},[],{"trials":3881,"activeCount":100},[],{"trials":3883,"activeCount":100},[3884],{"nctId":3885,"briefTitle":3886,"status":108,"phases":3887,"primaryCompletion":695,"completion":695,"start":1413,"enrollment":3888,"conditions":3889,"interventions":3891},"NCT01976507","Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism",[91],101,[1088,3890],"Atrial Flutter",[3872],{"trials":3893,"activeCount":100},[],{"intervention":1006,"totalTrials":138,"cells":3895},{"EARLY_PHASE1":3896,"PHASE1":3898,"PHASE2":3900,"PHASE3":3902,"PHASE4":3904,"NA":3910},{"trials":3897,"activeCount":100},[],{"trials":3899,"activeCount":100},[],{"trials":3901,"activeCount":100},[],{"trials":3903,"activeCount":100},[],{"trials":3905,"activeCount":100},[3906],{"nctId":998,"briefTitle":999,"status":659,"phases":3907,"primaryCompletion":1001,"completion":1001,"start":1002,"enrollment":96,"conditions":3908,"interventions":3909},[91],[1004],[1006,891],{"trials":3911,"activeCount":100},[],{"intervention":3913,"totalTrials":138,"cells":3914},"Dexamethasone IV for PO",{"EARLY_PHASE1":3915,"PHASE1":3917,"PHASE2":3919,"PHASE3":3921,"PHASE4":3923,"NA":3935},{"trials":3916,"activeCount":100},[],{"trials":3918,"activeCount":100},[],{"trials":3920,"activeCount":100},[],{"trials":3922,"activeCount":100},[],{"trials":3924,"activeCount":100},[3925],{"nctId":3926,"briefTitle":3927,"status":659,"phases":3928,"primaryCompletion":3929,"completion":3929,"start":3930,"enrollment":412,"conditions":3931,"interventions":3933},"NCT03705273","Comparison of Dexamethasone Oral Preparations to Assess Taste and Acceptance in Children With Asthma and Croup",[91],"2020-10-02","2018-10-23",[2056,3932],"Croup",[3913,3934],"Dexamethasone crushed",{"trials":3936,"activeCount":100},[],{"intervention":3934,"totalTrials":138,"cells":3938},{"EARLY_PHASE1":3939,"PHASE1":3941,"PHASE2":3943,"PHASE3":3945,"PHASE4":3947,"NA":3953},{"trials":3940,"activeCount":100},[],{"trials":3942,"activeCount":100},[],{"trials":3944,"activeCount":100},[],{"trials":3946,"activeCount":100},[],{"trials":3948,"activeCount":100},[3949],{"nctId":3926,"briefTitle":3927,"status":659,"phases":3950,"primaryCompletion":3929,"completion":3929,"start":3930,"enrollment":412,"conditions":3951,"interventions":3952},[91],[2056,3932],[3913,3934],{"trials":3954,"activeCount":100},[],{"intervention":3956,"totalTrials":138,"cells":3957},"Risperdal (risperidone) Consta",{"EARLY_PHASE1":3958,"PHASE1":3960,"PHASE2":3962,"PHASE3":3964,"PHASE4":3966,"NA":3977},{"trials":3959,"activeCount":100},[],{"trials":3961,"activeCount":100},[],{"trials":3963,"activeCount":100},[],{"trials":3965,"activeCount":100},[],{"trials":3967,"activeCount":100},[3968],{"nctId":3969,"briefTitle":3970,"status":108,"phases":3971,"primaryCompletion":3972,"completion":3972,"start":1386,"enrollment":124,"conditions":3973,"interventions":3975},"NCT00571688","Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?",[91],"2009-02",[3974],"Bipolar Disorder",[3956,3976],"Treatment as usual",{"trials":3978,"activeCount":100},[],{"intervention":3976,"totalTrials":138,"cells":3980},{"EARLY_PHASE1":3981,"PHASE1":3983,"PHASE2":3985,"PHASE3":3987,"PHASE4":3989,"NA":3995},{"trials":3982,"activeCount":100},[],{"trials":3984,"activeCount":100},[],{"trials":3986,"activeCount":100},[],{"trials":3988,"activeCount":100},[],{"trials":3990,"activeCount":100},[3991],{"nctId":3969,"briefTitle":3970,"status":108,"phases":3992,"primaryCompletion":3972,"completion":3972,"start":1386,"enrollment":124,"conditions":3993,"interventions":3994},[91],[3974],[3956,3976],{"trials":3996,"activeCount":100},[],{"intervention":3998,"totalTrials":138,"cells":3999},"Enalapril 5mg",{"EARLY_PHASE1":4000,"PHASE1":4002,"PHASE2":4004,"PHASE3":4006,"PHASE4":4008,"NA":4019},{"trials":4001,"activeCount":100},[],{"trials":4003,"activeCount":100},[],{"trials":4005,"activeCount":100},[],{"trials":4007,"activeCount":100},[],{"trials":4009,"activeCount":100},[4010],{"nctId":4011,"briefTitle":4012,"status":108,"phases":4013,"primaryCompletion":4014,"completion":2176,"start":4015,"enrollment":1172,"conditions":4016,"interventions":4017},"NCT00666848","Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome",[91],"2009-08","2008-03",[1416,19],[3998,4018,1341],"Enalapril 10mg",{"trials":4020,"activeCount":100},[],{"intervention":4018,"totalTrials":138,"cells":4022},{"EARLY_PHASE1":4023,"PHASE1":4025,"PHASE2":4027,"PHASE3":4029,"PHASE4":4031,"NA":4037},{"trials":4024,"activeCount":100},[],{"trials":4026,"activeCount":100},[],{"trials":4028,"activeCount":100},[],{"trials":4030,"activeCount":100},[],{"trials":4032,"activeCount":100},[4033],{"nctId":4011,"briefTitle":4012,"status":108,"phases":4034,"primaryCompletion":4014,"completion":2176,"start":4015,"enrollment":1172,"conditions":4035,"interventions":4036},[91],[1416,19],[3998,4018,1341],{"trials":4038,"activeCount":100},[],{"intervention":4040,"totalTrials":138,"cells":4041},"Liposomal bupivacaine",{"EARLY_PHASE1":4042,"PHASE1":4044,"PHASE2":4046,"PHASE3":4048,"PHASE4":4050,"NA":4064},{"trials":4043,"activeCount":100},[],{"trials":4045,"activeCount":100},[],{"trials":4047,"activeCount":100},[],{"trials":4049,"activeCount":100},[],{"trials":4051,"activeCount":100},[4052],{"nctId":4053,"briefTitle":4054,"status":108,"phases":4055,"primaryCompletion":4056,"completion":4057,"start":4058,"enrollment":1133,"conditions":4059,"interventions":4062},"NCT03700970","Comparing Local Anesthetics for TAP Block During Abdominally-based Free Flap for Breast Reconstruction",[91],"2021-03-15","2021-03-30","2019-06-13",[4060,3026,4061],"Breast Reconstruction","Transverse Abdominis Plane Block",[4040,4063],"Regular bupivacaine",{"trials":4065,"activeCount":100},[],{"intervention":4063,"totalTrials":138,"cells":4067},{"EARLY_PHASE1":4068,"PHASE1":4070,"PHASE2":4072,"PHASE3":4074,"PHASE4":4076,"NA":4082},{"trials":4069,"activeCount":100},[],{"trials":4071,"activeCount":100},[],{"trials":4073,"activeCount":100},[],{"trials":4075,"activeCount":100},[],{"trials":4077,"activeCount":100},[4078],{"nctId":4053,"briefTitle":4054,"status":108,"phases":4079,"primaryCompletion":4056,"completion":4057,"start":4058,"enrollment":1133,"conditions":4080,"interventions":4081},[91],[4060,3026,4061],[4040,4063],{"trials":4083,"activeCount":100},[],{"intervention":4085,"totalTrials":138,"cells":4086},"anti-pseudomonal cephalosporin",{"EARLY_PHASE1":4087,"PHASE1":4089,"PHASE2":4091,"PHASE3":4093,"PHASE4":4095,"NA":4109},{"trials":4088,"activeCount":100},[],{"trials":4090,"activeCount":100},[],{"trials":4092,"activeCount":100},[],{"trials":4094,"activeCount":100},[],{"trials":4096,"activeCount":100},[4097],{"nctId":4098,"briefTitle":4099,"status":108,"phases":4100,"primaryCompletion":4101,"completion":4101,"start":4102,"enrollment":4103,"conditions":4104,"interventions":4107},"NCT05094154","Effect of Antibiotic Choice On ReNal Outcomes (ACORN)",[91],"2022-10-21","2021-11-10",2634,[722,4105,4106],"AKI","Neurotoxicity",[4085,4108],"anti-pseudomonal penicillin",{"trials":4110,"activeCount":100},[],{"intervention":4108,"totalTrials":138,"cells":4112},{"EARLY_PHASE1":4113,"PHASE1":4115,"PHASE2":4117,"PHASE3":4119,"PHASE4":4121,"NA":4127},{"trials":4114,"activeCount":100},[],{"trials":4116,"activeCount":100},[],{"trials":4118,"activeCount":100},[],{"trials":4120,"activeCount":100},[],{"trials":4122,"activeCount":100},[4123],{"nctId":4098,"briefTitle":4099,"status":108,"phases":4124,"primaryCompletion":4101,"completion":4101,"start":4102,"enrollment":4103,"conditions":4125,"interventions":4126},[91],[722,4105,4106],[4085,4108],{"trials":4128,"activeCount":100},[],{"intervention":4130,"totalTrials":138,"cells":4131},"Change from Prograf to Envarsus XR",{"EARLY_PHASE1":4132,"PHASE1":4134,"PHASE2":4136,"PHASE3":4138,"PHASE4":4140,"NA":4152},{"trials":4133,"activeCount":100},[],{"trials":4135,"activeCount":100},[],{"trials":4137,"activeCount":100},[],{"trials":4139,"activeCount":100},[],{"trials":4141,"activeCount":100},[4142],{"nctId":4143,"briefTitle":4144,"status":108,"phases":4145,"primaryCompletion":4146,"completion":4147,"start":4148,"enrollment":17,"conditions":4149,"interventions":4151},"NCT04838288","Cognitive Outcomes in Stable Renal Transplant Patients Switched fromTacrolimus to Envarsus XR™",[91],"2025-01-01","2025-10-22","2021-06-22",[4150],"Renal Transplant",[4130],{"trials":4153,"activeCount":100},[],{"intervention":4155,"totalTrials":138,"cells":4156},"Omegaven",{"EARLY_PHASE1":4157,"PHASE1":4159,"PHASE2":4161,"PHASE3":4163,"PHASE4":4165,"NA":4176},{"trials":4158,"activeCount":100},[],{"trials":4160,"activeCount":100},[],{"trials":4162,"activeCount":100},[],{"trials":4164,"activeCount":100},[],{"trials":4166,"activeCount":100},[4167],{"nctId":4168,"briefTitle":4169,"status":108,"phases":4170,"primaryCompletion":4171,"completion":4171,"start":4172,"enrollment":1206,"conditions":4173,"interventions":4175},"NCT00862446","Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease",[91],"2019-10","2009-03",[4174],"Parenteral Nutrition Associated Liver Disease",[4155],{"trials":4177,"activeCount":100},[],{"intervention":4179,"totalTrials":138,"cells":4180},"Neuropeptide Y",{"EARLY_PHASE1":4181,"PHASE1":4183,"PHASE2":4185,"PHASE3":4187,"PHASE4":4189,"NA":4202},{"trials":4182,"activeCount":100},[],{"trials":4184,"activeCount":100},[],{"trials":4186,"activeCount":100},[],{"trials":4188,"activeCount":100},[],{"trials":4190,"activeCount":100},[4191],{"nctId":4192,"briefTitle":4193,"status":108,"phases":4194,"primaryCompletion":4195,"completion":608,"start":4196,"enrollment":32,"conditions":4197,"interventions":4199},"NCT02639637","Effect of DPP4 Inhibition on Vasoconstriction",[91],"2017-06","2015-12",[4198],"Type 2 Diabetes Mellitus",[1341,4179,4200,4201],"Enalaprilat","Valsartan 160mg",{"trials":4203,"activeCount":100},[],{"intervention":4201,"totalTrials":138,"cells":4205},{"EARLY_PHASE1":4206,"PHASE1":4208,"PHASE2":4210,"PHASE3":4212,"PHASE4":4214,"NA":4220},{"trials":4207,"activeCount":100},[],{"trials":4209,"activeCount":100},[],{"trials":4211,"activeCount":100},[],{"trials":4213,"activeCount":100},[],{"trials":4215,"activeCount":100},[4216],{"nctId":4192,"briefTitle":4193,"status":108,"phases":4217,"primaryCompletion":4195,"completion":608,"start":4196,"enrollment":32,"conditions":4218,"interventions":4219},[91],[4198],[1341,4179,4200,4201],{"trials":4221,"activeCount":100},[],{"intervention":3804,"totalTrials":138,"cells":4223},{"EARLY_PHASE1":4224,"PHASE1":4226,"PHASE2":4228,"PHASE3":4230,"PHASE4":4232,"NA":4238},{"trials":4225,"activeCount":100},[],{"trials":4227,"activeCount":100},[],{"trials":4229,"activeCount":100},[],{"trials":4231,"activeCount":100},[],{"trials":4233,"activeCount":100},[4234],{"nctId":3783,"briefTitle":3784,"status":108,"phases":4235,"primaryCompletion":3786,"completion":3786,"start":3787,"enrollment":2250,"conditions":4236,"interventions":4237},[91],[3789,3790,3791,965,3792,3793,3794,3795,3796,3797,3798,3799,3800,3801,3802],[3804,3770],{"trials":4239,"activeCount":100},[],{"intervention":1340,"totalTrials":138,"cells":4241},{"EARLY_PHASE1":4242,"PHASE1":4244,"PHASE2":4246,"PHASE3":4248,"PHASE4":4250,"NA":4256},{"trials":4243,"activeCount":100},[],{"trials":4245,"activeCount":100},[],{"trials":4247,"activeCount":100},[],{"trials":4249,"activeCount":100},[],{"trials":4251,"activeCount":100},[4252],{"nctId":1331,"briefTitle":1332,"status":108,"phases":4253,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":1336,"conditions":4254,"interventions":4255},[91],[16,1338],[1340,1341,1056,1342],{"trials":4257,"activeCount":100},[],{"intervention":1342,"totalTrials":138,"cells":4259},{"EARLY_PHASE1":4260,"PHASE1":4262,"PHASE2":4264,"PHASE3":4266,"PHASE4":4268,"NA":4274},{"trials":4261,"activeCount":100},[],{"trials":4263,"activeCount":100},[],{"trials":4265,"activeCount":100},[],{"trials":4267,"activeCount":100},[],{"trials":4269,"activeCount":100},[4270],{"nctId":1331,"briefTitle":1332,"status":108,"phases":4271,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":1336,"conditions":4272,"interventions":4273},[91],[16,1338],[1340,1341,1056,1342],{"trials":4275,"activeCount":100},[],{"intervention":4277,"totalTrials":138,"cells":4278},"Comparison of Risperidone and Aripiprazole",{"EARLY_PHASE1":4279,"PHASE1":4281,"PHASE2":4283,"PHASE3":4285,"PHASE4":4287,"NA":4298},{"trials":4280,"activeCount":100},[],{"trials":4282,"activeCount":100},[],{"trials":4284,"activeCount":100},[],{"trials":4286,"activeCount":100},[],{"trials":4288,"activeCount":100},[4289],{"nctId":4290,"briefTitle":4291,"status":108,"phases":4292,"primaryCompletion":2248,"completion":2248,"start":4293,"enrollment":762,"conditions":4294,"interventions":4297},"NCT04903353","Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole",[91],"2022-02-01",[4295,28,4296],"Weight Gain","Medication Side Effect",[4277],{"trials":4299,"activeCount":100},[],{"intervention":4301,"totalTrials":138,"cells":4302},"Empiric Therapy: Drug",{"EARLY_PHASE1":4303,"PHASE1":4305,"PHASE2":4307,"PHASE3":4309,"PHASE4":4311,"NA":4324},{"trials":4304,"activeCount":100},[],{"trials":4306,"activeCount":100},[],{"trials":4308,"activeCount":100},[],{"trials":4310,"activeCount":100},[],{"trials":4312,"activeCount":100},[4313],{"nctId":4314,"briefTitle":4315,"status":108,"phases":4316,"primaryCompletion":4317,"completion":4317,"start":4318,"enrollment":17,"conditions":4319,"interventions":4322},"NCT05365477","Empiric Versus Selective Prevention Strategies for Kidney Stone Disease",[91],"2025-10-17","2022-08-04",[4320,4321],"Kidney Stones","Nephrolithiasis",[4301,4323],"Selective Therapy: Drug",{"trials":4325,"activeCount":100},[],{"intervention":4323,"totalTrials":138,"cells":4327},{"EARLY_PHASE1":4328,"PHASE1":4330,"PHASE2":4332,"PHASE3":4334,"PHASE4":4336,"NA":4342},{"trials":4329,"activeCount":100},[],{"trials":4331,"activeCount":100},[],{"trials":4333,"activeCount":100},[],{"trials":4335,"activeCount":100},[],{"trials":4337,"activeCount":100},[4338],{"nctId":4314,"briefTitle":4315,"status":108,"phases":4339,"primaryCompletion":4317,"completion":4317,"start":4318,"enrollment":17,"conditions":4340,"interventions":4341},[91],[4320,4321],[4301,4323],{"trials":4343,"activeCount":100},[],{"intervention":4345,"totalTrials":138,"cells":4346},"Sildenafil citrate",{"EARLY_PHASE1":4347,"PHASE1":4349,"PHASE2":4351,"PHASE3":4353,"PHASE4":4355,"NA":4363},{"trials":4348,"activeCount":100},[],{"trials":4350,"activeCount":100},[],{"trials":4352,"activeCount":100},[],{"trials":4354,"activeCount":100},[],{"trials":4356,"activeCount":100},[4357],{"nctId":4358,"briefTitle":4359,"status":108,"phases":4360,"primaryCompletion":1061,"completion":695,"start":1385,"enrollment":2514,"conditions":4361,"interventions":4362},"NCT02129725","Effect of Prolonged PDE-5 Inhibition on Insulin Signaling in Skeletal Muscle.",[91],[1416],[4345],{"trials":4364,"activeCount":100},[],{"intervention":4366,"totalTrials":138,"cells":4367},"ccIIV4",{"EARLY_PHASE1":4368,"PHASE1":4370,"PHASE2":4372,"PHASE3":4374,"PHASE4":4376,"NA":4388},{"trials":4369,"activeCount":100},[],{"trials":4371,"activeCount":100},[],{"trials":4373,"activeCount":100},[],{"trials":4375,"activeCount":100},[],{"trials":4377,"activeCount":100},[4378],{"nctId":4379,"briefTitle":4380,"status":108,"phases":4381,"primaryCompletion":4382,"completion":4382,"start":4383,"enrollment":412,"conditions":4384,"interventions":4386},"NCT02967393","Influenza Vaccine Feasibility Study in Children With Persistent Asthma",[91],"2017-02-01","2016-10-10",[4385],"Asthmatic",[4366,4387],"IIV4",{"trials":4389,"activeCount":100},[],{"intervention":4387,"totalTrials":138,"cells":4391},{"EARLY_PHASE1":4392,"PHASE1":4394,"PHASE2":4396,"PHASE3":4398,"PHASE4":4400,"NA":4406},{"trials":4393,"activeCount":100},[],{"trials":4395,"activeCount":100},[],{"trials":4397,"activeCount":100},[],{"trials":4399,"activeCount":100},[],{"trials":4401,"activeCount":100},[4402],{"nctId":4379,"briefTitle":4380,"status":108,"phases":4403,"primaryCompletion":4382,"completion":4382,"start":4383,"enrollment":412,"conditions":4404,"interventions":4405},[91],[4385],[4366,4387],{"trials":4407,"activeCount":100},[],{"intervention":4409,"totalTrials":138,"cells":4410},"Prevacid",{"EARLY_PHASE1":4411,"PHASE1":4413,"PHASE2":4415,"PHASE3":4417,"PHASE4":4419,"NA":4432},{"trials":4412,"activeCount":100},[],{"trials":4414,"activeCount":100},[],{"trials":4416,"activeCount":100},[],{"trials":4418,"activeCount":100},[],{"trials":4420,"activeCount":100},[4421],{"nctId":4422,"briefTitle":4423,"status":108,"phases":4424,"primaryCompletion":4172,"completion":4425,"start":4426,"enrollment":4427,"conditions":4428,"interventions":4431},"NCT00444145","Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment?",[91],"2009-12","2007-03",38,[4429,4430],"Larynx Disease","Gastroesophageal Reflux",[4409],{"trials":4433,"activeCount":100},[],{"intervention":4435,"totalTrials":138,"cells":4436},"Dilute unfractionated heparin",{"EARLY_PHASE1":4437,"PHASE1":4439,"PHASE2":4441,"PHASE3":4443,"PHASE4":4445,"NA":4458},{"trials":4438,"activeCount":100},[],{"trials":4440,"activeCount":100},[],{"trials":4442,"activeCount":100},[],{"trials":4444,"activeCount":100},[],{"trials":4446,"activeCount":100},[4447],{"nctId":4448,"briefTitle":4449,"status":659,"phases":4450,"primaryCompletion":4451,"completion":4451,"start":4452,"enrollment":1220,"conditions":4453,"interventions":4456},"NCT01318811","A Comparison of Dilute Versus Concentrated Heparin for CRRT Anticoagulation",[91],"2016-04-03","2011-03",[4454,4455,651],"Acute Kidney Injury","Acute Renal Failure",[4435,4457],"Standard concentration unfractionated heparin",{"trials":4459,"activeCount":100},[],{"intervention":4457,"totalTrials":138,"cells":4461},{"EARLY_PHASE1":4462,"PHASE1":4464,"PHASE2":4466,"PHASE3":4468,"PHASE4":4470,"NA":4476},{"trials":4463,"activeCount":100},[],{"trials":4465,"activeCount":100},[],{"trials":4467,"activeCount":100},[],{"trials":4469,"activeCount":100},[],{"trials":4471,"activeCount":100},[4472],{"nctId":4448,"briefTitle":4449,"status":659,"phases":4473,"primaryCompletion":4451,"completion":4451,"start":4452,"enrollment":1220,"conditions":4474,"interventions":4475},[91],[4454,4455,651],[4435,4457],{"trials":4477,"activeCount":100},[],{"intervention":4479,"totalTrials":138,"cells":4480},"Escitalopram",{"EARLY_PHASE1":4481,"PHASE1":4483,"PHASE2":4485,"PHASE3":4487,"PHASE4":4489,"NA":4500},{"trials":4482,"activeCount":100},[],{"trials":4484,"activeCount":100},[],{"trials":4486,"activeCount":100},[],{"trials":4488,"activeCount":100},[],{"trials":4490,"activeCount":100},[4491],{"nctId":4492,"briefTitle":4493,"status":108,"phases":4494,"primaryCompletion":4495,"completion":4495,"start":2160,"enrollment":1086,"conditions":4496,"interventions":4498},"NCT02332291","Connectivity Affecting the Antidepressant REsponse Study",[91],"2020-08",[4497],"Major Depressive Disorder",[4479,4499],"Bupropion XL",{"trials":4501,"activeCount":100},[],{"intervention":4499,"totalTrials":138,"cells":4503},{"EARLY_PHASE1":4504,"PHASE1":4506,"PHASE2":4508,"PHASE3":4510,"PHASE4":4512,"NA":4518},{"trials":4505,"activeCount":100},[],{"trials":4507,"activeCount":100},[],{"trials":4509,"activeCount":100},[],{"trials":4511,"activeCount":100},[],{"trials":4513,"activeCount":100},[4514],{"nctId":4492,"briefTitle":4493,"status":108,"phases":4515,"primaryCompletion":4495,"completion":4495,"start":2160,"enrollment":1086,"conditions":4516,"interventions":4517},[91],[4497],[4479,4499],{"trials":4519,"activeCount":100},[],{"intervention":1352,"totalTrials":138,"cells":4521},{"EARLY_PHASE1":4522,"PHASE1":4524,"PHASE2":4526,"PHASE3":4528,"PHASE4":4530,"NA":4536},{"trials":4523,"activeCount":100},[],{"trials":4525,"activeCount":100},[],{"trials":4527,"activeCount":100},[],{"trials":4529,"activeCount":100},[],{"trials":4531,"activeCount":100},[4532],{"nctId":1344,"briefTitle":1345,"status":605,"phases":4533,"primaryCompletion":1347,"completion":1347,"start":1348,"enrollment":100,"conditions":4534,"interventions":4535},[91],[1350],[1352,1056],{"trials":4537,"activeCount":100},[],{"intervention":1418,"totalTrials":138,"cells":4539},{"EARLY_PHASE1":4540,"PHASE1":4542,"PHASE2":4544,"PHASE3":4546,"PHASE4":4548,"NA":4554},{"trials":4541,"activeCount":100},[],{"trials":4543,"activeCount":100},[],{"trials":4545,"activeCount":100},[],{"trials":4547,"activeCount":100},[],{"trials":4549,"activeCount":100},[4550],{"nctId":1409,"briefTitle":1410,"status":108,"phases":4551,"primaryCompletion":1412,"completion":1412,"start":1413,"enrollment":1414,"conditions":4552,"interventions":4553},[91],[1416],[1418,1223],{"trials":4555,"activeCount":100},[],{"intervention":4557,"totalTrials":138,"cells":4558},"Ulipristal Acetate",{"EARLY_PHASE1":4559,"PHASE1":4561,"PHASE2":4563,"PHASE3":4565,"PHASE4":4567,"NA":4580},{"trials":4560,"activeCount":100},[],{"trials":4562,"activeCount":100},[],{"trials":4564,"activeCount":100},[],{"trials":4566,"activeCount":100},[],{"trials":4568,"activeCount":100},[4569],{"nctId":4570,"briefTitle":4571,"status":605,"phases":4572,"primaryCompletion":4573,"completion":4573,"start":4574,"enrollment":100,"conditions":4575,"interventions":4579},"NCT03325868","Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis",[91],"2019-05","2018-02",[4576,4577,4578],"Adenomyosis","Heavy Uterine Bleeding","Dysmenorrhea",[4557],{"trials":4581,"activeCount":100},[],{"intervention":4583,"totalTrials":138,"cells":4584},"Rapamycin",{"EARLY_PHASE1":4585,"PHASE1":4587,"PHASE2":4589,"PHASE3":4591,"PHASE4":4593,"NA":4603},{"trials":4586,"activeCount":100},[],{"trials":4588,"activeCount":100},[],{"trials":4590,"activeCount":100},[],{"trials":4592,"activeCount":100},[],{"trials":4594,"activeCount":100},[4595],{"nctId":4596,"briefTitle":4597,"status":108,"phases":4598,"primaryCompletion":1014,"completion":1014,"start":4599,"enrollment":29,"conditions":4600,"interventions":4602},"NCT00223678","Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure",[91],"2000-06",[4601],"Kidney Transplant",[4583],{"trials":4604,"activeCount":100},[],{"intervention":3709,"totalTrials":138,"cells":4606},{"EARLY_PHASE1":4607,"PHASE1":4609,"PHASE2":4611,"PHASE3":4613,"PHASE4":4615,"NA":4621},{"trials":4608,"activeCount":100},[],{"trials":4610,"activeCount":100},[],{"trials":4612,"activeCount":100},[],{"trials":4614,"activeCount":100},[],{"trials":4616,"activeCount":100},[4617],{"nctId":3703,"briefTitle":3704,"status":108,"phases":4618,"primaryCompletion":3706,"completion":3706,"start":732,"enrollment":2250,"conditions":4619,"interventions":4620},[91],[1107],[3421,3709,3422],{"trials":4622,"activeCount":100},[],{"intervention":4624,"totalTrials":138,"cells":4625},"extended-release exenatide",{"EARLY_PHASE1":4626,"PHASE1":4628,"PHASE2":4630,"PHASE3":4632,"PHASE4":4634,"NA":4645},{"trials":4627,"activeCount":100},[],{"trials":4629,"activeCount":100},[],{"trials":4631,"activeCount":100},[],{"trials":4633,"activeCount":100},[],{"trials":4635,"activeCount":100},[4636],{"nctId":4637,"briefTitle":4638,"status":659,"phases":4639,"primaryCompletion":4640,"completion":4640,"start":4641,"enrollment":683,"conditions":4642,"interventions":4644},"NCT01791465","Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults",[91],"2014-12","2013-03",[4643,3416],"Human Immunodeficiency Virus Infection",[4624],{"trials":4646,"activeCount":100},[],{"intervention":4648,"totalTrials":138,"cells":4649},"Fluzone-High Dose Quadrivalent",{"EARLY_PHASE1":4650,"PHASE1":4652,"PHASE2":4654,"PHASE3":4656,"PHASE4":4658,"NA":4671},{"trials":4651,"activeCount":100},[],{"trials":4653,"activeCount":100},[],{"trials":4655,"activeCount":100},[],{"trials":4657,"activeCount":100},[],{"trials":4659,"activeCount":100},[4660],{"nctId":4661,"briefTitle":4662,"status":108,"phases":4663,"primaryCompletion":4664,"completion":4664,"start":4665,"enrollment":2911,"conditions":4666,"interventions":4668},"NCT04077424","Senescent Immunity in Elders and Vaccine Responses (SILVER)",[91],"2020-02-01","2019-10-21",[4667],"Flu Vaccine",[4648,4669,4670],"Fluad","Flublock",{"trials":4672,"activeCount":100},[],{"intervention":4669,"totalTrials":138,"cells":4674},{"EARLY_PHASE1":4675,"PHASE1":4677,"PHASE2":4679,"PHASE3":4681,"PHASE4":4683,"NA":4689},{"trials":4676,"activeCount":100},[],{"trials":4678,"activeCount":100},[],{"trials":4680,"activeCount":100},[],{"trials":4682,"activeCount":100},[],{"trials":4684,"activeCount":100},[4685],{"nctId":4661,"briefTitle":4662,"status":108,"phases":4686,"primaryCompletion":4664,"completion":4664,"start":4665,"enrollment":2911,"conditions":4687,"interventions":4688},[91],[4667],[4648,4669,4670],{"trials":4690,"activeCount":100},[],{"intervention":4670,"totalTrials":138,"cells":4692},{"EARLY_PHASE1":4693,"PHASE1":4695,"PHASE2":4697,"PHASE3":4699,"PHASE4":4701,"NA":4707},{"trials":4694,"activeCount":100},[],{"trials":4696,"activeCount":100},[],{"trials":4698,"activeCount":100},[],{"trials":4700,"activeCount":100},[],{"trials":4702,"activeCount":100},[4703],{"nctId":4661,"briefTitle":4662,"status":108,"phases":4704,"primaryCompletion":4664,"completion":4664,"start":4665,"enrollment":2911,"conditions":4705,"interventions":4706},[91],[4667],[4648,4669,4670],{"trials":4708,"activeCount":100},[],{"intervention":3814,"totalTrials":138,"cells":4710},{"EARLY_PHASE1":4711,"PHASE1":4713,"PHASE2":4715,"PHASE3":4717,"PHASE4":4719,"NA":4725},{"trials":4712,"activeCount":100},[],{"trials":4714,"activeCount":100},[],{"trials":4716,"activeCount":100},[],{"trials":4718,"activeCount":100},[],{"trials":4720,"activeCount":100},[4721],{"nctId":3806,"briefTitle":3807,"status":108,"phases":4722,"primaryCompletion":3809,"completion":3809,"start":1348,"enrollment":3810,"conditions":4723,"interventions":4724},[91],[3812],[3814,3770],{"trials":4726,"activeCount":100},[],{"intervention":4728,"totalTrials":138,"cells":4729},"adalimumab",{"EARLY_PHASE1":4730,"PHASE1":4732,"PHASE2":4734,"PHASE3":4736,"PHASE4":4738,"NA":4749},{"trials":4731,"activeCount":100},[],{"trials":4733,"activeCount":100},[],{"trials":4735,"activeCount":100},[],{"trials":4737,"activeCount":100},[],{"trials":4739,"activeCount":100},[4740],{"nctId":4741,"briefTitle":4742,"status":108,"phases":4743,"primaryCompletion":4640,"completion":4196,"start":4744,"enrollment":2169,"conditions":4745,"interventions":4748},"NCT00517296","Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas",[91],"2008-01",[4746,4747],"Crohn Disease","Rectal Fistula",[4728],{"trials":4750,"activeCount":100},[],{"intervention":4752,"totalTrials":138,"cells":4753},"Hylenex",{"EARLY_PHASE1":4754,"PHASE1":4756,"PHASE2":4758,"PHASE3":4760,"PHASE4":4762,"NA":4775},{"trials":4755,"activeCount":100},[],{"trials":4757,"activeCount":100},[],{"trials":4759,"activeCount":100},[],{"trials":4761,"activeCount":100},[],{"trials":4763,"activeCount":100},[4764],{"nctId":4765,"briefTitle":4766,"status":108,"phases":4767,"primaryCompletion":4768,"completion":4768,"start":4769,"enrollment":35,"conditions":4770,"interventions":4774},"NCT01139294","Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in Pediatrics",[91],"2011-11","2010-02",[4771,4772,4773],"Dehydration","Cardiac Output","Pediatrics",[4752],{"trials":4776,"activeCount":100},[],{"intervention":4778,"totalTrials":138,"cells":4779},"Rivaroxaban 2.5 Mg Oral",{"EARLY_PHASE1":4780,"PHASE1":4782,"PHASE2":4784,"PHASE3":4786,"PHASE4":4788,"NA":4799},{"trials":4781,"activeCount":100},[],{"trials":4783,"activeCount":100},[],{"trials":4785,"activeCount":100},[],{"trials":4787,"activeCount":100},[],{"trials":4789,"activeCount":100},[4790],{"nctId":4791,"briefTitle":4792,"status":108,"phases":4793,"primaryCompletion":2247,"completion":2247,"start":4794,"enrollment":1133,"conditions":4795,"interventions":4797},"NCT05009862","The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease",[91],"2022-04-19",[4796],"Peripheral Arterial Disease",[4778,4798],"Aspirin 81Mg Ec Tab",{"trials":4800,"activeCount":100},[],{"intervention":4798,"totalTrials":138,"cells":4802},{"EARLY_PHASE1":4803,"PHASE1":4805,"PHASE2":4807,"PHASE3":4809,"PHASE4":4811,"NA":4817},{"trials":4804,"activeCount":100},[],{"trials":4806,"activeCount":100},[],{"trials":4808,"activeCount":100},[],{"trials":4810,"activeCount":100},[],{"trials":4812,"activeCount":100},[4813],{"nctId":4791,"briefTitle":4792,"status":108,"phases":4814,"primaryCompletion":2247,"completion":2247,"start":4794,"enrollment":1133,"conditions":4815,"interventions":4816},[91],[4796],[4778,4798],{"trials":4818,"activeCount":100},[],{"intervention":4820,"totalTrials":138,"cells":4821},"Cetirizine",{"EARLY_PHASE1":4822,"PHASE1":4824,"PHASE2":4826,"PHASE3":4828,"PHASE4":4830,"NA":4840},{"trials":4823,"activeCount":100},[],{"trials":4825,"activeCount":100},[],{"trials":4827,"activeCount":100},[],{"trials":4829,"activeCount":100},[],{"trials":4831,"activeCount":100},[4832],{"nctId":4833,"briefTitle":4834,"status":108,"phases":4835,"primaryCompletion":3548,"completion":3548,"start":682,"enrollment":762,"conditions":4836,"interventions":4838},"NCT00826943","Is Levocetirizine Less Sedating Than Cetirizine?",[91],[4837],"Allergic Rhinitis",[4820,4839],"Levocetirizine",{"trials":4841,"activeCount":100},[],{"intervention":4839,"totalTrials":138,"cells":4843},{"EARLY_PHASE1":4844,"PHASE1":4846,"PHASE2":4848,"PHASE3":4850,"PHASE4":4852,"NA":4858},{"trials":4845,"activeCount":100},[],{"trials":4847,"activeCount":100},[],{"trials":4849,"activeCount":100},[],{"trials":4851,"activeCount":100},[],{"trials":4853,"activeCount":100},[4854],{"nctId":4833,"briefTitle":4834,"status":108,"phases":4855,"primaryCompletion":3548,"completion":3548,"start":682,"enrollment":762,"conditions":4856,"interventions":4857},[91],[4837],[4820,4839],{"trials":4859,"activeCount":100},[],{"intervention":4861,"totalTrials":138,"cells":4862},"tolvaptan",{"EARLY_PHASE1":4863,"PHASE1":4865,"PHASE2":4867,"PHASE3":4869,"PHASE4":4871,"NA":4883},{"trials":4864,"activeCount":100},[],{"trials":4866,"activeCount":100},[],{"trials":4868,"activeCount":100},[],{"trials":4870,"activeCount":100},[],{"trials":4872,"activeCount":100},[4873],{"nctId":4874,"briefTitle":4875,"status":108,"phases":4876,"primaryCompletion":4877,"completion":4878,"start":662,"enrollment":1133,"conditions":4879,"interventions":4880},"NCT02606253","Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure",[91],"2018-09-27","2018-10-31",[651],[4861,4881,4882],"Chlorothiazide","Metolazone",{"trials":4884,"activeCount":100},[],{"intervention":4881,"totalTrials":138,"cells":4886},{"EARLY_PHASE1":4887,"PHASE1":4889,"PHASE2":4891,"PHASE3":4893,"PHASE4":4895,"NA":4901},{"trials":4888,"activeCount":100},[],{"trials":4890,"activeCount":100},[],{"trials":4892,"activeCount":100},[],{"trials":4894,"activeCount":100},[],{"trials":4896,"activeCount":100},[4897],{"nctId":4874,"briefTitle":4875,"status":108,"phases":4898,"primaryCompletion":4877,"completion":4878,"start":662,"enrollment":1133,"conditions":4899,"interventions":4900},[91],[651],[4861,4881,4882],{"trials":4902,"activeCount":100},[],{"intervention":4882,"totalTrials":138,"cells":4904},{"EARLY_PHASE1":4905,"PHASE1":4907,"PHASE2":4909,"PHASE3":4911,"PHASE4":4913,"NA":4919},{"trials":4906,"activeCount":100},[],{"trials":4908,"activeCount":100},[],{"trials":4910,"activeCount":100},[],{"trials":4912,"activeCount":100},[],{"trials":4914,"activeCount":100},[4915],{"nctId":4874,"briefTitle":4875,"status":108,"phases":4916,"primaryCompletion":4877,"completion":4878,"start":662,"enrollment":1133,"conditions":4917,"interventions":4918},[91],[651],[4861,4881,4882],{"trials":4920,"activeCount":100},[],{"intervention":4922,"totalTrials":138,"cells":4923},"Pentoxifylline",{"EARLY_PHASE1":4924,"PHASE1":4926,"PHASE2":4928,"PHASE3":4930,"PHASE4":4932,"NA":4942},{"trials":4925,"activeCount":100},[],{"trials":4927,"activeCount":100},[],{"trials":4929,"activeCount":100},[],{"trials":4931,"activeCount":100},[],{"trials":4933,"activeCount":100},[4934],{"nctId":4935,"briefTitle":4936,"status":108,"phases":4937,"primaryCompletion":3548,"completion":732,"start":4938,"enrollment":4939,"conditions":4940,"interventions":4941},"NCT00770328","The Effects of Pentoxifylline on PAI-1 in an Obese Population",[91],"2003-05",37,[16],[4922],{"trials":4943,"activeCount":100},[],{"intervention":740,"totalTrials":138,"cells":4945},{"EARLY_PHASE1":4946,"PHASE1":4948,"PHASE2":4950,"PHASE3":4952,"PHASE4":4954,"NA":4960},{"trials":4947,"activeCount":100},[],{"trials":4949,"activeCount":100},[],{"trials":4951,"activeCount":100},[],{"trials":4953,"activeCount":100},[],{"trials":4955,"activeCount":100},[4956],{"nctId":728,"briefTitle":729,"status":108,"phases":4957,"primaryCompletion":731,"completion":731,"start":732,"enrollment":733,"conditions":4958,"interventions":4959},[91],[735,736,737,738],[67,740],{"trials":4961,"activeCount":100},[],{"intervention":4963,"totalTrials":138,"cells":4964},"Medications",{"EARLY_PHASE1":4965,"PHASE1":4967,"PHASE2":4969,"PHASE3":4971,"PHASE4":4973,"NA":4984},{"trials":4966,"activeCount":100},[],{"trials":4968,"activeCount":100},[],{"trials":4970,"activeCount":100},[],{"trials":4972,"activeCount":100},[],{"trials":4974,"activeCount":100},[4975],{"nctId":4976,"briefTitle":4977,"status":108,"phases":4978,"primaryCompletion":3410,"completion":4979,"start":4980,"enrollment":4981,"conditions":4982,"interventions":4983},"NCT00057577","Prevention of Recurrence in Depression With Drugs and CT",[91],"2014-03","2002-10",452,[22],[4963],{"trials":4985,"activeCount":100},[],{"intervention":4987,"totalTrials":138,"cells":4988},"Dabigatran Etexilate Oral",{"EARLY_PHASE1":4989,"PHASE1":4991,"PHASE2":4993,"PHASE3":4995,"PHASE4":4997,"NA":5010},{"trials":4990,"activeCount":100},[],{"trials":4992,"activeCount":100},[],{"trials":4994,"activeCount":100},[],{"trials":4996,"activeCount":100},[],{"trials":4998,"activeCount":100},[4999],{"nctId":5000,"briefTitle":5001,"status":108,"phases":5002,"primaryCompletion":5003,"completion":5004,"start":1053,"enrollment":697,"conditions":5005,"interventions":5009},"NCT03539055","Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).",[91],"2023-12-31","2024-02-29",[1088,5006,5007,5008],"Device Related Thrombus","Left Atrial Appendage Thrombosis","Watchman LAA Closure Device",[4987],{"trials":5011,"activeCount":100},[],{"intervention":5013,"totalTrials":138,"cells":5014},"Medrol 4 MG Oral Tablet Includes Medrol Dosepak",{"EARLY_PHASE1":5015,"PHASE1":5017,"PHASE2":5019,"PHASE3":5021,"PHASE4":5023,"NA":5038},{"trials":5016,"activeCount":100},[],{"trials":5018,"activeCount":100},[],{"trials":5020,"activeCount":100},[],{"trials":5022,"activeCount":100},[],{"trials":5024,"activeCount":100},[5025],{"nctId":5026,"briefTitle":5027,"status":605,"phases":5028,"primaryCompletion":1987,"completion":1987,"start":5029,"enrollment":100,"conditions":5030,"interventions":5037},"NCT06483204","Steroids for Rhinoplasty: Pain, Nausea, Edema and Ecchymosis",[91],"2026-01",[5031,5032,5033,5034,5035,5036],"Edema","Bruising","Nasal Obstruction","Postoperative Pain","Postoperative Nausea","Postoperative Complications",[5013],{"trials":5039,"activeCount":100},[],{"intervention":5041,"totalTrials":138,"cells":5042},"Lisdexamfetamine",{"EARLY_PHASE1":5043,"PHASE1":5045,"PHASE2":5047,"PHASE3":5049,"PHASE4":5051,"NA":5063},{"trials":5044,"activeCount":100},[],{"trials":5046,"activeCount":100},[],{"trials":5048,"activeCount":100},[],{"trials":5050,"activeCount":100},[],{"trials":5052,"activeCount":100},[5053],{"nctId":5054,"briefTitle":5055,"status":108,"phases":5056,"primaryCompletion":5057,"completion":5057,"start":5058,"enrollment":29,"conditions":5059,"interventions":5062},"NCT02712996","Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children",[91],"2019-07-01","2017-02-06",[5060,5061],"Traumatic Brain Injury","Attention Deficit Disorder",[5041],{"trials":5064,"activeCount":100},[],{"intervention":5066,"totalTrials":138,"cells":5067},"Methylprednisolone Injectable Product",{"EARLY_PHASE1":5068,"PHASE1":5070,"PHASE2":5072,"PHASE3":5074,"PHASE4":5076,"NA":5090},{"trials":5069,"activeCount":100},[],{"trials":5071,"activeCount":100},[],{"trials":5073,"activeCount":100},[],{"trials":5075,"activeCount":100},[],{"trials":5077,"activeCount":100},[5078],{"nctId":5079,"briefTitle":5080,"status":108,"phases":5081,"primaryCompletion":5082,"completion":5082,"start":5083,"enrollment":138,"conditions":5084,"interventions":5088},"NCT03479502","Intra-articular Doxycycline: A Novel Treatment of Adhesive Capsulitis",[91],"2022-02-08","2018-03-05",[5085,5086,5087],"Adhesive Capsulitis","Adhesive Capsulitis of Unspecified Shoulder","Frozen Shoulder",[5066,5089],"Doxycycline",{"trials":5091,"activeCount":100},[],{"intervention":5089,"totalTrials":138,"cells":5093},{"EARLY_PHASE1":5094,"PHASE1":5096,"PHASE2":5098,"PHASE3":5100,"PHASE4":5102,"NA":5108},{"trials":5095,"activeCount":100},[],{"trials":5097,"activeCount":100},[],{"trials":5099,"activeCount":100},[],{"trials":5101,"activeCount":100},[],{"trials":5103,"activeCount":100},[5104],{"nctId":5079,"briefTitle":5080,"status":108,"phases":5105,"primaryCompletion":5082,"completion":5082,"start":5083,"enrollment":138,"conditions":5106,"interventions":5107},[91],[5085,5086,5087],[5066,5089],{"trials":5109,"activeCount":100},[],{"intervention":5111,"totalTrials":138,"cells":5112},"Baclofen bolus",{"EARLY_PHASE1":5113,"PHASE1":5115,"PHASE2":5117,"PHASE3":5119,"PHASE4":5121,"NA":5132},{"trials":5114,"activeCount":100},[],{"trials":5116,"activeCount":100},[],{"trials":5118,"activeCount":100},[],{"trials":5120,"activeCount":100},[],{"trials":5122,"activeCount":100},[5123],{"nctId":5124,"briefTitle":5125,"status":108,"phases":5126,"primaryCompletion":5127,"completion":5127,"start":5128,"enrollment":2796,"conditions":5129,"interventions":5131},"NCT02903823","Intrathecal (IT) Baclofen Drug Distribution",[91],"2019-02-01","2016-04-22",[5130],"Muscle Spasticity",[5111],{"trials":5133,"activeCount":100},[],{"intervention":3499,"totalTrials":138,"cells":5135},{"EARLY_PHASE1":5136,"PHASE1":5138,"PHASE2":5140,"PHASE3":5142,"PHASE4":5144,"NA":5150},{"trials":5137,"activeCount":100},[],{"trials":5139,"activeCount":100},[],{"trials":5141,"activeCount":100},[],{"trials":5143,"activeCount":100},[],{"trials":5145,"activeCount":100},[5146],{"nctId":3492,"briefTitle":3493,"status":659,"phases":5147,"primaryCompletion":3495,"completion":3495,"start":3496,"enrollment":2239,"conditions":5148,"interventions":5149},[91],[19],[3462,3499,3500,3501,3502,1341],{"trials":5151,"activeCount":100},[],{"intervention":3501,"totalTrials":138,"cells":5153},{"EARLY_PHASE1":5154,"PHASE1":5156,"PHASE2":5158,"PHASE3":5160,"PHASE4":5162,"NA":5168},{"trials":5155,"activeCount":100},[],{"trials":5157,"activeCount":100},[],{"trials":5159,"activeCount":100},[],{"trials":5161,"activeCount":100},[],{"trials":5163,"activeCount":100},[5164],{"nctId":3492,"briefTitle":3493,"status":659,"phases":5165,"primaryCompletion":3495,"completion":3495,"start":3496,"enrollment":2239,"conditions":5166,"interventions":5167},[91],[19],[3462,3499,3500,3501,3502,1341],{"trials":5169,"activeCount":100},[],{"intervention":3502,"totalTrials":138,"cells":5171},{"EARLY_PHASE1":5172,"PHASE1":5174,"PHASE2":5176,"PHASE3":5178,"PHASE4":5180,"NA":5186},{"trials":5173,"activeCount":100},[],{"trials":5175,"activeCount":100},[],{"trials":5177,"activeCount":100},[],{"trials":5179,"activeCount":100},[],{"trials":5181,"activeCount":100},[5182],{"nctId":3492,"briefTitle":3493,"status":659,"phases":5183,"primaryCompletion":3495,"completion":3495,"start":3496,"enrollment":2239,"conditions":5184,"interventions":5185},[91],[19],[3462,3499,3500,3501,3502,1341],{"trials":5187,"activeCount":100},[],{"intervention":5189,"totalTrials":138,"cells":5190},"Pegvisomant",{"EARLY_PHASE1":5191,"PHASE1":5193,"PHASE2":5195,"PHASE3":5197,"PHASE4":5199,"NA":5210},{"trials":5192,"activeCount":100},[],{"trials":5194,"activeCount":100},[],{"trials":5196,"activeCount":100},[],{"trials":5198,"activeCount":100},[],{"trials":5200,"activeCount":100},[5201],{"nctId":5202,"briefTitle":5203,"status":108,"phases":5204,"primaryCompletion":5205,"completion":5205,"start":5206,"enrollment":1414,"conditions":5207,"interventions":5208},"NCT01701973","Effect of DPP4 Inhibition on Growth Hormone Secretion",[91],"2017-05","2013-01",[16],[1341,5189,2179,5209],"Exendin 9-39",{"trials":5211,"activeCount":100},[],{"intervention":5209,"totalTrials":138,"cells":5213},{"EARLY_PHASE1":5214,"PHASE1":5216,"PHASE2":5218,"PHASE3":5220,"PHASE4":5222,"NA":5228},{"trials":5215,"activeCount":100},[],{"trials":5217,"activeCount":100},[],{"trials":5219,"activeCount":100},[],{"trials":5221,"activeCount":100},[],{"trials":5223,"activeCount":100},[5224],{"nctId":5202,"briefTitle":5203,"status":108,"phases":5225,"primaryCompletion":5205,"completion":5205,"start":5206,"enrollment":1414,"conditions":5226,"interventions":5227},[91],[16],[1341,5189,2179,5209],{"trials":5229,"activeCount":100},[],{"intervention":5231,"totalTrials":138,"cells":5232},"Periprocedural Antibiotics",{"EARLY_PHASE1":5233,"PHASE1":5235,"PHASE2":5237,"PHASE3":5239,"PHASE4":5241,"NA":5254},{"trials":5234,"activeCount":100},[],{"trials":5236,"activeCount":100},[],{"trials":5238,"activeCount":100},[],{"trials":5240,"activeCount":100},[],{"trials":5242,"activeCount":100},[5243],{"nctId":5244,"briefTitle":5245,"status":659,"phases":5246,"primaryCompletion":5247,"completion":5247,"start":5248,"enrollment":26,"conditions":5249,"interventions":5252},"NCT03508921","Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection",[91],"2022-06-01","2018-07-01",[5250,5251],"Overactive Bladder","Urinary Tract Infections",[5231,5253],"Extended Antibiotics",{"trials":5255,"activeCount":100},[],{"intervention":5253,"totalTrials":138,"cells":5257},{"EARLY_PHASE1":5258,"PHASE1":5260,"PHASE2":5262,"PHASE3":5264,"PHASE4":5266,"NA":5272},{"trials":5259,"activeCount":100},[],{"trials":5261,"activeCount":100},[],{"trials":5263,"activeCount":100},[],{"trials":5265,"activeCount":100},[],{"trials":5267,"activeCount":100},[5268],{"nctId":5244,"briefTitle":5245,"status":659,"phases":5269,"primaryCompletion":5247,"completion":5247,"start":5248,"enrollment":26,"conditions":5270,"interventions":5271},[91],[5250,5251],[5231,5253],{"trials":5273,"activeCount":100},[],{"intervention":5275,"totalTrials":138,"cells":5276},"4% liposomal lidocaine cream",{"EARLY_PHASE1":5277,"PHASE1":5279,"PHASE2":5281,"PHASE3":5283,"PHASE4":5285,"NA":5297},{"trials":5278,"activeCount":100},[],{"trials":5280,"activeCount":100},[],{"trials":5282,"activeCount":100},[],{"trials":5284,"activeCount":100},[],{"trials":5286,"activeCount":100},[5287],{"nctId":5288,"briefTitle":5289,"status":108,"phases":5290,"primaryCompletion":5291,"completion":5291,"start":5292,"enrollment":5293,"conditions":5294,"interventions":5296},"NCT04766684","Clubfoot Tenotomy Trial",[91],"2024-08-01","2021-06-01",107,[5295],"Clubfoot",[5275],{"trials":5298,"activeCount":100},[],{"intervention":137,"totalTrials":138,"cells":5300},{"EARLY_PHASE1":5301,"PHASE1":5303,"PHASE2":5305,"PHASE3":5307,"PHASE4":5309,"NA":5315},{"trials":5302,"activeCount":100},[],{"trials":5304,"activeCount":100},[],{"trials":5306,"activeCount":100},[],{"trials":5308,"activeCount":100},[],{"trials":5310,"activeCount":100},[5311],{"nctId":129,"briefTitle":130,"status":108,"phases":5312,"completion":132,"start":133,"enrollment":29,"conditions":5313,"interventions":5314},[91],[135],[95,137],{"trials":5316,"activeCount":100},[],{"intervention":5318,"totalTrials":138,"cells":5319},"fenofibrate",{"EARLY_PHASE1":5320,"PHASE1":5322,"PHASE2":5324,"PHASE3":5326,"PHASE4":5328,"NA":5337},{"trials":5321,"activeCount":100},[],{"trials":5323,"activeCount":100},[],{"trials":5325,"activeCount":100},[],{"trials":5327,"activeCount":100},[],{"trials":5329,"activeCount":100},[5330],{"nctId":5331,"briefTitle":5332,"status":108,"phases":5333,"primaryCompletion":3706,"completion":3706,"start":5334,"enrollment":300,"conditions":5335,"interventions":5336},"NCT00872599","The Effect of a Peroxisome Proliferator-activated Receptor (PPAR) Alpha Agonist on Cytochrome P450 (CYP) Monooxygenase Activity in Humans",[91],"2009-09",[19],[5318],{"trials":5338,"activeCount":100},[],{"intervention":5340,"totalTrials":138,"cells":5341},"Nicotine",{"EARLY_PHASE1":5342,"PHASE1":5344,"PHASE2":5346,"PHASE3":5348,"PHASE4":5350,"NA":5360},{"trials":5343,"activeCount":100},[],{"trials":5345,"activeCount":100},[],{"trials":5347,"activeCount":100},[],{"trials":5349,"activeCount":100},[],{"trials":5351,"activeCount":100},[5352],{"nctId":5353,"briefTitle":5354,"status":108,"phases":5355,"primaryCompletion":5356,"completion":5357,"start":1061,"enrollment":2514,"conditions":5358,"interventions":5359},"NCT02816138","Depressed Mood Improvement Through Nicotine Dosing (Depressed MIND Study)",[91],"2017-08-23","2017-09-12",[4497],[5340],{"trials":5361,"activeCount":100},[],{"intervention":5363,"totalTrials":138,"cells":5364},"Live Attenuated Influenza Vaccine",{"EARLY_PHASE1":5365,"PHASE1":5367,"PHASE2":5369,"PHASE3":5371,"PHASE4":5373,"NA":5387},{"trials":5366,"activeCount":100},[],{"trials":5368,"activeCount":100},[],{"trials":5370,"activeCount":100},[],{"trials":5372,"activeCount":100},[],{"trials":5374,"activeCount":100},[5375],{"nctId":5376,"briefTitle":5377,"status":108,"phases":5378,"primaryCompletion":5379,"completion":5379,"start":5380,"enrollment":3517,"conditions":5381,"interventions":5385},"NCT03600428","Safety of LAIV4 in Children With Asthma",[91],"2020-03-20","2018-10-15",[1486,5382,5383,2056,5384,1248],"Vaccine Adverse Reaction","Vaccine Reaction","Wheezing",[5363,5386],"Inactivated Influenza Vaccine",{"trials":5388,"activeCount":100},[],{"intervention":5386,"totalTrials":138,"cells":5390},{"EARLY_PHASE1":5391,"PHASE1":5393,"PHASE2":5395,"PHASE3":5397,"PHASE4":5399,"NA":5405},{"trials":5392,"activeCount":100},[],{"trials":5394,"activeCount":100},[],{"trials":5396,"activeCount":100},[],{"trials":5398,"activeCount":100},[],{"trials":5400,"activeCount":100},[5401],{"nctId":5376,"briefTitle":5377,"status":108,"phases":5402,"primaryCompletion":5379,"completion":5379,"start":5380,"enrollment":3517,"conditions":5403,"interventions":5404},[91],[1486,5382,5383,2056,5384,1248],[5363,5386],{"trials":5406,"activeCount":100},[],{"intervention":5408,"totalTrials":138,"cells":5409},"Triamcinolone Acetonide",{"EARLY_PHASE1":5410,"PHASE1":5412,"PHASE2":5414,"PHASE3":5416,"PHASE4":5418,"NA":5429},{"trials":5411,"activeCount":100},[],{"trials":5413,"activeCount":100},[],{"trials":5415,"activeCount":100},[],{"trials":5417,"activeCount":100},[],{"trials":5419,"activeCount":100},[5420],{"nctId":5421,"briefTitle":5422,"status":659,"phases":5423,"primaryCompletion":5424,"completion":5424,"start":5425,"enrollment":2647,"conditions":5426,"interventions":5428},"NCT03166761","Particulate Corticosteroid Versus Non-particulate Corticosteroid for Sacroiliac Joint Injection",[91],"2023-02-28","2017-09-14",[5427],"Sacro-Iliac Spondylosis",[3065,5408],{"trials":5430,"activeCount":100},[],{"intervention":5432,"totalTrials":138,"cells":5433},"Sirolimus",{"EARLY_PHASE1":5434,"PHASE1":5436,"PHASE2":5438,"PHASE3":5440,"PHASE4":5442,"NA":5453},{"trials":5435,"activeCount":100},[],{"trials":5437,"activeCount":100},[],{"trials":5439,"activeCount":100},[],{"trials":5441,"activeCount":100},[],{"trials":5443,"activeCount":100},[5444],{"nctId":5445,"briefTitle":5446,"status":108,"phases":5447,"completion":5448,"start":5449,"enrollment":2670,"conditions":5450,"interventions":5452},"NCT00305396","Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation",[91],"2005-03","2004-04",[5451],"Kidney Transplantation",[5432],{"trials":5454,"activeCount":100},[],{"intervention":5456,"totalTrials":138,"cells":5457},"orally-disintegrating olanzapine",{"EARLY_PHASE1":5458,"PHASE1":5460,"PHASE2":5462,"PHASE3":5464,"PHASE4":5466,"NA":5477},{"trials":5459,"activeCount":100},[],{"trials":5461,"activeCount":100},[],{"trials":5463,"activeCount":100},[],{"trials":5465,"activeCount":100},[],{"trials":5467,"activeCount":100},[5468],{"nctId":5469,"briefTitle":5470,"status":108,"phases":5471,"primaryCompletion":3412,"completion":3412,"start":5472,"enrollment":29,"conditions":5473,"interventions":5475},"NCT00384332","Medication, Weight Gain and GI Hormones",[91],"2007-01",[5474],"Bipolar Depression",[5456,5476],"regular olanzapine",{"trials":5478,"activeCount":100},[],{"intervention":5476,"totalTrials":138,"cells":5480},{"EARLY_PHASE1":5481,"PHASE1":5483,"PHASE2":5485,"PHASE3":5487,"PHASE4":5489,"NA":5495},{"trials":5482,"activeCount":100},[],{"trials":5484,"activeCount":100},[],{"trials":5486,"activeCount":100},[],{"trials":5488,"activeCount":100},[],{"trials":5490,"activeCount":100},[5491],{"nctId":5469,"briefTitle":5470,"status":108,"phases":5492,"primaryCompletion":3412,"completion":3412,"start":5472,"enrollment":29,"conditions":5493,"interventions":5494},[91],[5474],[5456,5476],{"trials":5496,"activeCount":100},[],{"intervention":5498,"totalTrials":138,"cells":5499},"Dapsone gel, 5%",{"EARLY_PHASE1":5500,"PHASE1":5502,"PHASE2":5504,"PHASE3":5506,"PHASE4":5508,"NA":5518},{"trials":5501,"activeCount":100},[],{"trials":5503,"activeCount":100},[],{"trials":5505,"activeCount":100},[],{"trials":5507,"activeCount":100},[],{"trials":5509,"activeCount":100},[5510],{"nctId":5511,"briefTitle":5512,"status":659,"phases":5513,"primaryCompletion":5514,"completion":5514,"start":3442,"enrollment":138,"conditions":5515,"interventions":5517},"NCT01115244","Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis",[91],"2012-03",[5516],"Dermatitis Herpetiformis",[5498],{"trials":5519,"activeCount":100},[],{"intervention":5521,"totalTrials":138,"cells":5522},"Transforaminal Epidural Steroid Injection with Dexamethasone",{"EARLY_PHASE1":5523,"PHASE1":5525,"PHASE2":5527,"PHASE3":5529,"PHASE4":5531,"NA":5542},{"trials":5524,"activeCount":100},[],{"trials":5526,"activeCount":100},[],{"trials":5528,"activeCount":100},[],{"trials":5530,"activeCount":100},[],{"trials":5532,"activeCount":100},[5533],{"nctId":5534,"briefTitle":5535,"status":605,"phases":5536,"primaryCompletion":3182,"completion":4171,"start":5537,"enrollment":100,"conditions":5538,"interventions":5540},"NCT03165825","Cervical Interlaminar Versus Transforaminal Epidural Steroid Injection",[91],"2018-01",[5539],"Cervical Radiculopathy",[5521,5541],"Interlaminar Epidural Steroid Injection with Betamethasone",{"trials":5543,"activeCount":100},[],{"intervention":5541,"totalTrials":138,"cells":5545},{"EARLY_PHASE1":5546,"PHASE1":5548,"PHASE2":5550,"PHASE3":5552,"PHASE4":5554,"NA":5560},{"trials":5547,"activeCount":100},[],{"trials":5549,"activeCount":100},[],{"trials":5551,"activeCount":100},[],{"trials":5553,"activeCount":100},[],{"trials":5555,"activeCount":100},[5556],{"nctId":5534,"briefTitle":5535,"status":605,"phases":5557,"primaryCompletion":3182,"completion":4171,"start":5537,"enrollment":100,"conditions":5558,"interventions":5559},[91],[5539],[5521,5541],{"trials":5561,"activeCount":100},[],{"intervention":5563,"totalTrials":138,"cells":5564},"Gabapentin",{"EARLY_PHASE1":5565,"PHASE1":5567,"PHASE2":5569,"PHASE3":5571,"PHASE4":5573,"NA":5586},{"trials":5566,"activeCount":100},[],{"trials":5568,"activeCount":100},[],{"trials":5570,"activeCount":100},[],{"trials":5572,"activeCount":100},[],{"trials":5574,"activeCount":100},[5575],{"nctId":5576,"briefTitle":5577,"status":605,"phases":5578,"primaryCompletion":5579,"completion":5580,"start":5581,"enrollment":100,"conditions":5582,"interventions":5585},"NCT03335436","Gabapentin in the Post-cesarean Pain Management of Buprenorphine Patient",[91],"2020-11","2020-12","2018-04-01",[5583,5584],"Cesarean Delivery","Pain Management",[5563],{"trials":5587,"activeCount":100},[],{"intervention":5589,"totalTrials":138,"cells":5590},"Risperidone",{"EARLY_PHASE1":5591,"PHASE1":5593,"PHASE2":5595,"PHASE3":5597,"PHASE4":5599,"NA":5609},{"trials":5592,"activeCount":100},[],{"trials":5594,"activeCount":100},[],{"trials":5596,"activeCount":100},[],{"trials":5598,"activeCount":100},[],{"trials":5600,"activeCount":100},[5601],{"nctId":5602,"briefTitle":5603,"status":605,"phases":5604,"primaryCompletion":110,"completion":110,"start":5605,"enrollment":100,"conditions":5606,"interventions":5608},"NCT00178854","Risperidone (Risperdal) Augmentation in Depressed Partial Responders to SRI Treatment",[91],"2004-05",[5607],"Treatment Resistant Depression",[5589],{"trials":5610,"activeCount":100},[],{"intervention":5612,"totalTrials":138,"cells":5613},"Valproic Acid",{"EARLY_PHASE1":5614,"PHASE1":5616,"PHASE2":5618,"PHASE3":5620,"PHASE4":5622,"NA":5633},{"trials":5615,"activeCount":100},[],{"trials":5617,"activeCount":100},[],{"trials":5619,"activeCount":100},[],{"trials":5621,"activeCount":100},[],{"trials":5623,"activeCount":100},[5624],{"nctId":5625,"briefTitle":5626,"status":108,"phases":5627,"primaryCompletion":5628,"completion":5628,"start":2142,"enrollment":5629,"conditions":5630,"interventions":5632},"NCT00609245","Effect of Valproic Acid Concentration on Photic Response",[91],"2008-12",13,[5631],"Photosensitive Epilepsy",[5612],{"trials":5634,"activeCount":100},[],{"intervention":5636,"totalTrials":138,"cells":5637},"Vitamin E",{"EARLY_PHASE1":5638,"PHASE1":5640,"PHASE2":5642,"PHASE3":5644,"PHASE4":5646,"NA":5659},{"trials":5639,"activeCount":100},[],{"trials":5641,"activeCount":100},[],{"trials":5643,"activeCount":100},[],{"trials":5645,"activeCount":100},[],{"trials":5647,"activeCount":100},[5648],{"nctId":5649,"briefTitle":5650,"status":108,"phases":5651,"primaryCompletion":5652,"completion":5652,"start":5653,"enrollment":2250,"conditions":5654,"interventions":5657},"NCT03176966","Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis",[91],"2021-10-22","2016-09-02",[5655,5656],"Muscle Cramp","Cirrhosis",[5636,5658],"Ropinirole",{"trials":5660,"activeCount":100},[],{"intervention":5658,"totalTrials":138,"cells":5662},{"EARLY_PHASE1":5663,"PHASE1":5665,"PHASE2":5667,"PHASE3":5669,"PHASE4":5671,"NA":5677},{"trials":5664,"activeCount":100},[],{"trials":5666,"activeCount":100},[],{"trials":5668,"activeCount":100},[],{"trials":5670,"activeCount":100},[],{"trials":5672,"activeCount":100},[5673],{"nctId":5649,"briefTitle":5650,"status":108,"phases":5674,"primaryCompletion":5652,"completion":5652,"start":5653,"enrollment":2250,"conditions":5675,"interventions":5676},[91],[5655,5656],[5636,5658],{"trials":5678,"activeCount":100},[],{"intervention":5680,"totalTrials":138,"cells":5681},"Natalizumab 300 MG in 15 ML",{"EARLY_PHASE1":5682,"PHASE1":5684,"PHASE2":5686,"PHASE3":5688,"PHASE4":5690,"NA":5701},{"trials":5683,"activeCount":100},[],{"trials":5685,"activeCount":100},[],{"trials":5687,"activeCount":100},[],{"trials":5689,"activeCount":100},[],{"trials":5691,"activeCount":100},[5692],{"nctId":5693,"briefTitle":5694,"status":659,"phases":5695,"primaryCompletion":5696,"completion":5696,"start":5697,"enrollment":138,"conditions":5698,"interventions":5700},"NCT05177718","Natalizumab and Chronic Inflammation",[91],"2023-04-05","2022-09-16",[5699],"Multiple Sclerosis",[5680],{"trials":5702,"activeCount":100},[],{"intervention":5704,"totalTrials":138,"cells":5705},"Fluid Bolus",{"EARLY_PHASE1":5706,"PHASE1":5708,"PHASE2":5710,"PHASE3":5712,"PHASE4":5714,"NA":5725},{"trials":5707,"activeCount":100},[],{"trials":5709,"activeCount":100},[],{"trials":5711,"activeCount":100},[],{"trials":5713,"activeCount":100},[],{"trials":5715,"activeCount":100},[5716],{"nctId":5717,"briefTitle":5718,"status":108,"phases":5719,"primaryCompletion":961,"completion":5720,"start":5127,"enrollment":5721,"conditions":5722,"interventions":5724},"NCT03787732","Preventing Cardiovascular Collapse With Administration of Fluid Resuscitation During Induction and Intubation",[91],"2021-06-21",1067,[3037,1820,5723],"Hypotension on Induction",[5704],{"trials":5726,"activeCount":100},[],{"intervention":5728,"totalTrials":138,"cells":5729},"Opioid Analgesic",{"EARLY_PHASE1":5730,"PHASE1":5732,"PHASE2":5734,"PHASE3":5736,"PHASE4":5738,"NA":5749},{"trials":5731,"activeCount":100},[],{"trials":5733,"activeCount":100},[],{"trials":5735,"activeCount":100},[],{"trials":5737,"activeCount":100},[],{"trials":5739,"activeCount":100},[5740],{"nctId":5741,"briefTitle":5742,"status":659,"phases":5743,"primaryCompletion":4293,"completion":4293,"start":5744,"enrollment":2150,"conditions":5745,"interventions":5747},"NCT04990804","Opioid Free vs. Standard Perioperative Pain Regimen for Anterior Cervical Discectomy and Fusion (ACDF) Surgery",[91],"2021-08-01",[3024,738,5746,2376,5034],"Surgery--Complications",[5728,5748],"Opioid-Free Postoperative Pain Regimen",{"trials":5750,"activeCount":100},[],{"intervention":5748,"totalTrials":138,"cells":5752},{"EARLY_PHASE1":5753,"PHASE1":5755,"PHASE2":5757,"PHASE3":5759,"PHASE4":5761,"NA":5767},{"trials":5754,"activeCount":100},[],{"trials":5756,"activeCount":100},[],{"trials":5758,"activeCount":100},[],{"trials":5760,"activeCount":100},[],{"trials":5762,"activeCount":100},[5763],{"nctId":5741,"briefTitle":5742,"status":659,"phases":5764,"primaryCompletion":4293,"completion":4293,"start":5744,"enrollment":2150,"conditions":5765,"interventions":5766},[91],[3024,738,5746,2376,5034],[5728,5748],{"trials":5768,"activeCount":100},[],{"intervention":5770,"totalTrials":138,"cells":5771},"Nebivolol",{"EARLY_PHASE1":5772,"PHASE1":5774,"PHASE2":5776,"PHASE3":5778,"PHASE4":5780,"NA":5790},{"trials":5773,"activeCount":100},[],{"trials":5775,"activeCount":100},[],{"trials":5777,"activeCount":100},[],{"trials":5779,"activeCount":100},[],{"trials":5781,"activeCount":100},[5782],{"nctId":5783,"briefTitle":5784,"status":108,"phases":5785,"primaryCompletion":948,"completion":948,"start":5786,"enrollment":649,"conditions":5787,"interventions":5788},"NCT00775671","Comparative Effect of Nebivolol vs. Metoprolol on Insulin Sensitivity and Fibrinolytic Balance in Metabolic Syndrome",[91],"2008-10",[1416],[5770,5789],"Metoprolol",{"trials":5791,"activeCount":100},[],{"intervention":5789,"totalTrials":138,"cells":5793},{"EARLY_PHASE1":5794,"PHASE1":5796,"PHASE2":5798,"PHASE3":5800,"PHASE4":5802,"NA":5808},{"trials":5795,"activeCount":100},[],{"trials":5797,"activeCount":100},[],{"trials":5799,"activeCount":100},[],{"trials":5801,"activeCount":100},[],{"trials":5803,"activeCount":100},[5804],{"nctId":5783,"briefTitle":5784,"status":108,"phases":5805,"primaryCompletion":948,"completion":948,"start":5786,"enrollment":649,"conditions":5806,"interventions":5807},[91],[1416],[5770,5789],{"trials":5809,"activeCount":100},[],{"intervention":5811,"totalTrials":138,"cells":5812},"Dexmedetomidine Hydrochloride - Cycling",{"EARLY_PHASE1":5813,"PHASE1":5815,"PHASE2":5817,"PHASE3":5819,"PHASE4":5821,"NA":5833},{"trials":5814,"activeCount":100},[],{"trials":5816,"activeCount":100},[],{"trials":5818,"activeCount":100},[],{"trials":5820,"activeCount":100},[],{"trials":5822,"activeCount":100},[5823],{"nctId":5824,"briefTitle":5825,"status":605,"phases":5826,"primaryCompletion":5827,"completion":5827,"start":5828,"enrollment":100,"conditions":5829,"interventions":5830},"NCT05003102","Dexmedetomidine Cycling and Sleep in the Pediatric ICU",[91],"2023-06-30","2023-02-20",[31,709,25],[5811,5831,5832],"Fentanyl - PICU Standard","Dexmedetomidine Hydrochloride - PICU Standard",{"trials":5834,"activeCount":100},[],{"intervention":5831,"totalTrials":138,"cells":5836},{"EARLY_PHASE1":5837,"PHASE1":5839,"PHASE2":5841,"PHASE3":5843,"PHASE4":5845,"NA":5851},{"trials":5838,"activeCount":100},[],{"trials":5840,"activeCount":100},[],{"trials":5842,"activeCount":100},[],{"trials":5844,"activeCount":100},[],{"trials":5846,"activeCount":100},[5847],{"nctId":5824,"briefTitle":5825,"status":605,"phases":5848,"primaryCompletion":5827,"completion":5827,"start":5828,"enrollment":100,"conditions":5849,"interventions":5850},[91],[31,709,25],[5811,5831,5832],{"trials":5852,"activeCount":100},[],{"intervention":5832,"totalTrials":138,"cells":5854},{"EARLY_PHASE1":5855,"PHASE1":5857,"PHASE2":5859,"PHASE3":5861,"PHASE4":5863,"NA":5869},{"trials":5856,"activeCount":100},[],{"trials":5858,"activeCount":100},[],{"trials":5860,"activeCount":100},[],{"trials":5862,"activeCount":100},[],{"trials":5864,"activeCount":100},[5865],{"nctId":5824,"briefTitle":5825,"status":605,"phases":5866,"primaryCompletion":5827,"completion":5827,"start":5828,"enrollment":100,"conditions":5867,"interventions":5868},[91],[31,709,25],[5811,5831,5832],{"trials":5870,"activeCount":100},[],{"intervention":5872,"totalTrials":531,"cells":5873},"Ziprasidone",{"EARLY_PHASE1":5874,"PHASE1":5876,"PHASE2":5878,"PHASE3":5890,"PHASE4":5903,"NA":5905},{"trials":5875,"activeCount":100},[],{"trials":5877,"activeCount":100},[],{"trials":5879,"activeCount":100},[5880],{"nctId":5881,"briefTitle":5882,"status":108,"phases":5883,"primaryCompletion":5884,"completion":5884,"start":5885,"enrollment":5886,"conditions":5887,"interventions":5889},"NCT00096863","The MIND Study: Modifying the INcidence of Delirium",[89],"2007-07","2004-12",102,[25,5888],"Cognition Disorders",[5872,3064],{"trials":5891,"activeCount":100},[5892],{"nctId":5893,"briefTitle":5894,"status":108,"phases":5895,"primaryCompletion":5896,"completion":5897,"start":5898,"enrollment":5899,"conditions":5900,"interventions":5902},"NCT01211522","The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study",[90],"2017-08-28","2018-07-19","2011-12-14",566,[25,723,5901],"Long Term Psychologic Disorders",[3064,5872],{"trials":5904,"activeCount":100},[],{"trials":5906,"activeCount":100},[],{"intervention":5908,"totalTrials":531,"cells":5909},"ibuprofen",{"EARLY_PHASE1":5910,"PHASE1":5912,"PHASE2":5918,"PHASE3":5920,"PHASE4":5933,"NA":5935},{"trials":5911,"activeCount":100},[],{"trials":5913,"activeCount":100},[5914],{"nctId":2594,"briefTitle":2595,"status":108,"phases":5915,"primaryCompletion":1434,"completion":1434,"start":2597,"enrollment":2598,"conditions":5916,"interventions":5917},[88],[2253,2186],[2601,2602,2603,2604,2605,2579,2606,2607,2608,2609,2610,2611,2220,2612,2613,2614,2615,2616,2617,2618],{"trials":5919,"activeCount":100},[],{"trials":5921,"activeCount":100},[5922],{"nctId":5923,"briefTitle":5924,"status":108,"phases":5925,"completion":5926,"start":5927,"conditions":5928,"interventions":5932},"NCT00000574","Ibuprofen in Sepsis Study",[90],"1995-07","1990-09",[5929,5930,5931],"Acute Respiratory Distress Syndrome","Lung Diseases","Shock, Septic",[5908],{"trials":5934,"activeCount":100},[],{"trials":5936,"activeCount":100},[],{"intervention":5938,"totalTrials":138,"cells":5939},"Baricitinib 4 MG",{"EARLY_PHASE1":5940,"PHASE1":5942,"PHASE2":5944,"PHASE3":5946,"PHASE4":5956,"NA":5958},{"trials":5941,"activeCount":100},[],{"trials":5943,"activeCount":100},[],{"trials":5945,"activeCount":100},[],{"trials":5947,"activeCount":100},[5948],{"nctId":5949,"briefTitle":5950,"status":605,"phases":5951,"primaryCompletion":803,"completion":5952,"start":5953,"enrollment":100,"conditions":5954,"interventions":5955},"NCT05858515","REVERSE-Long COVID-19 With Baricitinib Study",[90],"2029-12-30","2024-10-21",[1926],[5938],{"trials":5957,"activeCount":100},[],{"trials":5959,"activeCount":100},[],{"intervention":5961,"totalTrials":138,"cells":5962},"Moderate Dose Hydroxyurea",{"EARLY_PHASE1":5963,"PHASE1":5965,"PHASE2":5967,"PHASE3":5969,"PHASE4":5979,"NA":5981},{"trials":5964,"activeCount":100},[],{"trials":5966,"activeCount":100},[],{"trials":5968,"activeCount":100},[],{"trials":5970,"activeCount":100},[5971],{"nctId":5972,"briefTitle":5973,"status":108,"phases":5974,"primaryCompletion":5975,"completion":5975,"start":1434,"enrollment":162,"conditions":5976,"interventions":5977},"NCT02675790","Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa",[90],"2020-03-31",[504,478,505],[5961,5978],"Low Dose Hydroxyurea",{"trials":5980,"activeCount":100},[],{"trials":5982,"activeCount":100},[],{"intervention":5978,"totalTrials":138,"cells":5984},{"EARLY_PHASE1":5985,"PHASE1":5987,"PHASE2":5989,"PHASE3":5991,"PHASE4":5997,"NA":5999},{"trials":5986,"activeCount":100},[],{"trials":5988,"activeCount":100},[],{"trials":5990,"activeCount":100},[],{"trials":5992,"activeCount":100},[5993],{"nctId":5972,"briefTitle":5973,"status":108,"phases":5994,"primaryCompletion":5975,"completion":5975,"start":1434,"enrollment":162,"conditions":5995,"interventions":5996},[90],[504,478,505],[5961,5978],{"trials":5998,"activeCount":100},[],{"trials":6000,"activeCount":100},[],{"intervention":6002,"totalTrials":138,"cells":6003},"Raltegravir",{"EARLY_PHASE1":6004,"PHASE1":6006,"PHASE2":6008,"PHASE3":6010,"PHASE4":6019,"NA":6021},{"trials":6005,"activeCount":100},[],{"trials":6007,"activeCount":100},[],{"trials":6009,"activeCount":100},[],{"trials":6011,"activeCount":100},[6012],{"nctId":6013,"briefTitle":6014,"status":108,"phases":6015,"primaryCompletion":2927,"completion":663,"start":2233,"enrollment":412,"conditions":6016,"interventions":6018},"NCT00729924","Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid",[89,90],[6017],"HIV Infections",[6002],{"trials":6020,"activeCount":100},[],{"trials":6022,"activeCount":100},[],{"intervention":6024,"totalTrials":138,"cells":6025},"Oxygen - normoxia",{"EARLY_PHASE1":6026,"PHASE1":6028,"PHASE2":6030,"PHASE3":6032,"PHASE4":6046,"NA":6048},{"trials":6027,"activeCount":100},[],{"trials":6029,"activeCount":100},[],{"trials":6031,"activeCount":100},[],{"trials":6033,"activeCount":100},[6034],{"nctId":6035,"briefTitle":6036,"status":108,"phases":6037,"primaryCompletion":6038,"completion":6039,"start":6040,"enrollment":6041,"conditions":6042,"interventions":6044},"NCT02361944","Risk of Oxygen During Cardiac Surgery Trial",[89,90],"2020-10-08","2021-01-08","2016-04-05",213,[6043],"Cardiac Surgery",[6024,6045],"Oxygen - hyperoxia",{"trials":6047,"activeCount":100},[],{"trials":6049,"activeCount":100},[],{"intervention":6045,"totalTrials":138,"cells":6051},{"EARLY_PHASE1":6052,"PHASE1":6054,"PHASE2":6056,"PHASE3":6058,"PHASE4":6064,"NA":6066},{"trials":6053,"activeCount":100},[],{"trials":6055,"activeCount":100},[],{"trials":6057,"activeCount":100},[],{"trials":6059,"activeCount":100},[6060],{"nctId":6035,"briefTitle":6036,"status":108,"phases":6061,"primaryCompletion":6038,"completion":6039,"start":6040,"enrollment":6041,"conditions":6062,"interventions":6063},[89,90],[6043],[6024,6045],{"trials":6065,"activeCount":100},[],{"trials":6067,"activeCount":100},[],{"intervention":6069,"totalTrials":138,"cells":6070},"Lansoprazole",{"EARLY_PHASE1":6071,"PHASE1":6073,"PHASE2":6075,"PHASE3":6077,"PHASE4":6086,"NA":6088},{"trials":6072,"activeCount":100},[],{"trials":6074,"activeCount":100},[],{"trials":6076,"activeCount":100},[],{"trials":6078,"activeCount":100},[6079],{"nctId":6080,"briefTitle":6081,"status":108,"phases":6082,"primaryCompletion":5628,"completion":5628,"start":3751,"enrollment":300,"conditions":6083,"interventions":6084},"NCT00335283","Efficacy of Lansoprazole in Chronic Post Nasal Drip",[90],[4429],[6069,6085],"lansoprazole",{"trials":6087,"activeCount":100},[],{"trials":6089,"activeCount":100},[],{"intervention":6091,"totalTrials":138,"cells":6092},"Oral Silymarin",{"EARLY_PHASE1":6093,"PHASE1":6095,"PHASE2":6097,"PHASE3":6099,"PHASE4":6109,"NA":6111},{"trials":6094,"activeCount":100},[],{"trials":6096,"activeCount":100},[],{"trials":6098,"activeCount":100},[],{"trials":6100,"activeCount":100},[6101],{"nctId":6102,"briefTitle":6103,"status":605,"phases":6104,"primaryCompletion":2115,"completion":2115,"start":2115,"enrollment":100,"conditions":6105,"interventions":6107},"NCT01049178","Randomized Controlled Trial of Silymarin in Asthma",[89,90],[6106],"Atopic Asthma",[6091,6108],"Oral Silymarin, maintenance dose",{"trials":6110,"activeCount":100},[],{"trials":6112,"activeCount":100},[],{"intervention":6108,"totalTrials":138,"cells":6114},{"EARLY_PHASE1":6115,"PHASE1":6117,"PHASE2":6119,"PHASE3":6121,"PHASE4":6127,"NA":6129},{"trials":6116,"activeCount":100},[],{"trials":6118,"activeCount":100},[],{"trials":6120,"activeCount":100},[],{"trials":6122,"activeCount":100},[6123],{"nctId":6102,"briefTitle":6103,"status":605,"phases":6124,"primaryCompletion":2115,"completion":2115,"start":2115,"enrollment":100,"conditions":6125,"interventions":6126},[89,90],[6106],[6091,6108],{"trials":6128,"activeCount":100},[],{"trials":6130,"activeCount":100},[],{"intervention":6132,"totalTrials":138,"cells":6133},"HOE 140",{"EARLY_PHASE1":6134,"PHASE1":6136,"PHASE2":6138,"PHASE3":6140,"PHASE4":6150,"NA":6152},{"trials":6135,"activeCount":100},[],{"trials":6137,"activeCount":100},[],{"trials":6139,"activeCount":100},[],{"trials":6141,"activeCount":100},[6142],{"nctId":6143,"briefTitle":6144,"status":108,"phases":6145,"primaryCompletion":2939,"completion":2939,"start":3549,"enrollment":6146,"conditions":6147,"interventions":6148},"NCT00223704","Bradykinin Receptor Antagonism During Cardiopulmonary Bypass",[89,90],150,[3757,1108,3758,2376],[6132,6149],"Aminocaproic Acid",{"trials":6151,"activeCount":100},[],{"trials":6153,"activeCount":100},[],{"intervention":6149,"totalTrials":138,"cells":6155},{"EARLY_PHASE1":6156,"PHASE1":6158,"PHASE2":6160,"PHASE3":6162,"PHASE4":6168,"NA":6170},{"trials":6157,"activeCount":100},[],{"trials":6159,"activeCount":100},[],{"trials":6161,"activeCount":100},[],{"trials":6163,"activeCount":100},[6164],{"nctId":6143,"briefTitle":6144,"status":108,"phases":6165,"primaryCompletion":2939,"completion":2939,"start":3549,"enrollment":6146,"conditions":6166,"interventions":6167},[89,90],[3757,1108,3758,2376],[6132,6149],{"trials":6169,"activeCount":100},[],{"trials":6171,"activeCount":100},[],{"intervention":6173,"totalTrials":138,"cells":6174},"Placebos for acetaminophen and N-acetylcysteine",{"EARLY_PHASE1":6175,"PHASE1":6177,"PHASE2":6179,"PHASE3":6181,"PHASE4":6196,"NA":6198},{"trials":6176,"activeCount":100},[],{"trials":6178,"activeCount":100},[],{"trials":6180,"activeCount":100},[],{"trials":6182,"activeCount":100},[6183],{"nctId":6184,"briefTitle":6185,"status":659,"phases":6186,"primaryCompletion":6187,"completion":6187,"start":949,"enrollment":1414,"conditions":6188,"interventions":6191},"NCT00585559","Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm",[90],"2023-10-26",[6189,6190],"Aneurysmal Subarachnoid Hemorrhage","Cerebral Vasospasm",[6173,6192,6193,6194,6195],"APAP 1 gm every 6 hours and N-acetylcysteine placebo","NAC IV infusion at 0.5 gm hourly and APAP placebo","APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly","APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly",{"trials":6197,"activeCount":100},[],{"trials":6199,"activeCount":100},[],{"intervention":6192,"totalTrials":138,"cells":6201},{"EARLY_PHASE1":6202,"PHASE1":6204,"PHASE2":6206,"PHASE3":6208,"PHASE4":6214,"NA":6216},{"trials":6203,"activeCount":100},[],{"trials":6205,"activeCount":100},[],{"trials":6207,"activeCount":100},[],{"trials":6209,"activeCount":100},[6210],{"nctId":6184,"briefTitle":6185,"status":659,"phases":6211,"primaryCompletion":6187,"completion":6187,"start":949,"enrollment":1414,"conditions":6212,"interventions":6213},[90],[6189,6190],[6173,6192,6193,6194,6195],{"trials":6215,"activeCount":100},[],{"trials":6217,"activeCount":100},[],{"intervention":6193,"totalTrials":138,"cells":6219},{"EARLY_PHASE1":6220,"PHASE1":6222,"PHASE2":6224,"PHASE3":6226,"PHASE4":6232,"NA":6234},{"trials":6221,"activeCount":100},[],{"trials":6223,"activeCount":100},[],{"trials":6225,"activeCount":100},[],{"trials":6227,"activeCount":100},[6228],{"nctId":6184,"briefTitle":6185,"status":659,"phases":6229,"primaryCompletion":6187,"completion":6187,"start":949,"enrollment":1414,"conditions":6230,"interventions":6231},[90],[6189,6190],[6173,6192,6193,6194,6195],{"trials":6233,"activeCount":100},[],{"trials":6235,"activeCount":100},[],{"intervention":6194,"totalTrials":138,"cells":6237},{"EARLY_PHASE1":6238,"PHASE1":6240,"PHASE2":6242,"PHASE3":6244,"PHASE4":6250,"NA":6252},{"trials":6239,"activeCount":100},[],{"trials":6241,"activeCount":100},[],{"trials":6243,"activeCount":100},[],{"trials":6245,"activeCount":100},[6246],{"nctId":6184,"briefTitle":6185,"status":659,"phases":6247,"primaryCompletion":6187,"completion":6187,"start":949,"enrollment":1414,"conditions":6248,"interventions":6249},[90],[6189,6190],[6173,6192,6193,6194,6195],{"trials":6251,"activeCount":100},[],{"trials":6253,"activeCount":100},[],{"intervention":6195,"totalTrials":138,"cells":6255},{"EARLY_PHASE1":6256,"PHASE1":6258,"PHASE2":6260,"PHASE3":6262,"PHASE4":6268,"NA":6270},{"trials":6257,"activeCount":100},[],{"trials":6259,"activeCount":100},[],{"trials":6261,"activeCount":100},[],{"trials":6263,"activeCount":100},[6264],{"nctId":6184,"briefTitle":6185,"status":659,"phases":6265,"primaryCompletion":6187,"completion":6187,"start":949,"enrollment":1414,"conditions":6266,"interventions":6267},[90],[6189,6190],[6173,6192,6193,6194,6195],{"trials":6269,"activeCount":100},[],{"trials":6271,"activeCount":100},[],{"intervention":6273,"totalTrials":138,"cells":6274},"2% chlorhexidine gluconate cloths",{"EARLY_PHASE1":6275,"PHASE1":6277,"PHASE2":6279,"PHASE3":6281,"PHASE4":6293,"NA":6295},{"trials":6276,"activeCount":100},[],{"trials":6278,"activeCount":100},[],{"trials":6280,"activeCount":100},[],{"trials":6282,"activeCount":100},[6283],{"nctId":6284,"briefTitle":6285,"status":108,"phases":6286,"primaryCompletion":6287,"completion":622,"start":3183,"enrollment":6288,"conditions":6289,"interventions":6292},"NCT02490631","2% Chlorhexidine Gluconate Skin Cloths to Prevent SSI in Spine Surgery Patients",[90],"2018-12-30",158,[6290,6291],"Surgical Site Infections","Post Operative Complication",[6273],{"trials":6294,"activeCount":100},[],{"trials":6296,"activeCount":100},[],{"intervention":6298,"totalTrials":138,"cells":6299},"pathogen reduced SARS-CoV-2 convalescent plasma",{"EARLY_PHASE1":6300,"PHASE1":6302,"PHASE2":6304,"PHASE3":6306,"PHASE4":6321,"NA":6323},{"trials":6301,"activeCount":100},[],{"trials":6303,"activeCount":100},[],{"trials":6305,"activeCount":100},[],{"trials":6307,"activeCount":100},[6308],{"nctId":6309,"briefTitle":6310,"status":108,"phases":6311,"primaryCompletion":6312,"completion":6313,"start":6314,"enrollment":6315,"conditions":6316,"interventions":6320},"NCT04362176","Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults",[90],"2021-07-06","2021-08-06","2020-04-24",974,[6317,6318,6319],"COVID-19","Coronavirus","SARS-CoV-2",[6298],{"trials":6322,"activeCount":100},[],{"trials":6324,"activeCount":100},[],{"intervention":6326,"totalTrials":138,"cells":6327},"Dapagliflozin 10 MG",{"EARLY_PHASE1":6328,"PHASE1":6330,"PHASE2":6332,"PHASE3":6334,"PHASE4":6345,"NA":6347},{"trials":6329,"activeCount":100},[],{"trials":6331,"activeCount":100},[],{"trials":6333,"activeCount":100},[],{"trials":6335,"activeCount":100},[6336],{"nctId":6337,"briefTitle":6338,"status":108,"phases":6339,"primaryCompletion":6340,"completion":6340,"start":6341,"enrollment":3235,"conditions":6342,"interventions":6344},"NCT04298229","Efficacy and Safety of Dapagliflozin in Acute Heart Failure",[90],"2023-05-17","2020-04-01",[651,6343],"Diabetes Mellitus, Type 2",[6326],{"trials":6346,"activeCount":100},[],{"trials":6348,"activeCount":100},[],{"intervention":993,"totalTrials":138,"cells":6350},{"EARLY_PHASE1":6351,"PHASE1":6353,"PHASE2":6355,"PHASE3":6357,"PHASE4":6363,"NA":6365},{"trials":6352,"activeCount":100},[],{"trials":6354,"activeCount":100},[],{"trials":6356,"activeCount":100},[],{"trials":6358,"activeCount":100},[6359],{"nctId":980,"briefTitle":981,"status":108,"phases":6360,"primaryCompletion":983,"completion":984,"start":985,"enrollment":986,"conditions":6361,"interventions":6362},[90],[988,989,990,991],[993,994,891],{"trials":6364,"activeCount":100},[],{"trials":6366,"activeCount":100},[],{"intervention":994,"totalTrials":138,"cells":6368},{"EARLY_PHASE1":6369,"PHASE1":6371,"PHASE2":6373,"PHASE3":6375,"PHASE4":6381,"NA":6383},{"trials":6370,"activeCount":100},[],{"trials":6372,"activeCount":100},[],{"trials":6374,"activeCount":100},[],{"trials":6376,"activeCount":100},[6377],{"nctId":980,"briefTitle":981,"status":108,"phases":6378,"primaryCompletion":983,"completion":984,"start":985,"enrollment":986,"conditions":6379,"interventions":6380},[90],[988,989,990,991],[993,994,891],{"trials":6382,"activeCount":100},[],{"trials":6384,"activeCount":100},[],{"intervention":6386,"totalTrials":138,"cells":6387},"Antiarrhythmic drug",{"EARLY_PHASE1":6388,"PHASE1":6390,"PHASE2":6392,"PHASE3":6394,"PHASE4":6406,"NA":6408},{"trials":6389,"activeCount":100},[],{"trials":6391,"activeCount":100},[],{"trials":6393,"activeCount":100},[],{"trials":6395,"activeCount":100},[6396],{"nctId":6397,"briefTitle":6398,"status":659,"phases":6399,"primaryCompletion":6400,"completion":6400,"start":6401,"enrollment":461,"conditions":6402,"interventions":6405},"NCT04208997","Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation",[90],"2021-06-30","2019-12-19",[6403,6404],"Tachycardia, Ventricular","Catheter Ablation",[6386],{"trials":6407,"activeCount":100},[],{"trials":6409,"activeCount":100},[],{"intervention":6411,"totalTrials":138,"cells":6412},"Esomeprazole",{"EARLY_PHASE1":6413,"PHASE1":6415,"PHASE2":6417,"PHASE3":6419,"PHASE4":6428,"NA":6430},{"trials":6414,"activeCount":100},[],{"trials":6416,"activeCount":100},[],{"trials":6418,"activeCount":100},[],{"trials":6420,"activeCount":100},[6421],{"nctId":6422,"briefTitle":6423,"status":605,"phases":6424,"primaryCompletion":2176,"completion":2176,"start":6425,"enrollment":100,"conditions":6426,"interventions":6427},"NCT00567658","Effect of Acid Suppression With Esomeprazole on Vocal Cord Granulomas",[90],"2008-02",[4429],[6411],{"trials":6429,"activeCount":100},[],{"trials":6431,"activeCount":100},[],{"intervention":6433,"totalTrials":138,"cells":6434},"Harmonized supportive care",{"EARLY_PHASE1":6435,"PHASE1":6437,"PHASE2":6439,"PHASE3":6441,"PHASE4":6454,"NA":6456},{"trials":6436,"activeCount":100},[],{"trials":6438,"activeCount":100},[],{"trials":6440,"activeCount":100},[],{"trials":6442,"activeCount":100},[6443],{"nctId":6444,"briefTitle":6445,"status":108,"phases":6446,"primaryCompletion":6447,"completion":6447,"start":6448,"enrollment":531,"conditions":6449,"interventions":6452},"NCT02987257","NATIENS: Optimal Management and Mechanisms of SJS\u002FTEN",[90],"2025-10-31","2023-03-21",[6450,6451],"Stevens-Johnson Syndrome","Toxic Epidermal Necrolyses",[6433,6453],"Etanercept 50 mg sc day 1 and day 4",{"trials":6455,"activeCount":100},[],{"trials":6457,"activeCount":100},[],{"intervention":6453,"totalTrials":138,"cells":6459},{"EARLY_PHASE1":6460,"PHASE1":6462,"PHASE2":6464,"PHASE3":6466,"PHASE4":6472,"NA":6474},{"trials":6461,"activeCount":100},[],{"trials":6463,"activeCount":100},[],{"trials":6465,"activeCount":100},[],{"trials":6467,"activeCount":100},[6468],{"nctId":6444,"briefTitle":6445,"status":108,"phases":6469,"primaryCompletion":6447,"completion":6447,"start":6448,"enrollment":531,"conditions":6470,"interventions":6471},[90],[6450,6451],[6433,6453],{"trials":6473,"activeCount":100},[],{"trials":6475,"activeCount":100},[],{"intervention":6477,"totalTrials":138,"cells":6478},"Droxidopa Oral Product",{"EARLY_PHASE1":6479,"PHASE1":6481,"PHASE2":6483,"PHASE3":6485,"PHASE4":6495,"NA":6497},{"trials":6480,"activeCount":100},[],{"trials":6482,"activeCount":100},[],{"trials":6484,"activeCount":100},[],{"trials":6486,"activeCount":100},[6487],{"nctId":6488,"briefTitle":6489,"status":659,"phases":6490,"primaryCompletion":5580,"completion":5580,"start":6491,"enrollment":2150,"conditions":6492,"interventions":6494},"NCT00581477","Treatment of Orthostatic Hypotension",[89,90],"2004-01",[2995,2186,6493,2996],"Dopamine Beta-Hydroxylase Deficiency",[6477],{"trials":6496,"activeCount":100},[],{"trials":6498,"activeCount":100},[],{"intervention":6500,"totalTrials":138,"cells":6501},"Nicotine metabolism",{"EARLY_PHASE1":6502,"PHASE1":6504,"PHASE2":6506,"PHASE3":6508,"PHASE4":6524,"NA":6526},{"trials":6503,"activeCount":100},[],{"trials":6505,"activeCount":100},[],{"trials":6507,"activeCount":100},[],{"trials":6509,"activeCount":100},[6510],{"nctId":6511,"briefTitle":6512,"status":108,"phases":6513,"primaryCompletion":6514,"completion":6515,"start":6516,"enrollment":6517,"conditions":6518,"interventions":6520},"NCT03521141","PRecision Interventions for SMoking in the SCCS",[89,90],"2019-04-11","2019-04-25","2018-05-18",67,[6519],"Tobacco Use Cessation",[6521,6522,6500,6523],"Nicotine patch","Varenicline","Genetically-informed lung cancer risk score",{"trials":6525,"activeCount":100},[],{"trials":6527,"activeCount":100},[],{"intervention":6523,"totalTrials":138,"cells":6529},{"EARLY_PHASE1":6530,"PHASE1":6532,"PHASE2":6534,"PHASE3":6536,"PHASE4":6542,"NA":6544},{"trials":6531,"activeCount":100},[],{"trials":6533,"activeCount":100},[],{"trials":6535,"activeCount":100},[],{"trials":6537,"activeCount":100},[6538],{"nctId":6511,"briefTitle":6512,"status":108,"phases":6539,"primaryCompletion":6514,"completion":6515,"start":6516,"enrollment":6517,"conditions":6540,"interventions":6541},[89,90],[6519],[6521,6522,6500,6523],{"trials":6543,"activeCount":100},[],{"trials":6545,"activeCount":100},[],{"intervention":6547,"totalTrials":138,"cells":6548},"venlafaxine XR",{"EARLY_PHASE1":6549,"PHASE1":6551,"PHASE2":6553,"PHASE3":6555,"PHASE4":6565,"NA":6567},{"trials":6550,"activeCount":100},[],{"trials":6552,"activeCount":100},[],{"trials":6554,"activeCount":100},[],{"trials":6556,"activeCount":100},[6557],{"nctId":6558,"briefTitle":6559,"status":108,"phases":6560,"completion":2212,"start":6561,"enrollment":29,"conditions":6562,"interventions":6563},"NCT00179283","Sertraline vs. Venlafaxine XR",[90],"2002-04",[4497],[6564,6547],"sertraline",{"trials":6566,"activeCount":100},[],{"trials":6568,"activeCount":100},[],{"intervention":6570,"totalTrials":138,"cells":6571},"Dexmedetomidine Hydrochloride",{"EARLY_PHASE1":6572,"PHASE1":6574,"PHASE2":6576,"PHASE3":6578,"PHASE4":6590,"NA":6592},{"trials":6573,"activeCount":100},[],{"trials":6575,"activeCount":100},[],{"trials":6577,"activeCount":100},[],{"trials":6579,"activeCount":100},[6580],{"nctId":6581,"briefTitle":6582,"status":605,"phases":6583,"primaryCompletion":3706,"completion":3706,"start":4744,"enrollment":100,"conditions":6584,"interventions":6588},"NCT00608231","Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation",[89,90],[6585,6586,6587],"Parkinson's Disease","Essential Tremor","Dystonia",[6570,6589],"Normal Saline",{"trials":6591,"activeCount":100},[],{"trials":6593,"activeCount":100},[],{"intervention":6595,"totalTrials":138,"cells":6596},"Vyvanse",{"EARLY_PHASE1":6597,"PHASE1":6599,"PHASE2":6601,"PHASE3":6603,"PHASE4":6612,"NA":6614},{"trials":6598,"activeCount":100},[],{"trials":6600,"activeCount":100},[],{"trials":6602,"activeCount":100},[],{"trials":6604,"activeCount":100},[6605],{"nctId":6606,"briefTitle":6607,"status":659,"phases":6608,"primaryCompletion":681,"completion":6609,"start":1014,"enrollment":26,"conditions":6610,"interventions":6611},"NCT01000064","Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits",[90],"2015-05",[5060,5061],[6595],{"trials":6613,"activeCount":100},[],{"trials":6615,"activeCount":100},[],{"intervention":6617,"totalTrials":138,"cells":6618},"Rispridone",{"EARLY_PHASE1":6619,"PHASE1":6621,"PHASE2":6623,"PHASE3":6625,"PHASE4":6635,"NA":6637},{"trials":6620,"activeCount":100},[],{"trials":6622,"activeCount":100},[],{"trials":6624,"activeCount":100},[],{"trials":6626,"activeCount":100},[6627],{"nctId":6628,"briefTitle":6629,"status":108,"phases":6630,"completion":3444,"start":6631,"enrollment":762,"conditions":6632,"interventions":6634},"NCT00179244","Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant Depression",[90],"2004-07",[6633],"Unipolar Depression",[6617],{"trials":6636,"activeCount":100},[],{"trials":6638,"activeCount":100},[],{"intervention":6640,"totalTrials":138,"cells":6641},"Dantrolene\u002FRyanodex",{"EARLY_PHASE1":6642,"PHASE1":6644,"PHASE2":6646,"PHASE3":6648,"PHASE4":6660,"NA":6662},{"trials":6643,"activeCount":100},[],{"trials":6645,"activeCount":100},[],{"trials":6647,"activeCount":100},[],{"trials":6649,"activeCount":100},[6650],{"nctId":6651,"briefTitle":6652,"status":108,"phases":6653,"primaryCompletion":6654,"completion":6655,"start":6656,"enrollment":733,"conditions":6657,"interventions":6659},"NCT04134845","A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.",[89,90],"2025-05-29","2025-08-29","2020-08-21",[6658],"Ventricular Tachycardia",[6640],{"trials":6661,"activeCount":100},[],{"trials":6663,"activeCount":100},[],{"intervention":2601,"totalTrials":96,"cells":6665},{"EARLY_PHASE1":6666,"PHASE1":6668,"PHASE2":6681,"PHASE3":6692,"PHASE4":6694,"NA":6696},{"trials":6667,"activeCount":100},[],{"trials":6669,"activeCount":100},[6670,6674],{"nctId":2594,"briefTitle":2595,"status":108,"phases":6671,"primaryCompletion":1434,"completion":1434,"start":2597,"enrollment":2598,"conditions":6672,"interventions":6673},[88],[2253,2186],[2601,2602,2603,2604,2605,2579,2606,2607,2608,2609,2610,2611,2220,2612,2613,2614,2615,2616,2617,2618],{"nctId":6675,"briefTitle":6676,"status":659,"phases":6677,"primaryCompletion":6678,"completion":6678,"start":5248,"enrollment":2911,"conditions":6679,"interventions":6680},"NCT03808740","Orthostatic Intolerance After Bariatric Surgery",[88],"2021-05-31",[2996],[2601],{"trials":6682,"activeCount":100},[6683],{"nctId":6684,"briefTitle":6685,"status":108,"phases":6686,"primaryCompletion":6687,"completion":6688,"start":6689,"enrollment":1206,"conditions":6690,"interventions":6691},"NCT02784535","Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)",[89],"2021-05-12","2023-06","2016-08-29",[2252],[2601],{"trials":6693,"activeCount":100},[],{"trials":6695,"activeCount":100},[],{"trials":6697,"activeCount":100},[],{"intervention":6699,"totalTrials":96,"cells":6700},"nutritional supplementation",{"EARLY_PHASE1":6701,"PHASE1":6703,"PHASE2":6705,"PHASE3":6727,"PHASE4":6729,"NA":6731},{"trials":6702,"activeCount":100},[],{"trials":6704,"activeCount":100},[],{"trials":6706,"activeCount":100},[6707,6714,6720],{"nctId":6708,"briefTitle":6709,"status":108,"phases":6710,"primaryCompletion":3666,"completion":3666,"start":3444,"enrollment":624,"conditions":6711,"interventions":6713},"NCT00179179","The Effects of Nutrition Supplementation and Resistance Exercise During Hemodialysis",[89],[6712],"End Stage Renal Disease",[6699],{"nctId":6715,"briefTitle":6716,"status":108,"phases":6717,"primaryCompletion":5472,"completion":5472,"start":3444,"enrollment":2681,"conditions":6718,"interventions":6719},"NCT00179218","The Effects of Resistance Exercise and Protein Supplementation in Hemodialysis Patients",[89],[6712],[6699],{"nctId":6721,"briefTitle":6722,"status":108,"phases":6723,"primaryCompletion":132,"completion":132,"start":6724,"enrollment":23,"conditions":6725,"interventions":6726},"NCT00179140","The Effects of Protein Supplementation and Resistance Exercise in Hemodialysis Patients",[89],"2002-11",[6712],[6699],{"trials":6728,"activeCount":100},[],{"trials":6730,"activeCount":100},[],{"trials":6732,"activeCount":100},[],{"intervention":6734,"totalTrials":531,"cells":6735},"Alpha, gamma, beta, and delta (mixed) tocopherols",{"EARLY_PHASE1":6736,"PHASE1":6738,"PHASE2":6740,"PHASE3":6761,"PHASE4":6763,"NA":6765},{"trials":6737,"activeCount":100},[],{"trials":6739,"activeCount":100},[],{"trials":6741,"activeCount":100},[6742,6751],{"nctId":6743,"briefTitle":6744,"status":108,"phases":6745,"primaryCompletion":5884,"completion":5884,"start":110,"enrollment":6746,"conditions":6747,"interventions":6749},"NCT00308971","Tocopherols and Alpha Lipoic Acid Treatment Chronic Kidney Disease (TALAT)",[89],62,[6748],"Chronic Kidney Disease",[6734,6750],"alpha lipoic acid",{"nctId":6752,"briefTitle":6753,"status":108,"phases":6754,"primaryCompletion":2115,"completion":2115,"start":6755,"enrollment":6756,"conditions":6757,"interventions":6759},"NCT00237718","Provision of Antioxidant Therapy in Hemodialysis (PATH) Study",[89],"2006-04",385,[6758],"End-stage Renal Disease",[6734,6760],"Alpha lipoic acid",{"trials":6762,"activeCount":100},[],{"trials":6764,"activeCount":100},[],{"trials":6766,"activeCount":100},[],{"intervention":6750,"totalTrials":531,"cells":6768},{"EARLY_PHASE1":6769,"PHASE1":6771,"PHASE2":6773,"PHASE3":6783,"PHASE4":6785,"NA":6787},{"trials":6770,"activeCount":100},[],{"trials":6772,"activeCount":100},[],{"trials":6774,"activeCount":100},[6775,6779],{"nctId":6743,"briefTitle":6744,"status":108,"phases":6776,"primaryCompletion":5884,"completion":5884,"start":110,"enrollment":6746,"conditions":6777,"interventions":6778},[89],[6748],[6734,6750],{"nctId":6752,"briefTitle":6753,"status":108,"phases":6780,"primaryCompletion":2115,"completion":2115,"start":6755,"enrollment":6756,"conditions":6781,"interventions":6782},[89],[6758],[6734,6760],{"trials":6784,"activeCount":100},[],{"trials":6786,"activeCount":100},[],{"trials":6788,"activeCount":100},[],{"intervention":6790,"totalTrials":531,"cells":6791},"Azithromycin",{"EARLY_PHASE1":6792,"PHASE1":6794,"PHASE2":6796,"PHASE3":6817,"PHASE4":6819,"NA":6821},{"trials":6793,"activeCount":100},[],{"trials":6795,"activeCount":100},[],{"trials":6797,"activeCount":100},[6798,6805],{"nctId":6799,"briefTitle":6800,"status":605,"phases":6801,"primaryCompletion":6802,"completion":6802,"start":936,"enrollment":100,"conditions":6803,"interventions":6804},"NCT02960503","Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease",[88,89],"2018-10",[504],[6790],{"nctId":6806,"briefTitle":6807,"status":108,"phases":6808,"primaryCompletion":6809,"completion":6809,"start":4979,"enrollment":6810,"conditions":6811,"interventions":6813},"NCT02024555","Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis",[89],"2019-04-01",97,[6812],"Sarcoidosis; Antimycobacterial Therapy",[6814,6815,6790,6816],"Levofloxacin","Ethambutol","Rifampin",{"trials":6818,"activeCount":100},[],{"trials":6820,"activeCount":100},[],{"trials":6822,"activeCount":100},[],{"intervention":6824,"totalTrials":531,"cells":6825},"Citrulline",{"EARLY_PHASE1":6826,"PHASE1":6828,"PHASE2":6830,"PHASE3":6850,"PHASE4":6852,"NA":6854},{"trials":6827,"activeCount":100},[],{"trials":6829,"activeCount":100},[],{"trials":6831,"activeCount":100},[6832,6842],{"nctId":6833,"briefTitle":6834,"status":108,"phases":6835,"primaryCompletion":6836,"completion":4425,"start":6837,"enrollment":23,"conditions":6838,"interventions":6841},"NCT00201214","Citrulline for Children Undergoing Cardiopulmonary Bypass Surgery",[88,89],"2006-01","2003-12",[2997,6839,6840],"Heart Diseases","Heart Defects, Congenital",[6824],{"nctId":6843,"briefTitle":6844,"status":108,"phases":6845,"primaryCompletion":2142,"completion":2142,"start":6846,"enrollment":697,"conditions":6847,"interventions":6849},"NCT00223730","Chemotherapy Toxicity Reduction Via Urea Cycle Support",[89],"2001-10",[6848],"Cancer",[6824],{"trials":6851,"activeCount":100},[],{"trials":6853,"activeCount":100},[],{"trials":6855,"activeCount":100},[],{"intervention":6857,"totalTrials":531,"cells":6858},"Tamoxifen",{"EARLY_PHASE1":6859,"PHASE1":6861,"PHASE2":6863,"PHASE3":6887,"PHASE4":6889,"NA":6891},{"trials":6860,"activeCount":100},[],{"trials":6862,"activeCount":100},[],{"trials":6864,"activeCount":100},[6865,6878],{"nctId":6866,"briefTitle":6867,"status":108,"phases":6868,"primaryCompletion":6869,"completion":6869,"start":3787,"enrollment":32,"conditions":6870,"interventions":6877},"NCT03528902","Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension",[89],"2023-06-14",[19,6871,6872,6873,5930,6857,6874,6875,6876],"Pulmonary Arterial Hypertension","Familial Primary Pulmonary Hypertension","Primary Pulmonary Hypertension","Estrogen Receptor Antagonist","Hormone Antagonists","Estrogens",[6857],{"nctId":6879,"briefTitle":6880,"status":108,"phases":6881,"primaryCompletion":3431,"completion":3431,"start":5206,"enrollment":6882,"conditions":6883,"interventions":6886},"NCT02806544","Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low\u002FMiddle Income Country",[89],35,[6884,6885],"Breast Cancer","Breast Neoplasms",[6857],{"trials":6888,"activeCount":100},[],{"trials":6890,"activeCount":100},[],{"trials":6892,"activeCount":100},[],{"intervention":6894,"totalTrials":138,"cells":6895},"High Dose Citrulline",{"EARLY_PHASE1":6896,"PHASE1":6898,"PHASE2":6900,"PHASE3":6913,"PHASE4":6915,"NA":6917},{"trials":6897,"activeCount":100},[],{"trials":6899,"activeCount":100},[],{"trials":6901,"activeCount":100},[6902],{"nctId":6903,"briefTitle":6904,"status":108,"phases":6905,"primaryCompletion":6906,"completion":6906,"start":6907,"enrollment":1095,"conditions":6908,"interventions":6911},"NCT01474863","Citrulline in Severe Sepsis",[89],"2016-03","2012-08",[6909,6910],"Severe Sepsis","Acute Lung Injury",[6894,6912],"Low Dose Citrulline",{"trials":6914,"activeCount":100},[],{"trials":6916,"activeCount":100},[],{"trials":6918,"activeCount":100},[],{"intervention":6912,"totalTrials":138,"cells":6920},{"EARLY_PHASE1":6921,"PHASE1":6923,"PHASE2":6925,"PHASE3":6931,"PHASE4":6933,"NA":6935},{"trials":6922,"activeCount":100},[],{"trials":6924,"activeCount":100},[],{"trials":6926,"activeCount":100},[6927],{"nctId":6903,"briefTitle":6904,"status":108,"phases":6928,"primaryCompletion":6906,"completion":6906,"start":6907,"enrollment":1095,"conditions":6929,"interventions":6930},[89],[6909,6910],[6894,6912],{"trials":6932,"activeCount":100},[],{"trials":6934,"activeCount":100},[],{"trials":6936,"activeCount":100},[],{"intervention":6938,"totalTrials":138,"cells":6939},"dulaglutide",{"EARLY_PHASE1":6940,"PHASE1":6942,"PHASE2":6944,"PHASE3":6955,"PHASE4":6957,"NA":6959},{"trials":6941,"activeCount":100},[],{"trials":6943,"activeCount":100},[],{"trials":6945,"activeCount":100},[6946],{"nctId":6947,"briefTitle":6948,"status":108,"phases":6949,"primaryCompletion":6950,"completion":5291,"start":6951,"enrollment":900,"conditions":6952,"interventions":6954},"NCT05254418","Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease",[89],"2024-05-01","2022-03-15",[6953],"Chronic Kidney Diseases",[6938],{"trials":6956,"activeCount":100},[],{"trials":6958,"activeCount":100},[],{"trials":6960,"activeCount":100},[],{"intervention":6962,"totalTrials":138,"cells":6963},"Magnesium Citrate plus probiotic",{"EARLY_PHASE1":6964,"PHASE1":6966,"PHASE2":6968,"PHASE3":6979,"PHASE4":6981,"NA":6983},{"trials":6965,"activeCount":100},[],{"trials":6967,"activeCount":100},[],{"trials":6969,"activeCount":100},[6970],{"nctId":6971,"briefTitle":6972,"status":659,"phases":6973,"primaryCompletion":6974,"completion":6974,"start":6975,"enrollment":1447,"conditions":6976,"interventions":6978},"NCT04941703","\"CHANGE COVID-19 Severity\"",[88,89],"2022-06-25","2021-11-04",[6977],"COVID-19 Infection",[6962],{"trials":6980,"activeCount":100},[],{"trials":6982,"activeCount":100},[],{"trials":6984,"activeCount":100},[],{"intervention":6986,"totalTrials":138,"cells":6987},"Abatacept",{"EARLY_PHASE1":6988,"PHASE1":6990,"PHASE2":6992,"PHASE3":7000,"PHASE4":7002,"NA":7004},{"trials":6989,"activeCount":100},[],{"trials":6991,"activeCount":100},[],{"trials":6993,"activeCount":100},[6994],{"nctId":6995,"briefTitle":6996,"status":659,"phases":6997,"primaryCompletion":1062,"completion":1062,"start":2964,"enrollment":138,"conditions":6998,"interventions":6999},"NCT02232880","Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation",[89],[19],[6986],{"trials":7001,"activeCount":100},[],{"trials":7003,"activeCount":100},[],{"trials":7005,"activeCount":100},[],{"intervention":7007,"totalTrials":138,"cells":7008},"(R)-propafenone",{"EARLY_PHASE1":7009,"PHASE1":7011,"PHASE2":7013,"PHASE3":7025,"PHASE4":7027,"NA":7029},{"trials":7010,"activeCount":100},[],{"trials":7012,"activeCount":100},[],{"trials":7014,"activeCount":100},[7015],{"nctId":7016,"briefTitle":7017,"status":659,"phases":7018,"primaryCompletion":7019,"completion":7020,"start":1061,"enrollment":7021,"conditions":7022,"interventions":7023},"NCT02710669","New Formulations of Propafenone to Treat Atrial Fibrillation",[88,89],"2020-03-11","2020-04",193,[1088],[7007,7024],"(S)-Propafenone",{"trials":7026,"activeCount":100},[],{"trials":7028,"activeCount":100},[],{"trials":7030,"activeCount":100},[],{"intervention":7024,"totalTrials":138,"cells":7032},{"EARLY_PHASE1":7033,"PHASE1":7035,"PHASE2":7037,"PHASE3":7043,"PHASE4":7045,"NA":7047},{"trials":7034,"activeCount":100},[],{"trials":7036,"activeCount":100},[],{"trials":7038,"activeCount":100},[7039],{"nctId":7016,"briefTitle":7017,"status":659,"phases":7040,"primaryCompletion":7019,"completion":7020,"start":1061,"enrollment":7021,"conditions":7041,"interventions":7042},[88,89],[1088],[7007,7024],{"trials":7044,"activeCount":100},[],{"trials":7046,"activeCount":100},[],{"trials":7048,"activeCount":100},[],{"intervention":7050,"totalTrials":138,"cells":7051},"Polypill",{"EARLY_PHASE1":7052,"PHASE1":7054,"PHASE2":7056,"PHASE3":7067,"PHASE4":7069,"NA":7071},{"trials":7053,"activeCount":100},[],{"trials":7055,"activeCount":100},[],{"trials":7057,"activeCount":100},[7058],{"nctId":7059,"briefTitle":7060,"status":108,"phases":7061,"primaryCompletion":7062,"completion":7062,"start":4196,"enrollment":7063,"conditions":7064,"interventions":7066},"NCT02278471","The SCCS Polypill Pilot Trial",[89],"2018-06-27",303,[19,7065],"Hyperlipidemia",[7050],{"trials":7068,"activeCount":100},[],{"trials":7070,"activeCount":100},[],{"trials":7072,"activeCount":100},[],{"intervention":700,"totalTrials":138,"cells":7074},{"EARLY_PHASE1":7075,"PHASE1":7077,"PHASE2":7079,"PHASE3":7085,"PHASE4":7087,"NA":7089},{"trials":7076,"activeCount":100},[],{"trials":7078,"activeCount":100},[],{"trials":7080,"activeCount":100},[7081],{"nctId":691,"briefTitle":692,"status":108,"phases":7082,"primaryCompletion":694,"completion":695,"start":696,"enrollment":697,"conditions":7083,"interventions":7084},[89],[25],[67,700],{"trials":7086,"activeCount":100},[],{"trials":7088,"activeCount":100},[],{"trials":7090,"activeCount":100},[],{"intervention":1450,"totalTrials":138,"cells":7092},{"EARLY_PHASE1":7093,"PHASE1":7095,"PHASE2":7097,"PHASE3":7103,"PHASE4":7105,"NA":7107},{"trials":7094,"activeCount":100},[],{"trials":7096,"activeCount":100},[],{"trials":7098,"activeCount":100},[7099],{"nctId":1442,"briefTitle":1443,"status":108,"phases":7100,"primaryCompletion":1445,"completion":1445,"start":1446,"enrollment":1447,"conditions":7101,"interventions":7102},[88,89],[16],[1422,1450,1451],{"trials":7104,"activeCount":100},[],{"trials":7106,"activeCount":100},[],{"trials":7108,"activeCount":100},[],{"intervention":1451,"totalTrials":138,"cells":7110},{"EARLY_PHASE1":7111,"PHASE1":7113,"PHASE2":7115,"PHASE3":7121,"PHASE4":7123,"NA":7125},{"trials":7112,"activeCount":100},[],{"trials":7114,"activeCount":100},[],{"trials":7116,"activeCount":100},[7117],{"nctId":1442,"briefTitle":1443,"status":108,"phases":7118,"primaryCompletion":1445,"completion":1445,"start":1446,"enrollment":1447,"conditions":7119,"interventions":7120},[88,89],[16],[1422,1450,1451],{"trials":7122,"activeCount":100},[],{"trials":7124,"activeCount":100},[],{"trials":7126,"activeCount":100},[],{"intervention":7128,"totalTrials":138,"cells":7129},"Sildenafil Citrate in G allele carrier",{"EARLY_PHASE1":7130,"PHASE1":7132,"PHASE2":7134,"PHASE3":7145,"PHASE4":7147,"NA":7149},{"trials":7131,"activeCount":100},[],{"trials":7133,"activeCount":100},[],{"trials":7135,"activeCount":100},[7136],{"nctId":7137,"briefTitle":7138,"status":108,"phases":7139,"primaryCompletion":7140,"completion":7141,"start":1434,"enrollment":23,"conditions":7142,"interventions":7143},"NCT03012386","CD36 in Nutrient Delivery and Its Dysfunction",[88,89],"2021-07","2021-07-31",[916,358],[7128,7144],"Sildenafil Citrate in non G allele carrier",{"trials":7146,"activeCount":100},[],{"trials":7148,"activeCount":100},[],{"trials":7150,"activeCount":100},[],{"intervention":7144,"totalTrials":138,"cells":7152},{"EARLY_PHASE1":7153,"PHASE1":7155,"PHASE2":7157,"PHASE3":7163,"PHASE4":7165,"NA":7167},{"trials":7154,"activeCount":100},[],{"trials":7156,"activeCount":100},[],{"trials":7158,"activeCount":100},[7159],{"nctId":7137,"briefTitle":7138,"status":108,"phases":7160,"primaryCompletion":7140,"completion":7141,"start":1434,"enrollment":23,"conditions":7161,"interventions":7162},[88,89],[916,358],[7128,7144],{"trials":7164,"activeCount":100},[],{"trials":7166,"activeCount":100},[],{"trials":7168,"activeCount":100},[],{"intervention":7170,"totalTrials":138,"cells":7171},"Eicosapentanoic acid and docosahexanoic acid",{"EARLY_PHASE1":7172,"PHASE1":7174,"PHASE2":7176,"PHASE3":7189,"PHASE4":7191,"NA":7193},{"trials":7173,"activeCount":100},[],{"trials":7175,"activeCount":100},[],{"trials":7177,"activeCount":100},[7178],{"nctId":7179,"briefTitle":7180,"status":108,"phases":7181,"primaryCompletion":7182,"completion":1312,"start":7183,"enrollment":7184,"conditions":7185,"interventions":7187},"NCT01661764","Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention",[89],"2016-12-26","2013-02-04",141,[7186],"Colorectal Adenomatous Polyps",[7170,7188],"Oleic Acid",{"trials":7190,"activeCount":100},[],{"trials":7192,"activeCount":100},[],{"trials":7194,"activeCount":100},[],{"intervention":7188,"totalTrials":138,"cells":7196},{"EARLY_PHASE1":7197,"PHASE1":7199,"PHASE2":7201,"PHASE3":7207,"PHASE4":7209,"NA":7211},{"trials":7198,"activeCount":100},[],{"trials":7200,"activeCount":100},[],{"trials":7202,"activeCount":100},[7203],{"nctId":7179,"briefTitle":7180,"status":108,"phases":7204,"primaryCompletion":7182,"completion":1312,"start":7183,"enrollment":7184,"conditions":7205,"interventions":7206},[89],[7186],[7170,7188],{"trials":7208,"activeCount":100},[],{"trials":7210,"activeCount":100},[],{"trials":7212,"activeCount":100},[],{"intervention":7214,"totalTrials":138,"cells":7215},"Lisinopril",{"EARLY_PHASE1":7216,"PHASE1":7218,"PHASE2":7220,"PHASE3":7236,"PHASE4":7238,"NA":7240},{"trials":7217,"activeCount":100},[],{"trials":7219,"activeCount":100},[],{"trials":7221,"activeCount":100},[7222],{"nctId":7223,"briefTitle":7224,"status":659,"phases":7225,"primaryCompletion":7226,"completion":7227,"start":7228,"enrollment":7229,"conditions":7230,"interventions":7235},"NCT03201939","Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria",[89],"2021-11-30","2025-02-01","2021-04-01",66,[7231,7232,7233,7234],"HIV\u002FAIDS","Albuminuria","Kidney Diseases","Genetic Predisposition",[7214],{"trials":7237,"activeCount":100},[],{"trials":7239,"activeCount":100},[],{"trials":7241,"activeCount":100},[],{"intervention":7243,"totalTrials":138,"cells":7244},"IV Propranolol and Per Tube Clonidine",{"EARLY_PHASE1":7245,"PHASE1":7247,"PHASE2":7249,"PHASE3":7260,"PHASE4":7262,"NA":7264},{"trials":7246,"activeCount":100},[],{"trials":7248,"activeCount":100},[],{"trials":7250,"activeCount":100},[7251],{"nctId":7252,"briefTitle":7253,"status":108,"phases":7254,"primaryCompletion":2203,"completion":695,"start":663,"enrollment":1206,"conditions":7255,"interventions":7259},"NCT01322048","DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury",[89],[7256,7257,7258,5060],"Brain Injuries","Craniocerebral Trauma","Trauma, Nervous System",[7243],{"trials":7261,"activeCount":100},[],{"trials":7263,"activeCount":100},[],{"trials":7265,"activeCount":100},[],{"intervention":7267,"totalTrials":138,"cells":7268},"recombinant human growth hormone",{"EARLY_PHASE1":7269,"PHASE1":7271,"PHASE2":7273,"PHASE3":7282,"PHASE4":7284,"NA":7286},{"trials":7270,"activeCount":100},[],{"trials":7272,"activeCount":100},[],{"trials":7274,"activeCount":100},[7275],{"nctId":7276,"briefTitle":7277,"status":108,"phases":7278,"primaryCompletion":3751,"completion":3751,"start":7279,"enrollment":649,"conditions":7280,"interventions":7281},"NCT00244075","Effects of Nutritional Supplementation on Protein and Energy Homeostasis in Malnourished Chronic Hemodialysis Patients",[89],"1998-07",[6712],[7267],{"trials":7283,"activeCount":100},[],{"trials":7285,"activeCount":100},[],{"trials":7287,"activeCount":100},[],{"intervention":7289,"totalTrials":138,"cells":7290},"Lopinavir\u002FRitonavir 400 mg\u002F100 mg",{"EARLY_PHASE1":7291,"PHASE1":7293,"PHASE2":7295,"PHASE3":7306,"PHASE4":7308,"NA":7310},{"trials":7292,"activeCount":100},[],{"trials":7294,"activeCount":100},[],{"trials":7296,"activeCount":100},[7297],{"nctId":7298,"briefTitle":7299,"status":108,"phases":7300,"primaryCompletion":7301,"completion":7302,"start":7303,"enrollment":4981,"conditions":7304,"interventions":7305},"NCT04372628","Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19",[89],"2021-12-16","2022-01-18","2020-06-01",[6317],[7289],{"trials":7307,"activeCount":100},[],{"trials":7309,"activeCount":100},[],{"trials":7311,"activeCount":100},[],{"intervention":7313,"totalTrials":138,"cells":7314},"Acetyl-L-Carnitine",{"EARLY_PHASE1":7315,"PHASE1":7317,"PHASE2":7319,"PHASE3":7327,"PHASE4":7329,"NA":7331},{"trials":7316,"activeCount":100},[],{"trials":7318,"activeCount":100},[],{"trials":7320,"activeCount":100},[7321],{"nctId":7322,"briefTitle":7323,"status":108,"phases":7324,"primaryCompletion":4014,"completion":5334,"start":3751,"enrollment":5629,"conditions":7325,"interventions":7326},"NCT00592488","Acetyl-L-Carnitine in the Treatment of Septic Shock",[88,89],[2966],[7313],{"trials":7328,"activeCount":100},[],{"trials":7330,"activeCount":100},[],{"trials":7332,"activeCount":100},[],{"intervention":7334,"totalTrials":138,"cells":7335},"Rosuvastatin",{"EARLY_PHASE1":7336,"PHASE1":7338,"PHASE2":7340,"PHASE3":7349,"PHASE4":7351,"NA":7353},{"trials":7337,"activeCount":100},[],{"trials":7339,"activeCount":100},[],{"trials":7341,"activeCount":100},[7342],{"nctId":7343,"briefTitle":7344,"status":108,"phases":7345,"primaryCompletion":2927,"completion":947,"start":3412,"enrollment":412,"conditions":7346,"interventions":7348},"NCT00978419","Pilot Trial of Statin Use in Burn Patients",[89],[7347],"Burns",[7334],{"trials":7350,"activeCount":100},[],{"trials":7352,"activeCount":100},[],{"trials":7354,"activeCount":100},[],{"intervention":7356,"totalTrials":138,"cells":7357},"Exenatide",{"EARLY_PHASE1":7358,"PHASE1":7360,"PHASE2":7362,"PHASE3":7372,"PHASE4":7374,"NA":7376},{"trials":7359,"activeCount":100},[],{"trials":7361,"activeCount":100},[],{"trials":7363,"activeCount":100},[7364],{"nctId":7365,"briefTitle":7366,"status":108,"phases":7367,"primaryCompletion":1446,"completion":1446,"start":2939,"enrollment":2911,"conditions":7368,"interventions":7371},"NCT01484873","Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor",[89],[16,7369,7370],"Overweight","Craniopharyngioma",[7356],{"trials":7373,"activeCount":100},[],{"trials":7375,"activeCount":100},[],{"trials":7377,"activeCount":100},[],{"intervention":7379,"totalTrials":138,"cells":7380},"GSK2256294",{"EARLY_PHASE1":7381,"PHASE1":7383,"PHASE2":7385,"PHASE3":7395,"PHASE4":7397,"NA":7399},{"trials":7382,"activeCount":100},[],{"trials":7384,"activeCount":100},[],{"trials":7386,"activeCount":100},[7387],{"nctId":7388,"briefTitle":7389,"status":108,"phases":7390,"primaryCompletion":7391,"completion":7391,"start":7392,"enrollment":2116,"conditions":7393,"interventions":7394},"NCT03486223","Soluble Epoxide Hydrolase Inhibition and Insulin Resistance",[89],"2021-11-18","2018-05-17",[3416,3417,3418,1338,16],[7379],{"trials":7396,"activeCount":100},[],{"trials":7398,"activeCount":100},[],{"trials":7400,"activeCount":100},[],{"intervention":7402,"totalTrials":138,"cells":7403},"Tadalafil 20 MG",{"EARLY_PHASE1":7404,"PHASE1":7406,"PHASE2":7408,"PHASE3":7420,"PHASE4":7422,"NA":7424},{"trials":7405,"activeCount":100},[],{"trials":7407,"activeCount":100},[],{"trials":7409,"activeCount":100},[7410],{"nctId":7411,"briefTitle":7412,"status":108,"phases":7413,"primaryCompletion":7414,"completion":7415,"start":7416,"enrollment":7417,"conditions":7418,"interventions":7419},"NCT04684589","Effect of PDE5 Inhibition on Adipose Metabolism in Humans",[89],"2025-06-20","2025-06-24","2021-03-16",89,[16],[7402],{"trials":7421,"activeCount":100},[],{"trials":7423,"activeCount":100},[],{"trials":7425,"activeCount":100},[],{"intervention":7427,"totalTrials":138,"cells":7428},"Phenoxybenzamine",{"EARLY_PHASE1":7429,"PHASE1":7431,"PHASE2":7433,"PHASE3":7441,"PHASE4":7443,"NA":7445},{"trials":7430,"activeCount":100},[],{"trials":7432,"activeCount":100},[],{"trials":7434,"activeCount":100},[7435],{"nctId":7436,"briefTitle":7437,"status":605,"phases":7438,"primaryCompletion":3443,"completion":3443,"start":5786,"enrollment":100,"conditions":7439,"interventions":7440},"NCT00770705","Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery",[89],[856],[7427],{"trials":7442,"activeCount":100},[],{"trials":7444,"activeCount":100},[],{"trials":7446,"activeCount":100},[],{"intervention":614,"totalTrials":138,"cells":7448},{"EARLY_PHASE1":7449,"PHASE1":7451,"PHASE2":7453,"PHASE3":7459,"PHASE4":7461,"NA":7463},{"trials":7450,"activeCount":100},[],{"trials":7452,"activeCount":100},[],{"trials":7454,"activeCount":100},[7455],{"nctId":603,"briefTitle":604,"status":605,"phases":7456,"primaryCompletion":607,"completion":607,"start":608,"enrollment":100,"conditions":7457,"interventions":7458},[89],[610,611,612],[614,615,616,594],{"trials":7460,"activeCount":100},[],{"trials":7462,"activeCount":100},[],{"trials":7464,"activeCount":100},[],{"intervention":615,"totalTrials":138,"cells":7466},{"EARLY_PHASE1":7467,"PHASE1":7469,"PHASE2":7471,"PHASE3":7477,"PHASE4":7479,"NA":7481},{"trials":7468,"activeCount":100},[],{"trials":7470,"activeCount":100},[],{"trials":7472,"activeCount":100},[7473],{"nctId":603,"briefTitle":604,"status":605,"phases":7474,"primaryCompletion":607,"completion":607,"start":608,"enrollment":100,"conditions":7475,"interventions":7476},[89],[610,611,612],[614,615,616,594],{"trials":7478,"activeCount":100},[],{"trials":7480,"activeCount":100},[],{"trials":7482,"activeCount":100},[],{"intervention":616,"totalTrials":138,"cells":7484},{"EARLY_PHASE1":7485,"PHASE1":7487,"PHASE2":7489,"PHASE3":7495,"PHASE4":7497,"NA":7499},{"trials":7486,"activeCount":100},[],{"trials":7488,"activeCount":100},[],{"trials":7490,"activeCount":100},[7491],{"nctId":603,"briefTitle":604,"status":605,"phases":7492,"primaryCompletion":607,"completion":607,"start":608,"enrollment":100,"conditions":7493,"interventions":7494},[89],[610,611,612],[614,615,616,594],{"trials":7496,"activeCount":100},[],{"trials":7498,"activeCount":100},[],{"trials":7500,"activeCount":100},[],{"intervention":6814,"totalTrials":138,"cells":7502},{"EARLY_PHASE1":7503,"PHASE1":7505,"PHASE2":7507,"PHASE3":7513,"PHASE4":7515,"NA":7517},{"trials":7504,"activeCount":100},[],{"trials":7506,"activeCount":100},[],{"trials":7508,"activeCount":100},[7509],{"nctId":6806,"briefTitle":6807,"status":108,"phases":7510,"primaryCompletion":6809,"completion":6809,"start":4979,"enrollment":6810,"conditions":7511,"interventions":7512},[89],[6812],[6814,6815,6790,6816],{"trials":7514,"activeCount":100},[],{"trials":7516,"activeCount":100},[],{"trials":7518,"activeCount":100},[],{"intervention":6815,"totalTrials":138,"cells":7520},{"EARLY_PHASE1":7521,"PHASE1":7523,"PHASE2":7525,"PHASE3":7531,"PHASE4":7533,"NA":7535},{"trials":7522,"activeCount":100},[],{"trials":7524,"activeCount":100},[],{"trials":7526,"activeCount":100},[7527],{"nctId":6806,"briefTitle":6807,"status":108,"phases":7528,"primaryCompletion":6809,"completion":6809,"start":4979,"enrollment":6810,"conditions":7529,"interventions":7530},[89],[6812],[6814,6815,6790,6816],{"trials":7532,"activeCount":100},[],{"trials":7534,"activeCount":100},[],{"trials":7536,"activeCount":100},[],{"intervention":6816,"totalTrials":138,"cells":7538},{"EARLY_PHASE1":7539,"PHASE1":7541,"PHASE2":7543,"PHASE3":7549,"PHASE4":7551,"NA":7553},{"trials":7540,"activeCount":100},[],{"trials":7542,"activeCount":100},[],{"trials":7544,"activeCount":100},[7545],{"nctId":6806,"briefTitle":6807,"status":108,"phases":7546,"primaryCompletion":6809,"completion":6809,"start":4979,"enrollment":6810,"conditions":7547,"interventions":7548},[89],[6812],[6814,6815,6790,6816],{"trials":7550,"activeCount":100},[],{"trials":7552,"activeCount":100},[],{"trials":7554,"activeCount":100},[],{"intervention":7556,"totalTrials":138,"cells":7557},"Venlafaxine",{"EARLY_PHASE1":7558,"PHASE1":7560,"PHASE2":7562,"PHASE3":7572,"PHASE4":7574,"NA":7576},{"trials":7559,"activeCount":100},[],{"trials":7561,"activeCount":100},[],{"trials":7563,"activeCount":100},[7564],{"nctId":7565,"briefTitle":7566,"status":605,"phases":7567,"primaryCompletion":7568,"completion":7568,"start":830,"enrollment":100,"conditions":7569,"interventions":7571},"NCT05724849","Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer",[89],"2026-08-01",[7570,22],"Head and Neck Cancer",[7556],{"trials":7573,"activeCount":100},[],{"trials":7575,"activeCount":100},[],{"trials":7577,"activeCount":100},[],{"intervention":7579,"totalTrials":138,"cells":7580},"TPN nutritional supplement",{"EARLY_PHASE1":7581,"PHASE1":7583,"PHASE2":7585,"PHASE3":7594,"PHASE4":7596,"NA":7598},{"trials":7582,"activeCount":100},[],{"trials":7584,"activeCount":100},[],{"trials":7586,"activeCount":100},[7587],{"nctId":7588,"briefTitle":7589,"status":659,"phases":7590,"primaryCompletion":7591,"completion":7591,"start":2928,"enrollment":96,"conditions":7592,"interventions":7593},"NCT00179166","Assessment of Metabolic Response in Critically Ill Patients With Acute Renal Failure",[89],"2005-07",[4455],[7579],{"trials":7595,"activeCount":100},[],{"trials":7597,"activeCount":100},[],{"trials":7599,"activeCount":100},[],{"intervention":7601,"totalTrials":138,"cells":7602},"Nepro nutritional supplement",{"EARLY_PHASE1":7603,"PHASE1":7605,"PHASE2":7607,"PHASE3":7617,"PHASE4":7619,"NA":7621},{"trials":7604,"activeCount":100},[],{"trials":7606,"activeCount":100},[],{"trials":7608,"activeCount":100},[7609],{"nctId":7610,"briefTitle":7611,"status":659,"phases":7612,"primaryCompletion":7613,"completion":2142,"start":7614,"enrollment":2796,"conditions":7615,"interventions":7616},"NCT00179205","Complementary Intradialytic Nutritional Supplementation in Dialysis Patients",[89],"2006-11","2005-05",[6712],[7601],{"trials":7618,"activeCount":100},[],{"trials":7620,"activeCount":100},[],{"trials":7622,"activeCount":100},[],{"intervention":7624,"totalTrials":138,"cells":7625},"Low Dose Nicotine",{"EARLY_PHASE1":7626,"PHASE1":7628,"PHASE2":7630,"PHASE3":7642,"PHASE4":7644,"NA":7646},{"trials":7627,"activeCount":100},[],{"trials":7629,"activeCount":100},[],{"trials":7631,"activeCount":100},[7632],{"nctId":7633,"briefTitle":7634,"status":108,"phases":7635,"primaryCompletion":7636,"completion":7636,"start":7637,"enrollment":900,"conditions":7638,"interventions":7640},"NCT01778946","Nicotine Treatment of Cognitive Decline in Down Syndrome",[88,89],"2021-02","2013-04",[1723,7639],"Mild Cognitive Impairment",[7624,7641],"Moderate Dose Nicotine",{"trials":7643,"activeCount":100},[],{"trials":7645,"activeCount":100},[],{"trials":7647,"activeCount":100},[],{"intervention":7641,"totalTrials":138,"cells":7649},{"EARLY_PHASE1":7650,"PHASE1":7652,"PHASE2":7654,"PHASE3":7660,"PHASE4":7662,"NA":7664},{"trials":7651,"activeCount":100},[],{"trials":7653,"activeCount":100},[],{"trials":7655,"activeCount":100},[7656],{"nctId":7633,"briefTitle":7634,"status":108,"phases":7657,"primaryCompletion":7636,"completion":7636,"start":7637,"enrollment":900,"conditions":7658,"interventions":7659},[88,89],[1723,7639],[7624,7641],{"trials":7661,"activeCount":100},[],{"trials":7663,"activeCount":100},[],{"trials":7665,"activeCount":100},[],{"intervention":7667,"totalTrials":138,"cells":7668},"Montelukast added to Hydroxyurea",{"EARLY_PHASE1":7669,"PHASE1":7671,"PHASE2":7673,"PHASE3":7684,"PHASE4":7686,"NA":7688},{"trials":7670,"activeCount":100},[],{"trials":7672,"activeCount":100},[],{"trials":7674,"activeCount":100},[7675],{"nctId":7676,"briefTitle":7677,"status":108,"phases":7678,"primaryCompletion":7679,"completion":7679,"start":7680,"enrollment":649,"conditions":7681,"interventions":7683},"NCT01960413","Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia",[89],"2018-03","2013-11",[7682],"Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)",[7667],{"trials":7685,"activeCount":100},[],{"trials":7687,"activeCount":100},[],{"trials":7689,"activeCount":100},[],{"intervention":7691,"totalTrials":138,"cells":7692},"Metformin",{"EARLY_PHASE1":7693,"PHASE1":7695,"PHASE2":7697,"PHASE3":7710,"PHASE4":7712,"NA":7714},{"trials":7694,"activeCount":100},[],{"trials":7696,"activeCount":100},[],{"trials":7698,"activeCount":100},[7699],{"nctId":7700,"briefTitle":7701,"status":108,"phases":7702,"primaryCompletion":7703,"completion":7704,"start":7705,"enrollment":7706,"conditions":7707,"interventions":7709},"NCT03617458","Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension",[89],"2023-09-09","2025-08-19","2018-08-23",73,[7708],"Pulmonary Artery Hypertension",[7691],{"trials":7711,"activeCount":100},[],{"trials":7713,"activeCount":100},[],{"trials":7715,"activeCount":100},[],{"intervention":7717,"totalTrials":138,"cells":7718},"Misoprostol 100Mcg Tab",{"EARLY_PHASE1":7719,"PHASE1":7721,"PHASE2":7723,"PHASE3":7734,"PHASE4":7736,"NA":7738},{"trials":7720,"activeCount":100},[],{"trials":7722,"activeCount":100},[],{"trials":7724,"activeCount":100},[7725],{"nctId":7726,"briefTitle":7727,"status":659,"phases":7728,"primaryCompletion":7729,"completion":7729,"start":7730,"enrollment":683,"conditions":7731,"interventions":7733},"NCT03617172","PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol",[89],"2021-09-22","2018-11-26",[7732],"Clostridium Difficile",[7717],{"trials":7735,"activeCount":100},[],{"trials":7737,"activeCount":100},[],{"trials":7739,"activeCount":100},[],{"intervention":7741,"totalTrials":138,"cells":7742},"Granulocyte Colony Stimulating Factor",{"EARLY_PHASE1":7743,"PHASE1":7745,"PHASE2":7747,"PHASE3":7758,"PHASE4":7760,"NA":7762},{"trials":7744,"activeCount":100},[],{"trials":7746,"activeCount":100},[],{"trials":7748,"activeCount":100},[7749],{"nctId":7750,"briefTitle":7751,"status":108,"phases":7752,"primaryCompletion":2587,"completion":7753,"start":7754,"enrollment":900,"conditions":7755,"interventions":7757},"NCT01538862","Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa",[89],"2014-11","2012-02",[7756],"Dystrophic Epidermolysis Bullosa",[7741],{"trials":7759,"activeCount":100},[],{"trials":7761,"activeCount":100},[],{"trials":7763,"activeCount":100},[],{"intervention":7765,"totalTrials":138,"cells":7766},"L-Dopa",{"EARLY_PHASE1":7767,"PHASE1":7769,"PHASE2":7771,"PHASE3":7787,"PHASE4":7789,"NA":7791},{"trials":7768,"activeCount":100},[],{"trials":7770,"activeCount":100},[],{"trials":7772,"activeCount":100},[7773],{"nctId":7774,"briefTitle":7775,"status":108,"phases":7776,"primaryCompletion":7777,"completion":7777,"start":7778,"enrollment":7779,"conditions":7780,"interventions":7786},"NCT04469959","Dopaminergic Dysfunction in Late-Life Depression",[89],"2026-04-29","2021-02-15",79,[7781,7782,7783,7784,7785],"Late Life Depression","Cognitive Decline","Depressive Disorder, Treatment-Resistant","Levodopa","Gait Impairment",[7765],{"trials":7788,"activeCount":100},[],{"trials":7790,"activeCount":100},[],{"trials":7792,"activeCount":100},[],{"intervention":7794,"totalTrials":138,"cells":7795},"Ranolazine",{"EARLY_PHASE1":7796,"PHASE1":7798,"PHASE2":7800,"PHASE3":7812,"PHASE4":7814,"NA":7816},{"trials":7797,"activeCount":100},[],{"trials":7799,"activeCount":100},[],{"trials":7801,"activeCount":100},[7802],{"nctId":7803,"briefTitle":7804,"status":659,"phases":7805,"primaryCompletion":7806,"completion":7806,"start":7807,"enrollment":2239,"conditions":7808,"interventions":7811},"NCT04456517","Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy",[89],"2024-04-11","2022-10-18",[7809,7810],"Crohn's Disease","Inflammatory Bowel Disease",[7794],{"trials":7813,"activeCount":100},[],{"trials":7815,"activeCount":100},[],{"trials":7817,"activeCount":100},[],{"intervention":7819,"totalTrials":138,"cells":7820},"Transdermal nicotine",{"EARLY_PHASE1":7821,"PHASE1":7823,"PHASE2":7825,"PHASE3":7838,"PHASE4":7840,"NA":7842},{"trials":7822,"activeCount":100},[],{"trials":7824,"activeCount":100},[],{"trials":7826,"activeCount":100},[7827],{"nctId":7828,"briefTitle":7829,"status":108,"phases":7830,"primaryCompletion":7831,"completion":7831,"start":3183,"enrollment":26,"conditions":7832,"interventions":7837},"NCT02312934","Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study",[89],"2018-05",[7833,7834,7835,6884,7836],"Chemo Brain","Chemotherapy-related Cognitive Impairment","Chemo Fog","Chemobrain",[7819],{"trials":7839,"activeCount":100},[],{"trials":7841,"activeCount":100},[],{"trials":7843,"activeCount":100},[],{"intervention":7845,"totalTrials":138,"cells":7846},"Botox 200 UNT",{"EARLY_PHASE1":7847,"PHASE1":7849,"PHASE2":7851,"PHASE3":7862,"PHASE4":7864,"NA":7866},{"trials":7848,"activeCount":100},[],{"trials":7850,"activeCount":100},[],{"trials":7852,"activeCount":100},[7853],{"nctId":7854,"briefTitle":7855,"status":659,"phases":7856,"primaryCompletion":7857,"completion":7857,"start":7858,"enrollment":2239,"conditions":7859,"interventions":7861},"NCT03991299","Investigating Effects of BOTOX on Weight Loss and Glucose Tolerance in Obese, Type 2 Diabetic Subjects",[88,89],"2022-02-11","2021-04-29",[7860,6343],"Obese",[7845],{"trials":7863,"activeCount":100},[],{"trials":7865,"activeCount":100},[],{"trials":7867,"activeCount":100},[],{"intervention":967,"totalTrials":138,"cells":7869},{"EARLY_PHASE1":7870,"PHASE1":7872,"PHASE2":7874,"PHASE3":7880,"PHASE4":7882,"NA":7884},{"trials":7871,"activeCount":100},[],{"trials":7873,"activeCount":100},[],{"trials":7875,"activeCount":100},[7876],{"nctId":958,"briefTitle":959,"status":659,"phases":7877,"primaryCompletion":961,"completion":962,"start":963,"enrollment":96,"conditions":7878,"interventions":7879},[89],[965],[967,891],{"trials":7881,"activeCount":100},[],{"trials":7883,"activeCount":100},[],{"trials":7885,"activeCount":100},[],{"intervention":7887,"totalTrials":138,"cells":7888},"5-fluorouracil",{"EARLY_PHASE1":7889,"PHASE1":7891,"PHASE2":7893,"PHASE3":7905,"PHASE4":7907,"NA":7909},{"trials":7890,"activeCount":100},[],{"trials":7892,"activeCount":100},[],{"trials":7894,"activeCount":100},[7895],{"nctId":7896,"briefTitle":7897,"status":108,"phases":7898,"primaryCompletion":663,"completion":7680,"start":694,"enrollment":23,"conditions":7899,"interventions":7902},"NCT00515216","Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors",[89],[7900,7901],"Stomach Neoplasms","Esophageal Neoplasms",[7887,7903,7904],"Oxaliplatin","Leucovorin",{"trials":7906,"activeCount":100},[],{"trials":7908,"activeCount":100},[],{"trials":7910,"activeCount":100},[],{"intervention":7903,"totalTrials":138,"cells":7912},{"EARLY_PHASE1":7913,"PHASE1":7915,"PHASE2":7917,"PHASE3":7923,"PHASE4":7925,"NA":7927},{"trials":7914,"activeCount":100},[],{"trials":7916,"activeCount":100},[],{"trials":7918,"activeCount":100},[7919],{"nctId":7896,"briefTitle":7897,"status":108,"phases":7920,"primaryCompletion":663,"completion":7680,"start":694,"enrollment":23,"conditions":7921,"interventions":7922},[89],[7900,7901],[7887,7903,7904],{"trials":7924,"activeCount":100},[],{"trials":7926,"activeCount":100},[],{"trials":7928,"activeCount":100},[],{"intervention":7904,"totalTrials":138,"cells":7930},{"EARLY_PHASE1":7931,"PHASE1":7933,"PHASE2":7935,"PHASE3":7941,"PHASE4":7943,"NA":7945},{"trials":7932,"activeCount":100},[],{"trials":7934,"activeCount":100},[],{"trials":7936,"activeCount":100},[7937],{"nctId":7896,"briefTitle":7897,"status":108,"phases":7938,"primaryCompletion":663,"completion":7680,"start":694,"enrollment":23,"conditions":7939,"interventions":7940},[89],[7900,7901],[7887,7903,7904],{"trials":7942,"activeCount":100},[],{"trials":7944,"activeCount":100},[],{"trials":7946,"activeCount":100},[],{"intervention":7948,"totalTrials":138,"cells":7949},"Levetiracetam 500 mg",{"EARLY_PHASE1":7950,"PHASE1":7952,"PHASE2":7954,"PHASE3":7965,"PHASE4":7967,"NA":7969},{"trials":7951,"activeCount":100},[],{"trials":7953,"activeCount":100},[],{"trials":7955,"activeCount":100},[7956],{"nctId":7957,"briefTitle":7958,"status":659,"phases":7959,"primaryCompletion":7960,"completion":7960,"start":7961,"enrollment":138,"conditions":7962,"interventions":7964},"NCT04277936","Pharmacologic Modulation of Hippocampal Activity in Psychosis",[89],"2020-08-31","2020-05-11",[7963],"Schizophrenia; Psychosis",[7948],{"trials":7966,"activeCount":100},[],{"trials":7968,"activeCount":100},[],{"trials":7970,"activeCount":100},[],{"intervention":7972,"totalTrials":138,"cells":7973},"Rosiglitazone and Bexarotene",{"EARLY_PHASE1":7974,"PHASE1":7976,"PHASE2":7978,"PHASE3":7990,"PHASE4":7992,"NA":7994},{"trials":7975,"activeCount":100},[],{"trials":7977,"activeCount":100},[],{"trials":7979,"activeCount":100},[7980],{"nctId":7981,"briefTitle":7982,"status":108,"phases":7983,"primaryCompletion":4426,"completion":4426,"start":7984,"enrollment":2239,"conditions":7985,"interventions":7989},"NCT00178841","Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL",[89],"2005-06",[7986,7987,7988],"Cutaneous T-cell Lymphoma","Mycosis Fungoides","Sezary Syndrome",[7972],{"trials":7991,"activeCount":100},[],{"trials":7993,"activeCount":100},[],{"trials":7995,"activeCount":100},[],{"intervention":7997,"totalTrials":138,"cells":7998},"Antibiotic Regimen",{"EARLY_PHASE1":7999,"PHASE1":8001,"PHASE2":8003,"PHASE3":8012,"PHASE4":8014,"NA":8016},{"trials":8000,"activeCount":100},[],{"trials":8002,"activeCount":100},[],{"trials":8004,"activeCount":100},[8005],{"nctId":8006,"briefTitle":8007,"status":108,"phases":8008,"primaryCompletion":2927,"completion":2927,"start":4769,"enrollment":762,"conditions":8009,"interventions":8011},"NCT01074554","Trial of Antimycobacterial Therapy in Sarcoidosis",[88,89],[8010],"Sarcoidosis",[7997],{"trials":8013,"activeCount":100},[],{"trials":8015,"activeCount":100},[],{"trials":8017,"activeCount":100},[],{"intervention":8019,"totalTrials":138,"cells":8020},"2-HOBA",{"EARLY_PHASE1":8021,"PHASE1":8023,"PHASE2":8025,"PHASE3":8036,"PHASE4":8038,"NA":8040},{"trials":8022,"activeCount":100},[],{"trials":8024,"activeCount":100},[],{"trials":8026,"activeCount":100},[8027],{"nctId":8028,"briefTitle":8029,"status":108,"phases":8030,"primaryCompletion":8031,"completion":8031,"start":8032,"enrollment":3614,"conditions":8033,"interventions":8035},"NCT05274243","2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis",[89],"2025-05-28","2022-08-09",[8034],"Rheumatoid Arthritis",[8019],{"trials":8037,"activeCount":100},[],{"trials":8039,"activeCount":100},[],{"trials":8041,"activeCount":100},[],{"intervention":8043,"totalTrials":138,"cells":8044},"Levocarnitine",{"EARLY_PHASE1":8045,"PHASE1":8047,"PHASE2":8049,"PHASE3":8061,"PHASE4":8063,"NA":8065},{"trials":8046,"activeCount":100},[],{"trials":8048,"activeCount":100},[],{"trials":8050,"activeCount":100},[8051],{"nctId":8052,"briefTitle":8053,"status":108,"phases":8054,"primaryCompletion":8055,"completion":8055,"start":8056,"enrollment":2514,"conditions":8057,"interventions":8060},"NCT03953703","Levocarnitine for Dry Eye in Sjogren's Syndrome",[89],"2025-09-19","2021-11-17",[8058,8059],"Sjogren's Syndrome","Keratoconjunctivitis Sicca",[8043],{"trials":8062,"activeCount":100},[],{"trials":8064,"activeCount":100},[],{"trials":8066,"activeCount":100},[],{"intervention":3435,"totalTrials":138,"cells":8068},{"EARLY_PHASE1":8069,"PHASE1":8071,"PHASE2":8073,"PHASE3":8079,"PHASE4":8081,"NA":8083},{"trials":8070,"activeCount":100},[],{"trials":8072,"activeCount":100},[],{"trials":8074,"activeCount":100},[8075],{"nctId":3427,"briefTitle":3428,"status":108,"phases":8076,"primaryCompletion":3430,"completion":3430,"start":3431,"enrollment":3432,"conditions":8077,"interventions":8078},[89],[19],[3400,3435],{"trials":8080,"activeCount":100},[],{"trials":8082,"activeCount":100},[],{"trials":8084,"activeCount":100},[],{"intervention":8086,"totalTrials":138,"cells":8087},"PRP injection dose",{"EARLY_PHASE1":8088,"PHASE1":8090,"PHASE2":8092,"PHASE3":8102,"PHASE4":8104,"NA":8106},{"trials":8089,"activeCount":100},[],{"trials":8091,"activeCount":100},[],{"trials":8093,"activeCount":100},[8094],{"nctId":8095,"briefTitle":8096,"status":605,"phases":8097,"primaryCompletion":8098,"completion":8098,"start":8099,"enrollment":100,"conditions":8100,"interventions":8101},"NCT05330689","How Does Platelet Dose Impact Clinical Outcomes After PRP Treatment?",[89],"2022-09-07","2022-03-06",[330],[8086,8086,8086,8086],{"trials":8103,"activeCount":100},[],{"trials":8105,"activeCount":100},[],{"trials":8107,"activeCount":100},[],{"intervention":8109,"totalTrials":138,"cells":8110},"human regular insulin",{"EARLY_PHASE1":8111,"PHASE1":8113,"PHASE2":8115,"PHASE3":8125,"PHASE4":8127,"NA":8129},{"trials":8112,"activeCount":100},[],{"trials":8114,"activeCount":100},[],{"trials":8116,"activeCount":100},[8117],{"nctId":8118,"briefTitle":8119,"status":605,"phases":8120,"primaryCompletion":8121,"completion":8121,"start":8122,"enrollment":100,"conditions":8123,"interventions":8124},"NCT00592410","The Effects of Intensive Insulin on Somatic and Visceral Protein Turnover in Acute Kidney Injury (AKI)",[89],"2008-11","2007-02",[4455],[8109],{"trials":8126,"activeCount":100},[],{"trials":8128,"activeCount":100},[],{"trials":8130,"activeCount":100},[],{"intervention":8132,"totalTrials":138,"cells":8133},"Memantine",{"EARLY_PHASE1":8134,"PHASE1":8136,"PHASE2":8138,"PHASE3":8148,"PHASE4":8150,"NA":8152},{"trials":8135,"activeCount":100},[],{"trials":8137,"activeCount":100},[],{"trials":8139,"activeCount":100},[8140],{"nctId":8141,"briefTitle":8142,"status":108,"phases":8143,"primaryCompletion":8144,"completion":8144,"start":7705,"enrollment":3752,"conditions":8145,"interventions":8147},"NCT03527472","Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus",[89],"2026-02-28",[8146],"Lupus Erythematosus, Systemic",[8132],{"trials":8149,"activeCount":100},[],{"trials":8151,"activeCount":100},[],{"trials":8153,"activeCount":100},[],{"intervention":8155,"totalTrials":138,"cells":8156},"Levetiracetam (LEV) 500 mg",{"EARLY_PHASE1":8157,"PHASE1":8159,"PHASE2":8161,"PHASE3":8170,"PHASE4":8172,"NA":8174},{"trials":8158,"activeCount":100},[],{"trials":8160,"activeCount":100},[],{"trials":8162,"activeCount":100},[8163],{"nctId":8164,"briefTitle":8165,"status":108,"phases":8166,"primaryCompletion":5003,"completion":5003,"start":8167,"enrollment":6746,"conditions":8168,"interventions":8169},"NCT04559529","Pharmacological Modulation of Hippocampal Activity in Psychosis 2",[89],"2020-09-23",[7963],[8155],{"trials":8171,"activeCount":100},[],{"trials":8173,"activeCount":100},[],{"trials":8175,"activeCount":100},[],{"intervention":2323,"totalTrials":96,"cells":8177},{"EARLY_PHASE1":8178,"PHASE1":8180,"PHASE2":8201,"PHASE3":8203,"PHASE4":8205,"NA":8207},{"trials":8179,"activeCount":100},[],{"trials":8181,"activeCount":100},[8182,8188,8197],{"nctId":8183,"briefTitle":8184,"status":108,"phases":8185,"primaryCompletion":1434,"completion":1434,"start":6907,"enrollment":1315,"conditions":8186,"interventions":8187},"NCT01690884","Effect of Ticagrelor vs. Dipyridamole on Adenosine Uptake",[88],[3754],[2323],{"nctId":8189,"briefTitle":8190,"status":659,"phases":8191,"primaryCompletion":1434,"completion":1434,"start":8192,"enrollment":5629,"conditions":8193,"interventions":8195},"NCT00179010","AMP as a Better Delivery System of Adenosine",[88],"2003-10",[8194],"Ischemia",[2323,8196],"Adenosine Mono Phosphate",{"nctId":2317,"briefTitle":2318,"status":659,"phases":8198,"primaryCompletion":1434,"completion":1434,"start":2320,"enrollment":2150,"conditions":8199,"interventions":8200},[88],[1108],[2323,2310,2323],{"trials":8202,"activeCount":100},[],{"trials":8204,"activeCount":100},[],{"trials":8206,"activeCount":100},[],{"trials":8208,"activeCount":100},[],{"intervention":8210,"totalTrials":531,"cells":8211},"High-dose trivalent inactivated influenza vaccine",{"EARLY_PHASE1":8212,"PHASE1":8214,"PHASE2":8233,"PHASE3":8235,"PHASE4":8237,"NA":8239},{"trials":8213,"activeCount":100},[],{"trials":8215,"activeCount":100},[8216,8224],{"nctId":8217,"briefTitle":8218,"status":108,"phases":8219,"primaryCompletion":3679,"completion":3679,"start":2114,"enrollment":124,"conditions":8220,"interventions":8222},"NCT01216332","Standard Versus High-Dose Trivalent Inactivated Flu Vaccine in Pediatric Acute Lymphoblastic Leukemia Patients",[88],[8221],"Pediatric Patients With Acute Lymphoblastic Leukemia",[8210,8223],"Standard dose trivalent inactivated influenza vaccine",{"nctId":8225,"briefTitle":8226,"status":108,"phases":8227,"primaryCompletion":2939,"completion":731,"start":8228,"enrollment":4427,"conditions":8229,"interventions":8231},"NCT01525004","Standard Dose Versus High-Dose Inactivated Flu Vaccine in Pediatric Solid Organ Transplant Patients",[88],"2011-09",[8230],"Pediatric Solid Organ Transplant Patients",[8232,8223],"High-Dose trivalent inactivated influenza vaccine",{"trials":8234,"activeCount":100},[],{"trials":8236,"activeCount":100},[],{"trials":8238,"activeCount":100},[],{"trials":8240,"activeCount":100},[],{"intervention":8223,"totalTrials":531,"cells":8242},{"EARLY_PHASE1":8243,"PHASE1":8245,"PHASE2":8255,"PHASE3":8257,"PHASE4":8259,"NA":8261},{"trials":8244,"activeCount":100},[],{"trials":8246,"activeCount":100},[8247,8251],{"nctId":8217,"briefTitle":8218,"status":108,"phases":8248,"primaryCompletion":3679,"completion":3679,"start":2114,"enrollment":124,"conditions":8249,"interventions":8250},[88],[8221],[8210,8223],{"nctId":8225,"briefTitle":8226,"status":108,"phases":8252,"primaryCompletion":2939,"completion":731,"start":8228,"enrollment":4427,"conditions":8253,"interventions":8254},[88],[8230],[8232,8223],{"trials":8256,"activeCount":100},[],{"trials":8258,"activeCount":100},[],{"trials":8260,"activeCount":100},[],{"trials":8262,"activeCount":100},[],{"intervention":3420,"totalTrials":531,"cells":8264},{"EARLY_PHASE1":8265,"PHASE1":8267,"PHASE2":8277,"PHASE3":8279,"PHASE4":8281,"NA":8283},{"trials":8266,"activeCount":100},[],{"trials":8268,"activeCount":100},[8269,8273],{"nctId":3407,"briefTitle":3408,"status":108,"phases":8270,"primaryCompletion":3410,"completion":3411,"start":3412,"enrollment":3413,"conditions":8271,"interventions":8272},[88],[3415,3416,3417,3418],[3420,3421,3400,3422,3423],{"nctId":3513,"briefTitle":3514,"status":108,"phases":8274,"primaryCompletion":1434,"completion":1434,"start":3516,"enrollment":3517,"conditions":8275,"interventions":8276},[88],[19],[3520,3521,3522,3523,3524,3525,3526,3420,3527,3528,3506,3529,3530,3531,3532,3533,3534,3535,3536,3537],{"trials":8278,"activeCount":100},[],{"trials":8280,"activeCount":100},[],{"trials":8282,"activeCount":100},[],{"trials":8284,"activeCount":100},[],{"intervention":8286,"totalTrials":531,"cells":8287},"human ghrelin",{"EARLY_PHASE1":8288,"PHASE1":8290,"PHASE2":8304,"PHASE3":8306,"PHASE4":8308,"NA":8310},{"trials":8289,"activeCount":100},[],{"trials":8291,"activeCount":100},[8292,8300],{"nctId":8293,"briefTitle":8294,"status":108,"phases":8295,"primaryCompletion":8296,"completion":8296,"start":3706,"enrollment":8297,"conditions":8298,"interventions":8299},"NCT01474785","RYGB and the Gastric Adipose Axis",[88],"2015-07",49,[16],[8286],{"nctId":931,"briefTitle":932,"status":108,"phases":8301,"primaryCompletion":934,"completion":935,"start":936,"enrollment":937,"conditions":8302,"interventions":8303},[88],[16],[940,891],{"trials":8305,"activeCount":100},[],{"trials":8307,"activeCount":100},[],{"trials":8309,"activeCount":100},[],{"trials":8311,"activeCount":100},[],{"intervention":3530,"totalTrials":531,"cells":8313},{"EARLY_PHASE1":8314,"PHASE1":8316,"PHASE2":8331,"PHASE3":8333,"PHASE4":8335,"NA":8337},{"trials":8315,"activeCount":100},[],{"trials":8317,"activeCount":100},[8318,8322],{"nctId":3513,"briefTitle":3514,"status":108,"phases":8319,"primaryCompletion":1434,"completion":1434,"start":3516,"enrollment":3517,"conditions":8320,"interventions":8321},[88],[19],[3520,3521,3522,3523,3524,3525,3526,3420,3527,3528,3506,3529,3530,3531,3532,3533,3534,3535,3536,3537],{"nctId":8323,"briefTitle":8324,"status":659,"phases":8325,"primaryCompletion":8326,"completion":8326,"start":4452,"enrollment":1220,"conditions":8327,"interventions":8328},"NCT01292694","Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure",[88],"2017-03",[19,903,926],[8329,8330],"Losartan","Captopril",{"trials":8332,"activeCount":100},[],{"trials":8334,"activeCount":100},[],{"trials":8336,"activeCount":100},[],{"trials":8338,"activeCount":100},[],{"intervention":3532,"totalTrials":531,"cells":8340},{"EARLY_PHASE1":8341,"PHASE1":8343,"PHASE2":8353,"PHASE3":8355,"PHASE4":8357,"NA":8359},{"trials":8342,"activeCount":100},[],{"trials":8344,"activeCount":100},[8345,8349],{"nctId":3513,"briefTitle":3514,"status":108,"phases":8346,"primaryCompletion":1434,"completion":1434,"start":3516,"enrollment":3517,"conditions":8347,"interventions":8348},[88],[19],[3520,3521,3522,3523,3524,3525,3526,3420,3527,3528,3506,3529,3530,3531,3532,3533,3534,3535,3536,3537],{"nctId":8323,"briefTitle":8324,"status":659,"phases":8350,"primaryCompletion":8326,"completion":8326,"start":4452,"enrollment":1220,"conditions":8351,"interventions":8352},[88],[19,903,926],[8329,8330],{"trials":8354,"activeCount":100},[],{"trials":8356,"activeCount":100},[],{"trials":8358,"activeCount":100},[],{"trials":8360,"activeCount":100},[],{"intervention":8362,"totalTrials":531,"cells":8363},"Dose Escalation of VU319",{"EARLY_PHASE1":8364,"PHASE1":8366,"PHASE2":8388,"PHASE3":8390,"PHASE4":8392,"NA":8394},{"trials":8365,"activeCount":100},[],{"trials":8367,"activeCount":100},[8368,8380],{"nctId":8369,"briefTitle":8370,"status":108,"phases":8371,"primaryCompletion":8372,"completion":8372,"start":8373,"enrollment":8374,"conditions":8375,"interventions":8377},"NCT03220295","Putative Cognitive Enhancer VU319",[88],"2019-10-30","2017-07-28",52,[8376],"Cognitive Impairment",[8378,8379,8362],"Single Dose of VU319","Single Dose Placebo",{"nctId":8381,"briefTitle":8382,"status":605,"phases":8383,"primaryCompletion":8384,"completion":8384,"start":8384,"enrollment":100,"conditions":8385,"interventions":8386},"NCT04051801","Multiple Ascending Dose Putative Cognitive Enhancer VU319",[88],"2021-05-25",[8376],[8362,8387],"Dose Escalation of Placebo",{"trials":8389,"activeCount":100},[],{"trials":8391,"activeCount":100},[],{"trials":8393,"activeCount":100},[],{"trials":8395,"activeCount":100},[],{"intervention":2220,"totalTrials":531,"cells":8397},{"EARLY_PHASE1":8398,"PHASE1":8400,"PHASE2":8410,"PHASE3":8412,"PHASE4":8414,"NA":8416},{"trials":8399,"activeCount":100},[],{"trials":8401,"activeCount":100},[8402,8406],{"nctId":2594,"briefTitle":2595,"status":108,"phases":8403,"primaryCompletion":1434,"completion":1434,"start":2597,"enrollment":2598,"conditions":8404,"interventions":8405},[88],[2253,2186],[2601,2602,2603,2604,2605,2579,2606,2607,2608,2609,2610,2611,2220,2612,2613,2614,2615,2616,2617,2618],{"nctId":2209,"briefTitle":2210,"status":108,"phases":8407,"primaryCompletion":1434,"completion":1434,"start":2212,"enrollment":2213,"conditions":8408,"interventions":8409},[88],[2215,2216,2217,2218],[2149,2149,2220],{"trials":8411,"activeCount":100},[],{"trials":8413,"activeCount":100},[],{"trials":8415,"activeCount":100},[],{"trials":8417,"activeCount":100},[],{"intervention":8419,"totalTrials":531,"cells":8420},"L-Lysine",{"EARLY_PHASE1":8421,"PHASE1":8423,"PHASE2":8443,"PHASE3":8445,"PHASE4":8447,"NA":8449},{"trials":8422,"activeCount":100},[],{"trials":8424,"activeCount":100},[8425,8433],{"nctId":8426,"briefTitle":8427,"status":108,"phases":8428,"primaryCompletion":8429,"completion":8429,"start":8430,"enrollment":1447,"conditions":8431,"interventions":8432},"NCT05210504","Determinants of Alpha-aminoadipic Acid (2-AAA) and Relationship to Diabetes: Study 3",[88],"2023-01-27","2022-03-09",[6343],[8419,6589],{"nctId":8434,"briefTitle":8435,"status":108,"phases":8436,"primaryCompletion":8437,"completion":8437,"start":8438,"enrollment":5629,"conditions":8439,"interventions":8441},"NCT02756117","The Effect of Acute Lysine Administration on α-aminoadipic Acid",[88],"2016-10-01","2016-05",[2333,8440],"Pre-diabetic",[8419,8442],"Normal (0.9%) Saline",{"trials":8444,"activeCount":100},[],{"trials":8446,"activeCount":100},[],{"trials":8448,"activeCount":100},[],{"trials":8450,"activeCount":100},[],{"intervention":1305,"totalTrials":138,"cells":8452},{"EARLY_PHASE1":8453,"PHASE1":8455,"PHASE2":8461,"PHASE3":8463,"PHASE4":8465,"NA":8467},{"trials":8454,"activeCount":100},[],{"trials":8456,"activeCount":100},[8457],{"nctId":1296,"briefTitle":1297,"status":659,"phases":8458,"primaryCompletion":1299,"completion":1299,"start":1300,"enrollment":531,"conditions":8459,"interventions":8460},[88],[1302,1303],[1305,1056],{"trials":8462,"activeCount":100},[],{"trials":8464,"activeCount":100},[],{"trials":8466,"activeCount":100},[],{"trials":8468,"activeCount":100},[],{"intervention":8470,"totalTrials":138,"cells":8471},"Valganciclovir",{"EARLY_PHASE1":8472,"PHASE1":8474,"PHASE2":8485,"PHASE3":8487,"PHASE4":8489,"NA":8491},{"trials":8473,"activeCount":100},[],{"trials":8475,"activeCount":100},[8476],{"nctId":8477,"briefTitle":8478,"status":108,"phases":8479,"primaryCompletion":8480,"completion":8480,"start":8481,"enrollment":2250,"conditions":8482,"interventions":8484},"NCT02871401","A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)",[88],"2020-01-31","2018-01-03",[8483],"Idiopathic Pulmonary Fibrosis",[8470],{"trials":8486,"activeCount":100},[],{"trials":8488,"activeCount":100},[],{"trials":8490,"activeCount":100},[],{"trials":8492,"activeCount":100},[],{"intervention":8494,"totalTrials":138,"cells":8495},"supplemental liquid melatonin",{"EARLY_PHASE1":8496,"PHASE1":8498,"PHASE2":8509,"PHASE3":8511,"PHASE4":8513,"NA":8515},{"trials":8497,"activeCount":100},[],{"trials":8499,"activeCount":100},[8500],{"nctId":8501,"briefTitle":8502,"status":108,"phases":8503,"primaryCompletion":3557,"completion":2114,"start":4744,"enrollment":35,"conditions":8504,"interventions":8507},"NCT00927030","Melatonin for Sleep in Children With Autism",[88],[8505,8506],"Autistic Disorder","Insomnia",[8494,8508],"flavored liquid or liquid supplemental melatonin",{"trials":8510,"activeCount":100},[],{"trials":8512,"activeCount":100},[],{"trials":8514,"activeCount":100},[],{"trials":8516,"activeCount":100},[],{"intervention":8508,"totalTrials":138,"cells":8518},{"EARLY_PHASE1":8519,"PHASE1":8521,"PHASE2":8527,"PHASE3":8529,"PHASE4":8531,"NA":8533},{"trials":8520,"activeCount":100},[],{"trials":8522,"activeCount":100},[8523],{"nctId":8501,"briefTitle":8502,"status":108,"phases":8524,"primaryCompletion":3557,"completion":2114,"start":4744,"enrollment":35,"conditions":8525,"interventions":8526},[88],[8505,8506],[8494,8508],{"trials":8528,"activeCount":100},[],{"trials":8530,"activeCount":100},[],{"trials":8532,"activeCount":100},[],{"trials":8534,"activeCount":100},[],{"intervention":8536,"totalTrials":138,"cells":8537},"Pramipexole",{"EARLY_PHASE1":8538,"PHASE1":8540,"PHASE2":8550,"PHASE3":8552,"PHASE4":8554,"NA":8556},{"trials":8539,"activeCount":100},[],{"trials":8541,"activeCount":100},[8542],{"nctId":8543,"briefTitle":8544,"status":108,"phases":8545,"primaryCompletion":5247,"completion":8546,"start":8547,"enrollment":32,"conditions":8548,"interventions":8549},"NCT04249544","Social Decision Making in Parkinson's Disease",[88],"2022-09-01","2019-12-03",[303],[8536],{"trials":8551,"activeCount":100},[],{"trials":8553,"activeCount":100},[],{"trials":8555,"activeCount":100},[],{"trials":8557,"activeCount":100},[],{"intervention":8559,"totalTrials":138,"cells":8560},"Budesonide inhalation suspension",{"EARLY_PHASE1":8561,"PHASE1":8563,"PHASE2":8574,"PHASE3":8576,"PHASE4":8578,"NA":8580},{"trials":8562,"activeCount":100},[],{"trials":8564,"activeCount":100},[8565],{"nctId":8566,"briefTitle":8567,"status":108,"phases":8568,"primaryCompletion":695,"completion":8569,"start":8570,"enrollment":2331,"conditions":8571,"interventions":8573},"NCT02187445","Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial",[88],"2017-02-13","2014-06",[504,2056,8572],"Acute Chest Syndrome",[8559],{"trials":8575,"activeCount":100},[],{"trials":8577,"activeCount":100},[],{"trials":8579,"activeCount":100},[],{"trials":8581,"activeCount":100},[],{"intervention":8583,"totalTrials":138,"cells":8584},"SinuSurf irrigation twice daily",{"EARLY_PHASE1":8585,"PHASE1":8587,"PHASE2":8599,"PHASE3":8601,"PHASE4":8603,"NA":8605},{"trials":8586,"activeCount":100},[],{"trials":8588,"activeCount":100},[8589],{"nctId":8590,"briefTitle":8591,"status":108,"phases":8592,"primaryCompletion":8593,"completion":8593,"start":8594,"enrollment":412,"conditions":8595,"interventions":8597},"NCT02728505","SinuSurf vs. Saline Solution in Normal Subjects",[88],"2017-01-20","2016-04-12",[8596],"Rhinosinusitis",[8583,8598],"NeilMed Sinus rinse irrigation twice daily",{"trials":8600,"activeCount":100},[],{"trials":8602,"activeCount":100},[],{"trials":8604,"activeCount":100},[],{"trials":8606,"activeCount":100},[],{"intervention":8598,"totalTrials":138,"cells":8608},{"EARLY_PHASE1":8609,"PHASE1":8611,"PHASE2":8617,"PHASE3":8619,"PHASE4":8621,"NA":8623},{"trials":8610,"activeCount":100},[],{"trials":8612,"activeCount":100},[8613],{"nctId":8590,"briefTitle":8591,"status":108,"phases":8614,"primaryCompletion":8593,"completion":8593,"start":8594,"enrollment":412,"conditions":8615,"interventions":8616},[88],[8596],[8583,8598],{"trials":8618,"activeCount":100},[],{"trials":8620,"activeCount":100},[],{"trials":8622,"activeCount":100},[],{"trials":8624,"activeCount":100},[],{"intervention":3423,"totalTrials":138,"cells":8626},{"EARLY_PHASE1":8627,"PHASE1":8629,"PHASE2":8635,"PHASE3":8637,"PHASE4":8639,"NA":8641},{"trials":8628,"activeCount":100},[],{"trials":8630,"activeCount":100},[8631],{"nctId":3407,"briefTitle":3408,"status":108,"phases":8632,"primaryCompletion":3410,"completion":3411,"start":3412,"enrollment":3413,"conditions":8633,"interventions":8634},[88],[3415,3416,3417,3418],[3420,3421,3400,3422,3423],{"trials":8636,"activeCount":100},[],{"trials":8638,"activeCount":100},[],{"trials":8640,"activeCount":100},[],{"trials":8642,"activeCount":100},[],{"intervention":3520,"totalTrials":138,"cells":8644},{"EARLY_PHASE1":8645,"PHASE1":8647,"PHASE2":8653,"PHASE3":8655,"PHASE4":8657,"NA":8659},{"trials":8646,"activeCount":100},[],{"trials":8648,"activeCount":100},[8649],{"nctId":3513,"briefTitle":3514,"status":108,"phases":8650,"primaryCompletion":1434,"completion":1434,"start":3516,"enrollment":3517,"conditions":8651,"interventions":8652},[88],[19],[3520,3521,3522,3523,3524,3525,3526,3420,3527,3528,3506,3529,3530,3531,3532,3533,3534,3535,3536,3537],{"trials":8654,"activeCount":100},[],{"trials":8656,"activeCount":100},[],{"trials":8658,"activeCount":100},[],{"trials":8660,"activeCount":100},[],{"intervention":3521,"totalTrials":138,"cells":8662},{"EARLY_PHASE1":8663,"PHASE1":8665,"PHASE2":8671,"PHASE3":8673,"PHASE4":8675,"NA":8677},{"trials":8664,"activeCount":100},[],{"trials":8666,"activeCount":100},[8667],{"nctId":3513,"briefTitle":3514,"status":108,"phases":8668,"primaryCompletion":1434,"completion":1434,"start":3516,"enrollment":3517,"conditions":8669,"interventions":8670},[88],[19],[3520,3521,3522,3523,3524,3525,3526,3420,3527,3528,3506,3529,3530,3531,3532,3533,3534,3535,3536,3537],{"trials":8672,"activeCount":100},[],{"trials":8674,"activeCount":100},[],{"trials":8676,"activeCount":100},[],{"trials":8678,"activeCount":100},[],{"intervention":3522,"totalTrials":138,"cells":8680},{"EARLY_PHASE1":8681,"PHASE1":8683,"PHASE2":8689,"PHASE3":8691,"PHASE4":8693,"NA":8695},{"trials":8682,"activeCount":100},[],{"trials":8684,"activeCount":100},[8685],{"nctId":3513,"briefTitle":3514,"status":108,"phases":8686,"primaryCompletion":1434,"completion":1434,"start":3516,"enrollment":3517,"conditions":8687,"interventions":8688},[88],[19],[3520,3521,3522,3523,3524,3525,3526,3420,3527,3528,3506,3529,3530,3531,3532,3533,3534,3535,3536,3537],{"trials":8690,"activeCount":100},[],{"trials":8692,"activeCount":100},[],{"trials":8694,"activeCount":100},[],{"trials":8696,"activeCount":100},[],{"intervention":3523,"totalTrials":138,"cells":8698},{"EARLY_PHASE1":8699,"PHASE1":8701,"PHASE2":8707,"PHASE3":8709,"PHASE4":8711,"NA":8713},{"trials":8700,"activeCount":100},[],{"trials":8702,"activeCount":100},[8703],{"nctId":3513,"briefTitle":3514,"status":108,"phases":8704,"primaryCompletion":1434,"completion":1434,"start":3516,"enrollment":3517,"conditions":8705,"interventions":8706},[88],[19],[3520,3521,3522,3523,3524,3525,3526,3420,3527,3528,3506,3529,3530,3531,3532,3533,3534,3535,3536,3537],{"trials":8708,"activeCount":100},[],{"trials":8710,"activeCount":100},[],{"trials":8712,"activeCount":100},[],{"trials":8714,"activeCount":100},[],{"intervention":3526,"totalTrials":138,"cells":8716},{"EARLY_PHASE1":8717,"PHASE1":8719,"PHASE2":8725,"PHASE3":8727,"PHASE4":8729,"NA":8731},{"trials":8718,"activeCount":100},[],{"trials":8720,"activeCount":100},[8721],{"nctId":3513,"briefTitle":3514,"status":108,"phases":8722,"primaryCompletion":1434,"completion":1434,"start":3516,"enrollment":3517,"conditions":8723,"interventions":8724},[88],[19],[3520,3521,3522,3523,3524,3525,3526,3420,3527,3528,3506,3529,3530,3531,3532,3533,3534,3535,3536,3537],{"trials":8726,"activeCount":100},[],{"trials":8728,"activeCount":100},[],{"trials":8730,"activeCount":100},[],{"trials":8732,"activeCount":100},[],{"intervention":3527,"totalTrials":138,"cells":8734},{"EARLY_PHASE1":8735,"PHASE1":8737,"PHASE2":8743,"PHASE3":8745,"PHASE4":8747,"NA":8749},{"trials":8736,"activeCount":100},[],{"trials":8738,"activeCount":100},[8739],{"nctId":3513,"briefTitle":3514,"status":108,"phases":8740,"primaryCompletion":1434,"completion":1434,"start":3516,"enrollment":3517,"conditions":8741,"interventions":8742},[88],[19],[3520,3521,3522,3523,3524,3525,3526,3420,3527,3528,3506,3529,3530,3531,3532,3533,3534,3535,3536,3537],{"trials":8744,"activeCount":100},[],{"trials":8746,"activeCount":100},[],{"trials":8748,"activeCount":100},[],{"trials":8750,"activeCount":100},[],{"intervention":3533,"totalTrials":138,"cells":8752},{"EARLY_PHASE1":8753,"PHASE1":8755,"PHASE2":8761,"PHASE3":8763,"PHASE4":8765,"NA":8767},{"trials":8754,"activeCount":100},[],{"trials":8756,"activeCount":100},[8757],{"nctId":3513,"briefTitle":3514,"status":108,"phases":8758,"primaryCompletion":1434,"completion":1434,"start":3516,"enrollment":3517,"conditions":8759,"interventions":8760},[88],[19],[3520,3521,3522,3523,3524,3525,3526,3420,3527,3528,3506,3529,3530,3531,3532,3533,3534,3535,3536,3537],{"trials":8762,"activeCount":100},[],{"trials":8764,"activeCount":100},[],{"trials":8766,"activeCount":100},[],{"trials":8768,"activeCount":100},[],{"intervention":3534,"totalTrials":138,"cells":8770},{"EARLY_PHASE1":8771,"PHASE1":8773,"PHASE2":8779,"PHASE3":8781,"PHASE4":8783,"NA":8785},{"trials":8772,"activeCount":100},[],{"trials":8774,"activeCount":100},[8775],{"nctId":3513,"briefTitle":3514,"status":108,"phases":8776,"primaryCompletion":1434,"completion":1434,"start":3516,"enrollment":3517,"conditions":8777,"interventions":8778},[88],[19],[3520,3521,3522,3523,3524,3525,3526,3420,3527,3528,3506,3529,3530,3531,3532,3533,3534,3535,3536,3537],{"trials":8780,"activeCount":100},[],{"trials":8782,"activeCount":100},[],{"trials":8784,"activeCount":100},[],{"trials":8786,"activeCount":100},[],{"intervention":3535,"totalTrials":138,"cells":8788},{"EARLY_PHASE1":8789,"PHASE1":8791,"PHASE2":8797,"PHASE3":8799,"PHASE4":8801,"NA":8803},{"trials":8790,"activeCount":100},[],{"trials":8792,"activeCount":100},[8793],{"nctId":3513,"briefTitle":3514,"status":108,"phases":8794,"primaryCompletion":1434,"completion":1434,"start":3516,"enrollment":3517,"conditions":8795,"interventions":8796},[88],[19],[3520,3521,3522,3523,3524,3525,3526,3420,3527,3528,3506,3529,3530,3531,3532,3533,3534,3535,3536,3537],{"trials":8798,"activeCount":100},[],{"trials":8800,"activeCount":100},[],{"trials":8802,"activeCount":100},[],{"trials":8804,"activeCount":100},[],{"intervention":3536,"totalTrials":138,"cells":8806},{"EARLY_PHASE1":8807,"PHASE1":8809,"PHASE2":8815,"PHASE3":8817,"PHASE4":8819,"NA":8821},{"trials":8808,"activeCount":100},[],{"trials":8810,"activeCount":100},[8811],{"nctId":3513,"briefTitle":3514,"status":108,"phases":8812,"primaryCompletion":1434,"completion":1434,"start":3516,"enrollment":3517,"conditions":8813,"interventions":8814},[88],[19],[3520,3521,3522,3523,3524,3525,3526,3420,3527,3528,3506,3529,3530,3531,3532,3533,3534,3535,3536,3537],{"trials":8816,"activeCount":100},[],{"trials":8818,"activeCount":100},[],{"trials":8820,"activeCount":100},[],{"trials":8822,"activeCount":100},[],{"intervention":3537,"totalTrials":138,"cells":8824},{"EARLY_PHASE1":8825,"PHASE1":8827,"PHASE2":8833,"PHASE3":8835,"PHASE4":8837,"NA":8839},{"trials":8826,"activeCount":100},[],{"trials":8828,"activeCount":100},[8829],{"nctId":3513,"briefTitle":3514,"status":108,"phases":8830,"primaryCompletion":1434,"completion":1434,"start":3516,"enrollment":3517,"conditions":8831,"interventions":8832},[88],[19],[3520,3521,3522,3523,3524,3525,3526,3420,3527,3528,3506,3529,3530,3531,3532,3533,3534,3535,3536,3537],{"trials":8834,"activeCount":100},[],{"trials":8836,"activeCount":100},[],{"trials":8838,"activeCount":100},[],{"trials":8840,"activeCount":100},[],{"intervention":8378,"totalTrials":138,"cells":8842},{"EARLY_PHASE1":8843,"PHASE1":8845,"PHASE2":8851,"PHASE3":8853,"PHASE4":8855,"NA":8857},{"trials":8844,"activeCount":100},[],{"trials":8846,"activeCount":100},[8847],{"nctId":8369,"briefTitle":8370,"status":108,"phases":8848,"primaryCompletion":8372,"completion":8372,"start":8373,"enrollment":8374,"conditions":8849,"interventions":8850},[88],[8376],[8378,8379,8362],{"trials":8852,"activeCount":100},[],{"trials":8854,"activeCount":100},[],{"trials":8856,"activeCount":100},[],{"trials":8858,"activeCount":100},[],{"intervention":8379,"totalTrials":138,"cells":8860},{"EARLY_PHASE1":8861,"PHASE1":8863,"PHASE2":8869,"PHASE3":8871,"PHASE4":8873,"NA":8875},{"trials":8862,"activeCount":100},[],{"trials":8864,"activeCount":100},[8865],{"nctId":8369,"briefTitle":8370,"status":108,"phases":8866,"primaryCompletion":8372,"completion":8372,"start":8373,"enrollment":8374,"conditions":8867,"interventions":8868},[88],[8376],[8378,8379,8362],{"trials":8870,"activeCount":100},[],{"trials":8872,"activeCount":100},[],{"trials":8874,"activeCount":100},[],{"trials":8876,"activeCount":100},[],{"intervention":8878,"totalTrials":138,"cells":8879},"Dextroamphetamine",{"EARLY_PHASE1":8880,"PHASE1":8882,"PHASE2":8894,"PHASE3":8896,"PHASE4":8898,"NA":8900},{"trials":8881,"activeCount":100},[],{"trials":8883,"activeCount":100},[8884],{"nctId":8885,"briefTitle":8886,"status":108,"phases":8887,"primaryCompletion":8888,"completion":8888,"start":8889,"enrollment":8890,"conditions":8891,"interventions":8893},"NCT03512171","Decision Making Study in Young and Middle-Aged Adults: Part II",[88],"2018-05-15","2016-03-31",65,[8892],"Healthy Adults",[8878],{"trials":8895,"activeCount":100},[],{"trials":8897,"activeCount":100},[],{"trials":8899,"activeCount":100},[],{"trials":8901,"activeCount":100},[],{"intervention":8903,"totalTrials":138,"cells":8904},"Acuvail",{"EARLY_PHASE1":8905,"PHASE1":8907,"PHASE2":8916,"PHASE3":8918,"PHASE4":8920,"NA":8922},{"trials":8906,"activeCount":100},[],{"trials":8908,"activeCount":100},[8909],{"nctId":8910,"briefTitle":8911,"status":605,"phases":8912,"primaryCompletion":8913,"completion":8913,"start":5514,"enrollment":100,"conditions":8914,"interventions":8915},"NCT01609881","The Role of Prostaglandins in the Progression of Diabetic Retinopathy",[88],"2016-10-19",[1108],[8903],{"trials":8917,"activeCount":100},[],{"trials":8919,"activeCount":100},[],{"trials":8921,"activeCount":100},[],{"trials":8923,"activeCount":100},[],{"intervention":2602,"totalTrials":138,"cells":8925},{"EARLY_PHASE1":8926,"PHASE1":8928,"PHASE2":8934,"PHASE3":8936,"PHASE4":8938,"NA":8940},{"trials":8927,"activeCount":100},[],{"trials":8929,"activeCount":100},[8930],{"nctId":2594,"briefTitle":2595,"status":108,"phases":8931,"primaryCompletion":1434,"completion":1434,"start":2597,"enrollment":2598,"conditions":8932,"interventions":8933},[88],[2253,2186],[2601,2602,2603,2604,2605,2579,2606,2607,2608,2609,2610,2611,2220,2612,2613,2614,2615,2616,2617,2618],{"trials":8935,"activeCount":100},[],{"trials":8937,"activeCount":100},[],{"trials":8939,"activeCount":100},[],{"trials":8941,"activeCount":100},[],{"intervention":2603,"totalTrials":138,"cells":8943},{"EARLY_PHASE1":8944,"PHASE1":8946,"PHASE2":8952,"PHASE3":8954,"PHASE4":8956,"NA":8958},{"trials":8945,"activeCount":100},[],{"trials":8947,"activeCount":100},[8948],{"nctId":2594,"briefTitle":2595,"status":108,"phases":8949,"primaryCompletion":1434,"completion":1434,"start":2597,"enrollment":2598,"conditions":8950,"interventions":8951},[88],[2253,2186],[2601,2602,2603,2604,2605,2579,2606,2607,2608,2609,2610,2611,2220,2612,2613,2614,2615,2616,2617,2618],{"trials":8953,"activeCount":100},[],{"trials":8955,"activeCount":100},[],{"trials":8957,"activeCount":100},[],{"trials":8959,"activeCount":100},[],{"intervention":2604,"totalTrials":138,"cells":8961},{"EARLY_PHASE1":8962,"PHASE1":8964,"PHASE2":8970,"PHASE3":8972,"PHASE4":8974,"NA":8976},{"trials":8963,"activeCount":100},[],{"trials":8965,"activeCount":100},[8966],{"nctId":2594,"briefTitle":2595,"status":108,"phases":8967,"primaryCompletion":1434,"completion":1434,"start":2597,"enrollment":2598,"conditions":8968,"interventions":8969},[88],[2253,2186],[2601,2602,2603,2604,2605,2579,2606,2607,2608,2609,2610,2611,2220,2612,2613,2614,2615,2616,2617,2618],{"trials":8971,"activeCount":100},[],{"trials":8973,"activeCount":100},[],{"trials":8975,"activeCount":100},[],{"trials":8977,"activeCount":100},[],{"intervention":2605,"totalTrials":138,"cells":8979},{"EARLY_PHASE1":8980,"PHASE1":8982,"PHASE2":8988,"PHASE3":8990,"PHASE4":8992,"NA":8994},{"trials":8981,"activeCount":100},[],{"trials":8983,"activeCount":100},[8984],{"nctId":2594,"briefTitle":2595,"status":108,"phases":8985,"primaryCompletion":1434,"completion":1434,"start":2597,"enrollment":2598,"conditions":8986,"interventions":8987},[88],[2253,2186],[2601,2602,2603,2604,2605,2579,2606,2607,2608,2609,2610,2611,2220,2612,2613,2614,2615,2616,2617,2618],{"trials":8989,"activeCount":100},[],{"trials":8991,"activeCount":100},[],{"trials":8993,"activeCount":100},[],{"trials":8995,"activeCount":100},[],{"intervention":2606,"totalTrials":138,"cells":8997},{"EARLY_PHASE1":8998,"PHASE1":9000,"PHASE2":9006,"PHASE3":9008,"PHASE4":9010,"NA":9012},{"trials":8999,"activeCount":100},[],{"trials":9001,"activeCount":100},[9002],{"nctId":2594,"briefTitle":2595,"status":108,"phases":9003,"primaryCompletion":1434,"completion":1434,"start":2597,"enrollment":2598,"conditions":9004,"interventions":9005},[88],[2253,2186],[2601,2602,2603,2604,2605,2579,2606,2607,2608,2609,2610,2611,2220,2612,2613,2614,2615,2616,2617,2618],{"trials":9007,"activeCount":100},[],{"trials":9009,"activeCount":100},[],{"trials":9011,"activeCount":100},[],{"trials":9013,"activeCount":100},[],{"intervention":2607,"totalTrials":138,"cells":9015},{"EARLY_PHASE1":9016,"PHASE1":9018,"PHASE2":9024,"PHASE3":9026,"PHASE4":9028,"NA":9030},{"trials":9017,"activeCount":100},[],{"trials":9019,"activeCount":100},[9020],{"nctId":2594,"briefTitle":2595,"status":108,"phases":9021,"primaryCompletion":1434,"completion":1434,"start":2597,"enrollment":2598,"conditions":9022,"interventions":9023},[88],[2253,2186],[2601,2602,2603,2604,2605,2579,2606,2607,2608,2609,2610,2611,2220,2612,2613,2614,2615,2616,2617,2618],{"trials":9025,"activeCount":100},[],{"trials":9027,"activeCount":100},[],{"trials":9029,"activeCount":100},[],{"trials":9031,"activeCount":100},[],{"intervention":2608,"totalTrials":138,"cells":9033},{"EARLY_PHASE1":9034,"PHASE1":9036,"PHASE2":9042,"PHASE3":9044,"PHASE4":9046,"NA":9048},{"trials":9035,"activeCount":100},[],{"trials":9037,"activeCount":100},[9038],{"nctId":2594,"briefTitle":2595,"status":108,"phases":9039,"primaryCompletion":1434,"completion":1434,"start":2597,"enrollment":2598,"conditions":9040,"interventions":9041},[88],[2253,2186],[2601,2602,2603,2604,2605,2579,2606,2607,2608,2609,2610,2611,2220,2612,2613,2614,2615,2616,2617,2618],{"trials":9043,"activeCount":100},[],{"trials":9045,"activeCount":100},[],{"trials":9047,"activeCount":100},[],{"trials":9049,"activeCount":100},[],{"intervention":2609,"totalTrials":138,"cells":9051},{"EARLY_PHASE1":9052,"PHASE1":9054,"PHASE2":9060,"PHASE3":9062,"PHASE4":9064,"NA":9066},{"trials":9053,"activeCount":100},[],{"trials":9055,"activeCount":100},[9056],{"nctId":2594,"briefTitle":2595,"status":108,"phases":9057,"primaryCompletion":1434,"completion":1434,"start":2597,"enrollment":2598,"conditions":9058,"interventions":9059},[88],[2253,2186],[2601,2602,2603,2604,2605,2579,2606,2607,2608,2609,2610,2611,2220,2612,2613,2614,2615,2616,2617,2618],{"trials":9061,"activeCount":100},[],{"trials":9063,"activeCount":100},[],{"trials":9065,"activeCount":100},[],{"trials":9067,"activeCount":100},[],{"intervention":2610,"totalTrials":138,"cells":9069},{"EARLY_PHASE1":9070,"PHASE1":9072,"PHASE2":9078,"PHASE3":9080,"PHASE4":9082,"NA":9084},{"trials":9071,"activeCount":100},[],{"trials":9073,"activeCount":100},[9074],{"nctId":2594,"briefTitle":2595,"status":108,"phases":9075,"primaryCompletion":1434,"completion":1434,"start":2597,"enrollment":2598,"conditions":9076,"interventions":9077},[88],[2253,2186],[2601,2602,2603,2604,2605,2579,2606,2607,2608,2609,2610,2611,2220,2612,2613,2614,2615,2616,2617,2618],{"trials":9079,"activeCount":100},[],{"trials":9081,"activeCount":100},[],{"trials":9083,"activeCount":100},[],{"trials":9085,"activeCount":100},[],{"intervention":2611,"totalTrials":138,"cells":9087},{"EARLY_PHASE1":9088,"PHASE1":9090,"PHASE2":9096,"PHASE3":9098,"PHASE4":9100,"NA":9102},{"trials":9089,"activeCount":100},[],{"trials":9091,"activeCount":100},[9092],{"nctId":2594,"briefTitle":2595,"status":108,"phases":9093,"primaryCompletion":1434,"completion":1434,"start":2597,"enrollment":2598,"conditions":9094,"interventions":9095},[88],[2253,2186],[2601,2602,2603,2604,2605,2579,2606,2607,2608,2609,2610,2611,2220,2612,2613,2614,2615,2616,2617,2618],{"trials":9097,"activeCount":100},[],{"trials":9099,"activeCount":100},[],{"trials":9101,"activeCount":100},[],{"trials":9103,"activeCount":100},[],{"intervention":2612,"totalTrials":138,"cells":9105},{"EARLY_PHASE1":9106,"PHASE1":9108,"PHASE2":9114,"PHASE3":9116,"PHASE4":9118,"NA":9120},{"trials":9107,"activeCount":100},[],{"trials":9109,"activeCount":100},[9110],{"nctId":2594,"briefTitle":2595,"status":108,"phases":9111,"primaryCompletion":1434,"completion":1434,"start":2597,"enrollment":2598,"conditions":9112,"interventions":9113},[88],[2253,2186],[2601,2602,2603,2604,2605,2579,2606,2607,2608,2609,2610,2611,2220,2612,2613,2614,2615,2616,2617,2618],{"trials":9115,"activeCount":100},[],{"trials":9117,"activeCount":100},[],{"trials":9119,"activeCount":100},[],{"trials":9121,"activeCount":100},[],{"intervention":2613,"totalTrials":138,"cells":9123},{"EARLY_PHASE1":9124,"PHASE1":9126,"PHASE2":9132,"PHASE3":9134,"PHASE4":9136,"NA":9138},{"trials":9125,"activeCount":100},[],{"trials":9127,"activeCount":100},[9128],{"nctId":2594,"briefTitle":2595,"status":108,"phases":9129,"primaryCompletion":1434,"completion":1434,"start":2597,"enrollment":2598,"conditions":9130,"interventions":9131},[88],[2253,2186],[2601,2602,2603,2604,2605,2579,2606,2607,2608,2609,2610,2611,2220,2612,2613,2614,2615,2616,2617,2618],{"trials":9133,"activeCount":100},[],{"trials":9135,"activeCount":100},[],{"trials":9137,"activeCount":100},[],{"trials":9139,"activeCount":100},[],{"intervention":2615,"totalTrials":138,"cells":9141},{"EARLY_PHASE1":9142,"PHASE1":9144,"PHASE2":9150,"PHASE3":9152,"PHASE4":9154,"NA":9156},{"trials":9143,"activeCount":100},[],{"trials":9145,"activeCount":100},[9146],{"nctId":2594,"briefTitle":2595,"status":108,"phases":9147,"primaryCompletion":1434,"completion":1434,"start":2597,"enrollment":2598,"conditions":9148,"interventions":9149},[88],[2253,2186],[2601,2602,2603,2604,2605,2579,2606,2607,2608,2609,2610,2611,2220,2612,2613,2614,2615,2616,2617,2618],{"trials":9151,"activeCount":100},[],{"trials":9153,"activeCount":100},[],{"trials":9155,"activeCount":100},[],{"trials":9157,"activeCount":100},[],{"intervention":2616,"totalTrials":138,"cells":9159},{"EARLY_PHASE1":9160,"PHASE1":9162,"PHASE2":9168,"PHASE3":9170,"PHASE4":9172,"NA":9174},{"trials":9161,"activeCount":100},[],{"trials":9163,"activeCount":100},[9164],{"nctId":2594,"briefTitle":2595,"status":108,"phases":9165,"primaryCompletion":1434,"completion":1434,"start":2597,"enrollment":2598,"conditions":9166,"interventions":9167},[88],[2253,2186],[2601,2602,2603,2604,2605,2579,2606,2607,2608,2609,2610,2611,2220,2612,2613,2614,2615,2616,2617,2618],{"trials":9169,"activeCount":100},[],{"trials":9171,"activeCount":100},[],{"trials":9173,"activeCount":100},[],{"trials":9175,"activeCount":100},[],{"intervention":2617,"totalTrials":138,"cells":9177},{"EARLY_PHASE1":9178,"PHASE1":9180,"PHASE2":9186,"PHASE3":9188,"PHASE4":9190,"NA":9192},{"trials":9179,"activeCount":100},[],{"trials":9181,"activeCount":100},[9182],{"nctId":2594,"briefTitle":2595,"status":108,"phases":9183,"primaryCompletion":1434,"completion":1434,"start":2597,"enrollment":2598,"conditions":9184,"interventions":9185},[88],[2253,2186],[2601,2602,2603,2604,2605,2579,2606,2607,2608,2609,2610,2611,2220,2612,2613,2614,2615,2616,2617,2618],{"trials":9187,"activeCount":100},[],{"trials":9189,"activeCount":100},[],{"trials":9191,"activeCount":100},[],{"trials":9193,"activeCount":100},[],{"intervention":2618,"totalTrials":138,"cells":9195},{"EARLY_PHASE1":9196,"PHASE1":9198,"PHASE2":9204,"PHASE3":9206,"PHASE4":9208,"NA":9210},{"trials":9197,"activeCount":100},[],{"trials":9199,"activeCount":100},[9200],{"nctId":2594,"briefTitle":2595,"status":108,"phases":9201,"primaryCompletion":1434,"completion":1434,"start":2597,"enrollment":2598,"conditions":9202,"interventions":9203},[88],[2253,2186],[2601,2602,2603,2604,2605,2579,2606,2607,2608,2609,2610,2611,2220,2612,2613,2614,2615,2616,2617,2618],{"trials":9205,"activeCount":100},[],{"trials":9207,"activeCount":100},[],{"trials":9209,"activeCount":100},[],{"trials":9211,"activeCount":100},[],{"intervention":9213,"totalTrials":138,"cells":9214},"sapropterin dihydrochloride",{"EARLY_PHASE1":9215,"PHASE1":9217,"PHASE2":9227,"PHASE3":9229,"PHASE4":9231,"NA":9233},{"trials":9216,"activeCount":100},[],{"trials":9218,"activeCount":100},[9219],{"nctId":9220,"briefTitle":9221,"status":108,"phases":9222,"primaryCompletion":9223,"completion":5786,"start":4015,"enrollment":9224,"conditions":9225,"interventions":9226},"NCT00435331","6R-BH4 Pulmonary Arterial Hypertension Study",[88],"2008-09",14,[6871],[9213],{"trials":9228,"activeCount":100},[],{"trials":9230,"activeCount":100},[],{"trials":9232,"activeCount":100},[],{"trials":9234,"activeCount":100},[],{"intervention":9236,"totalTrials":138,"cells":9237},"Angiotensin II",{"EARLY_PHASE1":9238,"PHASE1":9240,"PHASE2":9250,"PHASE3":9252,"PHASE4":9254,"NA":9256},{"trials":9239,"activeCount":100},[],{"trials":9241,"activeCount":100},[9242],{"nctId":9243,"briefTitle":9244,"status":108,"phases":9245,"primaryCompletion":731,"completion":731,"start":9246,"enrollment":1315,"conditions":9247,"interventions":9249},"NCT00962949","The Renin-Aldosterone Axis in Postural Tachycardia Syndrome",[88],"2009-04",[9248],"Postural Orthostatic Tachycardia Syndrome (POTS)",[9236],{"trials":9251,"activeCount":100},[],{"trials":9253,"activeCount":100},[],{"trials":9255,"activeCount":100},[],{"trials":9257,"activeCount":100},[],{"intervention":8387,"totalTrials":138,"cells":9259},{"EARLY_PHASE1":9260,"PHASE1":9262,"PHASE2":9268,"PHASE3":9270,"PHASE4":9272,"NA":9274},{"trials":9261,"activeCount":100},[],{"trials":9263,"activeCount":100},[9264],{"nctId":8381,"briefTitle":8382,"status":605,"phases":9265,"primaryCompletion":8384,"completion":8384,"start":8384,"enrollment":100,"conditions":9266,"interventions":9267},[88],[8376],[8362,8387],{"trials":9269,"activeCount":100},[],{"trials":9271,"activeCount":100},[],{"trials":9273,"activeCount":100},[],{"trials":9275,"activeCount":100},[],{"intervention":9277,"totalTrials":138,"cells":9278},"F-18",{"EARLY_PHASE1":9279,"PHASE1":9281,"PHASE2":9290,"PHASE3":9292,"PHASE4":9294,"NA":9296},{"trials":9280,"activeCount":100},[],{"trials":9282,"activeCount":100},[9283],{"nctId":9284,"briefTitle":9285,"status":108,"phases":9286,"primaryCompletion":4452,"completion":2939,"start":5472,"enrollment":900,"conditions":9287,"interventions":9289},"NCT00801827","PET Imaging and Bariatric Surgery",[88],[9288],"Obesity, Morbid",[9277],{"trials":9291,"activeCount":100},[],{"trials":9293,"activeCount":100},[],{"trials":9295,"activeCount":100},[],{"trials":9297,"activeCount":100},[],{"intervention":687,"totalTrials":138,"cells":9299},{"EARLY_PHASE1":9300,"PHASE1":9302,"PHASE2":9308,"PHASE3":9310,"PHASE4":9312,"NA":9314},{"trials":9301,"activeCount":100},[],{"trials":9303,"activeCount":100},[9304],{"nctId":678,"briefTitle":679,"status":659,"phases":9305,"primaryCompletion":681,"completion":681,"start":682,"enrollment":683,"conditions":9306,"interventions":9307},[88],[25,685],[67,687],{"trials":9309,"activeCount":100},[],{"trials":9311,"activeCount":100},[],{"trials":9313,"activeCount":100},[],{"trials":9315,"activeCount":100},[],{"intervention":9317,"totalTrials":138,"cells":9318},"Nevirapine and Efavirenz",{"EARLY_PHASE1":9319,"PHASE1":9321,"PHASE2":9329,"PHASE3":9331,"PHASE4":9333,"NA":9335},{"trials":9320,"activeCount":100},[],{"trials":9322,"activeCount":100},[9323],{"nctId":9324,"briefTitle":9325,"status":108,"phases":9326,"primaryCompletion":110,"completion":4014,"start":111,"enrollment":664,"conditions":9327,"interventions":9328},"NCT00730223","Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors",[88],[6017],[9317],{"trials":9330,"activeCount":100},[],{"trials":9332,"activeCount":100},[],{"trials":9334,"activeCount":100},[],{"trials":9336,"activeCount":100},[],{"intervention":9338,"totalTrials":138,"cells":9339},"Intravenous L-Citrulline",{"EARLY_PHASE1":9340,"PHASE1":9342,"PHASE2":9351,"PHASE3":9353,"PHASE4":9355,"NA":9357},{"trials":9341,"activeCount":100},[],{"trials":9343,"activeCount":100},[9344],{"nctId":9345,"briefTitle":9346,"status":605,"phases":9347,"primaryCompletion":4014,"completion":4014,"start":2233,"enrollment":100,"conditions":9348,"interventions":9350},"NCT00742534","Phase 1 Intravenous Citrulline for the Prevention of Bronchopulmonary Dysplasia in Preterm Infants",[88],[9349],"Bronchopulmonary Dysplasia",[9338],{"trials":9352,"activeCount":100},[],{"trials":9354,"activeCount":100},[],{"trials":9356,"activeCount":100},[],{"trials":9358,"activeCount":100},[],{"intervention":9360,"totalTrials":138,"cells":9361},"Intravitreal Ketorolac",{"EARLY_PHASE1":9362,"PHASE1":9364,"PHASE2":9372,"PHASE3":9374,"PHASE4":9376,"NA":9378},{"trials":9363,"activeCount":100},[],{"trials":9365,"activeCount":100},[9366],{"nctId":9367,"briefTitle":9368,"status":108,"phases":9369,"primaryCompletion":2977,"completion":2977,"start":4425,"enrollment":2911,"conditions":9370,"interventions":9371},"NCT01164085","Intravitreal Ketorolac for Chronic Uveitis: A Investigational Safety Study",[88],[1108],[9360],{"trials":9373,"activeCount":100},[],{"trials":9375,"activeCount":100},[],{"trials":9377,"activeCount":100},[],{"trials":9379,"activeCount":100},[],{"intervention":9381,"totalTrials":138,"cells":9382},"C-13 labeled Lysine",{"EARLY_PHASE1":9383,"PHASE1":9385,"PHASE2":9396,"PHASE3":9398,"PHASE4":9400,"NA":9402},{"trials":9384,"activeCount":100},[],{"trials":9386,"activeCount":100},[9387],{"nctId":9388,"briefTitle":9389,"status":108,"phases":9390,"primaryCompletion":9391,"completion":9391,"start":9392,"enrollment":531,"conditions":9393,"interventions":9394},"NCT03063476","The Effect of Acute Lysine Administration on α-aminoadipic Acid (Sub-study)",[88],"2017-05-18","2017-03-01",[2333],[9381,9395],"Normal saline",{"trials":9397,"activeCount":100},[],{"trials":9399,"activeCount":100},[],{"trials":9401,"activeCount":100},[],{"trials":9403,"activeCount":100},[],{"intervention":9405,"totalTrials":138,"cells":9406},"intramuscular Botox versus oral baclofen",{"EARLY_PHASE1":9407,"PHASE1":9409,"PHASE2":9417,"PHASE3":9419,"PHASE4":9421,"NA":9423},{"trials":9408,"activeCount":100},[],{"trials":9410,"activeCount":100},[9411],{"nctId":9412,"briefTitle":9413,"status":659,"phases":9414,"primaryCompletion":3972,"completion":3972,"start":132,"enrollment":2150,"conditions":9415,"interventions":9416},"NCT00280280","Botox vs. Baclofen for Upper Limb Spasticity",[88],[135],[9405],{"trials":9418,"activeCount":100},[],{"trials":9420,"activeCount":100},[],{"trials":9422,"activeCount":100},[],{"trials":9424,"activeCount":100},[],{"intervention":9426,"totalTrials":138,"cells":9427},"Ga-EC2115",{"EARLY_PHASE1":9428,"PHASE1":9430,"PHASE2":9442,"PHASE3":9444,"PHASE4":9446,"NA":9448},{"trials":9429,"activeCount":100},[],{"trials":9431,"activeCount":100},[9432],{"nctId":9433,"briefTitle":9434,"status":659,"phases":9435,"primaryCompletion":9436,"completion":9437,"start":9438,"enrollment":5629,"conditions":9439,"interventions":9441},"NCT03494114","Imaging Activated Macrophages in the Lungs",[88],"2019-11-20","2021-01-13","2018-11-29",[9440],"COPD",[9426],{"trials":9443,"activeCount":100},[],{"trials":9445,"activeCount":100},[],{"trials":9447,"activeCount":100},[],{"trials":9449,"activeCount":100},[],{"intervention":928,"totalTrials":138,"cells":9451},{"EARLY_PHASE1":9452,"PHASE1":9454,"PHASE2":9460,"PHASE3":9462,"PHASE4":9464,"NA":9466},{"trials":9453,"activeCount":100},[],{"trials":9455,"activeCount":100},[9456],{"nctId":920,"briefTitle":921,"status":605,"phases":9457,"primaryCompletion":923,"completion":923,"start":924,"enrollment":100,"conditions":9458,"interventions":9459},[88],[19,903,926],[928,928,929,928,891],{"trials":9461,"activeCount":100},[],{"trials":9463,"activeCount":100},[],{"trials":9465,"activeCount":100},[],{"trials":9467,"activeCount":100},[],{"intervention":9469,"totalTrials":138,"cells":9470},"Cetuximab",{"EARLY_PHASE1":9471,"PHASE1":9473,"PHASE2":9485,"PHASE3":9487,"PHASE4":9489,"NA":9491},{"trials":9472,"activeCount":100},[],{"trials":9474,"activeCount":100},[9475],{"nctId":9476,"briefTitle":9477,"status":108,"phases":9478,"primaryCompletion":2115,"completion":2115,"start":9479,"enrollment":9480,"conditions":9481,"interventions":9484},"NCT00477880","Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer",[88],"2001-04",9,[9482,9483],"Gastric Cancer","Precancerous Condition",[9469],{"trials":9486,"activeCount":100},[],{"trials":9488,"activeCount":100},[],{"trials":9490,"activeCount":100},[],{"trials":9492,"activeCount":100},[],{"intervention":9494,"totalTrials":138,"cells":9495},"Benzocaine Infusion into Duodenum",{"EARLY_PHASE1":9496,"PHASE1":9498,"PHASE2":9509,"PHASE3":9511,"PHASE4":9513,"NA":9515},{"trials":9497,"activeCount":100},[],{"trials":9499,"activeCount":100},[9500],{"nctId":9501,"briefTitle":9502,"status":108,"phases":9503,"primaryCompletion":9504,"completion":9504,"start":9505,"enrollment":2116,"conditions":9506,"interventions":9508},"NCT01694004","Nutrient Sensing in the Duodenum",[88],"2014-10-27","2012-11",[9507],"The Effect of LCFA on Nutrient Absorption",[9494],{"trials":9510,"activeCount":100},[],{"trials":9512,"activeCount":100},[],{"trials":9514,"activeCount":100},[],{"trials":9516,"activeCount":100},[],{"intervention":8196,"totalTrials":138,"cells":9518},{"EARLY_PHASE1":9519,"PHASE1":9521,"PHASE2":9527,"PHASE3":9529,"PHASE4":9531,"NA":9533},{"trials":9520,"activeCount":100},[],{"trials":9522,"activeCount":100},[9523],{"nctId":8189,"briefTitle":8190,"status":659,"phases":9524,"primaryCompletion":1434,"completion":1434,"start":8192,"enrollment":5629,"conditions":9525,"interventions":9526},[88],[8194],[2323,8196],{"trials":9528,"activeCount":100},[],{"trials":9530,"activeCount":100},[],{"trials":9532,"activeCount":100},[],{"trials":9534,"activeCount":100},[],{"intervention":9536,"totalTrials":138,"cells":9537},"HOE-140",{"EARLY_PHASE1":9538,"PHASE1":9540,"PHASE2":9550,"PHASE3":9552,"PHASE4":9554,"NA":9556},{"trials":9539,"activeCount":100},[],{"trials":9541,"activeCount":100},[9542],{"nctId":9543,"briefTitle":9544,"status":659,"phases":9545,"primaryCompletion":8228,"completion":4196,"start":9546,"enrollment":5629,"conditions":9547,"interventions":9549},"NCT00517582","Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema",[88],"2007-09",[9548],"Angioneurotic Edema",[9536],{"trials":9551,"activeCount":100},[],{"trials":9553,"activeCount":100},[],{"trials":9555,"activeCount":100},[],{"trials":9557,"activeCount":100},[],{"intervention":8442,"totalTrials":138,"cells":9559},{"EARLY_PHASE1":9560,"PHASE1":9562,"PHASE2":9568,"PHASE3":9570,"PHASE4":9572,"NA":9574},{"trials":9561,"activeCount":100},[],{"trials":9563,"activeCount":100},[9564],{"nctId":8434,"briefTitle":8435,"status":108,"phases":9565,"primaryCompletion":8437,"completion":8437,"start":8438,"enrollment":5629,"conditions":9566,"interventions":9567},[88],[2333,8440],[8419,8442],{"trials":9569,"activeCount":100},[],{"trials":9571,"activeCount":100},[],{"trials":9573,"activeCount":100},[],{"trials":9575,"activeCount":100},[],{"intervention":9577,"totalTrials":138,"cells":9578},"Polyethylene glycol",{"EARLY_PHASE1":9579,"PHASE1":9581,"PHASE2":9593,"PHASE3":9595,"PHASE4":9597,"NA":9599},{"trials":9580,"activeCount":100},[],{"trials":9582,"activeCount":100},[9583],{"nctId":9584,"briefTitle":9585,"status":108,"phases":9586,"primaryCompletion":9587,"completion":9587,"start":9588,"enrollment":9589,"conditions":9590,"interventions":9592},"NCT02359825","Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function",[88],"2026-05-21","2019-09-19",45,[9591],"Peripheral Nerve Injury",[9577],{"trials":9594,"activeCount":100},[],{"trials":9596,"activeCount":100},[],{"trials":9598,"activeCount":100},[],{"trials":9600,"activeCount":100},[],{"intervention":9602,"totalTrials":138,"cells":9603},"Glutamine",{"EARLY_PHASE1":9604,"PHASE1":9606,"PHASE2":9617,"PHASE3":9619,"PHASE4":9621,"NA":9623},{"trials":9605,"activeCount":100},[],{"trials":9607,"activeCount":100},[9608],{"nctId":9609,"briefTitle":9610,"status":108,"phases":9611,"primaryCompletion":6400,"completion":9612,"start":9613,"enrollment":461,"conditions":9614,"interventions":9616},"NCT04388371","Glutamine PET Imaging in LAM",[88],"2021-08-10","2019-10-18",[9615],"Lymphangioleiomyomatosis (LAM)",[9602],{"trials":9618,"activeCount":100},[],{"trials":9620,"activeCount":100},[],{"trials":9622,"activeCount":100},[],{"trials":9624,"activeCount":100},[],{"intervention":9626,"totalTrials":138,"cells":9627},"Insulin Glargine 0.5 u\u002Fkg body wt SC",{"EARLY_PHASE1":9628,"PHASE1":9630,"PHASE2":9641,"PHASE3":9643,"PHASE4":9645,"NA":9647},{"trials":9629,"activeCount":100},[],{"trials":9631,"activeCount":100},[9632],{"nctId":9633,"briefTitle":9634,"status":108,"phases":9635,"primaryCompletion":5334,"completion":2176,"start":4426,"enrollment":29,"conditions":9636,"interventions":9637},"NCT00574912","Characteristics of Glargine in Type 2 Diabetics",[88],[34],[9626,9638,9639,9640],"Insulin Glargine 1.0 u\u002Fkg body wt SC","Insulin Glargine 1.5 u\u002Fkg body wt SC","Insulin Glargine 2.0 u\u002Fkg body wt SC",{"trials":9642,"activeCount":100},[],{"trials":9644,"activeCount":100},[],{"trials":9646,"activeCount":100},[],{"trials":9648,"activeCount":100},[],{"intervention":9638,"totalTrials":138,"cells":9650},{"EARLY_PHASE1":9651,"PHASE1":9653,"PHASE2":9659,"PHASE3":9661,"PHASE4":9663,"NA":9665},{"trials":9652,"activeCount":100},[],{"trials":9654,"activeCount":100},[9655],{"nctId":9633,"briefTitle":9634,"status":108,"phases":9656,"primaryCompletion":5334,"completion":2176,"start":4426,"enrollment":29,"conditions":9657,"interventions":9658},[88],[34],[9626,9638,9639,9640],{"trials":9660,"activeCount":100},[],{"trials":9662,"activeCount":100},[],{"trials":9664,"activeCount":100},[],{"trials":9666,"activeCount":100},[],{"intervention":9639,"totalTrials":138,"cells":9668},{"EARLY_PHASE1":9669,"PHASE1":9671,"PHASE2":9677,"PHASE3":9679,"PHASE4":9681,"NA":9683},{"trials":9670,"activeCount":100},[],{"trials":9672,"activeCount":100},[9673],{"nctId":9633,"briefTitle":9634,"status":108,"phases":9674,"primaryCompletion":5334,"completion":2176,"start":4426,"enrollment":29,"conditions":9675,"interventions":9676},[88],[34],[9626,9638,9639,9640],{"trials":9678,"activeCount":100},[],{"trials":9680,"activeCount":100},[],{"trials":9682,"activeCount":100},[],{"trials":9684,"activeCount":100},[],{"intervention":9640,"totalTrials":138,"cells":9686},{"EARLY_PHASE1":9687,"PHASE1":9689,"PHASE2":9695,"PHASE3":9697,"PHASE4":9699,"NA":9701},{"trials":9688,"activeCount":100},[],{"trials":9690,"activeCount":100},[9691],{"nctId":9633,"briefTitle":9634,"status":108,"phases":9692,"primaryCompletion":5334,"completion":2176,"start":4426,"enrollment":29,"conditions":9693,"interventions":9694},[88],[34],[9626,9638,9639,9640],{"trials":9696,"activeCount":100},[],{"trials":9698,"activeCount":100},[],{"trials":9700,"activeCount":100},[],{"trials":9702,"activeCount":100},[],{"intervention":2207,"totalTrials":138,"cells":9704},{"EARLY_PHASE1":9705,"PHASE1":9707,"PHASE2":9713,"PHASE3":9715,"PHASE4":9717,"NA":9719},{"trials":9706,"activeCount":100},[],{"trials":9708,"activeCount":100},[9709],{"nctId":2199,"briefTitle":2200,"status":659,"phases":9710,"primaryCompletion":2202,"completion":2202,"start":2203,"enrollment":1172,"conditions":9711,"interventions":9712},[88],[19,2205],[2207,2149,565],{"trials":9714,"activeCount":100},[],{"trials":9716,"activeCount":100},[],{"trials":9718,"activeCount":100},[],{"trials":9720,"activeCount":100},[],{"intervention":9722,"totalTrials":138,"cells":9723},"phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine",{"EARLY_PHASE1":9724,"PHASE1":9726,"PHASE2":9736,"PHASE3":9738,"PHASE4":9740,"NA":9742},{"trials":9725,"activeCount":100},[],{"trials":9727,"activeCount":100},[9728],{"nctId":9729,"briefTitle":9730,"status":108,"phases":9731,"primaryCompletion":5580,"completion":5580,"start":9732,"enrollment":2911,"conditions":9733,"interventions":9734},"NCT00748059","The Pathophysiology of Orthostatic Hypotension",[88],"1996-12",[2995,2186,6493,2996],[9722,9735],"clonidine,yohimbine,metoclopramide,alpha-methyldopa",{"trials":9737,"activeCount":100},[],{"trials":9739,"activeCount":100},[],{"trials":9741,"activeCount":100},[],{"trials":9743,"activeCount":100},[],{"intervention":9735,"totalTrials":138,"cells":9745},{"EARLY_PHASE1":9746,"PHASE1":9748,"PHASE2":9754,"PHASE3":9756,"PHASE4":9758,"NA":9760},{"trials":9747,"activeCount":100},[],{"trials":9749,"activeCount":100},[9750],{"nctId":9729,"briefTitle":9730,"status":108,"phases":9751,"primaryCompletion":5580,"completion":5580,"start":9732,"enrollment":2911,"conditions":9752,"interventions":9753},[88],[2995,2186,6493,2996],[9722,9735],{"trials":9755,"activeCount":100},[],{"trials":9757,"activeCount":100},[],{"trials":9759,"activeCount":100},[],{"trials":9761,"activeCount":100},[],{"intervention":9763,"totalTrials":138,"cells":9764},"Ghrelin infusion to assess effects on insulin sensitivity",{"EARLY_PHASE1":9765,"PHASE1":9767,"PHASE2":9777,"PHASE3":9779,"PHASE4":9781,"NA":9783},{"trials":9766,"activeCount":100},[],{"trials":9768,"activeCount":100},[9769],{"nctId":9770,"briefTitle":9771,"status":108,"phases":9772,"primaryCompletion":9773,"completion":9773,"start":663,"enrollment":29,"conditions":9774,"interventions":9776},"NCT00884494","Ghrelin and Insulin Resistance",[88],"2014-05",[16,916,9775],"Normal Weight,Healthy Controls",[9763],{"trials":9778,"activeCount":100},[],{"trials":9780,"activeCount":100},[],{"trials":9782,"activeCount":100},[],{"trials":9784,"activeCount":100},[],{"intervention":9786,"totalTrials":138,"cells":9787},"Hyperinsulinemic, euglycemic clamp",{"EARLY_PHASE1":9788,"PHASE1":9790,"PHASE2":9802,"PHASE3":9804,"PHASE4":9806,"NA":9808},{"trials":9789,"activeCount":100},[],{"trials":9791,"activeCount":100},[9792],{"nctId":9793,"briefTitle":9794,"status":108,"phases":9795,"primaryCompletion":9796,"completion":9796,"start":695,"enrollment":664,"conditions":9797,"interventions":9800},"NCT02971202","Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)",[88],"2019-02",[2798,9798,9799,916],"Maturity-Onset Diabetes of the Young, Type 2","MODY2",[9786,9801],"20% dextrose",{"trials":9803,"activeCount":100},[],{"trials":9805,"activeCount":100},[],{"trials":9807,"activeCount":100},[],{"trials":9809,"activeCount":100},[],{"intervention":9801,"totalTrials":138,"cells":9811},{"EARLY_PHASE1":9812,"PHASE1":9814,"PHASE2":9820,"PHASE3":9822,"PHASE4":9824,"NA":9826},{"trials":9813,"activeCount":100},[],{"trials":9815,"activeCount":100},[9816],{"nctId":9793,"briefTitle":9794,"status":108,"phases":9817,"primaryCompletion":9796,"completion":9796,"start":695,"enrollment":664,"conditions":9818,"interventions":9819},[88],[2798,9798,9799,916],[9786,9801],{"trials":9821,"activeCount":100},[],{"trials":9823,"activeCount":100},[],{"trials":9825,"activeCount":100},[],{"trials":9827,"activeCount":100},[],{"intervention":9829,"totalTrials":138,"cells":9830},"levaquin; ethambutol; rifampin and azithromycin.",{"EARLY_PHASE1":9831,"PHASE1":9833,"PHASE2":9844,"PHASE3":9846,"PHASE4":9848,"NA":9850},{"trials":9832,"activeCount":100},[],{"trials":9834,"activeCount":100},[9835],{"nctId":9836,"briefTitle":9837,"status":108,"phases":9838,"primaryCompletion":9839,"completion":9839,"start":3442,"enrollment":2514,"conditions":9840,"interventions":9843},"NCT01169038","Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis",[88],"2010-11",[9841,9842],"Pulmonary Sarcoidosis","Lung Function",[9829],{"trials":9845,"activeCount":100},[],{"trials":9847,"activeCount":100},[],{"trials":9849,"activeCount":100},[],{"trials":9851,"activeCount":100},[],{"intervention":9853,"totalTrials":138,"cells":9854},"Intravitreal Celecoxib",{"EARLY_PHASE1":9855,"PHASE1":9857,"PHASE2":9866,"PHASE3":9868,"PHASE4":9870,"NA":9872},{"trials":9856,"activeCount":100},[],{"trials":9858,"activeCount":100},[9859],{"nctId":9860,"briefTitle":9861,"status":659,"phases":9862,"primaryCompletion":9863,"completion":9863,"start":1062,"enrollment":2239,"conditions":9864,"interventions":9865},"NCT02131012","Intravitreal Celecoxib for Chronic Uveitis",[88],"2016-11-01",[1108],[9853],{"trials":9867,"activeCount":100},[],{"trials":9869,"activeCount":100},[],{"trials":9871,"activeCount":100},[],{"trials":9873,"activeCount":100},[],{"intervention":9875,"totalTrials":138,"cells":9876},"L-NMMA trimethaphan",{"EARLY_PHASE1":9877,"PHASE1":9879,"PHASE2":9889,"PHASE3":9891,"PHASE4":9893,"NA":9895},{"trials":9878,"activeCount":100},[],{"trials":9880,"activeCount":100},[9881],{"nctId":9882,"briefTitle":9883,"status":108,"phases":9884,"primaryCompletion":1434,"completion":1434,"start":949,"enrollment":356,"conditions":9885,"interventions":9887},"NCT00580619","Autonomic Nervous System and Chronic Fatigue Syndrome",[88],[9886,2996,37],"Chronic Fatigue Syndrome",[9875,9888],"methyldopa",{"trials":9890,"activeCount":100},[],{"trials":9892,"activeCount":100},[],{"trials":9894,"activeCount":100},[],{"trials":9896,"activeCount":100},[],{"intervention":9888,"totalTrials":138,"cells":9898},{"EARLY_PHASE1":9899,"PHASE1":9901,"PHASE2":9907,"PHASE3":9909,"PHASE4":9911,"NA":9913},{"trials":9900,"activeCount":100},[],{"trials":9902,"activeCount":100},[9903],{"nctId":9882,"briefTitle":9883,"status":108,"phases":9904,"primaryCompletion":1434,"completion":1434,"start":949,"enrollment":356,"conditions":9905,"interventions":9906},[88],[9886,2996,37],[9875,9888],{"trials":9908,"activeCount":100},[],{"trials":9910,"activeCount":100},[],{"trials":9912,"activeCount":100},[],{"trials":9914,"activeCount":100},[],{"intervention":9916,"totalTrials":138,"cells":9917},"aspirin and meloxicam",{"EARLY_PHASE1":9918,"PHASE1":9920,"PHASE2":9930,"PHASE3":9932,"PHASE4":9934,"NA":9936},{"trials":9919,"activeCount":100},[],{"trials":9921,"activeCount":100},[9922],{"nctId":9923,"briefTitle":9924,"status":108,"phases":9925,"primaryCompletion":9926,"completion":9926,"start":3444,"enrollment":937,"conditions":9927,"interventions":9929},"NCT00731302","Aspirin Resistance in Systemic Lupus Erythematosus (SLE)",[88],"2017-04",[9928],"Systemic Lupus Erythematosus",[9916],{"trials":9931,"activeCount":100},[],{"trials":9933,"activeCount":100},[],{"trials":9935,"activeCount":100},[],{"trials":9937,"activeCount":100},[],{"intervention":9939,"totalTrials":138,"cells":9940},"enteric-coated aspirin",{"EARLY_PHASE1":9941,"PHASE1":9952,"PHASE2":9954,"PHASE3":9956,"PHASE4":9958,"NA":9960},{"trials":9942,"activeCount":100},[9943],{"nctId":9944,"briefTitle":9945,"status":108,"phases":9946,"primaryCompletion":663,"completion":4979,"start":9947,"enrollment":9948,"conditions":9949,"interventions":9950},"NCT00753935","Aspirin Resistance in Coronary Artery Disease",[87],"2006-06",92,[3754],[9939,9951],"Chewable aspirin",{"trials":9953,"activeCount":100},[],{"trials":9955,"activeCount":100},[],{"trials":9957,"activeCount":100},[],{"trials":9959,"activeCount":100},[],{"trials":9961,"activeCount":100},[],{"intervention":9951,"totalTrials":138,"cells":9963},{"EARLY_PHASE1":9964,"PHASE1":9970,"PHASE2":9972,"PHASE3":9974,"PHASE4":9976,"NA":9978},{"trials":9965,"activeCount":100},[9966],{"nctId":9944,"briefTitle":9945,"status":108,"phases":9967,"primaryCompletion":663,"completion":4979,"start":9947,"enrollment":9948,"conditions":9968,"interventions":9969},[87],[3754],[9939,9951],{"trials":9971,"activeCount":100},[],{"trials":9973,"activeCount":100},[],{"trials":9975,"activeCount":100},[],{"trials":9977,"activeCount":100},[],{"trials":9979,"activeCount":100},[],{"intervention":9981,"totalTrials":138,"cells":9982},"Donor Blood",{"EARLY_PHASE1":9983,"PHASE1":9994,"PHASE2":9996,"PHASE3":9998,"PHASE4":10000,"NA":10002},{"trials":9984,"activeCount":100},[9985],{"nctId":9986,"briefTitle":9987,"status":605,"phases":9988,"primaryCompletion":7140,"completion":7140,"start":5580,"enrollment":100,"conditions":9989,"interventions":9992},"NCT04383756","Utilization of Donor Whole Blood for Blood Transfusion in Deceased Donor Liver Transplantation",[87],[9990,9991],"Transfusion Related Complication","Liver Transplant",[9981,9993],"Banked Blood",{"trials":9995,"activeCount":100},[],{"trials":9997,"activeCount":100},[],{"trials":9999,"activeCount":100},[],{"trials":10001,"activeCount":100},[],{"trials":10003,"activeCount":100},[],{"intervention":9993,"totalTrials":138,"cells":10005},{"EARLY_PHASE1":10006,"PHASE1":10012,"PHASE2":10014,"PHASE3":10016,"PHASE4":10018,"NA":10020},{"trials":10007,"activeCount":100},[10008],{"nctId":9986,"briefTitle":9987,"status":605,"phases":10009,"primaryCompletion":7140,"completion":7140,"start":5580,"enrollment":100,"conditions":10010,"interventions":10011},[87],[9990,9991],[9981,9993],{"trials":10013,"activeCount":100},[],{"trials":10015,"activeCount":100},[],{"trials":10017,"activeCount":100},[],{"trials":10019,"activeCount":100},[],{"trials":10021,"activeCount":100},[],{"intervention":10023,"totalTrials":138,"cells":10024},"Misoprostol - buccal",{"EARLY_PHASE1":10025,"PHASE1":10036,"PHASE2":10038,"PHASE3":10040,"PHASE4":10042,"NA":10044},{"trials":10026,"activeCount":100},[10027],{"nctId":10028,"briefTitle":10029,"status":108,"phases":10030,"primaryCompletion":8296,"completion":10031,"start":7753,"enrollment":2514,"conditions":10032,"interventions":10034},"NCT02259309","Immune Modulation by Misoprostol",[87],"2015-11",[10033],"Gynecological Infection",[10023,10035],"Misoprostol - vaginal",{"trials":10037,"activeCount":100},[],{"trials":10039,"activeCount":100},[],{"trials":10041,"activeCount":100},[],{"trials":10043,"activeCount":100},[],{"trials":10045,"activeCount":100},[],{"intervention":10035,"totalTrials":138,"cells":10047},{"EARLY_PHASE1":10048,"PHASE1":10054,"PHASE2":10056,"PHASE3":10058,"PHASE4":10060,"NA":10062},{"trials":10049,"activeCount":100},[10050],{"nctId":10028,"briefTitle":10029,"status":108,"phases":10051,"primaryCompletion":8296,"completion":10031,"start":7753,"enrollment":2514,"conditions":10052,"interventions":10053},[87],[10033],[10023,10035],{"trials":10055,"activeCount":100},[],{"trials":10057,"activeCount":100},[],{"trials":10059,"activeCount":100},[],{"trials":10061,"activeCount":100},[],{"trials":10063,"activeCount":100},[],{"intervention":10065,"totalTrials":138,"cells":10066},"methyl-D9-choline",{"EARLY_PHASE1":10067,"PHASE1":10078,"PHASE2":10080,"PHASE3":10082,"PHASE4":10084,"NA":10086},{"trials":10068,"activeCount":100},[10069],{"nctId":10070,"briefTitle":10071,"status":605,"phases":10072,"primaryCompletion":10073,"completion":10074,"start":1413,"enrollment":100,"conditions":10075,"interventions":10077},"NCT01807910","ER Stress in NAFLD",[87],"2017-10","2018-04",[16,10076],"NAFLD",[10065],{"trials":10079,"activeCount":100},[],{"trials":10081,"activeCount":100},[],{"trials":10083,"activeCount":100},[],{"trials":10085,"activeCount":100},[],{"trials":10087,"activeCount":100},[],{"intervention":10089,"totalTrials":138,"cells":10090},"Amitriptyline",{"EARLY_PHASE1":10091,"PHASE1":10102,"PHASE2":10104,"PHASE3":10106,"PHASE4":10108,"NA":10110},{"trials":10092,"activeCount":100},[10093],{"nctId":10094,"briefTitle":10095,"status":605,"phases":10096,"primaryCompletion":10097,"completion":10097,"start":10098,"enrollment":100,"conditions":10099,"interventions":10101},"NCT06417684","Comparison of Amitriptyline to Lifestyle Modification as Intervention for Vestibular Migraine",[87],"2026-03-11","2024-06-19",[10100],"Vestibular Migraine",[10089],{"trials":10103,"activeCount":100},[],{"trials":10105,"activeCount":100},[],{"trials":10107,"activeCount":100},[],{"trials":10109,"activeCount":100},[],{"trials":10111,"activeCount":100},[],{"intervention":10113,"totalTrials":138,"cells":10114},"Cyproheptadine Oral",{"EARLY_PHASE1":10115,"PHASE1":10126,"PHASE2":10128,"PHASE3":10130,"PHASE4":10132,"NA":10134},{"trials":10116,"activeCount":100},[10117],{"nctId":10118,"briefTitle":10119,"status":108,"phases":10120,"primaryCompletion":10121,"completion":10121,"start":10122,"enrollment":1773,"conditions":10123,"interventions":10125},"NCT03593811","Noninvasive Markers of Functional Nausea in Children",[87],"2021-04-02","2018-08-03",[10124],"Nausea",[3081,10113],{"trials":10127,"activeCount":100},[],{"trials":10129,"activeCount":100},[],{"trials":10131,"activeCount":100},[],{"trials":10133,"activeCount":100},[],{"trials":10135,"activeCount":100},[],{"intervention":10137,"totalTrials":138,"cells":10138},"INOmax Inhalation",{"EARLY_PHASE1":10139,"PHASE1":10150,"PHASE2":10152,"PHASE3":10154,"PHASE4":10156,"NA":10158},{"trials":10140,"activeCount":100},[10141],{"nctId":10142,"briefTitle":10143,"status":108,"phases":10144,"primaryCompletion":10145,"completion":10145,"start":10146,"enrollment":35,"conditions":10147,"interventions":10149},"NCT02220023","Dynamic Assessment of Right Ventricular Function With Inhaled Nitric Oxide During Cardiac MRI",[87],"2017-02","2014-07",[10148],"Pulmonary Vascular Disorder",[10137],{"trials":10151,"activeCount":100},[],{"trials":10153,"activeCount":100},[],{"trials":10155,"activeCount":100},[],{"trials":10157,"activeCount":100},[],{"trials":10159,"activeCount":100},[],{"intervention":10161,"totalTrials":138,"cells":10162},"Nesiritide",{"EARLY_PHASE1":10163,"PHASE1":10173,"PHASE2":10175,"PHASE3":10177,"PHASE4":10179,"NA":10181},{"trials":10164,"activeCount":100},[10165],{"nctId":10166,"briefTitle":10167,"status":605,"phases":10168,"primaryCompletion":10145,"completion":10145,"enrollment":100,"conditions":10169,"interventions":10171},"NCT02642523","Natriuretic Peptides and Metabolic Risk in Obesity",[87],[16,10170],"Hyperinsulinemia",[10161,10172],"Insulin",{"trials":10174,"activeCount":100},[],{"trials":10176,"activeCount":100},[],{"trials":10178,"activeCount":100},[],{"trials":10180,"activeCount":100},[],{"trials":10182,"activeCount":100},[],{"intervention":10184,"totalTrials":138,"cells":10185},"CREON",{"EARLY_PHASE1":10186,"PHASE1":10196,"PHASE2":10198,"PHASE3":10200,"PHASE4":10202,"NA":10204},{"trials":10187,"activeCount":100},[10188],{"nctId":10189,"briefTitle":10190,"status":108,"phases":10191,"primaryCompletion":10192,"completion":10192,"start":10193,"enrollment":624,"conditions":10194,"interventions":10195},"NCT05266963","Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes",[87],"2024-03-22","2022-09-02",[1174],[10184],{"trials":10197,"activeCount":100},[],{"trials":10199,"activeCount":100},[],{"trials":10201,"activeCount":100},[],{"trials":10203,"activeCount":100},[],{"trials":10205,"activeCount":100},[],{"intervention":10207,"totalTrials":138,"cells":10208},"sodium citrate",{"EARLY_PHASE1":10209,"PHASE1":10218,"PHASE2":10220,"PHASE3":10222,"PHASE4":10224,"NA":10226},{"trials":10210,"activeCount":100},[10211],{"nctId":10212,"briefTitle":10213,"status":108,"phases":10214,"primaryCompletion":1062,"completion":1062,"start":2176,"enrollment":531,"conditions":10215,"interventions":10217},"NCT00968565","Study Using Citrate to Replace Heparin in Babies Requiring Extracorporeal Membrane Oxygenation (ECMO)",[87],[6840,10216],"Respiratory Insufficiency",[10207],{"trials":10219,"activeCount":100},[],{"trials":10221,"activeCount":100},[],{"trials":10223,"activeCount":100},[],{"trials":10225,"activeCount":100},[],{"trials":10227,"activeCount":100},[],{"intervention":10229,"totalTrials":138,"cells":10230},"Aspirin 325 mg daily",{"EARLY_PHASE1":10231,"PHASE1":10242,"PHASE2":10244,"PHASE3":10246,"PHASE4":10248,"NA":10250},{"trials":10232,"activeCount":100},[10233],{"nctId":10234,"briefTitle":10235,"status":108,"phases":10236,"primaryCompletion":662,"completion":662,"start":10237,"enrollment":683,"conditions":10238,"interventions":10240},"NCT01796951","Low Dose Aspirin Inhibition of COX-2 Derived PGE2 in Male Smokers",[87],"2013-02",[1374,10239],"Smoking",[10229,10241],"Celecoxib 200 mg BID",{"trials":10243,"activeCount":100},[],{"trials":10245,"activeCount":100},[],{"trials":10247,"activeCount":100},[],{"trials":10249,"activeCount":100},[],{"trials":10251,"activeCount":100},[],{"intervention":10241,"totalTrials":138,"cells":10253},{"EARLY_PHASE1":10254,"PHASE1":10260,"PHASE2":10262,"PHASE3":10264,"PHASE4":10266,"NA":10268},{"trials":10255,"activeCount":100},[10256],{"nctId":10234,"briefTitle":10235,"status":108,"phases":10257,"primaryCompletion":662,"completion":662,"start":10237,"enrollment":683,"conditions":10258,"interventions":10259},[87],[1374,10239],[10229,10241],{"trials":10261,"activeCount":100},[],{"trials":10263,"activeCount":100},[],{"trials":10265,"activeCount":100},[],{"trials":10267,"activeCount":100},[],{"trials":10269,"activeCount":100},[],{"intervention":10271,"totalTrials":138,"cells":10272},"Pseudoephedrine + 480 ml water",{"EARLY_PHASE1":10273,"PHASE1":10282,"PHASE2":10284,"PHASE3":10286,"PHASE4":10288,"NA":10290},{"trials":10274,"activeCount":100},[10275],{"nctId":10276,"briefTitle":10277,"status":659,"phases":10278,"primaryCompletion":5580,"completion":5580,"start":2587,"enrollment":6882,"conditions":10279,"interventions":10280},"NCT02149901","Water and Sudafed in Autonomic Failure",[87],[904,926],[10271,10281],"Pseudoephedrine + 50 ml water",{"trials":10283,"activeCount":100},[],{"trials":10285,"activeCount":100},[],{"trials":10287,"activeCount":100},[],{"trials":10289,"activeCount":100},[],{"trials":10291,"activeCount":100},[],{"intervention":10281,"totalTrials":138,"cells":10293},{"EARLY_PHASE1":10294,"PHASE1":10300,"PHASE2":10302,"PHASE3":10304,"PHASE4":10306,"NA":10308},{"trials":10295,"activeCount":100},[10296],{"nctId":10276,"briefTitle":10277,"status":659,"phases":10297,"primaryCompletion":5580,"completion":5580,"start":2587,"enrollment":6882,"conditions":10298,"interventions":10299},[87],[904,926],[10271,10281],{"trials":10301,"activeCount":100},[],{"trials":10303,"activeCount":100},[],{"trials":10305,"activeCount":100},[],{"trials":10307,"activeCount":100},[],{"trials":10309,"activeCount":100},[],{"intervention":10311,"totalTrials":138,"cells":10312},"Iloprost",{"EARLY_PHASE1":10313,"PHASE1":10322,"PHASE2":10324,"PHASE3":10326,"PHASE4":10328,"NA":10330},{"trials":10314,"activeCount":100},[10315],{"nctId":10316,"briefTitle":10317,"status":108,"phases":10318,"primaryCompletion":10319,"completion":10319,"start":2115,"enrollment":1172,"conditions":10320,"interventions":10321},"NCT01209533","Inhaled Iloprost in Mild Asthma",[87],"2011-07",[2056],[10311],{"trials":10323,"activeCount":100},[],{"trials":10325,"activeCount":100},[],{"trials":10327,"activeCount":100},[],{"trials":10329,"activeCount":100},[],{"trials":10331,"activeCount":100},[],{"intervention":1341,"totalTrials":2150,"cells":10333},{"EARLY_PHASE1":10334,"PHASE1":10336,"PHASE2":10338,"PHASE3":10340,"PHASE4":10342,"NA":10372},{"trials":10335,"activeCount":100},[],{"trials":10337,"activeCount":100},[],{"trials":10339,"activeCount":100},[],{"trials":10341,"activeCount":100},[],{"trials":10343,"activeCount":100},[10344,10348,10352,10356,10364,10368],{"nctId":4011,"briefTitle":4012,"status":108,"phases":10345,"primaryCompletion":4014,"completion":2176,"start":4015,"enrollment":1172,"conditions":10346,"interventions":10347},[91],[1416,19],[3998,4018,1341],{"nctId":4192,"briefTitle":4193,"status":108,"phases":10349,"primaryCompletion":4195,"completion":608,"start":4196,"enrollment":32,"conditions":10350,"interventions":10351},[91],[4198],[1341,4179,4200,4201],{"nctId":1331,"briefTitle":1332,"status":108,"phases":10353,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":1336,"conditions":10354,"interventions":10355},[91],[16,1338],[1340,1341,1056,1342],{"nctId":10357,"briefTitle":10358,"status":108,"phases":10359,"primaryCompletion":10360,"completion":10360,"start":662,"enrollment":1447,"conditions":10361,"interventions":10363},"NCT02122380","The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome",[91],"2019-08-01",[10362],"Polycystic Ovary Syndrome",[1341],{"nctId":3492,"briefTitle":3493,"status":659,"phases":10365,"primaryCompletion":3495,"completion":3495,"start":3496,"enrollment":2239,"conditions":10366,"interventions":10367},[91],[19],[3462,3499,3500,3501,3502,1341],{"nctId":5202,"briefTitle":5203,"status":108,"phases":10369,"primaryCompletion":5205,"completion":5205,"start":5206,"enrollment":1414,"conditions":10370,"interventions":10371},[91],[16],[1341,5189,2179,5209],{"trials":10373,"activeCount":100},[10374,10387],{"nctId":10375,"briefTitle":10376,"status":108,"phases":10377,"primaryCompletion":10378,"completion":10146,"start":4768,"enrollment":1414,"conditions":10379,"interventions":10381},"NCT01413542","Pharmacogenetics of Ace Inhibitor-Associated Angioedema",[92],"2013-07",[19,10380],"Diabetes Type 2",[1341,10382,10383,10384,10385,10386],"Substance P,","bradykinin","enalaprilat","Glucagon-like peptide 1","brain natriuretic peptide",{"nctId":10388,"briefTitle":10389,"status":108,"phases":10390,"primaryCompletion":10391,"completion":4495,"start":8570,"enrollment":2979,"conditions":10392,"interventions":10393},"NCT02130687","Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure",[92],"2020-05",[4198,19],[1341,3068],{"intervention":3500,"totalTrials":900,"cells":10395},{"EARLY_PHASE1":10396,"PHASE1":10398,"PHASE2":10406,"PHASE3":10408,"PHASE4":10410,"NA":10416},{"trials":10397,"activeCount":100},[],{"trials":10399,"activeCount":100},[10400],{"nctId":10401,"briefTitle":10402,"status":659,"phases":10403,"primaryCompletion":2977,"completion":2977,"start":6837,"enrollment":2116,"conditions":10404,"interventions":10405},"NCT00868855","Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease",[88],[3754],[3500],{"trials":10407,"activeCount":100},[],{"trials":10409,"activeCount":100},[],{"trials":10411,"activeCount":100},[10412],{"nctId":3492,"briefTitle":3493,"status":659,"phases":10413,"primaryCompletion":3495,"completion":3495,"start":3496,"enrollment":2239,"conditions":10414,"interventions":10415},[91],[19],[3462,3499,3500,3501,3502,1341],{"trials":10417,"activeCount":100},[10418,10425,10429,10440,10447],{"nctId":10419,"briefTitle":10420,"status":659,"phases":10421,"primaryCompletion":10422,"completion":947,"start":5472,"enrollment":5629,"conditions":10423,"interventions":10424},"NCT00780481","Characterization of Brachial Arterial t-PA Release, Endothelial Function, Obesity and Inflammation",[92],"2011-01",[16],[3500],{"nctId":10375,"briefTitle":10376,"status":108,"phases":10426,"primaryCompletion":10378,"completion":10146,"start":4768,"enrollment":1414,"conditions":10427,"interventions":10428},[92],[19,10380],[1341,10382,10383,10384,10385,10386],{"nctId":10430,"briefTitle":10431,"status":108,"phases":10432,"primaryCompletion":8296,"completion":8296,"start":10146,"enrollment":10433,"conditions":10434,"interventions":10435},"NCT02189122","Comparative Effects of Aspirin and NHP-544C",[92],61,[2333],[3500,10436,10437,10438,10439],"Aspirin 81 mg","Aspirin 162 mg","NHP544-C 81 mg","NHP544C 162 mg",{"nctId":10441,"briefTitle":10442,"status":605,"phases":10443,"primaryCompletion":10422,"completion":947,"start":5786,"enrollment":100,"conditions":10444,"interventions":10446},"NCT00780377","Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients",[92],[10445],"Heart Transplantation",[3500],{"nctId":10448,"briefTitle":10449,"status":605,"phases":10450,"primaryCompletion":10422,"completion":947,"start":5786,"enrollment":100,"conditions":10451,"interventions":10452},"NCT00780637","Brachial Artery t-PA Release in Heart Transplant Recipients",[92],[10445],[3500],{"intervention":3448,"totalTrials":683,"cells":10454},{"EARLY_PHASE1":10455,"PHASE1":10457,"PHASE2":10459,"PHASE3":10465,"PHASE4":10475,"NA":10485},{"trials":10456,"activeCount":100},[],{"trials":10458,"activeCount":100},[],{"trials":10460,"activeCount":100},[10461],{"nctId":3471,"briefTitle":3472,"status":108,"phases":10462,"primaryCompletion":2978,"completion":2978,"start":2233,"enrollment":2681,"conditions":10463,"interventions":10464},[89],[3475,3476],[3448,3462],{"trials":10466,"activeCount":100},[10467,10471],{"nctId":3481,"briefTitle":3482,"status":659,"phases":10468,"primaryCompletion":1062,"completion":1062,"start":2176,"enrollment":3484,"conditions":10469,"interventions":10470},[90],[1437,358],[3487,3488],{"nctId":3439,"briefTitle":3440,"status":108,"phases":10472,"primaryCompletion":3442,"completion":3443,"start":3444,"enrollment":3445,"conditions":10473,"interventions":10474},[89,90],[1088],[3448,3400],{"trials":10476,"activeCount":100},[10477,10481],{"nctId":3545,"briefTitle":3546,"status":659,"phases":10478,"primaryCompletion":3548,"completion":947,"start":3549,"enrollment":2239,"conditions":10479,"interventions":10480},[91],[3551],[3506,3448],{"nctId":3748,"briefTitle":3749,"status":108,"phases":10482,"primaryCompletion":663,"completion":2978,"start":3751,"enrollment":3752,"conditions":10483,"interventions":10484},[91],[3754,3755,3756,3757,3758,1108],[3448,3735],{"trials":10486,"activeCount":100},[10487],{"nctId":10488,"briefTitle":10489,"status":108,"phases":10490,"primaryCompletion":682,"completion":3548,"start":2646,"enrollment":2796,"conditions":10491,"interventions":10492},"NCT00750308","Renin Angiotensin Aldosterone System (RAAS) and Fibrinolysis in Humans: ACEi and PE5i",[92],[1416],[3448,493],{"intervention":9395,"totalTrials":683,"cells":10494},{"EARLY_PHASE1":10495,"PHASE1":10497,"PHASE2":10507,"PHASE3":10509,"PHASE4":10524,"NA":10537},{"trials":10496,"activeCount":100},[],{"trials":10498,"activeCount":100},[10499,10503],{"nctId":9388,"briefTitle":9389,"status":108,"phases":10500,"primaryCompletion":9391,"completion":9391,"start":9392,"enrollment":531,"conditions":10501,"interventions":10502},[88],[2333],[9381,9395],{"nctId":8426,"briefTitle":8427,"status":108,"phases":10504,"primaryCompletion":8429,"completion":8429,"start":8430,"enrollment":1447,"conditions":10505,"interventions":10506},[88],[6343],[8419,6589],{"trials":10508,"activeCount":100},[],{"trials":10510,"activeCount":100},[10511,10520],{"nctId":10512,"briefTitle":10513,"status":108,"phases":10514,"primaryCompletion":10515,"completion":10515,"start":10516,"enrollment":162,"conditions":10517,"interventions":10518},"NCT00678379","Pediatric Tonsillectomy Pain Reduction Study",[90],"2009-11","2008-04",[5034],[10519,9395,582],"lidocaine",{"nctId":6581,"briefTitle":6582,"status":605,"phases":10521,"primaryCompletion":3706,"completion":3706,"start":4744,"enrollment":100,"conditions":10522,"interventions":10523},[89,90],[6585,6586,6587],[6570,6589],{"trials":10525,"activeCount":100},[10526],{"nctId":10527,"briefTitle":10528,"status":605,"phases":10529,"primaryCompletion":10530,"completion":6809,"start":10531,"enrollment":100,"conditions":10532,"interventions":10536},"NCT03143530","Effect of Pectoralis Block on Analgesia After Simple Mastectomy",[91],"2019-03-01","2017-12",[10533,10534,10535],"Mastectomy","Nerve Block","Analgesia, Postoperative",[9395,585],{"trials":10538,"activeCount":100},[10539],{"nctId":10540,"briefTitle":10541,"status":659,"phases":10542,"primaryCompletion":5786,"completion":5786,"start":4426,"enrollment":10543,"conditions":10544,"interventions":10545},"NCT00655642","Comparison of Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult ED",[92],171,[10124],[3081,3069,3066,6589],{"intervention":3766,"totalTrials":683,"cells":10547},{"EARLY_PHASE1":10548,"PHASE1":10550,"PHASE2":10552,"PHASE3":10554,"PHASE4":10566,"NA":10586},{"trials":10549,"activeCount":100},[],{"trials":10551,"activeCount":100},[],{"trials":10553,"activeCount":100},[],{"trials":10555,"activeCount":100},[10556,10562],{"nctId":10557,"briefTitle":10558,"status":108,"phases":10559,"completion":5448,"start":2928,"enrollment":29,"conditions":10560,"interventions":10561},"NCT00179257","The Effectiveness of Sertraline in Patients Who Have Had Inadequate Response to Escitalopram",[90],[4497],[6564],{"nctId":6558,"briefTitle":6559,"status":108,"phases":10563,"completion":2212,"start":6561,"enrollment":29,"conditions":10564,"interventions":10565},[90],[4497],[6564,6547],{"trials":10567,"activeCount":100},[10568,10575,10582],{"nctId":10569,"briefTitle":10570,"status":108,"phases":10571,"primaryCompletion":10572,"completion":10572,"start":10378,"enrollment":2250,"conditions":10573,"interventions":10574},"NCT01896934","Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression",[91],"2016-06",[4497],[3766],{"nctId":10576,"briefTitle":10577,"status":108,"phases":10578,"primaryCompletion":7637,"completion":7637,"start":4980,"enrollment":1773,"conditions":10579,"interventions":10580},"NCT00178828","Dynamic Measures of Neurochemistry in Mood Disorders",[91],[22],[6564,10581],"bupropion",{"nctId":3761,"briefTitle":3762,"status":659,"phases":10583,"primaryCompletion":1446,"completion":1446,"start":3679,"enrollment":138,"conditions":10584,"interventions":10585},[91],[22,19],[3766,3735],{"trials":10587,"activeCount":100},[10588],{"nctId":10589,"briefTitle":10590,"status":605,"phases":10591,"primaryCompletion":3578,"start":731,"enrollment":100,"conditions":10592,"interventions":10593},"NCT01751828","Late-life Depression and Cerebral Perfusion",[92],[22],[3766],{"intervention":10595,"totalTrials":2239,"cells":10596},"gene expression analysis",{"EARLY_PHASE1":10597,"PHASE1":10599,"PHASE2":10601,"PHASE3":10603,"PHASE4":10605,"NA":10607},{"trials":10598,"activeCount":100},[],{"trials":10600,"activeCount":100},[],{"trials":10602,"activeCount":100},[],{"trials":10604,"activeCount":100},[],{"trials":10606,"activeCount":100},[],{"trials":10608,"activeCount":100},[10609,10623,10632,10640],{"nctId":10610,"briefTitle":10611,"status":108,"phases":10612,"primaryCompletion":3183,"completion":10613,"start":10614,"enrollment":10615,"conditions":10616,"interventions":10618},"NCT00899028","Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants",[],"2016-08","2001-05",689,[10617],"Lung Cancer",[10619,10620,10595,10621,10622],"comparative genomic hybridization","fluorescence in situ hybridization","microarray analysis","protein expression analysis",{"nctId":10624,"briefTitle":10625,"status":108,"phases":10626,"primaryCompletion":3410,"completion":3410,"start":111,"enrollment":1371,"conditions":10627,"interventions":10628},"NCT00482872","Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer",[],[7570],[10595,10629,10630,10631],"mutation analysis","polymerase chain reaction","polymorphism analysis",{"nctId":10633,"briefTitle":10634,"status":108,"phases":10635,"start":7614,"conditions":10636,"interventions":10637},"NCT00896948","Study of Proteins in Head and Neck Cancer Cells",[],[7570],[10638,10639,10595,10622],"Southern blotting","TdT-mediated dUTP nick end labeling assay",{"nctId":10641,"briefTitle":10642,"status":108,"phases":10643,"start":6755,"enrollment":412,"conditions":10644,"interventions":10645},"NCT00897988","DNA Analysis of Tumor Tissue Samples From Patients With Human Papilloma Virus-Associated Cancer of the Oropharynx",[],[7570],[10595,10629,10646,10630,10622,10647],"polyacrylamide gel electrophoresis","reverse transcriptase-polymerase chain reaction",{"intervention":10622,"totalTrials":2239,"cells":10649},{"EARLY_PHASE1":10650,"PHASE1":10652,"PHASE2":10654,"PHASE3":10656,"PHASE4":10658,"NA":10660},{"trials":10651,"activeCount":100},[],{"trials":10653,"activeCount":100},[],{"trials":10655,"activeCount":100},[],{"trials":10657,"activeCount":100},[],{"trials":10659,"activeCount":100},[],{"trials":10661,"activeCount":100},[10662,10666,10670,10674],{"nctId":10610,"briefTitle":10611,"status":108,"phases":10663,"primaryCompletion":3183,"completion":10613,"start":10614,"enrollment":10615,"conditions":10664,"interventions":10665},[],[10617],[10619,10620,10595,10621,10622],{"nctId":10633,"briefTitle":10634,"status":108,"phases":10667,"start":7614,"conditions":10668,"interventions":10669},[],[7570],[10638,10639,10595,10622],{"nctId":10641,"briefTitle":10642,"status":108,"phases":10671,"start":6755,"enrollment":412,"conditions":10672,"interventions":10673},[],[7570],[10595,10629,10646,10630,10622,10647],{"nctId":10675,"briefTitle":10676,"status":108,"phases":10677,"start":3444,"enrollment":697,"conditions":10678,"interventions":10679},"NCT00899769","Biomarkers in Patients With Head and Neck Cancer and in Healthy Volunteers",[],[7570],[10622,10680],"proteomic profiling",{"intervention":560,"totalTrials":2239,"cells":10682},{"EARLY_PHASE1":10683,"PHASE1":10685,"PHASE2":10687,"PHASE3":10689,"PHASE4":10695,"NA":10697},{"trials":10684,"activeCount":100},[],{"trials":10686,"activeCount":100},[],{"trials":10688,"activeCount":100},[],{"trials":10690,"activeCount":100},[10691],{"nctId":715,"briefTitle":716,"status":108,"phases":10692,"primaryCompletion":718,"completion":718,"start":719,"enrollment":720,"conditions":10693,"interventions":10694},[90],[722,25,723],[67,560],{"trials":10696,"activeCount":100},[],{"trials":10698,"activeCount":100},[10699,10703,10716],{"nctId":550,"briefTitle":551,"status":108,"phases":10700,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":10701,"interventions":10702},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"nctId":10704,"briefTitle":10705,"status":108,"phases":10706,"primaryCompletion":2278,"completion":10707,"start":10708,"enrollment":10709,"conditions":10710,"interventions":10713},"NCT02584452","Trial Evaluating Postop Pain and Muscle Strength Among Regional Anesthesia Techniques for Ambulatory ACL Reconstruction",[92],"2018-04-10","2015-11-03",59,[10711,10712],"Rupture of Anterior Cruciate Ligament","Tear of Anterior Cruciate Ligament",[586,10714,10715,560,3070],"Normal Saline as bolus followed by bupivacaine","ropivacaine and dexamethasone",{"nctId":3052,"briefTitle":3053,"status":108,"phases":10717,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":10718,"interventions":10719},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":10721,"totalTrials":2239,"cells":10722},"Guanfacine",{"EARLY_PHASE1":10723,"PHASE1":10725,"PHASE2":10731,"PHASE3":10752,"PHASE4":10754,"NA":10756},{"trials":10724,"activeCount":100},[],{"trials":10726,"activeCount":100},[10727],{"nctId":3513,"briefTitle":3514,"status":108,"phases":10728,"primaryCompletion":1434,"completion":1434,"start":3516,"enrollment":3517,"conditions":10729,"interventions":10730},[88],[19],[3520,3521,3522,3523,3524,3525,3526,3420,3527,3528,3506,3529,3530,3531,3532,3533,3534,3535,3536,3537],{"trials":10732,"activeCount":100},[10733,10742],{"nctId":10734,"briefTitle":10735,"status":108,"phases":10736,"primaryCompletion":10737,"completion":10738,"start":10739,"enrollment":649,"conditions":10740,"interventions":10741},"NCT04742673","Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study",[89],"2024-03-30","2025-11-30","2021-05-04",[31,25,8376],[10721],{"nctId":10743,"briefTitle":10744,"status":108,"phases":10745,"primaryCompletion":10746,"completion":10747,"start":10748,"enrollment":4939,"conditions":10749,"interventions":10751},"NCT03865940","Efficacy of Guanfacine and Lidocaine Combination in Trigeminal Nerve Block for Pain Management in Trigeminal Neuropathy",[89],"2023-10-04","2024-01-31","2019-11-04",[10750],"Trigeminal Neuralgia",[582,10721],{"trials":10753,"activeCount":100},[],{"trials":10755,"activeCount":100},[],{"trials":10757,"activeCount":100},[10758],{"nctId":10759,"briefTitle":10760,"status":108,"phases":10761,"primaryCompletion":10145,"completion":10145,"start":1988,"enrollment":10762,"conditions":10763,"interventions":10764},"NCT02882854","Guanfacine for PONV and Pain After Sinus Surgery",[92],84,[3060,3027],[10721],{"intervention":3065,"totalTrials":2239,"cells":10766},{"EARLY_PHASE1":10767,"PHASE1":10769,"PHASE2":10781,"PHASE3":10783,"PHASE4":10785,"NA":10791},{"trials":10768,"activeCount":100},[],{"trials":10770,"activeCount":100},[10771],{"nctId":10772,"briefTitle":10773,"status":108,"phases":10774,"primaryCompletion":10775,"completion":10776,"start":10777,"enrollment":2911,"conditions":10778,"interventions":10780},"NCT03035929","Diagnosing Natriuretic Peptide Deficiency",[88],"2017-06-08","2018-01-01","2017-01-01",[2333,10779],"Lean",[3065],{"trials":10782,"activeCount":100},[],{"trials":10784,"activeCount":100},[],{"trials":10786,"activeCount":100},[10787],{"nctId":5421,"briefTitle":5422,"status":659,"phases":10788,"primaryCompletion":5424,"completion":5424,"start":5425,"enrollment":2647,"conditions":10789,"interventions":10790},[91],[5427],[3065,5408],{"trials":10792,"activeCount":100},[10793,10800],{"nctId":10794,"briefTitle":10795,"status":605,"phases":10796,"primaryCompletion":2115,"completion":2115,"start":2115,"enrollment":100,"conditions":10797,"interventions":10798},"NCT00608101","Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus",[92],[1174],[10799,3065],"Fludrocortisone",{"nctId":3052,"briefTitle":3053,"status":108,"phases":10801,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":10802,"interventions":10803},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":10630,"totalTrials":96,"cells":10805},{"EARLY_PHASE1":10806,"PHASE1":10808,"PHASE2":10810,"PHASE3":10812,"PHASE4":10814,"NA":10816},{"trials":10807,"activeCount":100},[],{"trials":10809,"activeCount":100},[],{"trials":10811,"activeCount":100},[],{"trials":10813,"activeCount":100},[],{"trials":10815,"activeCount":100},[],{"trials":10817,"activeCount":100},[10818,10834,10838],{"nctId":10819,"briefTitle":10820,"status":659,"phases":10821,"primaryCompletion":4640,"completion":4640,"start":4769,"enrollment":1172,"conditions":10822,"interventions":10832},"NCT01077440","Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant",[],[10823,10824,10825,10826,10827,10828,10829,10830,10831],"Cancer Survivor","Chronic Myeloproliferative Disorders","Leukemia","Lymphoma","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasms","Neuroblastoma","Testicular Germ Cell Tumor",[10833,10630],"DNA analysis",{"nctId":10624,"briefTitle":10625,"status":108,"phases":10835,"primaryCompletion":3410,"completion":3410,"start":111,"enrollment":1371,"conditions":10836,"interventions":10837},[],[7570],[10595,10629,10630,10631],{"nctId":10641,"briefTitle":10642,"status":108,"phases":10839,"start":6755,"enrollment":412,"conditions":10840,"interventions":10841},[],[7570],[10595,10629,10646,10630,10622,10647],{"intervention":2179,"totalTrials":96,"cells":10843},{"EARLY_PHASE1":10844,"PHASE1":10846,"PHASE2":10852,"PHASE3":10854,"PHASE4":10856,"NA":10862},{"trials":10845,"activeCount":100},[],{"trials":10847,"activeCount":100},[10848],{"nctId":2173,"briefTitle":2174,"status":108,"phases":10849,"primaryCompletion":1988,"completion":1988,"start":2176,"enrollment":20,"conditions":10850,"interventions":10851},[88],[16,19],[2179,2149],{"trials":10853,"activeCount":100},[],{"trials":10855,"activeCount":100},[],{"trials":10857,"activeCount":100},[10858],{"nctId":5202,"briefTitle":5203,"status":108,"phases":10859,"primaryCompletion":5205,"completion":5205,"start":5206,"enrollment":1414,"conditions":10860,"interventions":10861},[91],[16],[1341,5189,2179,5209],{"trials":10863,"activeCount":100},[10864],{"nctId":2230,"briefTitle":2231,"status":108,"phases":10865,"primaryCompletion":2233,"completion":2233,"start":133,"enrollment":2234,"conditions":10866,"interventions":10867},[92],[19,903],[2179,2149],{"intervention":10869,"totalTrials":96,"cells":10870},"epinephrine",{"EARLY_PHASE1":10871,"PHASE1":10873,"PHASE2":10875,"PHASE3":10877,"PHASE4":10879,"NA":10881},{"trials":10872,"activeCount":100},[],{"trials":10874,"activeCount":100},[],{"trials":10876,"activeCount":100},[],{"trials":10878,"activeCount":100},[],{"trials":10880,"activeCount":100},[],{"trials":10882,"activeCount":100},[10883,10887,10893],{"nctId":550,"briefTitle":551,"status":108,"phases":10884,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":10885,"interventions":10886},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"nctId":10888,"briefTitle":10889,"status":605,"phases":10890,"enrollment":100,"conditions":10891,"interventions":10892},"NCT00608816","Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q4",[92],[1174],[10869,10869],{"nctId":10894,"briefTitle":10895,"status":605,"phases":10896,"enrollment":100,"conditions":10897,"interventions":10898},"NCT00605774","Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q5",[92],[1174],[10869,10869],{"intervention":582,"totalTrials":96,"cells":10900},{"EARLY_PHASE1":10901,"PHASE1":10903,"PHASE2":10905,"PHASE3":10911,"PHASE4":10917,"NA":10919},{"trials":10902,"activeCount":100},[],{"trials":10904,"activeCount":100},[],{"trials":10906,"activeCount":100},[10907],{"nctId":10743,"briefTitle":10744,"status":108,"phases":10908,"primaryCompletion":10746,"completion":10747,"start":10748,"enrollment":4939,"conditions":10909,"interventions":10910},[89],[10750],[582,10721],{"trials":10912,"activeCount":100},[10913],{"nctId":10512,"briefTitle":10513,"status":108,"phases":10914,"primaryCompletion":10515,"completion":10515,"start":10516,"enrollment":162,"conditions":10915,"interventions":10916},[90],[5034],[10519,9395,582],{"trials":10918,"activeCount":100},[],{"trials":10920,"activeCount":100},[10921],{"nctId":550,"briefTitle":551,"status":108,"phases":10922,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":10923,"interventions":10924},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":10926,"totalTrials":96,"cells":10927},"Acetaminophen",{"EARLY_PHASE1":10928,"PHASE1":10930,"PHASE2":10932,"PHASE3":10940,"PHASE4":10942,"NA":10944},{"trials":10929,"activeCount":100},[],{"trials":10931,"activeCount":100},[],{"trials":10933,"activeCount":100},[10934],{"nctId":10935,"briefTitle":10936,"status":108,"phases":10937,"primaryCompletion":681,"completion":681,"start":7637,"enrollment":1414,"conditions":10938,"interventions":10939},"NCT01739361","Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis",[89],[6909],[10926],{"trials":10941,"activeCount":100},[],{"trials":10943,"activeCount":100},[],{"trials":10945,"activeCount":100},[10946,10953],{"nctId":10947,"briefTitle":10948,"status":605,"phases":10949,"primaryCompletion":3410,"completion":3410,"start":10319,"enrollment":100,"conditions":10950,"interventions":10952},"NCT01120769","Acetaminophen to Prevent Ischemic Oxidative Reperfusion Injury During Percutaneous Coronary Intervention for Acute Myocardial Infarction",[92],[10951],"Acute Myocardial Infarction",[10926],{"nctId":10954,"briefTitle":10955,"status":108,"phases":10956,"primaryCompletion":10957,"completion":10957,"start":10319,"enrollment":6517,"conditions":10958,"interventions":10960},"NCT01366976","Inhibition of Lipid Peroxidation During Cardiac Surgery",[92],"2013-06",[10959],"Cardiopulmonary Bypass Induced Lipid Peroxidation",[10926],{"intervention":3064,"totalTrials":96,"cells":10962},{"EARLY_PHASE1":10963,"PHASE1":10965,"PHASE2":10967,"PHASE3":10973,"PHASE4":10979,"NA":10981},{"trials":10964,"activeCount":100},[],{"trials":10966,"activeCount":100},[],{"trials":10968,"activeCount":100},[10969],{"nctId":5881,"briefTitle":5882,"status":108,"phases":10970,"primaryCompletion":5884,"completion":5884,"start":5885,"enrollment":5886,"conditions":10971,"interventions":10972},[89],[25,5888],[5872,3064],{"trials":10974,"activeCount":100},[10975],{"nctId":5893,"briefTitle":5894,"status":108,"phases":10976,"primaryCompletion":5896,"completion":5897,"start":5898,"enrollment":5899,"conditions":10977,"interventions":10978},[90],[25,723,5901],[3064,5872],{"trials":10980,"activeCount":100},[],{"trials":10982,"activeCount":100},[10983],{"nctId":3052,"briefTitle":3053,"status":108,"phases":10984,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":10985,"interventions":10986},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":3081,"totalTrials":96,"cells":10988},{"EARLY_PHASE1":10989,"PHASE1":10995,"PHASE2":10997,"PHASE3":10999,"PHASE4":11001,"NA":11003},{"trials":10990,"activeCount":100},[10991],{"nctId":10118,"briefTitle":10119,"status":108,"phases":10992,"primaryCompletion":10121,"completion":10121,"start":10122,"enrollment":1773,"conditions":10993,"interventions":10994},[87],[10124],[3081,10113],{"trials":10996,"activeCount":100},[],{"trials":10998,"activeCount":100},[],{"trials":11000,"activeCount":100},[],{"trials":11002,"activeCount":100},[],{"trials":11004,"activeCount":100},[11005,11009],{"nctId":10540,"briefTitle":10541,"status":659,"phases":11006,"primaryCompletion":5786,"completion":5786,"start":4426,"enrollment":10543,"conditions":11007,"interventions":11008},[92],[10124],[3081,3069,3066,6589],{"nctId":3052,"briefTitle":3053,"status":108,"phases":11010,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":11011,"interventions":11012},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":493,"totalTrials":96,"cells":11014},{"EARLY_PHASE1":11015,"PHASE1":11017,"PHASE2":11019,"PHASE3":11032,"PHASE4":11034,"NA":11036},{"trials":11016,"activeCount":100},[],{"trials":11018,"activeCount":100},[],{"trials":11020,"activeCount":100},[11021,11028],{"nctId":11022,"briefTitle":11023,"status":108,"phases":11024,"primaryCompletion":11025,"completion":11025,"start":3057,"enrollment":7184,"conditions":11026,"interventions":11027},"NCT02819440","PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction",[89],"2020-06",[2333,7860],[493],{"nctId":483,"briefTitle":484,"status":108,"phases":11029,"primaryCompletion":486,"completion":487,"start":488,"enrollment":489,"conditions":11030,"interventions":11031},[89],[491],[493,460],{"trials":11033,"activeCount":100},[],{"trials":11035,"activeCount":100},[],{"trials":11037,"activeCount":100},[11038],{"nctId":10488,"briefTitle":10489,"status":108,"phases":11039,"primaryCompletion":682,"completion":3548,"start":2646,"enrollment":2796,"conditions":11040,"interventions":11041},[92],[1416],[3448,493],{"intervention":3068,"totalTrials":96,"cells":11043},{"EARLY_PHASE1":11044,"PHASE1":11046,"PHASE2":11048,"PHASE3":11050,"PHASE4":11052,"NA":11061},{"trials":11045,"activeCount":100},[],{"trials":11047,"activeCount":100},[],{"trials":11049,"activeCount":100},[],{"trials":11051,"activeCount":100},[],{"trials":11053,"activeCount":100},[11054],{"nctId":11055,"briefTitle":11056,"status":659,"phases":11057,"primaryCompletion":8296,"completion":3057,"start":7754,"enrollment":900,"conditions":11058,"interventions":11060},"NCT01625455","Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome",[91],[7988,11059],"Pruritus",[3068],{"trials":11062,"activeCount":100},[11063,11067],{"nctId":10388,"briefTitle":10389,"status":108,"phases":11064,"primaryCompletion":10391,"completion":4495,"start":8570,"enrollment":2979,"conditions":11065,"interventions":11066},[92],[4198,19],[1341,3068],{"nctId":3052,"briefTitle":3053,"status":108,"phases":11068,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":11069,"interventions":11070},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":11072,"totalTrials":531,"cells":11073},"Growth Hormone",{"EARLY_PHASE1":11074,"PHASE1":11076,"PHASE2":11078,"PHASE3":11080,"PHASE4":11082,"NA":11084},{"trials":11075,"activeCount":100},[],{"trials":11077,"activeCount":100},[],{"trials":11079,"activeCount":100},[],{"trials":11081,"activeCount":100},[],{"trials":11083,"activeCount":100},[],{"trials":11085,"activeCount":100},[11086,11093],{"nctId":11087,"briefTitle":11088,"status":659,"phases":11089,"completion":2646,"start":3667,"enrollment":23,"conditions":11090,"interventions":11092},"NCT00397319","Growth Hormone's Effect on the Cardiovascular System",[],[11091],"Growth Hormone Deficiency",[11072],{"nctId":11094,"briefTitle":11095,"status":108,"phases":11096,"completion":5472,"start":3751,"enrollment":32,"conditions":11097,"interventions":11099},"NCT00397592","Growth Hormone's Effect on Endothelial Progenitor Cells",[92],[11098],"Cardiovascular Disease",[11072],{"intervention":10384,"totalTrials":531,"cells":11101},{"EARLY_PHASE1":11102,"PHASE1":11104,"PHASE2":11106,"PHASE3":11108,"PHASE4":11110,"NA":11116},{"trials":11103,"activeCount":100},[],{"trials":11105,"activeCount":100},[],{"trials":11107,"activeCount":100},[],{"trials":11109,"activeCount":100},[],{"trials":11111,"activeCount":100},[11112],{"nctId":4192,"briefTitle":4193,"status":108,"phases":11113,"primaryCompletion":4195,"completion":608,"start":4196,"enrollment":32,"conditions":11114,"interventions":11115},[91],[4198],[1341,4179,4200,4201],{"trials":11117,"activeCount":100},[11118],{"nctId":10375,"briefTitle":10376,"status":108,"phases":11119,"primaryCompletion":10378,"completion":10146,"start":4768,"enrollment":1414,"conditions":11120,"interventions":11121},[92],[19,10380],[1341,10382,10383,10384,10385,10386],{"intervention":11123,"totalTrials":531,"cells":11124},"hydroxychloroquine",{"EARLY_PHASE1":11125,"PHASE1":11127,"PHASE2":11136,"PHASE3":11138,"PHASE4":11140,"NA":11142},{"trials":11126,"activeCount":100},[],{"trials":11128,"activeCount":100},[11129],{"nctId":11130,"briefTitle":11131,"status":108,"phases":11132,"primaryCompletion":2142,"completion":2142,"start":110,"enrollment":29,"conditions":11133,"interventions":11135},"NCT00311883","Hydroxychloroquine in Cystic Fibrosis",[88],[11134],"Cystic Fibrosis",[11123],{"trials":11137,"activeCount":100},[],{"trials":11139,"activeCount":100},[],{"trials":11141,"activeCount":100},[],{"trials":11143,"activeCount":100},[11144],{"nctId":11145,"briefTitle":11146,"status":605,"phases":11147,"primaryCompletion":2939,"completion":2939,"start":948,"enrollment":100,"conditions":11148,"interventions":11150},"NCT01073852","Hydroxychloroquine Efficacy in Chronic Urticaria",[92],[11149],"Chronic Urticaria",[11151],"Hydroxychloroquine",{"intervention":561,"totalTrials":531,"cells":11153},{"EARLY_PHASE1":11154,"PHASE1":11156,"PHASE2":11158,"PHASE3":11160,"PHASE4":11162,"NA":11164},{"trials":11155,"activeCount":100},[],{"trials":11157,"activeCount":100},[],{"trials":11159,"activeCount":100},[],{"trials":11161,"activeCount":100},[],{"trials":11163,"activeCount":100},[],{"trials":11165,"activeCount":100},[11166,11170],{"nctId":550,"briefTitle":551,"status":108,"phases":11167,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":11168,"interventions":11169},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"nctId":3052,"briefTitle":3053,"status":108,"phases":11171,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":11172,"interventions":11173},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":562,"totalTrials":531,"cells":11175},{"EARLY_PHASE1":11176,"PHASE1":11178,"PHASE2":11180,"PHASE3":11182,"PHASE4":11184,"NA":11186},{"trials":11177,"activeCount":100},[],{"trials":11179,"activeCount":100},[],{"trials":11181,"activeCount":100},[],{"trials":11183,"activeCount":100},[],{"trials":11185,"activeCount":100},[],{"trials":11187,"activeCount":100},[11188,11192],{"nctId":550,"briefTitle":551,"status":108,"phases":11189,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":11190,"interventions":11191},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"nctId":3052,"briefTitle":3053,"status":108,"phases":11193,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":11194,"interventions":11195},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":563,"totalTrials":531,"cells":11197},{"EARLY_PHASE1":11198,"PHASE1":11200,"PHASE2":11202,"PHASE3":11204,"PHASE4":11206,"NA":11208},{"trials":11199,"activeCount":100},[],{"trials":11201,"activeCount":100},[],{"trials":11203,"activeCount":100},[],{"trials":11205,"activeCount":100},[],{"trials":11207,"activeCount":100},[],{"trials":11209,"activeCount":100},[11210,11214],{"nctId":550,"briefTitle":551,"status":108,"phases":11211,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":11212,"interventions":11213},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"nctId":3052,"briefTitle":3053,"status":108,"phases":11215,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":11216,"interventions":11217},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":566,"totalTrials":531,"cells":11219},{"EARLY_PHASE1":11220,"PHASE1":11222,"PHASE2":11224,"PHASE3":11226,"PHASE4":11228,"NA":11234},{"trials":11221,"activeCount":100},[],{"trials":11223,"activeCount":100},[],{"trials":11225,"activeCount":100},[],{"trials":11227,"activeCount":100},[],{"trials":11229,"activeCount":100},[11230],{"nctId":2960,"briefTitle":2961,"status":659,"phases":11231,"primaryCompletion":2963,"completion":2963,"start":2964,"enrollment":35,"conditions":11232,"interventions":11233},[91],[2966,722,2967,2968,2969],[565,566],{"trials":11235,"activeCount":100},[11236],{"nctId":550,"briefTitle":551,"status":108,"phases":11237,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":11238,"interventions":11239},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":572,"totalTrials":531,"cells":11241},{"EARLY_PHASE1":11242,"PHASE1":11244,"PHASE2":11246,"PHASE3":11248,"PHASE4":11250,"NA":11252},{"trials":11243,"activeCount":100},[],{"trials":11245,"activeCount":100},[],{"trials":11247,"activeCount":100},[],{"trials":11249,"activeCount":100},[],{"trials":11251,"activeCount":100},[],{"trials":11253,"activeCount":100},[11254,11258],{"nctId":550,"briefTitle":551,"status":108,"phases":11255,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":11256,"interventions":11257},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"nctId":11259,"briefTitle":11260,"status":108,"phases":11261,"primaryCompletion":9796,"completion":9796,"start":1061,"enrollment":683,"conditions":11262,"interventions":11264},"NCT02927223","Atropine in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)",[92],[11263],"Catecholaminergic Polymorphic Ventricular Tachycardia",[572],{"intervention":583,"totalTrials":531,"cells":11266},{"EARLY_PHASE1":11267,"PHASE1":11269,"PHASE2":11271,"PHASE3":11273,"PHASE4":11275,"NA":11277},{"trials":11268,"activeCount":100},[],{"trials":11270,"activeCount":100},[],{"trials":11272,"activeCount":100},[],{"trials":11274,"activeCount":100},[],{"trials":11276,"activeCount":100},[],{"trials":11278,"activeCount":100},[11279,11283],{"nctId":550,"briefTitle":551,"status":108,"phases":11280,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":11281,"interventions":11282},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"nctId":11284,"briefTitle":11285,"status":108,"phases":11286,"primaryCompletion":11287,"completion":11287,"start":3557,"enrollment":412,"conditions":11288,"interventions":11289},"NCT01087931","Pain Relief at Iliac Crest Bone Harvest Sites in Spine Surgery Using Bupivacaine",[92],"2011-10",[166],[583],{"intervention":585,"totalTrials":531,"cells":11291},{"EARLY_PHASE1":11292,"PHASE1":11294,"PHASE2":11296,"PHASE3":11298,"PHASE4":11300,"NA":11306},{"trials":11293,"activeCount":100},[],{"trials":11295,"activeCount":100},[],{"trials":11297,"activeCount":100},[],{"trials":11299,"activeCount":100},[],{"trials":11301,"activeCount":100},[11302],{"nctId":10527,"briefTitle":10528,"status":605,"phases":11303,"primaryCompletion":10530,"completion":6809,"start":10531,"enrollment":100,"conditions":11304,"interventions":11305},[91],[10533,10534,10535],[9395,585],{"trials":11307,"activeCount":100},[11308],{"nctId":550,"briefTitle":551,"status":108,"phases":11309,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":11310,"interventions":11311},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":586,"totalTrials":531,"cells":11313},{"EARLY_PHASE1":11314,"PHASE1":11316,"PHASE2":11318,"PHASE3":11320,"PHASE4":11322,"NA":11324},{"trials":11315,"activeCount":100},[],{"trials":11317,"activeCount":100},[],{"trials":11319,"activeCount":100},[],{"trials":11321,"activeCount":100},[],{"trials":11323,"activeCount":100},[],{"trials":11325,"activeCount":100},[11326,11330],{"nctId":550,"briefTitle":551,"status":108,"phases":11327,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":11328,"interventions":11329},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"nctId":10704,"briefTitle":10705,"status":108,"phases":11331,"primaryCompletion":2278,"completion":10707,"start":10708,"enrollment":10709,"conditions":11332,"interventions":11333},[92],[10711,10712],[586,10714,10715,560,3070],{"intervention":591,"totalTrials":531,"cells":11335},{"EARLY_PHASE1":11336,"PHASE1":11338,"PHASE2":11348,"PHASE3":11350,"PHASE4":11352,"NA":11354},{"trials":11337,"activeCount":100},[],{"trials":11339,"activeCount":100},[11340],{"nctId":11341,"briefTitle":11342,"status":108,"phases":11343,"primaryCompletion":11344,"completion":11344,"start":661,"enrollment":2796,"conditions":11345,"interventions":11346},"NCT02537314","Role of the Foregut in Nutrient Metabolism in Lean and Obese Humans",[88],"2022-12-08",[16],[11347],"benzocaine",{"trials":11349,"activeCount":100},[],{"trials":11351,"activeCount":100},[],{"trials":11353,"activeCount":100},[],{"trials":11355,"activeCount":100},[11356],{"nctId":550,"briefTitle":551,"status":108,"phases":11357,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":11358,"interventions":11359},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":6522,"totalTrials":531,"cells":11361},{"EARLY_PHASE1":11362,"PHASE1":11364,"PHASE2":11366,"PHASE3":11368,"PHASE4":11374,"NA":11376},{"trials":11363,"activeCount":100},[],{"trials":11365,"activeCount":100},[],{"trials":11367,"activeCount":100},[],{"trials":11369,"activeCount":100},[11370],{"nctId":6511,"briefTitle":6512,"status":108,"phases":11371,"primaryCompletion":6514,"completion":6515,"start":6516,"enrollment":6517,"conditions":11372,"interventions":11373},[89,90],[6519],[6521,6522,6500,6523],{"trials":11375,"activeCount":100},[],{"trials":11377,"activeCount":100},[11378],{"nctId":11379,"briefTitle":11380,"status":108,"phases":11381,"primaryCompletion":11382,"completion":2513,"start":11383,"enrollment":11384,"conditions":11385,"interventions":11387},"NCT03227679","Metabolism-informed Care for Smoking Cessation",[92],"2016-10-08","2016-05-18",82,[11386,6519],"Tobacco Use",[6522,11388,6521],"Bupropion",{"intervention":11388,"totalTrials":531,"cells":11390},{"EARLY_PHASE1":11391,"PHASE1":11393,"PHASE2":11395,"PHASE3":11397,"PHASE4":11399,"NA":11405},{"trials":11392,"activeCount":100},[],{"trials":11394,"activeCount":100},[],{"trials":11396,"activeCount":100},[],{"trials":11398,"activeCount":100},[],{"trials":11400,"activeCount":100},[11401],{"nctId":10576,"briefTitle":10577,"status":108,"phases":11402,"primaryCompletion":7637,"completion":7637,"start":4980,"enrollment":1773,"conditions":11403,"interventions":11404},[91],[22],[6564,10581],{"trials":11406,"activeCount":100},[11407],{"nctId":11379,"briefTitle":11380,"status":108,"phases":11408,"primaryCompletion":11382,"completion":2513,"start":11383,"enrollment":11384,"conditions":11409,"interventions":11410},[92],[11386,6519],[6522,11388,6521],{"intervention":6521,"totalTrials":531,"cells":11412},{"EARLY_PHASE1":11413,"PHASE1":11415,"PHASE2":11417,"PHASE3":11419,"PHASE4":11425,"NA":11427},{"trials":11414,"activeCount":100},[],{"trials":11416,"activeCount":100},[],{"trials":11418,"activeCount":100},[],{"trials":11420,"activeCount":100},[11421],{"nctId":6511,"briefTitle":6512,"status":108,"phases":11422,"primaryCompletion":6514,"completion":6515,"start":6516,"enrollment":6517,"conditions":11423,"interventions":11424},[89,90],[6519],[6521,6522,6500,6523],{"trials":11426,"activeCount":100},[],{"trials":11428,"activeCount":100},[11429],{"nctId":11379,"briefTitle":11380,"status":108,"phases":11430,"primaryCompletion":11382,"completion":2513,"start":11383,"enrollment":11384,"conditions":11431,"interventions":11432},[92],[11386,6519],[6522,11388,6521],{"intervention":3525,"totalTrials":531,"cells":11434},{"EARLY_PHASE1":11435,"PHASE1":11437,"PHASE2":11443,"PHASE3":11445,"PHASE4":11447,"NA":11449},{"trials":11436,"activeCount":100},[],{"trials":11438,"activeCount":100},[11439],{"nctId":3513,"briefTitle":3514,"status":108,"phases":11440,"primaryCompletion":1434,"completion":1434,"start":3516,"enrollment":3517,"conditions":11441,"interventions":11442},[88],[19],[3520,3521,3522,3523,3524,3525,3526,3420,3527,3528,3506,3529,3530,3531,3532,3533,3534,3535,3536,3537],{"trials":11444,"activeCount":100},[],{"trials":11446,"activeCount":100},[],{"trials":11448,"activeCount":100},[],{"trials":11450,"activeCount":100},[11451],{"nctId":11452,"briefTitle":11453,"status":605,"phases":11454,"primaryCompletion":9773,"completion":9773,"start":3410,"enrollment":100,"conditions":11455,"interventions":11457},"NCT01586286","A Study Examining the Use of Vaginal Nifedipine With Pelvic Floor Physical Therapy for Levator Myalgia and Pelvic Pain",[92],[11456],"Levator Ani Syndrome",[3525],{"intervention":11459,"totalTrials":531,"cells":11460},"Atenolol",{"EARLY_PHASE1":11461,"PHASE1":11463,"PHASE2":11465,"PHASE3":11467,"PHASE4":11469,"NA":11471},{"trials":11462,"activeCount":100},[],{"trials":11464,"activeCount":100},[],{"trials":11466,"activeCount":100},[],{"trials":11468,"activeCount":100},[],{"trials":11470,"activeCount":100},[],{"trials":11472,"activeCount":100},[11473,11479],{"nctId":11474,"briefTitle":11475,"status":108,"phases":11476,"primaryCompletion":936,"completion":936,"start":5206,"enrollment":4427,"conditions":11477,"interventions":11478},"NCT01719367","Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation",[92],[1088],[11459],{"nctId":11480,"briefTitle":11481,"status":108,"phases":11482,"primaryCompletion":11483,"completion":11484,"start":682,"enrollment":11485,"conditions":11486,"interventions":11487},"NCT00837902","Genetic Determinants of Response to Beta Blockade",[92],"2012-12-31","2014-12-31",154,[2333],[11459],{"intervention":10631,"totalTrials":531,"cells":11489},{"EARLY_PHASE1":11490,"PHASE1":11492,"PHASE2":11494,"PHASE3":11496,"PHASE4":11498,"NA":11500},{"trials":11491,"activeCount":100},[],{"trials":11493,"activeCount":100},[],{"trials":11495,"activeCount":100},[],{"trials":11497,"activeCount":100},[],{"trials":11499,"activeCount":100},[],{"trials":11501,"activeCount":100},[11502,11514],{"nctId":11503,"briefTitle":11504,"status":108,"phases":11505,"primaryCompletion":1446,"completion":1446,"start":11506,"enrollment":11507,"conditions":11508,"interventions":11511},"NCT00875238","Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab",[],"2008-06",133,[6884,11509,11510],"Cardiac Toxicity","Cardiovascular Complications",[11512,11513,10631],"trastuzumab","doxorubicin hydrochloride",{"nctId":10624,"briefTitle":10625,"status":108,"phases":11515,"primaryCompletion":3410,"completion":3410,"start":111,"enrollment":1371,"conditions":11516,"interventions":11517},[],[7570],[10595,10629,10630,10631],{"intervention":10629,"totalTrials":531,"cells":11519},{"EARLY_PHASE1":11520,"PHASE1":11522,"PHASE2":11524,"PHASE3":11526,"PHASE4":11528,"NA":11530},{"trials":11521,"activeCount":100},[],{"trials":11523,"activeCount":100},[],{"trials":11525,"activeCount":100},[],{"trials":11527,"activeCount":100},[],{"trials":11529,"activeCount":100},[],{"trials":11531,"activeCount":100},[11532,11536],{"nctId":10624,"briefTitle":10625,"status":108,"phases":11533,"primaryCompletion":3410,"completion":3410,"start":111,"enrollment":1371,"conditions":11534,"interventions":11535},[],[7570],[10595,10629,10630,10631],{"nctId":10641,"briefTitle":10642,"status":108,"phases":11537,"start":6755,"enrollment":412,"conditions":11538,"interventions":11539},[],[7570],[10595,10629,10646,10630,10622,10647],{"intervention":10172,"totalTrials":531,"cells":11541},{"EARLY_PHASE1":11542,"PHASE1":11548,"PHASE2":11550,"PHASE3":11552,"PHASE4":11554,"NA":11556},{"trials":11543,"activeCount":100},[11544],{"nctId":10166,"briefTitle":10167,"status":605,"phases":11545,"primaryCompletion":10145,"completion":10145,"enrollment":100,"conditions":11546,"interventions":11547},[87],[16,10170],[10161,10172],{"trials":11549,"activeCount":100},[],{"trials":11551,"activeCount":100},[],{"trials":11553,"activeCount":100},[],{"trials":11555,"activeCount":100},[],{"trials":11557,"activeCount":100},[11558],{"nctId":11559,"briefTitle":11560,"status":108,"phases":11561,"primaryCompletion":6755,"completion":2977,"start":3444,"enrollment":1172,"conditions":11562,"interventions":11563},"NCT00927524","Insulin Exposure and Glucose Response to Meals in Type 1 Diabetic Subjects Administered Two Different Insulin Regimens Compared to the Endogenous Insulin Exposure and Glucose Response to Meals In Healthy Adult Controls",[92],[1174],[11564,10172],"Insulin glulisine",{"intervention":11566,"totalTrials":531,"cells":11567},"pioglitazone",{"EARLY_PHASE1":11568,"PHASE1":11570,"PHASE2":11572,"PHASE3":11580,"PHASE4":11582,"NA":11584},{"trials":11569,"activeCount":100},[],{"trials":11571,"activeCount":100},[],{"trials":11573,"activeCount":100},[11574],{"nctId":11575,"briefTitle":11576,"status":659,"phases":11577,"primaryCompletion":9546,"completion":9546,"start":6755,"enrollment":1220,"conditions":11578,"interventions":11579},"NCT00368017","Metabolic Effects of Thiazolidinediones in Chronic Kidney Disease",[89],[6748],[11566],{"trials":11581,"activeCount":100},[],{"trials":11583,"activeCount":100},[],{"trials":11585,"activeCount":100},[11586],{"nctId":11587,"briefTitle":11588,"status":108,"phases":11589,"primaryCompletion":1022,"completion":681,"start":9246,"enrollment":20,"conditions":11590,"interventions":11591},"NCT00763139","Inflammation and Insulin Resistance in Rheumatoid Arthritis",[92],[8034],[11592],"Pioglitazone",{"intervention":3070,"totalTrials":531,"cells":11594},{"EARLY_PHASE1":11595,"PHASE1":11597,"PHASE2":11599,"PHASE3":11601,"PHASE4":11603,"NA":11605},{"trials":11596,"activeCount":100},[],{"trials":11598,"activeCount":100},[],{"trials":11600,"activeCount":100},[],{"trials":11602,"activeCount":100},[],{"trials":11604,"activeCount":100},[],{"trials":11606,"activeCount":100},[11607,11611],{"nctId":10704,"briefTitle":10705,"status":108,"phases":11608,"primaryCompletion":2278,"completion":10707,"start":10708,"enrollment":10709,"conditions":11609,"interventions":11610},[92],[10711,10712],[586,10714,10715,560,3070],{"nctId":3052,"briefTitle":3053,"status":108,"phases":11612,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":11613,"interventions":11614},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":3069,"totalTrials":531,"cells":11616},{"EARLY_PHASE1":11617,"PHASE1":11619,"PHASE2":11621,"PHASE3":11623,"PHASE4":11625,"NA":11627},{"trials":11618,"activeCount":100},[],{"trials":11620,"activeCount":100},[],{"trials":11622,"activeCount":100},[],{"trials":11624,"activeCount":100},[],{"trials":11626,"activeCount":100},[],{"trials":11628,"activeCount":100},[11629,11633],{"nctId":10540,"briefTitle":10541,"status":659,"phases":11630,"primaryCompletion":5786,"completion":5786,"start":4426,"enrollment":10543,"conditions":11631,"interventions":11632},[92],[10124],[3081,3069,3066,6589],{"nctId":3052,"briefTitle":3053,"status":108,"phases":11634,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":11635,"interventions":11636},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":3066,"totalTrials":531,"cells":11638},{"EARLY_PHASE1":11639,"PHASE1":11641,"PHASE2":11643,"PHASE3":11645,"PHASE4":11647,"NA":11649},{"trials":11640,"activeCount":100},[],{"trials":11642,"activeCount":100},[],{"trials":11644,"activeCount":100},[],{"trials":11646,"activeCount":100},[],{"trials":11648,"activeCount":100},[],{"trials":11650,"activeCount":100},[11651,11655],{"nctId":10540,"briefTitle":10541,"status":659,"phases":11652,"primaryCompletion":5786,"completion":5786,"start":4426,"enrollment":10543,"conditions":11653,"interventions":11654},[92],[10124],[3081,3069,3066,6589],{"nctId":3052,"briefTitle":3053,"status":108,"phases":11656,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":11657,"interventions":11658},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":3074,"totalTrials":531,"cells":11660},{"EARLY_PHASE1":11661,"PHASE1":11663,"PHASE2":11665,"PHASE3":11667,"PHASE4":11669,"NA":11671},{"trials":11662,"activeCount":100},[],{"trials":11664,"activeCount":100},[],{"trials":11666,"activeCount":100},[],{"trials":11668,"activeCount":100},[],{"trials":11670,"activeCount":100},[],{"trials":11672,"activeCount":100},[11673,11677],{"nctId":3052,"briefTitle":3053,"status":108,"phases":11674,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":11675,"interventions":11676},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"nctId":3179,"briefTitle":3180,"status":108,"phases":11678,"primaryCompletion":3182,"completion":3182,"start":3183,"enrollment":3184,"conditions":11679,"interventions":11680},[92],[3186],[3074,3188],{"intervention":11682,"totalTrials":138,"cells":11683},"Cosyntropin administration",{"EARLY_PHASE1":11684,"PHASE1":11686,"PHASE2":11688,"PHASE3":11690,"PHASE4":11692,"NA":11694},{"trials":11685,"activeCount":100},[],{"trials":11687,"activeCount":100},[],{"trials":11689,"activeCount":100},[],{"trials":11691,"activeCount":100},[],{"trials":11693,"activeCount":100},[],{"trials":11695,"activeCount":100},[11696],{"nctId":11697,"briefTitle":11698,"status":108,"phases":11699,"primaryCompletion":11700,"completion":11700,"start":5206,"enrollment":5629,"conditions":11701,"interventions":11702},"NCT01764711","Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS)",[92],"2020-12-31",[37],[11682],{"intervention":11704,"totalTrials":138,"cells":11705},"Steroid and Proton Pump Inhibitor Therapy",{"EARLY_PHASE1":11706,"PHASE1":11708,"PHASE2":11710,"PHASE3":11712,"PHASE4":11714,"NA":11716},{"trials":11707,"activeCount":100},[],{"trials":11709,"activeCount":100},[],{"trials":11711,"activeCount":100},[],{"trials":11713,"activeCount":100},[],{"trials":11715,"activeCount":100},[],{"trials":11717,"activeCount":100},[11718],{"nctId":11719,"briefTitle":11720,"status":108,"phases":11721,"primaryCompletion":681,"completion":681,"start":2233,"enrollment":124,"conditions":11722,"interventions":11724},"NCT00880906","Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis",[92],[11723],"Suspected Eosinophilic Esophagitis",[11704],{"intervention":11726,"totalTrials":138,"cells":11727},"Normal Saline 0.9% Infusion Solution Bag",{"EARLY_PHASE1":11728,"PHASE1":11730,"PHASE2":11732,"PHASE3":11734,"PHASE4":11736,"NA":11738},{"trials":11729,"activeCount":100},[],{"trials":11731,"activeCount":100},[],{"trials":11733,"activeCount":100},[],{"trials":11735,"activeCount":100},[],{"trials":11737,"activeCount":100},[],{"trials":11739,"activeCount":100},[11740],{"nctId":11741,"briefTitle":11742,"status":108,"phases":11743,"primaryCompletion":11744,"completion":11744,"start":11745,"enrollment":32,"conditions":11746,"interventions":11747},"NCT04223531","The Natriuretic Peptide Response to Saline Infusion",[92],"2022-06-17","2020-10-26",[16],[11726],{"intervention":10382,"totalTrials":138,"cells":11749},{"EARLY_PHASE1":11750,"PHASE1":11752,"PHASE2":11754,"PHASE3":11756,"PHASE4":11758,"NA":11760},{"trials":11751,"activeCount":100},[],{"trials":11753,"activeCount":100},[],{"trials":11755,"activeCount":100},[],{"trials":11757,"activeCount":100},[],{"trials":11759,"activeCount":100},[],{"trials":11761,"activeCount":100},[11762],{"nctId":10375,"briefTitle":10376,"status":108,"phases":11763,"primaryCompletion":10378,"completion":10146,"start":4768,"enrollment":1414,"conditions":11764,"interventions":11765},[92],[19,10380],[1341,10382,10383,10384,10385,10386],{"intervention":10385,"totalTrials":138,"cells":11767},{"EARLY_PHASE1":11768,"PHASE1":11770,"PHASE2":11772,"PHASE3":11774,"PHASE4":11776,"NA":11778},{"trials":11769,"activeCount":100},[],{"trials":11771,"activeCount":100},[],{"trials":11773,"activeCount":100},[],{"trials":11775,"activeCount":100},[],{"trials":11777,"activeCount":100},[],{"trials":11779,"activeCount":100},[11780],{"nctId":10375,"briefTitle":10376,"status":108,"phases":11781,"primaryCompletion":10378,"completion":10146,"start":4768,"enrollment":1414,"conditions":11782,"interventions":11783},[92],[19,10380],[1341,10382,10383,10384,10385,10386],{"intervention":10386,"totalTrials":138,"cells":11785},{"EARLY_PHASE1":11786,"PHASE1":11788,"PHASE2":11790,"PHASE3":11792,"PHASE4":11794,"NA":11796},{"trials":11787,"activeCount":100},[],{"trials":11789,"activeCount":100},[],{"trials":11791,"activeCount":100},[],{"trials":11793,"activeCount":100},[],{"trials":11795,"activeCount":100},[],{"trials":11797,"activeCount":100},[11798],{"nctId":10375,"briefTitle":10376,"status":108,"phases":11799,"primaryCompletion":10378,"completion":10146,"start":4768,"enrollment":1414,"conditions":11800,"interventions":11801},[92],[19,10380],[1341,10382,10383,10384,10385,10386],{"intervention":11803,"totalTrials":138,"cells":11804},"Influenza Vaccine Recipients",{"EARLY_PHASE1":11805,"PHASE1":11807,"PHASE2":11809,"PHASE3":11811,"PHASE4":11813,"NA":11815},{"trials":11806,"activeCount":100},[],{"trials":11808,"activeCount":100},[],{"trials":11810,"activeCount":100},[],{"trials":11812,"activeCount":100},[],{"trials":11814,"activeCount":100},[],{"trials":11816,"activeCount":100},[11817],{"nctId":11818,"briefTitle":11819,"status":108,"phases":11820,"primaryCompletion":3284,"completion":3284,"start":11821,"enrollment":2911,"conditions":11822,"interventions":11828},"NCT03743688","Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults",[],"2018-12-04",[1248,11823,5383,11824,11825,11826,11827],"Influenza, Human","Influenza A","Influenza Type B","Influenza A H1N1","Influenza A H3N2",[11803],{"intervention":11830,"totalTrials":138,"cells":11831},"ropivicaine",{"EARLY_PHASE1":11832,"PHASE1":11834,"PHASE2":11836,"PHASE3":11838,"PHASE4":11840,"NA":11842},{"trials":11833,"activeCount":100},[],{"trials":11835,"activeCount":100},[],{"trials":11837,"activeCount":100},[],{"trials":11839,"activeCount":100},[],{"trials":11841,"activeCount":100},[],{"trials":11843,"activeCount":100},[11844],{"nctId":11845,"briefTitle":11846,"status":605,"phases":11847,"primaryCompletion":3411,"completion":3411,"start":5334,"enrollment":100,"conditions":11848,"interventions":11850},"NCT00945620","Trans-Abdominis Plane Block Efficacy for Post-Cesarean Section Pain",[92],[11849],"Pain Control",[11830],{"intervention":10833,"totalTrials":138,"cells":11852},{"EARLY_PHASE1":11853,"PHASE1":11855,"PHASE2":11857,"PHASE3":11859,"PHASE4":11861,"NA":11863},{"trials":11854,"activeCount":100},[],{"trials":11856,"activeCount":100},[],{"trials":11858,"activeCount":100},[],{"trials":11860,"activeCount":100},[],{"trials":11862,"activeCount":100},[],{"trials":11864,"activeCount":100},[11865],{"nctId":10819,"briefTitle":10820,"status":659,"phases":11866,"primaryCompletion":4640,"completion":4640,"start":4769,"enrollment":1172,"conditions":11867,"interventions":11868},[],[10823,10824,10825,10826,10827,10828,10829,10830,10831],[10833,10630],{"intervention":11870,"totalTrials":138,"cells":11871},"chemotherapy",{"EARLY_PHASE1":11872,"PHASE1":11874,"PHASE2":11876,"PHASE3":11878,"PHASE4":11880,"NA":11882},{"trials":11873,"activeCount":100},[],{"trials":11875,"activeCount":100},[],{"trials":11877,"activeCount":100},[],{"trials":11879,"activeCount":100},[],{"trials":11881,"activeCount":100},[],{"trials":11883,"activeCount":100},[11884],{"nctId":11885,"briefTitle":11886,"status":108,"phases":11887,"primaryCompletion":4425,"completion":4425,"start":682,"enrollment":2647,"conditions":11888,"interventions":11892},"NCT00993694","Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone",[],[10824,10825,10826,11889,11890,10827,10828,10829,11891],"Lymphoproliferative Disorder","Methemoglobinemia","Nonmalignant Neoplasm",[11870,11893],"dapsone",{"intervention":11893,"totalTrials":138,"cells":11895},{"EARLY_PHASE1":11896,"PHASE1":11898,"PHASE2":11900,"PHASE3":11902,"PHASE4":11904,"NA":11906},{"trials":11897,"activeCount":100},[],{"trials":11899,"activeCount":100},[],{"trials":11901,"activeCount":100},[],{"trials":11903,"activeCount":100},[],{"trials":11905,"activeCount":100},[],{"trials":11907,"activeCount":100},[11908],{"nctId":11885,"briefTitle":11886,"status":108,"phases":11909,"primaryCompletion":4425,"completion":4425,"start":682,"enrollment":2647,"conditions":11910,"interventions":11911},[],[10824,10825,10826,11889,11890,10827,10828,10829,11891],[11870,11893],{"intervention":11913,"totalTrials":138,"cells":11914},"Flecainide Acetate",{"EARLY_PHASE1":11915,"PHASE1":11917,"PHASE2":11919,"PHASE3":11921,"PHASE4":11923,"NA":11925},{"trials":11916,"activeCount":100},[],{"trials":11918,"activeCount":100},[],{"trials":11920,"activeCount":100},[],{"trials":11922,"activeCount":100},[],{"trials":11924,"activeCount":100},[],{"trials":11926,"activeCount":100},[11927],{"nctId":11928,"briefTitle":11929,"status":108,"phases":11930,"primaryCompletion":4196,"completion":4196,"start":2978,"enrollment":9224,"conditions":11931,"interventions":11932},"NCT01117454","Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia",[92],[11263],[11913,11933],"Beta blocker",{"intervention":11933,"totalTrials":138,"cells":11935},{"EARLY_PHASE1":11936,"PHASE1":11938,"PHASE2":11940,"PHASE3":11942,"PHASE4":11944,"NA":11946},{"trials":11937,"activeCount":100},[],{"trials":11939,"activeCount":100},[],{"trials":11941,"activeCount":100},[],{"trials":11943,"activeCount":100},[],{"trials":11945,"activeCount":100},[],{"trials":11947,"activeCount":100},[11948],{"nctId":11928,"briefTitle":11929,"status":108,"phases":11949,"primaryCompletion":4196,"completion":4196,"start":2978,"enrollment":9224,"conditions":11950,"interventions":11951},[92],[11263],[11913,11933],{"intervention":10619,"totalTrials":138,"cells":11953},{"EARLY_PHASE1":11954,"PHASE1":11956,"PHASE2":11958,"PHASE3":11960,"PHASE4":11962,"NA":11964},{"trials":11955,"activeCount":100},[],{"trials":11957,"activeCount":100},[],{"trials":11959,"activeCount":100},[],{"trials":11961,"activeCount":100},[],{"trials":11963,"activeCount":100},[],{"trials":11965,"activeCount":100},[11966],{"nctId":10610,"briefTitle":10611,"status":108,"phases":11967,"primaryCompletion":3183,"completion":10613,"start":10614,"enrollment":10615,"conditions":11968,"interventions":11969},[],[10617],[10619,10620,10595,10621,10622],{"intervention":10620,"totalTrials":138,"cells":11971},{"EARLY_PHASE1":11972,"PHASE1":11974,"PHASE2":11976,"PHASE3":11978,"PHASE4":11980,"NA":11982},{"trials":11973,"activeCount":100},[],{"trials":11975,"activeCount":100},[],{"trials":11977,"activeCount":100},[],{"trials":11979,"activeCount":100},[],{"trials":11981,"activeCount":100},[],{"trials":11983,"activeCount":100},[11984],{"nctId":10610,"briefTitle":10611,"status":108,"phases":11985,"primaryCompletion":3183,"completion":10613,"start":10614,"enrollment":10615,"conditions":11986,"interventions":11987},[],[10617],[10619,10620,10595,10621,10622],{"intervention":10621,"totalTrials":138,"cells":11989},{"EARLY_PHASE1":11990,"PHASE1":11992,"PHASE2":11994,"PHASE3":11996,"PHASE4":11998,"NA":12000},{"trials":11991,"activeCount":100},[],{"trials":11993,"activeCount":100},[],{"trials":11995,"activeCount":100},[],{"trials":11997,"activeCount":100},[],{"trials":11999,"activeCount":100},[],{"trials":12001,"activeCount":100},[12002],{"nctId":10610,"briefTitle":10611,"status":108,"phases":12003,"primaryCompletion":3183,"completion":10613,"start":10614,"enrollment":10615,"conditions":12004,"interventions":12005},[],[10617],[10619,10620,10595,10621,10622],{"intervention":10436,"totalTrials":138,"cells":12007},{"EARLY_PHASE1":12008,"PHASE1":12010,"PHASE2":12012,"PHASE3":12014,"PHASE4":12016,"NA":12018},{"trials":12009,"activeCount":100},[],{"trials":12011,"activeCount":100},[],{"trials":12013,"activeCount":100},[],{"trials":12015,"activeCount":100},[],{"trials":12017,"activeCount":100},[],{"trials":12019,"activeCount":100},[12020],{"nctId":10430,"briefTitle":10431,"status":108,"phases":12021,"primaryCompletion":8296,"completion":8296,"start":10146,"enrollment":10433,"conditions":12022,"interventions":12023},[92],[2333],[3500,10436,10437,10438,10439],{"intervention":10437,"totalTrials":138,"cells":12025},{"EARLY_PHASE1":12026,"PHASE1":12028,"PHASE2":12030,"PHASE3":12032,"PHASE4":12034,"NA":12036},{"trials":12027,"activeCount":100},[],{"trials":12029,"activeCount":100},[],{"trials":12031,"activeCount":100},[],{"trials":12033,"activeCount":100},[],{"trials":12035,"activeCount":100},[],{"trials":12037,"activeCount":100},[12038],{"nctId":10430,"briefTitle":10431,"status":108,"phases":12039,"primaryCompletion":8296,"completion":8296,"start":10146,"enrollment":10433,"conditions":12040,"interventions":12041},[92],[2333],[3500,10436,10437,10438,10439],{"intervention":10438,"totalTrials":138,"cells":12043},{"EARLY_PHASE1":12044,"PHASE1":12046,"PHASE2":12048,"PHASE3":12050,"PHASE4":12052,"NA":12054},{"trials":12045,"activeCount":100},[],{"trials":12047,"activeCount":100},[],{"trials":12049,"activeCount":100},[],{"trials":12051,"activeCount":100},[],{"trials":12053,"activeCount":100},[],{"trials":12055,"activeCount":100},[12056],{"nctId":10430,"briefTitle":10431,"status":108,"phases":12057,"primaryCompletion":8296,"completion":8296,"start":10146,"enrollment":10433,"conditions":12058,"interventions":12059},[92],[2333],[3500,10436,10437,10438,10439],{"intervention":10439,"totalTrials":138,"cells":12061},{"EARLY_PHASE1":12062,"PHASE1":12064,"PHASE2":12066,"PHASE3":12068,"PHASE4":12070,"NA":12072},{"trials":12063,"activeCount":100},[],{"trials":12065,"activeCount":100},[],{"trials":12067,"activeCount":100},[],{"trials":12069,"activeCount":100},[],{"trials":12071,"activeCount":100},[],{"trials":12073,"activeCount":100},[12074],{"nctId":10430,"briefTitle":10431,"status":108,"phases":12075,"primaryCompletion":8296,"completion":8296,"start":10146,"enrollment":10433,"conditions":12076,"interventions":12077},[92],[2333],[3500,10436,10437,10438,10439],{"intervention":12079,"totalTrials":138,"cells":12080},"Antibiotic PEP",{"EARLY_PHASE1":12081,"PHASE1":12083,"PHASE2":12085,"PHASE3":12087,"PHASE4":12089,"NA":12091},{"trials":12082,"activeCount":100},[],{"trials":12084,"activeCount":100},[],{"trials":12086,"activeCount":100},[],{"trials":12088,"activeCount":100},[],{"trials":12090,"activeCount":100},[],{"trials":12092,"activeCount":100},[12093],{"nctId":12094,"briefTitle":12095,"status":108,"phases":12096,"primaryCompletion":4425,"completion":4425,"start":3666,"enrollment":12097,"conditions":12098,"interventions":12100},"NCT00469274","Vanderbilt Pertussis Exposure Study: PEP in Vaccinated Healthcare Workers Following Pertussis Exposure",[92],1102,[12099],"Pertussis",[12079,12079],{"intervention":564,"totalTrials":138,"cells":12102},{"EARLY_PHASE1":12103,"PHASE1":12105,"PHASE2":12107,"PHASE3":12109,"PHASE4":12111,"NA":12113},{"trials":12104,"activeCount":100},[],{"trials":12106,"activeCount":100},[],{"trials":12108,"activeCount":100},[],{"trials":12110,"activeCount":100},[],{"trials":12112,"activeCount":100},[],{"trials":12114,"activeCount":100},[12115],{"nctId":550,"briefTitle":551,"status":108,"phases":12116,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":12117,"interventions":12118},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":568,"totalTrials":138,"cells":12120},{"EARLY_PHASE1":12121,"PHASE1":12123,"PHASE2":12125,"PHASE3":12127,"PHASE4":12129,"NA":12131},{"trials":12122,"activeCount":100},[],{"trials":12124,"activeCount":100},[],{"trials":12126,"activeCount":100},[],{"trials":12128,"activeCount":100},[],{"trials":12130,"activeCount":100},[],{"trials":12132,"activeCount":100},[12133],{"nctId":550,"briefTitle":551,"status":108,"phases":12134,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":12135,"interventions":12136},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":569,"totalTrials":138,"cells":12138},{"EARLY_PHASE1":12139,"PHASE1":12141,"PHASE2":12143,"PHASE3":12145,"PHASE4":12147,"NA":12149},{"trials":12140,"activeCount":100},[],{"trials":12142,"activeCount":100},[],{"trials":12144,"activeCount":100},[],{"trials":12146,"activeCount":100},[],{"trials":12148,"activeCount":100},[],{"trials":12150,"activeCount":100},[12151],{"nctId":550,"briefTitle":551,"status":108,"phases":12152,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":12153,"interventions":12154},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":571,"totalTrials":138,"cells":12156},{"EARLY_PHASE1":12157,"PHASE1":12159,"PHASE2":12161,"PHASE3":12163,"PHASE4":12165,"NA":12167},{"trials":12158,"activeCount":100},[],{"trials":12160,"activeCount":100},[],{"trials":12162,"activeCount":100},[],{"trials":12164,"activeCount":100},[],{"trials":12166,"activeCount":100},[],{"trials":12168,"activeCount":100},[12169],{"nctId":550,"briefTitle":551,"status":108,"phases":12170,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":12171,"interventions":12172},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":573,"totalTrials":138,"cells":12174},{"EARLY_PHASE1":12175,"PHASE1":12177,"PHASE2":12179,"PHASE3":12181,"PHASE4":12183,"NA":12185},{"trials":12176,"activeCount":100},[],{"trials":12178,"activeCount":100},[],{"trials":12180,"activeCount":100},[],{"trials":12182,"activeCount":100},[],{"trials":12184,"activeCount":100},[],{"trials":12186,"activeCount":100},[12187],{"nctId":550,"briefTitle":551,"status":108,"phases":12188,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":12189,"interventions":12190},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":574,"totalTrials":138,"cells":12192},{"EARLY_PHASE1":12193,"PHASE1":12195,"PHASE2":12197,"PHASE3":12199,"PHASE4":12201,"NA":12203},{"trials":12194,"activeCount":100},[],{"trials":12196,"activeCount":100},[],{"trials":12198,"activeCount":100},[],{"trials":12200,"activeCount":100},[],{"trials":12202,"activeCount":100},[],{"trials":12204,"activeCount":100},[12205],{"nctId":550,"briefTitle":551,"status":108,"phases":12206,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":12207,"interventions":12208},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":575,"totalTrials":138,"cells":12210},{"EARLY_PHASE1":12211,"PHASE1":12213,"PHASE2":12215,"PHASE3":12217,"PHASE4":12219,"NA":12221},{"trials":12212,"activeCount":100},[],{"trials":12214,"activeCount":100},[],{"trials":12216,"activeCount":100},[],{"trials":12218,"activeCount":100},[],{"trials":12220,"activeCount":100},[],{"trials":12222,"activeCount":100},[12223],{"nctId":550,"briefTitle":551,"status":108,"phases":12224,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":12225,"interventions":12226},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":576,"totalTrials":138,"cells":12228},{"EARLY_PHASE1":12229,"PHASE1":12231,"PHASE2":12233,"PHASE3":12235,"PHASE4":12237,"NA":12239},{"trials":12230,"activeCount":100},[],{"trials":12232,"activeCount":100},[],{"trials":12234,"activeCount":100},[],{"trials":12236,"activeCount":100},[],{"trials":12238,"activeCount":100},[],{"trials":12240,"activeCount":100},[12241],{"nctId":550,"briefTitle":551,"status":108,"phases":12242,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":12243,"interventions":12244},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":577,"totalTrials":138,"cells":12246},{"EARLY_PHASE1":12247,"PHASE1":12249,"PHASE2":12251,"PHASE3":12253,"PHASE4":12255,"NA":12257},{"trials":12248,"activeCount":100},[],{"trials":12250,"activeCount":100},[],{"trials":12252,"activeCount":100},[],{"trials":12254,"activeCount":100},[],{"trials":12256,"activeCount":100},[],{"trials":12258,"activeCount":100},[12259],{"nctId":550,"briefTitle":551,"status":108,"phases":12260,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":12261,"interventions":12262},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":578,"totalTrials":138,"cells":12264},{"EARLY_PHASE1":12265,"PHASE1":12267,"PHASE2":12269,"PHASE3":12271,"PHASE4":12273,"NA":12275},{"trials":12266,"activeCount":100},[],{"trials":12268,"activeCount":100},[],{"trials":12270,"activeCount":100},[],{"trials":12272,"activeCount":100},[],{"trials":12274,"activeCount":100},[],{"trials":12276,"activeCount":100},[12277],{"nctId":550,"briefTitle":551,"status":108,"phases":12278,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":12279,"interventions":12280},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":579,"totalTrials":138,"cells":12282},{"EARLY_PHASE1":12283,"PHASE1":12285,"PHASE2":12287,"PHASE3":12289,"PHASE4":12291,"NA":12293},{"trials":12284,"activeCount":100},[],{"trials":12286,"activeCount":100},[],{"trials":12288,"activeCount":100},[],{"trials":12290,"activeCount":100},[],{"trials":12292,"activeCount":100},[],{"trials":12294,"activeCount":100},[12295],{"nctId":550,"briefTitle":551,"status":108,"phases":12296,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":12297,"interventions":12298},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":580,"totalTrials":138,"cells":12300},{"EARLY_PHASE1":12301,"PHASE1":12303,"PHASE2":12305,"PHASE3":12307,"PHASE4":12309,"NA":12311},{"trials":12302,"activeCount":100},[],{"trials":12304,"activeCount":100},[],{"trials":12306,"activeCount":100},[],{"trials":12308,"activeCount":100},[],{"trials":12310,"activeCount":100},[],{"trials":12312,"activeCount":100},[12313],{"nctId":550,"briefTitle":551,"status":108,"phases":12314,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":12315,"interventions":12316},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":581,"totalTrials":138,"cells":12318},{"EARLY_PHASE1":12319,"PHASE1":12321,"PHASE2":12323,"PHASE3":12325,"PHASE4":12327,"NA":12329},{"trials":12320,"activeCount":100},[],{"trials":12322,"activeCount":100},[],{"trials":12324,"activeCount":100},[],{"trials":12326,"activeCount":100},[],{"trials":12328,"activeCount":100},[],{"trials":12330,"activeCount":100},[12331],{"nctId":550,"briefTitle":551,"status":108,"phases":12332,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":12333,"interventions":12334},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":584,"totalTrials":138,"cells":12336},{"EARLY_PHASE1":12337,"PHASE1":12339,"PHASE2":12341,"PHASE3":12343,"PHASE4":12345,"NA":12347},{"trials":12338,"activeCount":100},[],{"trials":12340,"activeCount":100},[],{"trials":12342,"activeCount":100},[],{"trials":12344,"activeCount":100},[],{"trials":12346,"activeCount":100},[],{"trials":12348,"activeCount":100},[12349],{"nctId":550,"briefTitle":551,"status":108,"phases":12350,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":12351,"interventions":12352},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":587,"totalTrials":138,"cells":12354},{"EARLY_PHASE1":12355,"PHASE1":12357,"PHASE2":12359,"PHASE3":12361,"PHASE4":12363,"NA":12365},{"trials":12356,"activeCount":100},[],{"trials":12358,"activeCount":100},[],{"trials":12360,"activeCount":100},[],{"trials":12362,"activeCount":100},[],{"trials":12364,"activeCount":100},[],{"trials":12366,"activeCount":100},[12367],{"nctId":550,"briefTitle":551,"status":108,"phases":12368,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":12369,"interventions":12370},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":588,"totalTrials":138,"cells":12372},{"EARLY_PHASE1":12373,"PHASE1":12375,"PHASE2":12377,"PHASE3":12379,"PHASE4":12381,"NA":12383},{"trials":12374,"activeCount":100},[],{"trials":12376,"activeCount":100},[],{"trials":12378,"activeCount":100},[],{"trials":12380,"activeCount":100},[],{"trials":12382,"activeCount":100},[],{"trials":12384,"activeCount":100},[12385],{"nctId":550,"briefTitle":551,"status":108,"phases":12386,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":12387,"interventions":12388},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":589,"totalTrials":138,"cells":12390},{"EARLY_PHASE1":12391,"PHASE1":12393,"PHASE2":12395,"PHASE3":12397,"PHASE4":12399,"NA":12401},{"trials":12392,"activeCount":100},[],{"trials":12394,"activeCount":100},[],{"trials":12396,"activeCount":100},[],{"trials":12398,"activeCount":100},[],{"trials":12400,"activeCount":100},[],{"trials":12402,"activeCount":100},[12403],{"nctId":550,"briefTitle":551,"status":108,"phases":12404,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":12405,"interventions":12406},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":590,"totalTrials":138,"cells":12408},{"EARLY_PHASE1":12409,"PHASE1":12411,"PHASE2":12413,"PHASE3":12415,"PHASE4":12417,"NA":12419},{"trials":12410,"activeCount":100},[],{"trials":12412,"activeCount":100},[],{"trials":12414,"activeCount":100},[],{"trials":12416,"activeCount":100},[],{"trials":12418,"activeCount":100},[],{"trials":12420,"activeCount":100},[12421],{"nctId":550,"briefTitle":551,"status":108,"phases":12422,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":12423,"interventions":12424},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":592,"totalTrials":138,"cells":12426},{"EARLY_PHASE1":12427,"PHASE1":12429,"PHASE2":12431,"PHASE3":12433,"PHASE4":12435,"NA":12437},{"trials":12428,"activeCount":100},[],{"trials":12430,"activeCount":100},[],{"trials":12432,"activeCount":100},[],{"trials":12434,"activeCount":100},[],{"trials":12436,"activeCount":100},[],{"trials":12438,"activeCount":100},[12439],{"nctId":550,"briefTitle":551,"status":108,"phases":12440,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":12441,"interventions":12442},[92],[558],[560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,391,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592],{"intervention":12444,"totalTrials":138,"cells":12445},"Glimepiride",{"EARLY_PHASE1":12446,"PHASE1":12448,"PHASE2":12450,"PHASE3":12452,"PHASE4":12454,"NA":12456},{"trials":12447,"activeCount":100},[],{"trials":12449,"activeCount":100},[],{"trials":12451,"activeCount":100},[],{"trials":12453,"activeCount":100},[],{"trials":12455,"activeCount":100},[],{"trials":12457,"activeCount":100},[12458],{"nctId":12459,"briefTitle":12460,"status":108,"phases":12461,"primaryCompletion":2525,"completion":2977,"start":133,"enrollment":3614,"conditions":12462,"interventions":12463},"NCT00608179","Glimepiride Induced Insulin Secretion Will be Inhibited by Hypoglycemia",[92],[34],[12444,12464],"glyburide",{"intervention":12464,"totalTrials":138,"cells":12466},{"EARLY_PHASE1":12467,"PHASE1":12469,"PHASE2":12471,"PHASE3":12473,"PHASE4":12475,"NA":12477},{"trials":12468,"activeCount":100},[],{"trials":12470,"activeCount":100},[],{"trials":12472,"activeCount":100},[],{"trials":12474,"activeCount":100},[],{"trials":12476,"activeCount":100},[],{"trials":12478,"activeCount":100},[12479],{"nctId":12459,"briefTitle":12460,"status":108,"phases":12480,"primaryCompletion":2525,"completion":2977,"start":133,"enrollment":3614,"conditions":12481,"interventions":12482},[92],[34],[12444,12464],{"intervention":12484,"totalTrials":138,"cells":12485},"Definity Suspension for",{"EARLY_PHASE1":12486,"PHASE1":12488,"PHASE2":12490,"PHASE3":12492,"PHASE4":12494,"NA":12496},{"trials":12487,"activeCount":100},[],{"trials":12489,"activeCount":100},[],{"trials":12491,"activeCount":100},[],{"trials":12493,"activeCount":100},[],{"trials":12495,"activeCount":100},[],{"trials":12497,"activeCount":100},[12498],{"nctId":12499,"briefTitle":12500,"status":108,"phases":12501,"primaryCompletion":12502,"completion":12503,"start":12504,"enrollment":2116,"conditions":12505,"interventions":12506},"NCT05135169","Multi-organ Transit Time Acquisition Using Contrast Ultrasound",[],"2023-06-16","2025-06-30","2022-03-03",[2333],[12484],{"intervention":12508,"totalTrials":138,"cells":12509},"Scopolamine Injectable Product",{"EARLY_PHASE1":12510,"PHASE1":12512,"PHASE2":12514,"PHASE3":12516,"PHASE4":12518,"NA":12520},{"trials":12511,"activeCount":100},[],{"trials":12513,"activeCount":100},[],{"trials":12515,"activeCount":100},[],{"trials":12517,"activeCount":100},[],{"trials":12519,"activeCount":100},[],{"trials":12521,"activeCount":100},[12522],{"nctId":12523,"briefTitle":12524,"status":108,"phases":12525,"primaryCompletion":1433,"completion":1433,"start":4196,"enrollment":26,"conditions":12526,"interventions":12531},"NCT03244488","Mental Ability Challenge Study in Adults With and Without HIV",[],[12527,12528,8376,12529,12530],"HIV-1-infection","Aging, Premature","Memory Impairment","HIV-Associated Cognitive Motor Complex",[12508,12532],"Mecamylamine Pill",{"intervention":12532,"totalTrials":138,"cells":12534},{"EARLY_PHASE1":12535,"PHASE1":12537,"PHASE2":12539,"PHASE3":12541,"PHASE4":12543,"NA":12545},{"trials":12536,"activeCount":100},[],{"trials":12538,"activeCount":100},[],{"trials":12540,"activeCount":100},[],{"trials":12542,"activeCount":100},[],{"trials":12544,"activeCount":100},[],{"trials":12546,"activeCount":100},[12547],{"nctId":12523,"briefTitle":12524,"status":108,"phases":12548,"primaryCompletion":1433,"completion":1433,"start":4196,"enrollment":26,"conditions":12549,"interventions":12550},[],[12527,12528,8376,12529,12530],[12508,12532],{"intervention":12552,"totalTrials":138,"cells":12553},"methotrexate",{"EARLY_PHASE1":12554,"PHASE1":12556,"PHASE2":12558,"PHASE3":12560,"PHASE4":12562,"NA":12564},{"trials":12555,"activeCount":100},[],{"trials":12557,"activeCount":100},[],{"trials":12559,"activeCount":100},[],{"trials":12561,"activeCount":100},[],{"trials":12563,"activeCount":100},[],{"trials":12565,"activeCount":100},[12566],{"nctId":12567,"briefTitle":12568,"status":108,"phases":12569,"primaryCompletion":4425,"start":5628,"enrollment":2911,"conditions":12570,"interventions":12572},"NCT00993135","Kidney Dysfunction in Children and Young Adults Who Have Received Methotrexate for Acute Lymphoblastic Leukemia",[],[10825,12571],"Renal Toxicity",[12552],{"intervention":12574,"totalTrials":138,"cells":12575},"540,000 IU vitamin D3",{"EARLY_PHASE1":12576,"PHASE1":12578,"PHASE2":12580,"PHASE3":12582,"PHASE4":12584,"NA":12586},{"trials":12577,"activeCount":100},[],{"trials":12579,"activeCount":100},[],{"trials":12581,"activeCount":100},[],{"trials":12583,"activeCount":100},[],{"trials":12585,"activeCount":100},[],{"trials":12587,"activeCount":100},[12588],{"nctId":12589,"briefTitle":12590,"status":108,"phases":12591,"primaryCompletion":12592,"completion":12593,"start":12594,"enrollment":1086,"conditions":12595,"interventions":12596},"NCT03733418","Vitamin D to Improve Outcomes by Leveraging Early Treatment: Long-term Brain Outcomes in Vitamin D Deficient Patients",[],"2019-10-02","2020-02-21","2018-11-01",[7782],[12574],{"intervention":12598,"totalTrials":138,"cells":12599},"Statin, beta blocker",{"EARLY_PHASE1":12600,"PHASE1":12602,"PHASE2":12604,"PHASE3":12606,"PHASE4":12608,"NA":12610},{"trials":12601,"activeCount":100},[],{"trials":12603,"activeCount":100},[],{"trials":12605,"activeCount":100},[],{"trials":12607,"activeCount":100},[],{"trials":12609,"activeCount":100},[],{"trials":12611,"activeCount":100},[12612],{"nctId":12613,"briefTitle":12614,"status":108,"phases":12615,"primaryCompletion":1061,"completion":1988,"start":10515,"enrollment":12616,"conditions":12617,"interventions":12618},"NCT02548975","Risk Factors for Delirium Following Cardiac Surgery",[],5600,[25],[12598],{"intervention":11512,"totalTrials":138,"cells":12620},{"EARLY_PHASE1":12621,"PHASE1":12623,"PHASE2":12625,"PHASE3":12627,"PHASE4":12629,"NA":12631},{"trials":12622,"activeCount":100},[],{"trials":12624,"activeCount":100},[],{"trials":12626,"activeCount":100},[],{"trials":12628,"activeCount":100},[],{"trials":12630,"activeCount":100},[],{"trials":12632,"activeCount":100},[12633],{"nctId":11503,"briefTitle":11504,"status":108,"phases":12634,"primaryCompletion":1446,"completion":1446,"start":11506,"enrollment":11507,"conditions":12635,"interventions":12636},[],[6884,11509,11510],[11512,11513,10631],{"intervention":11513,"totalTrials":138,"cells":12638},{"EARLY_PHASE1":12639,"PHASE1":12641,"PHASE2":12643,"PHASE3":12645,"PHASE4":12647,"NA":12649},{"trials":12640,"activeCount":100},[],{"trials":12642,"activeCount":100},[],{"trials":12644,"activeCount":100},[],{"trials":12646,"activeCount":100},[],{"trials":12648,"activeCount":100},[],{"trials":12650,"activeCount":100},[12651],{"nctId":11503,"briefTitle":11504,"status":108,"phases":12652,"primaryCompletion":1446,"completion":1446,"start":11506,"enrollment":11507,"conditions":12653,"interventions":12654},[],[6884,11509,11510],[11512,11513,10631],{"intervention":12656,"totalTrials":138,"cells":12657},"Optimal drug therapy",{"EARLY_PHASE1":12658,"PHASE1":12660,"PHASE2":12662,"PHASE3":12664,"PHASE4":12666,"NA":12668},{"trials":12659,"activeCount":100},[],{"trials":12661,"activeCount":100},[],{"trials":12663,"activeCount":100},[],{"trials":12665,"activeCount":100},[],{"trials":12667,"activeCount":100},[],{"trials":12669,"activeCount":100},[12670],{"nctId":12671,"briefTitle":12672,"status":108,"phases":12673,"primaryCompletion":3706,"completion":12674,"start":110,"enrollment":4939,"conditions":12675,"interventions":12676},"NCT00282152","Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD)",[92],"2015-10",[6585],[12656],{"intervention":12678,"totalTrials":138,"cells":12679},"Procainamide",{"EARLY_PHASE1":12680,"PHASE1":12682,"PHASE2":12684,"PHASE3":12686,"PHASE4":12688,"NA":12690},{"trials":12681,"activeCount":100},[],{"trials":12683,"activeCount":100},[],{"trials":12685,"activeCount":100},[],{"trials":12687,"activeCount":100},[],{"trials":12689,"activeCount":100},[],{"trials":12691,"activeCount":100},[12692],{"nctId":12693,"briefTitle":12694,"status":108,"phases":12695,"primaryCompletion":1062,"completion":1062,"start":9839,"enrollment":12696,"conditions":12697,"interventions":12698},"NCT01205529","ST-segment Elevation as an AF Endophenotype",[92],161,[1088],[12678],{"intervention":12700,"totalTrials":138,"cells":12701},"kineret",{"EARLY_PHASE1":12702,"PHASE1":12704,"PHASE2":12706,"PHASE3":12708,"PHASE4":12710,"NA":12712},{"trials":12703,"activeCount":100},[],{"trials":12705,"activeCount":100},[],{"trials":12707,"activeCount":100},[],{"trials":12709,"activeCount":100},[],{"trials":12711,"activeCount":100},[],{"trials":12713,"activeCount":100},[12714],{"nctId":12715,"briefTitle":12716,"status":108,"phases":12717,"primaryCompletion":924,"completion":924,"start":4744,"enrollment":2250,"conditions":12718,"interventions":12719},"NCT00420290","Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients",[92],[6712],[12700],{"intervention":10638,"totalTrials":138,"cells":12721},{"EARLY_PHASE1":12722,"PHASE1":12724,"PHASE2":12726,"PHASE3":12728,"PHASE4":12730,"NA":12732},{"trials":12723,"activeCount":100},[],{"trials":12725,"activeCount":100},[],{"trials":12727,"activeCount":100},[],{"trials":12729,"activeCount":100},[],{"trials":12731,"activeCount":100},[],{"trials":12733,"activeCount":100},[12734],{"nctId":10633,"briefTitle":10634,"status":108,"phases":12735,"start":7614,"conditions":12736,"interventions":12737},[],[7570],[10638,10639,10595,10622],{"intervention":10639,"totalTrials":138,"cells":12739},{"EARLY_PHASE1":12740,"PHASE1":12742,"PHASE2":12744,"PHASE3":12746,"PHASE4":12748,"NA":12750},{"trials":12741,"activeCount":100},[],{"trials":12743,"activeCount":100},[],{"trials":12745,"activeCount":100},[],{"trials":12747,"activeCount":100},[],{"trials":12749,"activeCount":100},[],{"trials":12751,"activeCount":100},[12752],{"nctId":10633,"briefTitle":10634,"status":108,"phases":12753,"start":7614,"conditions":12754,"interventions":12755},[],[7570],[10638,10639,10595,10622],{"intervention":12757,"totalTrials":138,"cells":12758},"Alprazolam",{"EARLY_PHASE1":12759,"PHASE1":12761,"PHASE2":12763,"PHASE3":12765,"PHASE4":12767,"NA":12769},{"trials":12760,"activeCount":100},[],{"trials":12762,"activeCount":100},[],{"trials":12764,"activeCount":100},[],{"trials":12766,"activeCount":100},[],{"trials":12768,"activeCount":100},[],{"trials":12770,"activeCount":100},[12771],{"nctId":12772,"briefTitle":12773,"status":108,"phases":12774,"primaryCompletion":2320,"completion":732,"start":7984,"enrollment":17,"conditions":12775,"interventions":12776},"NCT00592332","Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2",[92],[1174],[12757],{"intervention":12778,"totalTrials":138,"cells":12779},"Walking Exercise Group",{"EARLY_PHASE1":12780,"PHASE1":12782,"PHASE2":12784,"PHASE3":12786,"PHASE4":12788,"NA":12790},{"trials":12781,"activeCount":100},[],{"trials":12783,"activeCount":100},[],{"trials":12785,"activeCount":100},[],{"trials":12787,"activeCount":100},[],{"trials":12789,"activeCount":100},[],{"trials":12791,"activeCount":100},[12792],{"nctId":12793,"briefTitle":12794,"status":108,"phases":12795,"primaryCompletion":12796,"completion":12796,"start":1021,"enrollment":9480,"conditions":12797,"interventions":12798},"NCT00937443","Effectiveness of a Walking Program Modulating Cardioreparative Factors in Heart Failure",[],"2014-01",[651],[12778],{"intervention":10646,"totalTrials":138,"cells":12800},{"EARLY_PHASE1":12801,"PHASE1":12803,"PHASE2":12805,"PHASE3":12807,"PHASE4":12809,"NA":12811},{"trials":12802,"activeCount":100},[],{"trials":12804,"activeCount":100},[],{"trials":12806,"activeCount":100},[],{"trials":12808,"activeCount":100},[],{"trials":12810,"activeCount":100},[],{"trials":12812,"activeCount":100},[12813],{"nctId":10641,"briefTitle":10642,"status":108,"phases":12814,"start":6755,"enrollment":412,"conditions":12815,"interventions":12816},[],[7570],[10595,10629,10646,10630,10622,10647],{"intervention":10647,"totalTrials":138,"cells":12818},{"EARLY_PHASE1":12819,"PHASE1":12821,"PHASE2":12823,"PHASE3":12825,"PHASE4":12827,"NA":12829},{"trials":12820,"activeCount":100},[],{"trials":12822,"activeCount":100},[],{"trials":12824,"activeCount":100},[],{"trials":12826,"activeCount":100},[],{"trials":12828,"activeCount":100},[],{"trials":12830,"activeCount":100},[12831],{"nctId":10641,"briefTitle":10642,"status":108,"phases":12832,"start":6755,"enrollment":412,"conditions":12833,"interventions":12834},[],[7570],[10595,10629,10646,10630,10622,10647],{"intervention":12836,"totalTrials":138,"cells":12837},"Albuterol and Ipratropium Continuous Nebulizer",{"EARLY_PHASE1":12838,"PHASE1":12840,"PHASE2":12842,"PHASE3":12844,"PHASE4":12846,"NA":12848},{"trials":12839,"activeCount":100},[],{"trials":12841,"activeCount":100},[],{"trials":12843,"activeCount":100},[],{"trials":12845,"activeCount":100},[],{"trials":12847,"activeCount":100},[],{"trials":12849,"activeCount":100},[12850],{"nctId":12851,"briefTitle":12852,"status":605,"phases":12853,"primaryCompletion":12854,"completion":12854,"start":8296,"enrollment":100,"conditions":12855,"interventions":12856},"NCT02458482","Trial of AccuPAP Device Versus Standard Nebulizer Therapy in Acute Asthma Exacerbation in Children",[92],"2020-11-11",[2056],[12836],{"intervention":12858,"totalTrials":138,"cells":12859},"olopatadine",{"EARLY_PHASE1":12860,"PHASE1":12862,"PHASE2":12864,"PHASE3":12866,"PHASE4":12868,"NA":12870},{"trials":12861,"activeCount":100},[],{"trials":12863,"activeCount":100},[],{"trials":12865,"activeCount":100},[],{"trials":12867,"activeCount":100},[],{"trials":12869,"activeCount":100},[],{"trials":12871,"activeCount":100},[12872],{"nctId":12873,"briefTitle":12874,"status":108,"phases":12875,"primaryCompletion":11506,"completion":11506,"start":4744,"enrollment":1172,"conditions":12876,"interventions":12878},"NCT00775658","Olopatadine Eye Drops and Allergy Skin Testing",[92],[4837,12877],"Allergic Conjunctivitis",[12858],{"intervention":11564,"totalTrials":138,"cells":12880},{"EARLY_PHASE1":12881,"PHASE1":12883,"PHASE2":12885,"PHASE3":12887,"PHASE4":12889,"NA":12891},{"trials":12882,"activeCount":100},[],{"trials":12884,"activeCount":100},[],{"trials":12886,"activeCount":100},[],{"trials":12888,"activeCount":100},[],{"trials":12890,"activeCount":100},[],{"trials":12892,"activeCount":100},[12893],{"nctId":11559,"briefTitle":11560,"status":108,"phases":12894,"primaryCompletion":6755,"completion":2977,"start":3444,"enrollment":1172,"conditions":12895,"interventions":12896},[92],[1174],[11564,10172],{"intervention":10799,"totalTrials":138,"cells":12898},{"EARLY_PHASE1":12899,"PHASE1":12901,"PHASE2":12903,"PHASE3":12905,"PHASE4":12907,"NA":12909},{"trials":12900,"activeCount":100},[],{"trials":12902,"activeCount":100},[],{"trials":12904,"activeCount":100},[],{"trials":12906,"activeCount":100},[],{"trials":12908,"activeCount":100},[],{"trials":12910,"activeCount":100},[12911],{"nctId":10794,"briefTitle":10795,"status":605,"phases":12912,"primaryCompletion":2115,"completion":2115,"start":2115,"enrollment":100,"conditions":12913,"interventions":12914},[92],[1174],[10799,3065],{"intervention":12916,"totalTrials":138,"cells":12917},"Angiotensin Converting Enzyme Inhibitor",{"EARLY_PHASE1":12918,"PHASE1":12920,"PHASE2":12922,"PHASE3":12924,"PHASE4":12926,"NA":12928},{"trials":12919,"activeCount":100},[],{"trials":12921,"activeCount":100},[],{"trials":12923,"activeCount":100},[],{"trials":12925,"activeCount":100},[],{"trials":12927,"activeCount":100},[],{"trials":12929,"activeCount":100},[12930],{"nctId":12931,"briefTitle":12932,"status":108,"phases":12933,"primaryCompletion":3442,"completion":3442,"start":9223,"enrollment":2169,"conditions":12934,"interventions":12935},"NCT00848250","Angiotensin Converting Enzyme Inhibitors During Cardiopulmonary Bypass in Infants and Children",[92],[856],[12916],{"intervention":12937,"totalTrials":138,"cells":12938},"Influenza Vaccine",{"EARLY_PHASE1":12939,"PHASE1":12941,"PHASE2":12943,"PHASE3":12945,"PHASE4":12947,"NA":12949},{"trials":12940,"activeCount":100},[],{"trials":12942,"activeCount":100},[],{"trials":12944,"activeCount":100},[],{"trials":12946,"activeCount":100},[],{"trials":12948,"activeCount":100},[],{"trials":12950,"activeCount":100},[12951],{"nctId":12952,"briefTitle":12953,"status":108,"phases":12954,"primaryCompletion":3442,"completion":12796,"start":5334,"enrollment":12955,"conditions":12956,"interventions":12958},"NCT02401893","Factors Associated With Maintenance of Antibody Responses to Influenza Vaccine in Older, Community-Dwelling Adults",[],510,[12957],"Aging",[12937],{"intervention":12960,"totalTrials":138,"cells":12961},"systemic chemotherapy",{"EARLY_PHASE1":12962,"PHASE1":12964,"PHASE2":12966,"PHASE3":12968,"PHASE4":12970,"NA":12972},{"trials":12963,"activeCount":100},[],{"trials":12965,"activeCount":100},[],{"trials":12967,"activeCount":100},[],{"trials":12969,"activeCount":100},[],{"trials":12971,"activeCount":100},[],{"trials":12973,"activeCount":100},[12974],{"nctId":12975,"briefTitle":12976,"status":108,"phases":12977,"primaryCompletion":682,"completion":682,"start":11506,"enrollment":1447,"conditions":12978,"interventions":12979},"NCT00751816","Head & Neck Cancer Survivorship: Physical and Functional Status",[],[7570],[12960],{"intervention":2145,"totalTrials":138,"cells":12981},{"EARLY_PHASE1":12982,"PHASE1":12984,"PHASE2":12986,"PHASE3":12988,"PHASE4":12990,"NA":12992},{"trials":12983,"activeCount":100},[],{"trials":12985,"activeCount":100},[],{"trials":12987,"activeCount":100},[],{"trials":12989,"activeCount":100},[],{"trials":12991,"activeCount":100},[],{"trials":12993,"activeCount":100},[12994],{"nctId":2139,"briefTitle":2140,"status":108,"phases":12995,"primaryCompletion":682,"completion":682,"start":2142,"enrollment":1172,"conditions":12996,"interventions":12997},[92],[16],[1555,2145,2146,2147],{"intervention":2146,"totalTrials":138,"cells":12999},{"EARLY_PHASE1":13000,"PHASE1":13002,"PHASE2":13004,"PHASE3":13006,"PHASE4":13008,"NA":13010},{"trials":13001,"activeCount":100},[],{"trials":13003,"activeCount":100},[],{"trials":13005,"activeCount":100},[],{"trials":13007,"activeCount":100},[],{"trials":13009,"activeCount":100},[],{"trials":13011,"activeCount":100},[13012],{"nctId":2139,"briefTitle":2140,"status":108,"phases":13013,"primaryCompletion":682,"completion":682,"start":2142,"enrollment":1172,"conditions":13014,"interventions":13015},[92],[16],[1555,2145,2146,2147],{"intervention":2147,"totalTrials":138,"cells":13017},{"EARLY_PHASE1":13018,"PHASE1":13020,"PHASE2":13022,"PHASE3":13024,"PHASE4":13026,"NA":13028},{"trials":13019,"activeCount":100},[],{"trials":13021,"activeCount":100},[],{"trials":13023,"activeCount":100},[],{"trials":13025,"activeCount":100},[],{"trials":13027,"activeCount":100},[],{"trials":13029,"activeCount":100},[13030],{"nctId":2139,"briefTitle":2140,"status":108,"phases":13031,"primaryCompletion":682,"completion":682,"start":2142,"enrollment":1172,"conditions":13032,"interventions":13033},[92],[16],[1555,2145,2146,2147],{"intervention":13035,"totalTrials":138,"cells":13036},"High dose influenza vaccine Sanofi-Pasteur",{"EARLY_PHASE1":13037,"PHASE1":13039,"PHASE2":13041,"PHASE3":13043,"PHASE4":13045,"NA":13047},{"trials":13038,"activeCount":100},[],{"trials":13040,"activeCount":100},[],{"trials":13042,"activeCount":100},[],{"trials":13044,"activeCount":100},[],{"trials":13046,"activeCount":100},[],{"trials":13048,"activeCount":100},[13049],{"nctId":13050,"briefTitle":13051,"status":108,"phases":13052,"primaryCompletion":663,"completion":3578,"start":3443,"enrollment":13053,"conditions":13054,"interventions":13056},"NCT01189123","Cell Mediated Immunity in Older Adults",[92],105,[13055],"Immunity to Influenza Vaccine",[13035,13057],"fluzone by sanofi pasteur",{"intervention":13057,"totalTrials":138,"cells":13059},{"EARLY_PHASE1":13060,"PHASE1":13062,"PHASE2":13064,"PHASE3":13066,"PHASE4":13068,"NA":13070},{"trials":13061,"activeCount":100},[],{"trials":13063,"activeCount":100},[],{"trials":13065,"activeCount":100},[],{"trials":13067,"activeCount":100},[],{"trials":13069,"activeCount":100},[],{"trials":13071,"activeCount":100},[13072],{"nctId":13050,"briefTitle":13051,"status":108,"phases":13073,"primaryCompletion":663,"completion":3578,"start":3443,"enrollment":13053,"conditions":13074,"interventions":13075},[92],[13055],[13035,13057],{"intervention":13077,"totalTrials":138,"cells":13078},"Mesna",{"EARLY_PHASE1":13079,"PHASE1":13081,"PHASE2":13083,"PHASE3":13085,"PHASE4":13087,"NA":13089},{"trials":13080,"activeCount":100},[],{"trials":13082,"activeCount":100},[],{"trials":13084,"activeCount":100},[],{"trials":13086,"activeCount":100},[],{"trials":13088,"activeCount":100},[],{"trials":13090,"activeCount":100},[13091],{"nctId":13092,"briefTitle":13093,"status":659,"phases":13094,"primaryCompletion":2233,"completion":4425,"start":13095,"enrollment":29,"conditions":13096,"interventions":13098},"NCT00758667","Chemically Assisted Capsulectomy-A New Clinical Approach",[92],"2005-01",[13097],"Implant Capsular Contracture",[13077],{"intervention":13100,"totalTrials":138,"cells":13101},"Albumin",{"EARLY_PHASE1":13102,"PHASE1":13104,"PHASE2":13106,"PHASE3":13108,"PHASE4":13110,"NA":13112},{"trials":13103,"activeCount":100},[],{"trials":13105,"activeCount":100},[],{"trials":13107,"activeCount":100},[],{"trials":13109,"activeCount":100},[],{"trials":13111,"activeCount":100},[],{"trials":13113,"activeCount":100},[13114],{"nctId":13115,"briefTitle":13116,"status":108,"phases":13117,"primaryCompletion":4641,"completion":4641,"start":3706,"enrollment":13118,"conditions":13119,"interventions":13121},"NCT02878733","Albumin Administration and Outcomes in Cardiac Surgery",[],6249,[13120],"Thoracic Surgery",[13100],{"intervention":13123,"totalTrials":138,"cells":13124},"atorvastatin",{"EARLY_PHASE1":13125,"PHASE1":13127,"PHASE2":13129,"PHASE3":13131,"PHASE4":13133,"NA":13135},{"trials":13126,"activeCount":100},[],{"trials":13128,"activeCount":100},[],{"trials":13130,"activeCount":100},[],{"trials":13132,"activeCount":100},[],{"trials":13134,"activeCount":100},[],{"trials":13136,"activeCount":100},[13137],{"nctId":13138,"briefTitle":13139,"status":108,"phases":13140,"primaryCompletion":2587,"completion":4640,"start":1021,"enrollment":13141,"conditions":13142,"interventions":13145},"NCT00791648","Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery",[92],653,[4454,13143,13144,4455,25],"Post-Operative Delirium","Icu Delirium",[13123],{"intervention":13147,"totalTrials":138,"cells":13148},"Nicotine Patch, 7 Mg\u002F24 Hr",{"EARLY_PHASE1":13149,"PHASE1":13151,"PHASE2":13153,"PHASE3":13155,"PHASE4":13157,"NA":13159},{"trials":13150,"activeCount":100},[],{"trials":13152,"activeCount":100},[],{"trials":13154,"activeCount":100},[],{"trials":13156,"activeCount":100},[],{"trials":13158,"activeCount":100},[],{"trials":13160,"activeCount":100},[13161],{"nctId":13162,"briefTitle":13163,"status":659,"phases":13164,"primaryCompletion":13165,"completion":13165,"start":13166,"enrollment":32,"conditions":13167,"interventions":13170},"NCT03838484","Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia",[92],"2020-02-24","2019-05-10",[13168,13169],"Schizophrenia","Impulsive Behavior",[13147],{"intervention":13172,"totalTrials":138,"cells":13173},"ESR-specific PET scan",{"EARLY_PHASE1":13174,"PHASE1":13176,"PHASE2":13178,"PHASE3":13180,"PHASE4":13182,"NA":13184},{"trials":13175,"activeCount":100},[],{"trials":13177,"activeCount":100},[],{"trials":13179,"activeCount":100},[],{"trials":13181,"activeCount":100},[],{"trials":13183,"activeCount":100},[],{"trials":13185,"activeCount":100},[13186],{"nctId":13187,"briefTitle":13188,"status":605,"phases":13189,"primaryCompletion":5003,"completion":5003,"start":13190,"enrollment":100,"conditions":13191,"interventions":13192},"NCT04280523","TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH",[],"2021-01-05",[6871],[13172],{"intervention":13194,"totalTrials":138,"cells":13195},"Vancomycin powder",{"EARLY_PHASE1":13196,"PHASE1":13198,"PHASE2":13200,"PHASE3":13202,"PHASE4":13204,"NA":13206},{"trials":13197,"activeCount":100},[],{"trials":13199,"activeCount":100},[],{"trials":13201,"activeCount":100},[],{"trials":13203,"activeCount":100},[],{"trials":13205,"activeCount":100},[],{"trials":13207,"activeCount":100},[13208],{"nctId":13209,"briefTitle":13210,"status":605,"phases":13211,"primaryCompletion":4640,"completion":4640,"start":2939,"enrollment":100,"conditions":13212,"interventions":13214},"NCT01566422","Comparative Effectiveness and Cost-Benefit Analysis of Vancomycin Powder in High Risk Spine Surgery Patients",[92],[13213],"Surgical Site Infection",[13194],{"intervention":13216,"totalTrials":138,"cells":13217},"PrEP",{"EARLY_PHASE1":13218,"PHASE1":13220,"PHASE2":13222,"PHASE3":13224,"PHASE4":13226,"NA":13228},{"trials":13219,"activeCount":100},[],{"trials":13221,"activeCount":100},[],{"trials":13223,"activeCount":100},[],{"trials":13225,"activeCount":100},[],{"trials":13227,"activeCount":100},[],{"trials":13229,"activeCount":100},[13230],{"nctId":13231,"briefTitle":13232,"status":108,"phases":13233,"primaryCompletion":13234,"completion":13234,"start":13235,"enrollment":2213,"conditions":13236,"interventions":13237},"NCT04071470","Storytelling to Increase Family Support for Pre Exposure Prophylaxis Use",[92],"2023-06-20","2021-01-01",[6017],[13216],{"intervention":1026,"totalTrials":138,"cells":13239},{"EARLY_PHASE1":13240,"PHASE1":13242,"PHASE2":13244,"PHASE3":13246,"PHASE4":13248,"NA":13250},{"trials":13241,"activeCount":100},[],{"trials":13243,"activeCount":100},[],{"trials":13245,"activeCount":100},[],{"trials":13247,"activeCount":100},[],{"trials":13249,"activeCount":100},[],{"trials":13251,"activeCount":100},[13252],{"nctId":1018,"briefTitle":1019,"status":108,"phases":13253,"primaryCompletion":1021,"completion":1022,"start":696,"enrollment":300,"conditions":13254,"interventions":13255},[92],[1024],[1026,1027],{"intervention":13257,"totalTrials":138,"cells":13258},"olanzapine versus risperidone",{"EARLY_PHASE1":13259,"PHASE1":13261,"PHASE2":13263,"PHASE3":13265,"PHASE4":13267,"NA":13269},{"trials":13260,"activeCount":100},[],{"trials":13262,"activeCount":100},[],{"trials":13264,"activeCount":100},[],{"trials":13266,"activeCount":100},[],{"trials":13268,"activeCount":100},[],{"trials":13270,"activeCount":100},[13271],{"nctId":13272,"briefTitle":13273,"status":108,"phases":13274,"primaryCompletion":2320,"completion":2320,"start":13275,"enrollment":13276,"conditions":13277,"interventions":13280},"NCT00179062","Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder",[92],"2000-02",300,[13168,13278,13279,3974],"Schizoaffective Disorder","Depressive Disorder, Major",[13257],{"intervention":10680,"totalTrials":138,"cells":13282},{"EARLY_PHASE1":13283,"PHASE1":13285,"PHASE2":13287,"PHASE3":13289,"PHASE4":13291,"NA":13293},{"trials":13284,"activeCount":100},[],{"trials":13286,"activeCount":100},[],{"trials":13288,"activeCount":100},[],{"trials":13290,"activeCount":100},[],{"trials":13292,"activeCount":100},[],{"trials":13294,"activeCount":100},[13295],{"nctId":10675,"briefTitle":10676,"status":108,"phases":13296,"start":3444,"enrollment":697,"conditions":13297,"interventions":13298},[],[7570],[10622,10680],{"intervention":13300,"totalTrials":138,"cells":13301},"Selenium Supplements",{"EARLY_PHASE1":13302,"PHASE1":13304,"PHASE2":13306,"PHASE3":13308,"PHASE4":13310,"NA":13312},{"trials":13303,"activeCount":100},[],{"trials":13305,"activeCount":100},[],{"trials":13307,"activeCount":100},[],{"trials":13309,"activeCount":100},[],{"trials":13311,"activeCount":100},[],{"trials":13313,"activeCount":100},[13314],{"nctId":13315,"briefTitle":13316,"status":108,"phases":13317,"primaryCompletion":13318,"completion":13318,"start":13319,"enrollment":1206,"conditions":13320,"interventions":13322},"NCT00212186","Selenium Supplementation of Patients With Cirrhosis",[92],"2003-11","1998-10",[2333,13321],"Liver Cirrhosis",[13300],{"intervention":13324,"totalTrials":138,"cells":13325},"mineralocorticoid receptor antagonist",{"EARLY_PHASE1":13326,"PHASE1":13328,"PHASE2":13330,"PHASE3":13332,"PHASE4":13334,"NA":13336},{"trials":13327,"activeCount":100},[],{"trials":13329,"activeCount":100},[],{"trials":13331,"activeCount":100},[],{"trials":13333,"activeCount":100},[],{"trials":13335,"activeCount":100},[],{"trials":13337,"activeCount":100},[13338],{"nctId":13339,"briefTitle":13340,"status":108,"phases":13341,"primaryCompletion":607,"completion":607,"start":2203,"enrollment":2911,"conditions":13342,"interventions":13344},"NCT02362308","Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas",[],[13343],"Primary Aldosteronism",[13324],{"intervention":13346,"totalTrials":138,"cells":13347},"Fluoxetine",{"EARLY_PHASE1":13348,"PHASE1":13350,"PHASE2":13352,"PHASE3":13354,"PHASE4":13356,"NA":13358},{"trials":13349,"activeCount":100},[],{"trials":13351,"activeCount":100},[],{"trials":13353,"activeCount":100},[],{"trials":13355,"activeCount":100},[],{"trials":13357,"activeCount":100},[],{"trials":13359,"activeCount":100},[13360],{"nctId":13361,"briefTitle":13362,"status":108,"phases":13363,"primaryCompletion":2320,"completion":5786,"start":5448,"enrollment":1206,"conditions":13364,"interventions":13365},"NCT00592670","Hypoglycemia Associated Autonomic Failure in Type 1 DM",[92],[1174],[13346],{"intervention":13367,"totalTrials":138,"cells":13368},"TDAP",{"EARLY_PHASE1":13369,"PHASE1":13371,"PHASE2":13373,"PHASE3":13375,"PHASE4":13377,"NA":13379},{"trials":13370,"activeCount":100},[],{"trials":13372,"activeCount":100},[],{"trials":13374,"activeCount":100},[],{"trials":13376,"activeCount":100},[],{"trials":13378,"activeCount":100},[],{"trials":13380,"activeCount":100},[13381],{"nctId":13382,"briefTitle":13383,"status":108,"phases":13384,"primaryCompletion":8438,"completion":13385,"start":9773,"enrollment":13386,"conditions":13387,"interventions":13388},"NCT02209623","TDAP Safety in Pregnant Women",[],"2017-12-18",375,[12099],[13367],{"intervention":13390,"totalTrials":138,"cells":13391},"indole-3-carbinol",{"EARLY_PHASE1":13392,"PHASE1":13394,"PHASE2":13396,"PHASE3":13398,"PHASE4":13400,"NA":13402},{"trials":13393,"activeCount":100},[],{"trials":13395,"activeCount":100},[],{"trials":13397,"activeCount":100},[],{"trials":13399,"activeCount":100},[],{"trials":13401,"activeCount":100},[],{"trials":13403,"activeCount":100},[13404],{"nctId":13405,"briefTitle":13406,"status":108,"phases":13407,"primaryCompletion":5472,"completion":9839,"start":5448,"enrollment":7229,"conditions":13408,"interventions":13410},"NCT00607932","Brassica Vegetables or Indole-3-Carbinol in Treating Patients With PSA Recurrence After Surgery for Prostate Cancer",[92],[13409],"Prostate Cancer",[13390],{"intervention":13412,"totalTrials":138,"cells":13413},"2% Chlorohexidine Gluconate Standard of Care",{"EARLY_PHASE1":13414,"PHASE1":13416,"PHASE2":13418,"PHASE3":13420,"PHASE4":13422,"NA":13424},{"trials":13415,"activeCount":100},[],{"trials":13417,"activeCount":100},[],{"trials":13419,"activeCount":100},[],{"trials":13421,"activeCount":100},[],{"trials":13423,"activeCount":100},[],{"trials":13425,"activeCount":100},[13426],{"nctId":13427,"briefTitle":13428,"status":108,"phases":13429,"primaryCompletion":13430,"completion":13430,"start":3183,"enrollment":13431,"conditions":13432,"interventions":13433},"NCT02385708","Use of 2% Chlorhexidine Cloths Reduce Surgical Site Infections",[92],"2018-06-21",163,[13213],[13412,13434],"2% Chlorohexidine Gluconate Chin to Toe",{"intervention":13434,"totalTrials":138,"cells":13436},{"EARLY_PHASE1":13437,"PHASE1":13439,"PHASE2":13441,"PHASE3":13443,"PHASE4":13445,"NA":13447},{"trials":13438,"activeCount":100},[],{"trials":13440,"activeCount":100},[],{"trials":13442,"activeCount":100},[],{"trials":13444,"activeCount":100},[],{"trials":13446,"activeCount":100},[],{"trials":13448,"activeCount":100},[13449],{"nctId":13427,"briefTitle":13428,"status":108,"phases":13450,"primaryCompletion":13430,"completion":13430,"start":3183,"enrollment":13431,"conditions":13451,"interventions":13452},[92],[13213],[13412,13434],{"intervention":13454,"totalTrials":138,"cells":13455},"Nebivolol 5 mg",{"EARLY_PHASE1":13456,"PHASE1":13458,"PHASE2":13460,"PHASE3":13462,"PHASE4":13464,"NA":13466},{"trials":13457,"activeCount":100},[],{"trials":13459,"activeCount":100},[],{"trials":13461,"activeCount":100},[],{"trials":13463,"activeCount":100},[],{"trials":13465,"activeCount":100},[],{"trials":13467,"activeCount":100},[13468],{"nctId":13469,"briefTitle":13470,"status":108,"phases":13471,"primaryCompletion":10146,"completion":2964,"start":2176,"enrollment":29,"conditions":13472,"interventions":13473},"NCT01044693","Nebivolol in the Supine Hypertension of Autonomic Failure",[92],[19,903,926],[13454,13474,13475],"metoprolol tartrate 50 mg","Sildenafil25 mg",{"intervention":13474,"totalTrials":138,"cells":13477},{"EARLY_PHASE1":13478,"PHASE1":13480,"PHASE2":13482,"PHASE3":13484,"PHASE4":13486,"NA":13488},{"trials":13479,"activeCount":100},[],{"trials":13481,"activeCount":100},[],{"trials":13483,"activeCount":100},[],{"trials":13485,"activeCount":100},[],{"trials":13487,"activeCount":100},[],{"trials":13489,"activeCount":100},[13490],{"nctId":13469,"briefTitle":13470,"status":108,"phases":13491,"primaryCompletion":10146,"completion":2964,"start":2176,"enrollment":29,"conditions":13492,"interventions":13493},[92],[19,903,926],[13454,13474,13475],{"intervention":13475,"totalTrials":138,"cells":13495},{"EARLY_PHASE1":13496,"PHASE1":13498,"PHASE2":13500,"PHASE3":13502,"PHASE4":13504,"NA":13506},{"trials":13497,"activeCount":100},[],{"trials":13499,"activeCount":100},[],{"trials":13501,"activeCount":100},[],{"trials":13503,"activeCount":100},[],{"trials":13505,"activeCount":100},[],{"trials":13507,"activeCount":100},[13508],{"nctId":13469,"briefTitle":13470,"status":108,"phases":13509,"primaryCompletion":10146,"completion":2964,"start":2176,"enrollment":29,"conditions":13510,"interventions":13511},[92],[19,903,926],[13454,13474,13475],{"intervention":13513,"totalTrials":138,"cells":13514},"Blocked",{"EARLY_PHASE1":13515,"PHASE1":13517,"PHASE2":13519,"PHASE3":13521,"PHASE4":13523,"NA":13525},{"trials":13516,"activeCount":100},[],{"trials":13518,"activeCount":100},[],{"trials":13520,"activeCount":100},[],{"trials":13522,"activeCount":100},[],{"trials":13524,"activeCount":100},[],{"trials":13526,"activeCount":100},[13527],{"nctId":13528,"briefTitle":13529,"status":108,"phases":13530,"primaryCompletion":6609,"completion":6609,"start":2233,"enrollment":17,"conditions":13531,"interventions":13532},"NCT00580957","The Autonomic Nervous System and the Metabolic Syndrome",[92],[16],[13513,13533],"Intact",{"intervention":13533,"totalTrials":138,"cells":13535},{"EARLY_PHASE1":13536,"PHASE1":13538,"PHASE2":13540,"PHASE3":13542,"PHASE4":13544,"NA":13546},{"trials":13537,"activeCount":100},[],{"trials":13539,"activeCount":100},[],{"trials":13541,"activeCount":100},[],{"trials":13543,"activeCount":100},[],{"trials":13545,"activeCount":100},[],{"trials":13547,"activeCount":100},[13548],{"nctId":13528,"briefTitle":13529,"status":108,"phases":13549,"primaryCompletion":6609,"completion":6609,"start":2233,"enrollment":17,"conditions":13550,"interventions":13551},[92],[16],[13513,13533],{"intervention":10714,"totalTrials":138,"cells":13553},{"EARLY_PHASE1":13554,"PHASE1":13556,"PHASE2":13558,"PHASE3":13560,"PHASE4":13562,"NA":13564},{"trials":13555,"activeCount":100},[],{"trials":13557,"activeCount":100},[],{"trials":13559,"activeCount":100},[],{"trials":13561,"activeCount":100},[],{"trials":13563,"activeCount":100},[],{"trials":13565,"activeCount":100},[13566],{"nctId":10704,"briefTitle":10705,"status":108,"phases":13567,"primaryCompletion":2278,"completion":10707,"start":10708,"enrollment":10709,"conditions":13568,"interventions":13569},[92],[10711,10712],[586,10714,10715,560,3070],{"intervention":10715,"totalTrials":138,"cells":13571},{"EARLY_PHASE1":13572,"PHASE1":13574,"PHASE2":13576,"PHASE3":13578,"PHASE4":13580,"NA":13582},{"trials":13573,"activeCount":100},[],{"trials":13575,"activeCount":100},[],{"trials":13577,"activeCount":100},[],{"trials":13579,"activeCount":100},[],{"trials":13581,"activeCount":100},[],{"trials":13583,"activeCount":100},[13584],{"nctId":10704,"briefTitle":10705,"status":108,"phases":13585,"primaryCompletion":2278,"completion":10707,"start":10708,"enrollment":10709,"conditions":13586,"interventions":13587},[92],[10711,10712],[586,10714,10715,560,3070],{"intervention":13589,"totalTrials":138,"cells":13590},"Aldosterone",{"EARLY_PHASE1":13591,"PHASE1":13593,"PHASE2":13595,"PHASE3":13597,"PHASE4":13599,"NA":13601},{"trials":13592,"activeCount":100},[],{"trials":13594,"activeCount":100},[],{"trials":13596,"activeCount":100},[],{"trials":13598,"activeCount":100},[],{"trials":13600,"activeCount":100},[],{"trials":13602,"activeCount":100},[13603],{"nctId":13604,"briefTitle":13605,"status":108,"phases":13606,"primaryCompletion":1022,"completion":681,"start":9223,"enrollment":20,"conditions":13607,"interventions":13608},"NCT00732160","Aldosterone and Glucose Homeostasis",[92],[3416],[13589,13609],"Vehicle",{"intervention":13609,"totalTrials":138,"cells":13611},{"EARLY_PHASE1":13612,"PHASE1":13614,"PHASE2":13616,"PHASE3":13618,"PHASE4":13620,"NA":13622},{"trials":13613,"activeCount":100},[],{"trials":13615,"activeCount":100},[],{"trials":13617,"activeCount":100},[],{"trials":13619,"activeCount":100},[],{"trials":13621,"activeCount":100},[],{"trials":13623,"activeCount":100},[13624],{"nctId":13604,"briefTitle":13605,"status":108,"phases":13625,"primaryCompletion":1022,"completion":681,"start":9223,"enrollment":20,"conditions":13626,"interventions":13627},[92],[3416],[13589,13609],{"intervention":13629,"totalTrials":138,"cells":13630},"Chlorhexidine irrigation",{"EARLY_PHASE1":13631,"PHASE1":13633,"PHASE2":13635,"PHASE3":13637,"PHASE4":13639,"NA":13641},{"trials":13632,"activeCount":100},[],{"trials":13634,"activeCount":100},[],{"trials":13636,"activeCount":100},[],{"trials":13638,"activeCount":100},[],{"trials":13640,"activeCount":100},[],{"trials":13642,"activeCount":100},[13643],{"nctId":13644,"briefTitle":13645,"status":108,"phases":13646,"primaryCompletion":5580,"completion":5580,"start":4196,"enrollment":13647,"conditions":13648,"interventions":13649},"NCT02395614","Surgical Site Infection With 0.05% Chlorhexidine (CHG) Compared to Triple Antibiotic Irrigation",[92],88,[6884],[13629,13650],"triple antibiotic irrigation",{"intervention":13650,"totalTrials":138,"cells":13652},{"EARLY_PHASE1":13653,"PHASE1":13655,"PHASE2":13657,"PHASE3":13659,"PHASE4":13661,"NA":13663},{"trials":13654,"activeCount":100},[],{"trials":13656,"activeCount":100},[],{"trials":13658,"activeCount":100},[],{"trials":13660,"activeCount":100},[],{"trials":13662,"activeCount":100},[],{"trials":13664,"activeCount":100},[13665],{"nctId":13644,"briefTitle":13645,"status":108,"phases":13666,"primaryCompletion":5580,"completion":5580,"start":4196,"enrollment":13647,"conditions":13667,"interventions":13668},[92],[6884],[13629,13650],{"intervention":13670,"totalTrials":138,"cells":13671},"Natural source d-α-tocopheryl acetate",{"EARLY_PHASE1":13672,"PHASE1":13674,"PHASE2":13676,"PHASE3":13678,"PHASE4":13680,"NA":13682},{"trials":13673,"activeCount":100},[],{"trials":13675,"activeCount":100},[],{"trials":13677,"activeCount":100},[],{"trials":13679,"activeCount":100},[],{"trials":13681,"activeCount":100},[],{"trials":13683,"activeCount":100},[13684],{"nctId":13685,"briefTitle":13686,"status":108,"phases":13687,"primaryCompletion":3234,"completion":11287,"start":2646,"enrollment":664,"conditions":13688,"interventions":13690},"NCT00581048","Study on the Role of Treatment With Vitamin E on Asthmatic Responses in Allergic Asthmatics",[92],[13689],"Allergic Asthma",[13670],{"intervention":13692,"totalTrials":138,"cells":13693},"Standard of Care",{"EARLY_PHASE1":13694,"PHASE1":13696,"PHASE2":13698,"PHASE3":13700,"PHASE4":13702,"NA":13704},{"trials":13695,"activeCount":100},[],{"trials":13697,"activeCount":100},[],{"trials":13699,"activeCount":100},[],{"trials":13701,"activeCount":100},[],{"trials":13703,"activeCount":100},[],{"trials":13705,"activeCount":100},[13706],{"nctId":13707,"briefTitle":13708,"status":108,"phases":13709,"primaryCompletion":13710,"completion":13711,"start":13712,"enrollment":13713,"conditions":13714,"interventions":13715},"NCT03076359","Traditional Healers as Adherence Partners for Persons Living With HIV in Rural Mozambique",[92],"2019-05-30","2019-06-30","2015-06-10",320,[7231],[13692],{"intervention":3062,"totalTrials":138,"cells":13717},{"EARLY_PHASE1":13718,"PHASE1":13720,"PHASE2":13722,"PHASE3":13724,"PHASE4":13726,"NA":13728},{"trials":13719,"activeCount":100},[],{"trials":13721,"activeCount":100},[],{"trials":13723,"activeCount":100},[],{"trials":13725,"activeCount":100},[],{"trials":13727,"activeCount":100},[],{"trials":13729,"activeCount":100},[13730],{"nctId":3052,"briefTitle":3053,"status":108,"phases":13731,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":13732,"interventions":13733},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":3063,"totalTrials":138,"cells":13735},{"EARLY_PHASE1":13736,"PHASE1":13738,"PHASE2":13740,"PHASE3":13742,"PHASE4":13744,"NA":13746},{"trials":13737,"activeCount":100},[],{"trials":13739,"activeCount":100},[],{"trials":13741,"activeCount":100},[],{"trials":13743,"activeCount":100},[],{"trials":13745,"activeCount":100},[],{"trials":13747,"activeCount":100},[13748],{"nctId":3052,"briefTitle":3053,"status":108,"phases":13749,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":13750,"interventions":13751},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":3067,"totalTrials":138,"cells":13753},{"EARLY_PHASE1":13754,"PHASE1":13756,"PHASE2":13758,"PHASE3":13760,"PHASE4":13762,"NA":13764},{"trials":13755,"activeCount":100},[],{"trials":13757,"activeCount":100},[],{"trials":13759,"activeCount":100},[],{"trials":13761,"activeCount":100},[],{"trials":13763,"activeCount":100},[],{"trials":13765,"activeCount":100},[13766],{"nctId":3052,"briefTitle":3053,"status":108,"phases":13767,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":13768,"interventions":13769},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":3071,"totalTrials":138,"cells":13771},{"EARLY_PHASE1":13772,"PHASE1":13774,"PHASE2":13776,"PHASE3":13778,"PHASE4":13780,"NA":13782},{"trials":13773,"activeCount":100},[],{"trials":13775,"activeCount":100},[],{"trials":13777,"activeCount":100},[],{"trials":13779,"activeCount":100},[],{"trials":13781,"activeCount":100},[],{"trials":13783,"activeCount":100},[13784],{"nctId":3052,"briefTitle":3053,"status":108,"phases":13785,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":13786,"interventions":13787},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":3072,"totalTrials":138,"cells":13789},{"EARLY_PHASE1":13790,"PHASE1":13792,"PHASE2":13794,"PHASE3":13796,"PHASE4":13798,"NA":13800},{"trials":13791,"activeCount":100},[],{"trials":13793,"activeCount":100},[],{"trials":13795,"activeCount":100},[],{"trials":13797,"activeCount":100},[],{"trials":13799,"activeCount":100},[],{"trials":13801,"activeCount":100},[13802],{"nctId":3052,"briefTitle":3053,"status":108,"phases":13803,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":13804,"interventions":13805},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":3073,"totalTrials":138,"cells":13807},{"EARLY_PHASE1":13808,"PHASE1":13810,"PHASE2":13812,"PHASE3":13814,"PHASE4":13816,"NA":13818},{"trials":13809,"activeCount":100},[],{"trials":13811,"activeCount":100},[],{"trials":13813,"activeCount":100},[],{"trials":13815,"activeCount":100},[],{"trials":13817,"activeCount":100},[],{"trials":13819,"activeCount":100},[13820],{"nctId":3052,"briefTitle":3053,"status":108,"phases":13821,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":13822,"interventions":13823},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":3075,"totalTrials":138,"cells":13825},{"EARLY_PHASE1":13826,"PHASE1":13828,"PHASE2":13830,"PHASE3":13832,"PHASE4":13834,"NA":13836},{"trials":13827,"activeCount":100},[],{"trials":13829,"activeCount":100},[],{"trials":13831,"activeCount":100},[],{"trials":13833,"activeCount":100},[],{"trials":13835,"activeCount":100},[],{"trials":13837,"activeCount":100},[13838],{"nctId":3052,"briefTitle":3053,"status":108,"phases":13839,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":13840,"interventions":13841},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":3076,"totalTrials":138,"cells":13843},{"EARLY_PHASE1":13844,"PHASE1":13846,"PHASE2":13848,"PHASE3":13850,"PHASE4":13852,"NA":13854},{"trials":13845,"activeCount":100},[],{"trials":13847,"activeCount":100},[],{"trials":13849,"activeCount":100},[],{"trials":13851,"activeCount":100},[],{"trials":13853,"activeCount":100},[],{"trials":13855,"activeCount":100},[13856],{"nctId":3052,"briefTitle":3053,"status":108,"phases":13857,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":13858,"interventions":13859},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":3077,"totalTrials":138,"cells":13861},{"EARLY_PHASE1":13862,"PHASE1":13864,"PHASE2":13866,"PHASE3":13868,"PHASE4":13870,"NA":13872},{"trials":13863,"activeCount":100},[],{"trials":13865,"activeCount":100},[],{"trials":13867,"activeCount":100},[],{"trials":13869,"activeCount":100},[],{"trials":13871,"activeCount":100},[],{"trials":13873,"activeCount":100},[13874],{"nctId":3052,"briefTitle":3053,"status":108,"phases":13875,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":13876,"interventions":13877},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":3079,"totalTrials":138,"cells":13879},{"EARLY_PHASE1":13880,"PHASE1":13882,"PHASE2":13884,"PHASE3":13886,"PHASE4":13888,"NA":13890},{"trials":13881,"activeCount":100},[],{"trials":13883,"activeCount":100},[],{"trials":13885,"activeCount":100},[],{"trials":13887,"activeCount":100},[],{"trials":13889,"activeCount":100},[],{"trials":13891,"activeCount":100},[13892],{"nctId":3052,"briefTitle":3053,"status":108,"phases":13893,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":13894,"interventions":13895},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":3080,"totalTrials":138,"cells":13897},{"EARLY_PHASE1":13898,"PHASE1":13900,"PHASE2":13902,"PHASE3":13904,"PHASE4":13906,"NA":13908},{"trials":13899,"activeCount":100},[],{"trials":13901,"activeCount":100},[],{"trials":13903,"activeCount":100},[],{"trials":13905,"activeCount":100},[],{"trials":13907,"activeCount":100},[],{"trials":13909,"activeCount":100},[13910],{"nctId":3052,"briefTitle":3053,"status":108,"phases":13911,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":13912,"interventions":13913},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":3082,"totalTrials":138,"cells":13915},{"EARLY_PHASE1":13916,"PHASE1":13918,"PHASE2":13920,"PHASE3":13922,"PHASE4":13924,"NA":13926},{"trials":13917,"activeCount":100},[],{"trials":13919,"activeCount":100},[],{"trials":13921,"activeCount":100},[],{"trials":13923,"activeCount":100},[],{"trials":13925,"activeCount":100},[],{"trials":13927,"activeCount":100},[13928],{"nctId":3052,"briefTitle":3053,"status":108,"phases":13929,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":13930,"interventions":13931},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":3083,"totalTrials":138,"cells":13933},{"EARLY_PHASE1":13934,"PHASE1":13936,"PHASE2":13938,"PHASE3":13940,"PHASE4":13942,"NA":13944},{"trials":13935,"activeCount":100},[],{"trials":13937,"activeCount":100},[],{"trials":13939,"activeCount":100},[],{"trials":13941,"activeCount":100},[],{"trials":13943,"activeCount":100},[],{"trials":13945,"activeCount":100},[13946],{"nctId":3052,"briefTitle":3053,"status":108,"phases":13947,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":13948,"interventions":13949},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":3084,"totalTrials":138,"cells":13951},{"EARLY_PHASE1":13952,"PHASE1":13954,"PHASE2":13956,"PHASE3":13958,"PHASE4":13960,"NA":13962},{"trials":13953,"activeCount":100},[],{"trials":13955,"activeCount":100},[],{"trials":13957,"activeCount":100},[],{"trials":13959,"activeCount":100},[],{"trials":13961,"activeCount":100},[],{"trials":13963,"activeCount":100},[13964],{"nctId":3052,"briefTitle":3053,"status":108,"phases":13965,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":13966,"interventions":13967},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":3085,"totalTrials":138,"cells":13969},{"EARLY_PHASE1":13970,"PHASE1":13972,"PHASE2":13974,"PHASE3":13976,"PHASE4":13978,"NA":13980},{"trials":13971,"activeCount":100},[],{"trials":13973,"activeCount":100},[],{"trials":13975,"activeCount":100},[],{"trials":13977,"activeCount":100},[],{"trials":13979,"activeCount":100},[],{"trials":13981,"activeCount":100},[13982],{"nctId":3052,"briefTitle":3053,"status":108,"phases":13983,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":13984,"interventions":13985},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":3086,"totalTrials":138,"cells":13987},{"EARLY_PHASE1":13988,"PHASE1":13990,"PHASE2":13992,"PHASE3":13994,"PHASE4":13996,"NA":13998},{"trials":13989,"activeCount":100},[],{"trials":13991,"activeCount":100},[],{"trials":13993,"activeCount":100},[],{"trials":13995,"activeCount":100},[],{"trials":13997,"activeCount":100},[],{"trials":13999,"activeCount":100},[14000],{"nctId":3052,"briefTitle":3053,"status":108,"phases":14001,"primaryCompletion":3055,"completion":3056,"start":3057,"enrollment":3058,"conditions":14002,"interventions":14003},[92],[3060],[560,561,563,562,3062,3063,3064,3065,3066,3067,3068,3069,3070,3071,3072,3073,3074,3075,3076,3077,3078,3079,3080,3003,3081,3082,3083,3084,3085,3086],{"intervention":14005,"totalTrials":138,"cells":14006},"Nasal steroid",{"EARLY_PHASE1":14007,"PHASE1":14009,"PHASE2":14011,"PHASE3":14013,"PHASE4":14015,"NA":14017},{"trials":14008,"activeCount":100},[],{"trials":14010,"activeCount":100},[],{"trials":14012,"activeCount":100},[],{"trials":14014,"activeCount":100},[],{"trials":14016,"activeCount":100},[],{"trials":14018,"activeCount":100},[14019],{"nctId":14020,"briefTitle":14021,"status":605,"phases":14022,"primaryCompletion":3578,"completion":3578,"start":6907,"enrollment":100,"conditions":14023,"interventions":14026},"NCT01661777","Refractory Eustachian Tube Dysfunction: Are the Symptoms Related to Endolymphatic Hydrops",[92],[14024,14025],"Eustachian Tube Dysfunction","Endolymphatic Hydrops",[14005,14027,14028],"Diuretic","Antihistamine",{"intervention":14027,"totalTrials":138,"cells":14030},{"EARLY_PHASE1":14031,"PHASE1":14033,"PHASE2":14035,"PHASE3":14037,"PHASE4":14039,"NA":14041},{"trials":14032,"activeCount":100},[],{"trials":14034,"activeCount":100},[],{"trials":14036,"activeCount":100},[],{"trials":14038,"activeCount":100},[],{"trials":14040,"activeCount":100},[],{"trials":14042,"activeCount":100},[14043],{"nctId":14020,"briefTitle":14021,"status":605,"phases":14044,"primaryCompletion":3578,"completion":3578,"start":6907,"enrollment":100,"conditions":14045,"interventions":14046},[92],[14024,14025],[14005,14027,14028],{"intervention":14028,"totalTrials":138,"cells":14048},{"EARLY_PHASE1":14049,"PHASE1":14051,"PHASE2":14053,"PHASE3":14055,"PHASE4":14057,"NA":14059},{"trials":14050,"activeCount":100},[],{"trials":14052,"activeCount":100},[],{"trials":14054,"activeCount":100},[],{"trials":14056,"activeCount":100},[],{"trials":14058,"activeCount":100},[],{"trials":14060,"activeCount":100},[14061],{"nctId":14020,"briefTitle":14021,"status":605,"phases":14062,"primaryCompletion":3578,"completion":3578,"start":6907,"enrollment":100,"conditions":14063,"interventions":14064},[92],[14024,14025],[14005,14027,14028],{"intervention":14066,"totalTrials":138,"cells":14067},"olanzapine vs. clozapine",{"EARLY_PHASE1":14068,"PHASE1":14070,"PHASE2":14072,"PHASE3":14074,"PHASE4":14076,"NA":14078},{"trials":14069,"activeCount":100},[],{"trials":14071,"activeCount":100},[],{"trials":14073,"activeCount":100},[],{"trials":14075,"activeCount":100},[],{"trials":14077,"activeCount":100},[],{"trials":14079,"activeCount":100},[14080],{"nctId":14081,"briefTitle":14082,"status":108,"phases":14083,"completion":14084,"start":14085,"enrollment":2670,"conditions":14086,"interventions":14087},"NCT00179231","Olanzapine Versus Clozapine in Treatment Refractory Schizophrenia",[92],"2004-02","2000-05",[13168,13278],[14066],{"intervention":14089,"totalTrials":138,"cells":14090},"Vaginal Misoprostol",{"EARLY_PHASE1":14091,"PHASE1":14093,"PHASE2":14095,"PHASE3":14097,"PHASE4":14099,"NA":14101},{"trials":14092,"activeCount":100},[],{"trials":14094,"activeCount":100},[],{"trials":14096,"activeCount":100},[],{"trials":14098,"activeCount":100},[],{"trials":14100,"activeCount":100},[],{"trials":14102,"activeCount":100},[14103],{"nctId":14104,"briefTitle":14105,"status":108,"phases":14106,"primaryCompletion":9773,"completion":9773,"start":3410,"enrollment":14107,"conditions":14108,"interventions":14110},"NCT01634854","A Study Comparing Vaginal Misoprostol and Intravenous Oxytocin for Induction of Labor",[92],130,[14109],"Induction of Labor in Multiparous Women",[14089,14111],"Intravenous Oxytocin",{"intervention":14111,"totalTrials":138,"cells":14113},{"EARLY_PHASE1":14114,"PHASE1":14116,"PHASE2":14118,"PHASE3":14120,"PHASE4":14122,"NA":14124},{"trials":14115,"activeCount":100},[],{"trials":14117,"activeCount":100},[],{"trials":14119,"activeCount":100},[],{"trials":14121,"activeCount":100},[],{"trials":14123,"activeCount":100},[],{"trials":14125,"activeCount":100},[14126],{"nctId":14104,"briefTitle":14105,"status":108,"phases":14127,"primaryCompletion":9773,"completion":9773,"start":3410,"enrollment":14107,"conditions":14128,"interventions":14129},[92],[14109],[14089,14111],{"intervention":14131,"totalTrials":138,"cells":14132},"Magnevist",{"EARLY_PHASE1":14133,"PHASE1":14135,"PHASE2":14137,"PHASE3":14139,"PHASE4":14141,"NA":14143},{"trials":14134,"activeCount":100},[],{"trials":14136,"activeCount":100},[],{"trials":14138,"activeCount":100},[],{"trials":14140,"activeCount":100},[],{"trials":14142,"activeCount":100},[],{"trials":14144,"activeCount":100},[14145],{"nctId":14146,"briefTitle":14147,"status":108,"phases":14148,"primaryCompletion":6809,"completion":6809,"start":14149,"enrollment":14150,"conditions":14151,"interventions":14153},"NCT03910114","Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography",[],"1990-07-01",500,[14152],"Magnetic Resonance Imaging Contrast Agents",[14131,14154,14155],"Dotarem","Gadovist",{"intervention":14154,"totalTrials":138,"cells":14157},{"EARLY_PHASE1":14158,"PHASE1":14160,"PHASE2":14162,"PHASE3":14164,"PHASE4":14166,"NA":14168},{"trials":14159,"activeCount":100},[],{"trials":14161,"activeCount":100},[],{"trials":14163,"activeCount":100},[],{"trials":14165,"activeCount":100},[],{"trials":14167,"activeCount":100},[],{"trials":14169,"activeCount":100},[14170],{"nctId":14146,"briefTitle":14147,"status":108,"phases":14171,"primaryCompletion":6809,"completion":6809,"start":14149,"enrollment":14150,"conditions":14172,"interventions":14173},[],[14152],[14131,14154,14155],{"intervention":14155,"totalTrials":138,"cells":14175},{"EARLY_PHASE1":14176,"PHASE1":14178,"PHASE2":14180,"PHASE3":14182,"PHASE4":14184,"NA":14186},{"trials":14177,"activeCount":100},[],{"trials":14179,"activeCount":100},[],{"trials":14181,"activeCount":100},[],{"trials":14183,"activeCount":100},[],{"trials":14185,"activeCount":100},[],{"trials":14187,"activeCount":100},[14188],{"nctId":14146,"briefTitle":14147,"status":108,"phases":14189,"primaryCompletion":6809,"completion":6809,"start":14149,"enrollment":14150,"conditions":14190,"interventions":14191},[],[14152],[14131,14154,14155],{"intervention":14193,"totalTrials":138,"cells":14194},"Propranolol then Placebo",{"EARLY_PHASE1":14195,"PHASE1":14197,"PHASE2":14199,"PHASE3":14201,"PHASE4":14203,"NA":14205},{"trials":14196,"activeCount":100},[],{"trials":14198,"activeCount":100},[],{"trials":14200,"activeCount":100},[],{"trials":14202,"activeCount":100},[],{"trials":14204,"activeCount":100},[],{"trials":14206,"activeCount":100},[14207],{"nctId":14208,"briefTitle":14209,"status":108,"phases":14210,"primaryCompletion":6609,"completion":6609,"start":8121,"enrollment":1220,"conditions":14211,"interventions":14212},"NCT00770484","Effect of Exercise in OI",[92],[2996,37],[14193]]